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Preface to ”Nucleic Acid Architectures for
Therapeutics, Diagnostics, Devices and Materials”
Nucleic acids (RNA and DNA) and their chemical analogs have been utilized as building
materials due to their biocompatibility and programmability. RNA, which naturally possesses a
wide range of different functions, is now being widely investigated for its role as a responsive
biomaterial which dynamically reacts to changes in the surrounding environment. It is now evident
that artificially designed self-assembling RNAs that can form programmable nanoparticles and
supra-assemblies will play an increasingly important part in a diverse range of applications, such
as macromolecular therapies, drug delivery systems, biosensing, tissue engineering, programmable
scaffolds for material organization, logic gates, and soft actuators, to name but a few. The current
exciting Special Issue comprises research highlights, short communications, research articles, and
reviews that all bring together the leading scientists who are exploring a wide range of the
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The use of nucleic acids (RNA and DNA) offers a unique and multifunctional platform for
numerous applications including therapeutics, diagnostics, nanodevices, and materials. The ubiquity
of nucleic acids and their broad functional involvement in various biological processes place them before
other biocompatible materials suitable for controlled bottom-up nanofabrication. Systematic elucidation
of RNA and DNA folding, physicochemical properties, and relevant biological activities have fueled
an increased involvement of nucleic acid-based nanotechnology in various biomedical challenges.
This special issue assembles 11 original articles (with seven research manuscripts and four
reviews) which nicely outline several advances made in the field of RNA and DNA nanotechnology.
Unified by the versatile use of the intriguing biopolymers, these manuscripts explore the various facets
of nucleic acid nanostructures such as design, production, and characterization of RNA and DNA
nanoassemblies [1–4], rational design of functional molecular machines [5–8], immunorecognition
of nucleic acid nanoparticles [8], in vivo delivery of therapeutic nucleic acids [9,10], and nucleic
acid-based biosensors [11]. We anticipate this special issue to be accessible to a wide audience, as it
explores not only the biological aspects of nucleic acid nanodesigns, but also different methodologies
of their production, their interactions with other classes of biological molecules, physicochemical
characteristics, and possible applications.
Drawing inspiration from naturally-occurring structural and long-range interacting RNA motifs,
Chopra et al. describe a novel design that combines the internal ribosome entry site of the hepatitis C
virus together with the RNA kissing loop motifs to form hexagonal assemblies which are amenable
to functionalization with various aptamers [1]. The aptamers include malachite green, PP7, Spinach,
and an aptamer against streptavidin, demonstrating the coordination of proteins and small molecules
on RNA scaffolds with structural regularity. The use of RNA in this nanodesign also allowed for
co-transcriptional production of functional nanoassemblies.
O’Hara et al. describe an innovative approach, integrating a split aptamer system into internal
portions of hexagonal RNA rings [2]. Using a split-Spinach aptamer, the authors demonstrate that the
intensity of the fluorescent signal associated with the formation of the complete aptamer is dependent
on the formation of the RNA rings, thus allowing researchers to monitor the assembly of nanostructures.
In a different approach, Yourston et al. describe the use of nanostructured DNA assemblies
for DNA-templated production and organization silver nanoclusters (AgNCs) with unique optical
properties [3]. Their work expands the protocols for synthesis of AgNCs on various DNA templates
and identifies some structural requirements for altering the fluorescent properties of the AgNCs.
Design and characterization of nanostructured nucleic acids is of paramount importance in both
achieving and modulating their functional goals. The majority of characterization techniques of nucleic
acid nanostructures involve the use of electrophoretic mobility shift assays, atomic force microscopy,
cryogenic electron microscopy, or dynamic light scattering; each approach has its unique benefits and
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drawbacks. Oliver et al. propose a new approach to characterizing nucleic acid nanoparticles using
small angle X-ray or neutron scattering [4]. Their in-depth review examines the structural and chemical
requirements for studying various biomolecules in their natural confirmations. It also highlights
the multitude of requirements for solution and sample preparations, and discusses the precise data
yielded from these techniques. Finally, it discusses the prospects for enhancing the characterization of
nanostructured nucleic acid architectures.
Following design and characterization, advances in the use of DNA and RNA nanostructures in
devices and molecular machines is highlighted in this issue. One such device is the DNA nanopore,
which offers a unique membrane-bound tool for furthering biophysical research and biosensing. In
this issue, Burns and Howorka describe the design and evaluation of a DNA nanopore in various
biological milieu [5]. The authors identify parameters for the assembly of a hexameric DNA nanopore
using gel electrophoresis and fluorescence spectroscopy, and further confirm its integrity in cell media,
as well as its successful integration into lipid membranes.
Beyond the development of biophysical tools, this special issue contains two original manuscripts
detailing the use of DNA and RNA nanostructures in the design of molecular logic gates. Using
“light-up” malachite green and Broccoli aptamers, Goldsworthy et al. describe the design of robust and
precise RNA nanodevices with several Boolean logic functions, including AND, OR, NAND, and NOR
capabilities [6]. The binding of the small molecule dyes to their aptamers in the conditional situations
causes a fluorescent output based strictly on the input of the designed strands. Using this approach,
the authors designed and integrated parallel XOR and AND gates within a single RNA nanoparticle.
Towards that end, Zakrevsky et al. describe the use of logic gates to mimic complex molecular
biological phenomena with the potential for use in cells [7]. In their research, the authors
computationally design and characterize DNA/RNA hybrid-based logic gates suited for the conditional
release of single- and double-stranded nucleic acids, thus displaying the possibility of therapeutic
action. Their set of logic gates offers an eclectic approach inspired by molecular beacons and other
trigger-responsive multi-stranded assemblies.
The concept of smart-responsive or logic-based nucleic acid nanoassemblies is further expanded
in the review by Chandler and Afonin [8]. In their review, several advances in the design and function
of stimuli-responsive DNA and RNA nanoconstructs are discussed, including simple trigger/activation
designs of shape-switching nanoparticles with controlled immunomodulatory properties. Furthermore,
they outline the potential of using these dynamic nucleic acid nanoparticles for the conditional
stimulation of an immune response, which has been determined to be dependent on the structure and
composition of the given nucleic acid nanoparticle.
As therapeutics, nanostructured nucleic acids hold great potential in the treatment of various
maladies. Gwak and Lee describe the use of a cationic amphiphilic co-polymer nanoparticles to
efficiently deliver plasmid DNA, as well as a small molecule anti-viral therapy for successful treatment
of spinal cord injuries using “suicide gene therapy” [9]. The authors further describe the stability of
the nanoparticles over time and demonstrate their use in animal models.
In the same regard, Caffery et al. describe in depth the possibility of treating glioblastomas
with a combination of gene therapy and various nanoscale carriers [10]. Their comprehensive review
discusses both the various therapeutic nucleic acids as well as the various delivery platforms to deliver
these therapeutic cargos. The authors also discuss possible limitations to each of these approaches, as
well as the challenges of crossing the blood brain barrier.
Finally, this special issue features a review by Sun et al. on the use of genetically encoded
RNA-based molecular sensors (GERMS) [11]. The review provides a well-rounded outline of the
various design principles and applications for GERMS including their most common use of intracellular
imaging. The authors go on to discuss the outlook for this novel technology and potential milestones
towards developing next generation RNA based sensors.
Together, this special issue details several important advancements in the field of nucleic acid
nanotechnology by focusing on design and characterization, use in devices and molecular machines,
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and implementation into therapeutics and sensors. The works enclosed here demonstrate the various
possible applications for these burgeoning technologies.
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Abstract: Co-transcriptionally folding RNA nanostructures have great potential as biomolecular
scaffolds, which can be used to organize small molecules or proteins into spatially ordered
assemblies. Here, we develop an RNA tile composed of three parallel RNA double helices, which can
associate into small hexagonal assemblies via kissing loop interactions between its two outer helices.
The inner RNA helix is modified with an RNA motif found in the internal ribosome entry site
(IRES) of the hepatitis C virus (HCV), which provides a 90◦ bend. This modification is used to
functionalize the RNA structures with aptamers pointing perpendicularly away from the tile plane.
We demonstrate modifications with the fluorogenic malachite green and Spinach aptamers as well
with the protein-binding PP7 and streptavidin aptamers. The modified structures retain the ability to
associate into larger assemblies, representing a step towards RNA hybrid nanostructures extending
in three dimensions.
Keywords: RNA nanotechnology; aptamers; cotranscriptional folding
1. Introduction
Over the past two decades, RNA has been found to be involved in many essential cellular
processes other than the conventional roles it fulfils as mRNA, tRNA, or rRNA. Non-coding RNAs
(ncRNAs) and many RNA–protein complexes are involved in regulatory functions at the transcriptional
and translational levels, and have roles in scaffolding [1], genome-editing, RNA interference,
clustered regularly interspaced repeats (CRISPR), and chromatin remodeling [2]. Many naturally
occurring ncRNAs fold and assemble into complex 3D architectures via a plethora of secondary and
tertiary interactions, and also via association with a wide range of RNA-binding proteins. More recently,
the exceptional folding capability and modularity of biological RNAs have inspired the emergence
of RNA nanotechnology, which aims at the construction and assembly of artificial nanostructures
made from RNA [3]. Compared to DNA, RNA offers a variety of interesting features as a material for
nanotechnology: RNA nanostructures can draw from a diverse variety of naturally occurring tertiary
motifs [4–6], they can be enzymatically generated in large amounts via transcription, and they can be
genetically encoded and expressed in cells [7,8].
Most naturally occurring RNAs are single-stranded and contain self-complementary sequences
that facilitate intramolecular folding into distinct secondary structures. In addition, rigid structural
motifs consisting of canonical or noncanonical base-pairing, kissing interactions, and stacking of
helices play a significant role in RNA folding, resulting in complex 3D structures exhibiting helices,
loops, junctions, bulges, stems, hairpins, and pseudoknots [4–6]. Seeking inspiration from the
design principles found in nature and employing naturally occurring RNA motifs, several assembly
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strategies have been developed for RNA nano-construction. They include RNA architectonics [9,10],
self-assembly of RNA/DNA hybrids [11,12] and single-strand RNA assembly [13]. RNA architectonics
is based on the modular character of RNA, which allows 3D RNA motifs to be organized in alternative
combinations in order to create different RNA nano-architectures. Large libraries of thermodynamically
stable modular RNAs, which include both structural and functional motifs, have been identified and
characterized from natural RNA molecules. Furthermore, such motifs have been used as suitable
“parts” for designing self-assembling RNA units (or tectoRNAs) [10]. For instance, in this context,
in silico methods have been developed to screen for natural RNA motifs capable of self-assembling
into closed ring structures [14]. The DNA/RNA hybrid strategy leverages the properties of both RNA
and DNA. It has been used for producing large nucleic acid structures based on the DNA origami
technique, where a large RNA scaffold is folded with a number of complementary DNA/RNA staples.
Single strand RNA assembly relies on a number of RNA strands that are unstructured by themselves
but when mixed together assemble into a structure [12].
A technique dubbed cotranscriptional ssRNA origami has been developed, in which a single
RNA strand folds into a predefined RNA tile that further assembles into hexagonal and rectilinear
lattices while the RNA is produced by the RNA polymerase [13]. It employs a variety of RNA tertiary
motifs to mediate the intra- and inter-tile interactions. Improved unimolecular DNA and RNA folding
strategies have been developed based on minimizing the knotting complexity by employing parallel
crossovers to avoid kinetic trapping during folding. This has resulted in RNA nanostructures of a
variety of shapes and up to 6000 nt in length [15].
Rationally designed RNA nanostructures and devices have great potential for applications in
synthetic biology, metabolic engineering, and nanomedicine [3,16–19]. In particular, the three-way
junction from pRNA (a component of the phage phi29 packaging motor) has been found to be
an extremely stable motif that can be used as the basis of multifunctional RNA nanoparticles for
therapeutic applications [19]. More recently, RNA tiles designed by the cotranscriptional ssRNA
origami technique have been used in combination with fluorogenic RNA aptamers to function
as nanoscale aptamer-based Förster resonance energy transfer (FRET) sensors [20]. Additionally,
programmed folding of RNA nanostructures of different shapes has also been performed in vivo [21].
Furthermore, hybrid multicomponent RNA-protein nanostructures have been characterized in vivo
and in cell-free gene expression systems [22].
In the present work, we construct a novel three-helix “antiparallel even” RNA tile (3H-AE)
based on the cotranscriptional ssRNA origami approach. In our design, the outer two helices of
the 3H-AE tile provide a rigid RNA scaffold that can interact with other tiles via kissing loop (KL)
interactions. The central RNA double-helical extensions, however, are conceived as modular plug-in
modules, which can be modified at will without interfering with two-dimensional tile assembly.
Specifically, we modified the plug-in helices with subdomain IIa of the internal ribosomal entry site
(IRES) of the Hepatitis C virus (HCV) genome [23], which allowed attachment of arbitrary RNA
modules perpendicularly protruding either above or below the plane defined by the 3H-AE RNA
tile. As examples, we positioned the two fluorogenic malachite green (MG) [24] and Spinach [25,26]
aptamers above and below the tile plane, respectively, which allowed us to monitor functional assembly
of the tile structures via fluorescence spectroscopy. In order to demonstrate the modularity of the
design, the top (malachite green) aptamer was also replaced with other aptamers such as the PP7
aptamer for the viral coat protein PCP [27,28] and an RNA aptamer for streptavidin [22]. We finally
show that the streptavidin aptamer module can be used to immobilize the RNA tiles on streptavidin
coated surfaces, while presenting a second function via another aptamer, indicating the potential for
functionalizing surfaces with unmodified proteins or other ligands in controlled orientations.
Our results demonstrate the modularity of the RNA origami tile approach and represent a step
towards multifunctional RNA assemblies extending in three dimensions. The most salient feature
of the three-helix tile structure introduced in this work is the modular extension of the middle helix
with aptamer functions. This allows for connecting the tiles in 2D while presenting separate binding
5
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modalities on the two sides of the 2D assembly. Furthermore, it is conceivable to create 3D lattices
from such structures by also polymerizing along the z-direction.
2. Materials and Methods
2.1. Design of Three-Helix RNA Tiles (3H-AE)
3H-AE and its subsequent modifications were designed by the cotranscriptional ssRNA origami
method that has been previously described in detail [13,29]. Briefly, using the 3D modeling
programs Swiss-PdbViewer [30] and UCSF Chimera [31], three standard A-form RNA double helices
(#1-3, Figure 1a) were positioned over one another and rotated to create an optimal spacing for an
anti-parallel even (AE) double crossover (DX). An internal 180◦ KL (HIV-1 DIS, PDB ID: 2B8R) [32]
was placed between the crossovers on helix number 1 (top). UUCG tetraloops (extracted from PDB
ID: 1F7Y) [33] were positioned at the ends and in between crossovers on helix number 2 (middle).
In addition, 120◦ KLs (RNA i/ii inverse loop, PDB ID: 2BJ2) [34] were positioned at the ends of double
helices numbers 1 and 3 to allow formation of hexagonal lattices. The 180◦ KL forms 6 base pairs
between the two loops resulting in a coaxial stack and is in phase with the A-form helix of RNA,
whereas the 120◦ KL forms 7 base pairs between the loops resulting in a continuous, but bent coaxial
stack. Modifications in the 3H-AE design included additional RNA motifs such as subdomain IIa
(PDB ID: 2PN4) and domain IIa (PDB ID: 1P5M) of the IRES of the HCV genome, which were used
as connectors between the RNA tile and the malachite green aptamer (MGA) (PDB ID: 1F1T) [24].
These domains consist of a 90◦ angle [35,36] which allows for almost perpendicular arrangement
of the added RNA motifs to the tile. An additional RNA sequence encoding Spinach aptamer
(PDB ID: 4KZD) [26] was connected to 3H-AE with MGA V1 via subdomain IIa to generate the
modified structure 3H-AE-MGA-Spinach. Additional variants of 3H-AE-MGA-Spinach without 120◦
KL were constructed. The MGA was further replaced by either a streptavidin aptamer [22] or an
aptamer binding to bacteriophage PP7 coat protein fused with mCherry (PCP-mCherry, PDB ID:
2QUX) [28], respectively.
After the initial modeling, the 3D structures were ligated with a Perl script (“ligate.pl”, which was
available from [37] and refined using a recursive geometric refinement function in the program
Assemble [38]. 3D models in this work were rendered in UCSF Chimera. The designed structure
was further traced using a Perl script (“trace.pl”, which is also available from [37]) and an input
was generated that was used for the design of the corresponding RNA sequences in Nupack [39].
The sequences of the 180◦ KLs, 120◦ KLs, tetraloops, subdomain IIa, domain IIa, MGA, Spinach
aptamer and PP7 aptamer were chosen from the PDB files and added to the respective designs
(assuming a stable folding behavior of the aptamers, the corresponding sequences were modularly
replaced, keeping the rest of the 3H-AE sequence constant). Additionally, some of the base pairs in
the dovetail seam were constrained to be strongly stacking G-C pairs in an attempt to immobilize
it to a static position. Sequences were further constrained to contain at least one G-U wobble pair
per every eight continuous base pairs in order to avoid secondary structures in the RNA-encoding
DNA template and simplify its synthesis. All of the remaining positions were designed by Nupack.
The 5’-end of each sequence was constrained to begin with GGG, an optimal leader sequence for T7
RNA polymerase. In addition, 2D blueprints of the final structures resulting from this process are
shown in Supplementary Figure S1.
Primers were generated specific to DNA sequence generated by Nupack and their melting
temperature was calculated using the NEB Tm calculator [40].
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Figure 1. Design and characterization of the 3H-AE RNA tile. (a) schematic representation of designed
3H-AE RNA tile. Structural motifs are color coded as described in the legend; (b) denaturing PAGE gel
showing the correct length of the RNA tile. L: LowRange RiboRuler, 1-2: RNA tile transcribed from DNA
template amplified from Phusion High-Fidelity Master mix with HF or GC, buffer, respectively. (c) 3H-AE
RNA tiles can interact with each other via 120◦ kissing loop (KL) motifs; (d) AFM images showing correct
assembly and interaction of the RNA tiles. Tile assemblies were prepared by snap-cooling followed by
incubation on mica at 37 ◦C (cf. Materials and Methods). The region enclosed by the dashed circle is
further zoomed in to show the interactions of the 120◦ KL. Scale bars: 50 nm.
2.2. Preparation of RNA Tiles
Genetic templates for all RNA tiles were amplified from “custom dsDNA gBlocks” from Integrated
DNA Technologies (IDT) using the polymerase chain reaction (PCR). RNA tiles were then prepared
using in vitro transcription from these templates as described in detail in the Supplementary Methods.
2.3. Characterization of RNA Tiles and Tile Assemblies
The formation of the RNA tiles was characterized using gel electrophoresis and atomic
force microscopy (AFM). The transcription of RNA tiles modified with fluorogenic aptamers was
followed using fluorescence spectroscopy. RNA tiles containing streptavidin aptamers were further
investigated using streptavidin-coated microbeads. Detailed experimental procedures are found in the
Supplementary Methods.
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3. Results and Discussion
3.1. Design and Folding of the 3H-AE RNA Tile
We designed a novel three-helix “antiparallel even” (3H-AE) RNA tile as described in detail in
the Methods section above. In contrast to previously described RNA tiles [13], it was constructed from
three RNA double helices placed over one another connected via double crossovers, and converted into
a cotranscriptionally folding continuous ssRNA using one 180◦ KLs, four 120◦ KLs and four tetraloops
(Figure 1a). The central (inner) helices (#2a and #2b) of the 3H-AE tile were modularly functionalized
with various aptamers as discussed in the following sections.
Custom dsDNA segments containing the sequence for the 3H-AE RNA tile and its subsequent
modifications were ordered from a gene synthesis supplier and PCR amplified using a Phusion
High-Fidelity PCR Master mix (with HF or GC buffer). The purity and amplification of the samples
was checked using agarose gel electrophoresis (Supplementary Figure S2). Transcription and folding
of RNA structures (3H-AE RNA tile, 248 nt) were verified via a denaturing PAGE. The transcribed
RNA was observed at the correct length as shown in Figure 1b. As indicated in Figure 1c, the 3H-AE
RNA tiles were modified with 120◦ KLs to enable formation of hexagonal assemblies from multiple
interacting structures. Correct folding of the RNA tiles and their assembly into super-structures
were assessed via atomic force microscopy (Figure 1d). In addition, 120◦ KL interactions between
individual tiles resulted in the assembly of hexagonal lattices on the length scale of a few tens of
nanometers. Larger, more disordered molecular networks were formed with hundreds of nanometers
in size (Supplementary Figure S3). The dimensions of the RNA tiles observed via AFM were in
accordance with the design of Figure 1a.
3.2. Modification of the 3H-AE RNA Tile with Aptamers
We next designed modified versions of the 3H-AE RNA tile with one or more fluorescent RNA
aptamers. The first version included the replacement of one of the two interior tetraloops (sitting on one
of the central RNA helices of the three-helix structure, (#2a) by two additional RNA motifs—subdomain
IIa of the internal ribosomal entry site (IRES) of the HCV genome (PDB ID: 2PN4) and the malachite
green aptamer (MGA) (Figure 2a). Subdomain IIa is an L-shaped structural motif that provides a 90◦
bend of the double helix center axis before and after the motif. The length of helix #2a and subdomain
IIa together facilitated the attachment of an additional RNA domain protruding perpendicularly
from the plane defined by the 3H-AE tile. As an example, for this attachment strategy, we elongated
subdomain IIa with the fluorogenic MG aptamer (3H-AE with MGA V1, cf. Figure 2a).
This modification resulted in an increase in the number of nucleotides in the tile from 248 to 297 nt,
which was verified by denaturing PAGE (Figure 2b). The presence of the fluorescent aptamer on the
RNA tile further enabled real-time monitoring of the production of RNA tiles via in vitro transcription
(Figure 2c). The stability of the signal over more than 20 h suggests negligible degradation of the
RNA structure under our reaction conditions. AFM observation of small hexagonal assemblies by
the MGA-functionalized tiles showed their correct folding and also demonstrated that the 120◦ KL
interactions remained intact despite the modifications (Figure 2d).
We also created a variation of 3H-AE-MGA V1 by replacing the connecting motif subdomain IIa
(PDB ID: 2PN4) by the slightly larger HCV IRES domain IIa (PDB ID: 1P5M), which includes a few
additional unpaired bases. As a result, the length of the tile was increased by six bases from 297 nt to
303 nt (3H-AE-MGA V2), and the angle of MGA with respect to the tile was expected to tilt slightly
(Supplementary Figure S4). Characterization by fluorescence spectroscopy and AFM showed very
similar behaviors for both connection motifs (Supplementary Figure S4a,d).
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Figure 2. Modification of the 3H-AE RNA tile with the malachite green aptamer (MGA). (a) schematic
representation showing different views of 3H-AE RNA tiles with and without the addition of MGA
(green) connected via subdomain IIa in IRES of HCV virus (orange); (b) denaturing PAGE gel showing
the length of the unmodified (no aptamer) and modified RNA tiles (with MGA). L: LowRange
RiboRuler, 1: 3H-AE RNA tile, 2: 3H-AE RNA tile with MGA; (c) real-time fluorescence of MG
recorded during transcription of MGA modified RNA tiles (fluorescence normalized to maximum
value). The transcription reaction typically ceases after 3–4 h due to activity loss of the RNAP; (d) AFM
image showing formation of a hexagonal mini-lattice with elevated features resulting from the MGA
modifications (note that not all of the modifications are visible equally well, probably depending on the
orientation of the extensions with respect to the AFM scanning direction). The sample was prepared by
snap-cooling and incubation on mica as described in the Materials and Methods.
3.3. Double Functionalization of the 3H-AE RNA Tile with Two Aptamers
Next, the complexity of the MGA-functionalized 3H-AE tiles was further increased by the addition
of another aptamer via an additional subdomain IIa connected to the second internal tetraloop of the tile
structure. As shown in Figure 3a,b, we used this approach to attach the fluorogenic Spinach aptamer
(PDB ID: 4KZD) pointing perpendicularly away from the tile in the direction opposite to the initial MGA
functionalization. Accordingly, the length of the tile’s RNA sequence increased to 388 nt, which was
confirmed by denaturing PAGE (Figure 3c). AFM of the double-modified RNA tiles showed structures
with local, 120◦ KL-mediated hexagonal order (Figure 3d,e). As expected, larger assemblies were not
observed, as the extension of the aptamers in opposite directions did not allow the RNA tiles to lie flat on
the mica surface. AFM imaging of the double-modified tiles therefore also turned out to be particularly
challenging, in part probably due to the reduced contact area of the structures with the mica surface.
As before, transcription of the double-modified RNA tile was monitored via the fluorescence
signal generated by the two aptamers in their respective emission channels (Figure 4), indicating
proper folding of the aptamer domains and stability of the structure.
We also designed a modification of 3H-AE-MGA-Spinach-KL, in which the 120◦ KLs were
replaced by tetraloops to avoid inter-tile interactions, keeping all the other features unaltered.
The non-interacting tile displayed similar behavior in native gel electrophoresis and fluorescence
experiments (Supplementary Figures S5–S7). An enhanced fluorescence value observed for the
tetraloop-containing structure (Supplementary Figure S6c) potentially indicates a slightly better folding
of the tile, which would be consistent with the fact that tetraloops support the intramolecular folding
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process. Alternatively, it is possible that the two structures are transcribed at different rates given the
different sizes and base compositions of the sequences.
Figure 3. Modification of the MGA functionalized 3H-AE tile with an additional Spinach aptamer
(resulting in 3H-AE-MGA-Spinach). (a) schematic representation of the addition of MGA (green)
and Spinach aptamer (cyan) to the 3H-AE RNA tile connected via subdomain IIa (orange); (b)
different views of 3H-AE-MGA-Spinach; (c) denaturing PAGE gel showing the correct length of
3H-AE-MGA-Spinach. L: LowRange RiboRuler, 1: 3H-AE-MGA-Spinach (388 nt); (d,e) AFM images
corresponding to different areas of imaging—1 μm × 1 μm and 0.5 μm × 0.5 μm, respectively. Samples
prepared by snap-cooling followed by incubation on mica.
For specific applications, the fluorogenic aptamer modifications can be easily replaced with other
functional RNA sequences. As a proof of concept, two variants of 3H-AE-MGA-spinach-Tetraloop
structure were designed and constructed with the MGA replaced by the PP7 aptamer [28] or a
streptavidin aptamer, respectively (Figure 5a and Figure S8). The production of the structures
was validated by real-time fluorescence of the (remaining) spinach aptamer and denaturing PAGE
(Figure 5b,c). Interactions of the tiles with streptavidin (Figure 5d) and PCP-mCherry fusion proteins
(Supplementary Figures S9–S11) were further verified by EMSA.
In order to indicate one potential application for double-functionalized 3H-AE tiles, we utilized
the streptavidin aptamer module to specifically arrange RNA tiles on the surface of streptavidin-coated
polystyrene microbeads. 3H-AE tiles double-functionalized with the Spinach and streptavidin aptamer
are expected to present the Spinach aptamer in an orientation pointing away from the surface of
the beads (Figure 6a). Indeed, binding of the RNA tiles to the microparticles is observed only
with nanostructures containing the streptavidin aptamer (Figure 6b). While in this experiment the
fluorogenic Spinach aptamer was used as the second function on the RNA tile, it is easily conceivable
to generate protein-functionalized surfaces or membranes using other aptamer modules in a similar
manner. Such surfaces should be of interest for the spatial organization of enzymes or other biochemical
functions. As the formation of such functionalized surfaces could be triggered by the transcription of
the RNA tiles, this process would also be genetically controllable.
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Figure 4. Monitoring transcription of RNA tiles via aptamer fluorescence. MG and the Spinach aptamer
fluorophore 3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI) were added to transcription
reactions of all four versions of RNA tiles. The structure of the 3H-AE-MG-Spinach-KL RNA tile is shown
as an inset to the figures: (a) MGA and (b) Spinach (DFHBI) fluorescence recorded during transcription of
the various RNA tiles constructed (Ex = 615–645 nm, Em = 669–699 nm for MG and Ex = 475–495 nm,
Em = 515–545 nm for DFHBI; fluorescence intensities normalized with respect to maximum fluorescence).
Figure 5. (a) schematic representation of 3H-AE-MGA-Spinach RNA tile without 120◦ KL. The MG
aptamer can be modularly replaced by other RNA aptamers as indicated; (b) denaturing PAGE gel
showing the length of 3H-AE-Spinach with different secondary aptamer modifications. L: LowRange
RiboRuler, 1: 3H-AE-Spinach with streptavidin aptamer (390 nt), 2: 3H-AE-Spinach with PP7 aptamer
(363 nt), 3: 3H-AE-MGA-Spinach (376 nt); (c) real-time fluorescence of DFHBI during transcription of
RNA tiles containing different aptamers; (d) native agarose gel (2% agarose in 1X tris-borate EDTA
(TBE) buffer + 2 mM MgCl2) stained with SyBr Green showing the retardation of RNA tile containing
streptavidin aptamer (3H-AE-Spinach with streptavidin aptamer) in presence of streptavidin. 1: RNA
tile only, 2: 3H-AE-Spinach with streptavidin aptamer + streptavidin (100 nM), 3: 3H-AE-Spinach with
streptavidin aptamer + streptavidin (200 nM), 4: Streptavidin only (100 nM). RNA tiles were prepared
by heat denaturation/renaturation as described in the Supporting Materials and Methods.
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Figure 6. Assembly of double-functionalized 3H-AE tiles on microparticles. (a) schematic representation
of attachment of 3H-AE-Spinach tiles with streptavidin aptamer on the surface of streptavidin coated
beads. The streptavidin aptamer is expected to be anchored on the surface of streptavidin particles and
thus the Spinach aptamer points away from it; (b) fluorescence images of different RNA tiles interacting
with 20 μm streptavidin coated polystyrene beads after washing. Only the RNA tiles carrying Spinach
and a streptavidin aptamer lead to a fluorescent signal localized to the beads; scale bars: 20 μm.
4. Conclusions
The results demonstrated here represent initial efforts towards the design and synthesis of
multifunctional tile-based RNA nanostructures extending in three dimensions. Three-helix RNA tiles
were folded from a single RNA strand, which was composed of a variety of naturally occurring RNA
motifs that assist in reaching the desired target shape. The main focus of the present work was put
on domain IIa and subdomain IIa, which are RNA motifs found in the HCV IRES. Both these motifs
contain a 90◦ bend that allows positioning of other RNA modules such as fluorogenic RNA aptamers
perpendicular to the RNA tile structure. As examples, we created 3H-AE tile structures either modified
with a single malachite green aptamer or with MGA and a Spinach aptamer pointing in opposite
directions. Importantly, the modified 3H-AE-tiles retained the ability to associate into hexagonal
assemblies via kissing loop interactions.
Among the most promising applications of such multi-functionalized RNA tile structures,
we envision the creation of artificial ribonucleoprotein complexes, in which RNA structures scaffold
the co-localization and arrangement of proteins, e.g., for membrane-less compartmentalization or
for the creation of multienzyme structures. As the RNA tiles can be made to polymerize in 2D,
it is also conceivable to create extended RNA sheets or “membranes”, which are functionalized
with aptamers on either side, which could be used to further spatially organize proteins in order to
enhance their structural or enzymatic functions. From these, in turn, one could generate RNA/protein
covered surfaces (e.g., with catalytic function) via self-assembly of such structures. Importantly,
such self-assembly processes could all be controlled via gene expression from a plasmid. From a
nanotechnology point of view, another interesting opportunity lies in the possibility to stack several
such RNA sheets on top of each other—mediated by the perpendicular RNA extensions, resulting in
multilayered RNA nanostructures extending in 3D.
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Abstract: The fact that structural RNA motifs can direct RNAs to fold and self-assemble into predictable
pre-defined structures is an attractive quality and driving force for RNA’s use in nanotechnology. RNA’s
recognized diversity concerning cellular and synthetically selected functionalities, however, help explain
why it continues to draw attention for new nano-applications. Herein, we report the modification
of a bifurcated reporter system based on the previously documented Spinach aptamer/DFHBI
fluorophore pair that affords the ability to confirm the assembly of contiguous RNA strands within the
context of the previously reported multi-stranded RNA nanoring. Exploration of the sequence space
associated with the base pairs flanking the aptamer core demonstrate that fluorescent feedback can be
optimized to minimize the fluorescence associated with partially-assembled RNA nanorings. Finally, we
demonstrate that the aptamer-integrated nanoring is capable of assembling directly from transcribed
DNA in one pot.
Keywords: RNA nanotechnology; RNA self-assembly; light-up aptamer; RNA nanoparticle
1. Introduction
RNA nanotechnology leverages the formation of programmable base pairs and regular
three-dimensional folding patterns of structural RNA moieties to construct materials with precise,
predefined shapes [1–5]. As a building material, RNA offers several unique benefits such as
biocompatibility, the ability to generate or add diverse biological functions, and the potential to
generate and assemble nanoparticles directly from DNA transcripts [6–8]. As a consequence, RNA
nanoparticles have been used in a variety of applications including the delivery of therapeutics, as
stable scaffolds for the attachment of functional moieties, and as molecular signaling devices [9–12].
While much progress has been made in the manufacturing of rationally designed RNA structures,
few tools exist to monitor their assembly and/or allow the subsequent tracking of wholly formed
nanoparticles. As the design and utilization of nanostructures with increased complexity continues to
progress, new methods and systems intended to monitor and verify the assembly of nanoparticles will
be required to advance the field of RNA nanotechnology further.
A promising strategy that has been developed to visualize RNA in recent years involves the
use of light-up RNA aptamer/fluorophore pairs [13–17]. Several RNA-based aptamer/fluorophore
pairs have been developed to allow the monitoring of any RNA transcript [18–21]. Fluorescent-based,
label-free RNA tracking methods are thought to offer distinct advantages over other investigative
strategies because they can be integrated non-intrusively into virtually any RNA of interest in a variety
of different contexts [22–27]. The advent RNA aptamer/fluorophore pairs with tunable wavelengths
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and the development of user-friendly toolkits continues to provide greater accessibility and inspire
new applications [28–30]. Multiple RNA light-up aptamers have been bifurcated in order to enable the
monitoring of more than one RNA transcript [18,31–33]. Split-aptamer systems rely on the fact that the
functional aptamer forms only when both non-functional halves combine in the presence of a small
molecular fluorophore. Given the dynamic nature of aptamer assembly, such fluorogenic systems have
opened up new applications that include high-throughput assays, controlled reporting of assembly
and processing, the development of logic gates and molecular computation, and more [23,33–35].
While split-aptamers offer the ability to monitor the assembly of two unique RNA strands (or three
if formed on a scaffold-strand), most RNA nanoparticles are composed of several unique strands of
RNA. Thus the ability to confirm the assembly of multiple RNAs is an important requirement where
the assembly of more complex nanoparticles is concerned. With this understanding in mind we set
out to design a modified bifurcated platform that provides the capability to monitor the assembly of a
nanoparticle comprised of more than two RNA strands.
Given its unique structure and demonstrated ability to be functionalized with a variety of RNA-based
functional groups, we chose to integrate the split-Spinach aptamer into the previously reported RNA
nanoring [36,37]. The nanoring/split-aptamer reporter system represents a significant expansion of
previous uses of the light-up aptamer/fluorophore pairs which rely on the direct interactions at the
secondary structure level alone. The goal of our system was to be able to detect tertiary contacts formed by
RNAs not directly coupled to the split-aptamer. In this regard, our design focused on finding an optimal
thermodynamic balance between split-aptamer assembly and nanoparticle assembly where the formation
of the functional aptamer depended more on the assembly of the whole nanoring so that maximum
fluorescence occurred only in the presence of the whole nanoparticle. Herein, we report a split-Spinach
aptamer system with the ability to monitor the assembly of six strands of RNA in a single nanoparticle. We
demonstrate that the integrated light-up aptamer exhibits significant sensitivity for fully- assembled over
partially-assembled nanoring nanoparticles. In doing so, we believe this to be the first system developed
with the ability to detect adjacent, long-range tertiary interactions as opposed to base pairing directly
mediated by the aptamer itself. Finally, we discuss the particular design constraints associated with our
system in order to suggest general considerations that could be applied to the development of future
multi-stranded reporter systems.
2. Materials and Methods
2.1. Design and Synthesis of Split-Spinach Aptamer and Fluorophore
The previously published Spinach aptamer (PBD ID: 4TS2) [33,38] was modeled into the RNA
nanoring [37] using the Swiss PDB-Viewer [39]. Placement of the aptamer inside the nanoring provided
an initial estimate regarding stem and linker-strand lengths as well as optimal orientation of the
aptamer. The split-Spinach strands were fused to two of the opposing nanoring struts (Figure 1A).
Individual RNA strands were rationally-designed and evaluated for unintended secondary folding
patterns prior to their synthesis and experimentation [40,41]. Sequences associated with helical
regions of the nanoring struts were optimized to avoid secondary structures that would interfere
with nanoring loops and/or the core of the Spinach aptamer—both sequence regions which could
not be altered. DNA sequences, corresponding to the RNA sequences of interest, were designed by
adding a T7 polymerase promoter site sequence (TTCTAATACGACTCACTATA) to the 5’ end of each
RNA. Corresponding DNA templates and primers were purchased from Integrated DNA technologies
(IDT, San Diego, CA, USA), amplified using taq DNA polymerase (Thermo Fisher Scientific, Waltham,
MA, USA) via polymerase chain reaction (PCR), and isolated by a DNA purification kit (Epoch
Life Sciences, Missouri, MO, USA). Transcription of amplified DNA was accomplished using T7
RNA polymerase (Thermo Fisher Scientific, Waltham, MA, USA) in vitro. The resulting transcripts
were purified by polyacrylamide gel electrophoresis (PAGE) [8–10% polyacrylamide, 8 M urea,
1×(89 mM, pH 8.2) Tris Borate (TB)]. Excised gel fragments containing RNA were placed in Crush
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and Soak buffer (200 mM NaCl, 10 mM Tris pH 7.5, 1 mM filtrated Na2EDTA pH 8, water), shook
overnight at 5 ◦C, and the RNA was isolated the next day via ethanol precipitation. The fluorophore,
3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI), was synthesized as previously reported
according the protocol of the Paige research group [21]. A complete list of RNA sequences used in the
study can be found in the Supporting Information.
 
Figure 1. Design and integration of the split-Spinach aptamer and RNA nanoring. (A) The central
portion of the Spinach aptamer crystallized by Huang et al. (PDB ID: 3IVK) [42] was placed in the
interior of the previously reported RNA nanoring and grafted onto two of the nanoring’s opposing
helical struts. Based on initial placement, the Spinach aptamer was modeled to contain two short stems
and single-stranded linkers with variable lengths. (B) 2D diagram resulting from initial modification
and modeling of the split-Spinach aptamer into the RNA nanoring. (C) Stereoview of split-aptamer
integrated into RNA nanoring. (D) The variable stem and single-stranded linker lengths were tested
via fluorescent spectroscopy in the presence of the light-up chromophore DFHBI. The combination
containing 5- and 6-bp stems and 6-nt linkers (5bp/6p/6nt) showed the highest response and was
therefore chosen as the initial base model for further refinement.
2.2. Monitoring Nanoring Assembly
Assembly of the split-aptamer integrated nanoring was evaluated by native PAGE (40 mM HEPES,
pH 8.2 buffer and 2 mM Mg(OAc)2) and fluorescent spectroscopy. RNAs were assembled by combining
equimolar concentrations of RNA strands (at a concentration of 500 mM unless noted otherwise) and
the snap cool process (2 min at 95 ◦C and 3 min on ice). After snap cooling, an association buffer
was added to achieve a final concentration of 40 mM HEPES (pH 8.2), 1 mM Mg(OAc)2, and 50 mM
KCl. This mixture was incubated at 37 ◦C for 20 min and evaluated by fluorescence spectroscopy with
an LS 55 luminescence spectrometer (PerkinElmer, Waltham, MA, USA). DFHBI was added (either
before or after incubation) to final concentration of 1 mM. Samples were loaded into a 15 uL quartz
cuvette (Starna Cells, Inc., Atascadero, CA, USA) and excited at 469 nm. Emission was recorded at
509 nm. Assembly products were also analyzed by a gel shift assay. Products were loaded into a 7%
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polyacrylamide gel of 1× HEPES (40 mM HEPES) buffer and 1 mM Mg(OAc)2. Gels were run at 6 W
for 3−4 h at 4 ◦C. Gels were stained with Sybr Gold (Invitrogen, Carlsbad, CA, USA) and imaged
using a FluoroChemQ gel imager (Protein Simple, San Jose, CA, USA).
2.3. Co-Transcriptional Assembly
Amplified DNA (0.35 μM of each individual strand) for the RNA ring pieces and/or aptamer
were added to 5× co-transcription buffer (DTT (100 mM), NTPs (25 mM each), IPP (0.1 u/μL), RNasin
(40 u/μL), and T7 RNA polymerase (20-120U)). The amount of T7 RNA polymerase was normalized
to the total amount of DNA in each reaction mixture. The total volume of reaction mixtures was
20 μL. In a typical experiment, reaction mixtures were incubated at 37 ◦C for 60 min. After incubation,
3 μL of DNase I (1 u/μL) was added to each reaction mixture and then incubated for an additional
15 min at 37 ◦C. Aliquots of each reaction mixture were evaluated by fluorescence (17 μL) and/or by
gel electrophoresis (3 μL) as described above. All fluorescence signals were normalized to the 5 base
pair (bp) full-length Spinach aptamer reported by Huang et al which was used as a control in each
individual experiment conducted [42].
3. Results & Discussion
3.1. Initial Design of the Split-Spinach/Nanoring System
The overall structural architecture of the RNA nanoring provided a unique opportunity to place
a functional split-aptamer in the interior of the ring (Figure 1). The ability to rationally design and
integrate the split-Spinach/fluorophore system into the nanoring was made possible because of the
previously reported crystal structure of the full-length Spinach aptamer (PBD ID: 4TS2)—which
was essential for evaluating its potential placement within the interior of the six-membered RNA
nanoring in silico (Figure 1A) [36,42]. The two main stems flanking, and responsible for stabilizing,
the fluorophore binding pocket were both shortened to approximately the same length in order to
allow the fully-formed aptamer to sit comfortably in the middle of the interior region of the nanoring
(Figure 1A). Previous reports revealed that one of the closing stems responsible for stabilizing the
aptamer’s core—formed between the 5’ and 3’ ends of the full-length RNA strand and referred to as
stem 1—could be reduced to five base pairs (bp) without compromising the binding and fluorescence
of the fluorophore [42]. In order to convert the full-length aptamer into a bifurcated system we
eliminated the terminal hairpin loop (which was subsequently replaced with a loop from the class
I ligase ribozyme to create a binding site for the crystallization chaperone Fab BL3-6). This second
closing stem (stem 2), on the opposite side of the aptamer core and which also functions to stabilize the
formation of the aptamer’s binding pocket, was shortened to seven bps for initial testing (Figure 1B).
Visual inspection of the model built using the Swiss PDB-Viewer [39] revealed that the nanoring
could readily accommodate a 5-bp stem adjacent to the two uracil bulge near the binding pocket.
Each strand of the minimized split-aptamer was tethered to one of the opposing helical struts of the
nanoring via flexible single-stranded linkers. Our three-dimensional model based on the previously
reported structures of the Spinach aptamer and the RNA nanoring indicated that linker strands of five
to six nucleotides were needed to span the gap between the aptamer and nanoring struts (Figure 1B).
Finally, realizing that the orientation of the linker strand exiting the nanoring depends on its nucleotide
position within the nanoring stem, modeling revealed that grafting the linker strands on the sixth
nucleotide from 5’ end of each of two struts of the nanoring directed the formation of the aptamer
toward the interior of ring.
Using the visually-constructed three-dimensional model as our guide, we tested a small set of
nanoring/split-aptamer systems with variable stem and linker lengths. We evaluated the fluorescence
of the ring strands containing the split-aptamer sequences in the presence and absence of the
peripheral helical struts responsible for complete nanoring formation. Our results showed that
the nanoring/aptamer system possessing stem lengths of five base pairs on one side of the aptamer
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(stem 1) and six base pairs on the other side (stem 2)—in conjunction with linkers of six nucleotides
(referred to as 5bp/6bp/6nt)—produced the greatest difference between ring and split-aptamer only
assemblies (Figure 1D). In both cases where a longer stem was used, the fluorescence associated with
the ring was lower. This data suggests that the longer stem lengths may have been sterically hindered
within the interior of the ring. This is partially corroborated by the fact that 5bp/7bp/5nt exhibited
higher fluorescence as a dimer than 5bp/6bp/6nt as expected given the longer stem but was lower
when placed in the context of the ring.
3.2. Optimization and Assessment of Split-Spinach Variants
In the ideal case, the functional nanoring/split-aptamer would possess the ability to bind DFHBI
and fluoresce only after all six strands of the nanoring were present and able to assemble into the
complete nanoring. We theorized that if we wanted to rely on the split-aptamer to identify the assembly
of contiguous RNA strands not directly connected to the aptamer core then we had to destabilize the
split-aptamer’s propensity to assemble and create a functional aptamer on its own. Building off of our
initial results, we set out to improve upon the 5bp/6bp/6nt version of the split-aptamer to provide
maximum sensitivity for fully-assembled nanorings over partially-assembled ones. We hypothesized
that just the right degree of destabilization in the aptamer stems could allow the formation of the
nanoring to play a greater factor in promoting the formation of a functional split-aptamer which
would in turn function to minimize the fluorescent signal induced by incomplete or partial assemblies.
With this goal in mind, we created variants of the split-Spinach aptamer with different base pairs in
the two stems surrounding the binding pocket—seeking to find a split-aptamer system that abided
by a Goldilocks-like principle: just stable enough, but not too stable. We targeted the three base
pairs formed at the 5’/3’ interfaces of both respective aptamer halves as prime locations to alter stem
stabilities without compromising the aptamer core (Figure 2A). We theorized that they were far away
from the aptamer core that their alteration could affect aptamer core stability while having a minimal
effect on or interference with DFHBI binding. Base pairs were intentionally mutated and/or deleted at
these positions with the goal of destabilizing the aptamer in order to prevent its functional formation
in the absence of the supporting ring struts. In each case, the various split-aptamer variants were
evaluated by their fluorescence intensities—normalized to the fluorescent intensity of the full-length
Spinach aptamer as a control.
As a means of judging aptamer sensitivities, assemblies involving all ring strands were compared
to those consisting of just the two ring strands possessing each half of the split-aptamer (alpha and
delta strands) in the absence of the nanoring’s remaining supporting struts (beta, gamma, epsilon, and
zeta strands respectively) (Figure 2). In order to compare and assess the sensitivity of the different
variant combinations, we calculated the ratio of fluorescence of the rings to their corresponding
dimers without the supporting struts. We hypothesized that substituting stronger interacting base
pairs with weaker ones (i.e., replacing GC bps with AU or GU bps) or disrupting base pairs by
removing nucleotides in these two regions would destabilize the aptamer and thereby provide greater
split-aptamer sensitivity over stems with increased stabilities. Generally, this hypothesis held true.
In all cases where the overall stability of the split-aptamer was increased by replacing an AU bp with
a GC bp the resulting variants showed higher fluorescent signals in the context of fully-assembled
nanoparticles—with one combination showing nearly the same intensity as the single full-length
Spinach control. The sensitivity of these stabilized systems however was generally lower than their
destabilized counterparts (Figure 2B). This was due to the fact that the fluorescent signals from the
dimers also increased (and in greater proportion than that of the fully formed ring systems). In most
cases where the stems were destabilized, the split-aptamer showed markedly lower signals for alpha
and delta strands in the absence of the four ring struts as desired. In the most extreme instances
(e.g., when a nucleotide was removed from the 3’ end of each strand to remove a base pair on each
side of the aptamer) the fluorescence signal associated with both the assembled ring and dimer were
significantly diminished. In other situations however, the dimer signal decreased without affecting the
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signal from the fully-assembled ring (e.g., in cases where a GC in stem 1 was removed or replaced with
an AU or GU). It is also worth noting that attempts to invert all three base pairs in stem 1 produced
lower sensitivities and/or lower overall fluorescence signal in all but one case. In a few instances,
attempts to destabilize stem 2 actually increased the split-aptamer’s fluorescence intensity associated
with both the dimers and the assembled rings. For example, the introduction of a G at position 51
of the delta strand (changing an AU bp to a GU bp) showed increased fluorescence over the initial
5bp/6bp/6nt model (Figure 2B). This instance suggests that stem stability alone is not the only factor
responsible for the split-aptamer’s performance within the context of the nanoring. Other aspects such
as folding dynamics and the secondary structure of each strand is also thought to be important.
 
Figure 2. Optimization of split-Spinach as reporter for RNA nanoring assembly. (A) 2D diagram of
split-Spinach aptamer core (adapted from Ouellet Front. Chem. 2016) [16] (B) Fluorescent data of
variant split-Spinach sequences tested normalized to unimolecular Spinach control (black bar). Green
bars indicate fluorescence associated with the fully-assembled nanoring while grey bars represent
fluorescence associated with the incubation of the alpha and delta strands containing the split aptamer
alone. Variants are ranked according to their respective sensitivities (i.e., ratio of fluorescence in
ring/fluorescence of dimer shown above the green and grey bars). Split-Spinach variants that differ
from each other in the linker sequences are identified by colored asterisks (alpha strand) or stars (delta
strand). Pairs that differ by only a single linker are identified by the same color. The number of asterisks
or stars indicate the identity of the particular linker strand used. Data is based on a minimum of three
trials. The error bars represent the standard deviation associated with each collection of measurements.
In addition to varying the composition of base pairs around the aptamer’s core we also explored
the way in which different linker sequences could affect split-Spinach function. The linker sequences
make up an important design element because they represent the only truly unconstrained sequence
space associated with each split-aptamer strand (of course, in terms of the whole system the nucleotide
sequences associated with the helical struts could also be altered by covariation of base pairs they
are thought to have little to no influence on the aptamer system as a whole). We postulated that the
primary influence linker sequences could have on the reporter system’s performance was through
its effect on the individual strand’s secondary structure. We reasoned that linkers which were able
to fold in a way that partially sequestered the portions of the split-aptamer involved in forming the
stabilizing helixes could provide further sensitivity with regard to distinguishing between the presence
and absence of fully-assembled nanorings. For example, in the absence of the ring the partially blocked
strands would have a more difficult time forming a functional aptamer than when they are brought in
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close proximity due to the assembly of the nanoring. In terms of their overall design, we intentionally
relied predominately on uracils (for flexibility) and adenines (to avoid unintended pairings with
the multiple guanine’s associated with the aptamer core). We evaluated the folding of candidate
sequences in silico using Mfold in order to find the potential secondary structures associated with each
unique sequence (see Supporting Information) [41]. Generally, we found that additional secondary
structure resulted in increased sensitivity. For example the addition of a GC bp to stem 2 produced the
highest fluorescent signal—on par with the full the length aptamer but it lacked sensitivity because the
fluorescent signal of the dimer was also the highest out of any of the constructs tested. By introducing
a linker sequence that predicted a more robust secondary structure, the overall sensitivity increased
by about 60% (from 3.46 to 5.48) (See supporting information, Figure S2). In other cases, strands
with similar secondary structures exhibited different sensitivities—suggesting that other factors like
individual folding pathways also provide subtle effects. It is clear however that the stability of the
stems surrounding the aptamer core had the largest influence on a combination’s overall performance.
After evaluating stem stabilities and linker contributions we identified several sequence
combinations that provided at least a 10-fold increase in signal between the split-aptamer in the
presence of all the ring components compared to split-aptamer strands incubated by themselves with
the highest ratio reaching nearly a 20-fold fluorescence gain. Following these results we evaluated the
ability for the split-aptamer system to distinguish between fully- and partially-assembled nanorings.
Partially-assembled rings (composed of five out of the six nanoring struts) were expected to produce
a higher fluorescent signal than the split-aptamer dimers alone because, like the fully-assembled
nanorings, they provide a physical conduit for the split-aptamer strands to be brought together.
Previous evaluation of the nanoring however showed that partially-assembled rings are not as
thermodynamically stable as fully-assembled rings and so we postulated that the split-aptamer system
should be able to show some level of discrimination between the two [37] In order to evaluate the
utility of split-aptamer/nanoring system further, we selected the seven most sensitive combinations
(by comparing fully-assembled and split-aptamer dimers only) for further assessment in the context of
partially-formed nanorings (Figure 3).
Evaluation of the partially-assembled rings revealed a number of interesting insights (Figure 3).
In the first case, the strength of the fluorescence signal of the partially-assembled rings was found to
be influenced by the precise identity of the missing strut. Absence of the same strut did not universally
increase fluorescence across different combinations. We found that each particular split-aptamer
combination had its own characteristic profile with regards to the missing strut (Figure S3). For
example, for some combinations the absence of the epsilon strut produced routinely produced the
highest signal while for others the highest signal involved the absence of the gamma, or zeta strut.
Given the variances observed between the different split-aptamer systems we chose to compare
the fluorescent response associated with the highest partially-assembled nanoring signal within
each variant system—providing a worst-case scenario in terms of background signal against the
fully-assembled nanoring. Secondly, while the partially-assembled constructs generally produced
higher fluorescence signals than the dimer alone, we identified two split-aptamer variants that showed
virtually no overall increase in fluorescent signal for partially-assembled rings compared to the dimer.
In these two cases, the sensitivity of fully- over partially-assembled remained approximately 15-fold
more sensitive for the fully-assembled nanoring over the partially-assembled one (Figure 3C).
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Figure 3. Comparison of fully- and partially-assembled nanorings. (A) In order to function as an
effective tool for verifying and monitoring nanoring assembly the system needed to be able distinguish
between whole and incomplete or partially-assembled nanorings. (B) Fluorescent data comparing
fully-assembled to nanorings missing one of the four supporting struts (beta, gamma, epsilon, or zeta).
(C) Summary of average fluorescent values for whole nanoring assemblies and partial assemblies
compared to Spinach control where the green bar represents the complete nanoring and the blue bar
represents the partially-assembled nanoring. The ratio of fluorescence of ring to partially-assembled
(ring missing one strut) is shown above each plot. Data is based on a minimum of three trials. The error
bars represent the standard deviation associated with each collection of measurements.
3.3. Co-Transcriptional Assembly
A distinct advantage of RNA-based nanoparticles relates to their ability to self-assemble isothermally
directly from their transcription via DNA templates [6,18,43]. This ability, paired with the rise of new
RNA aptamer/fluorophore pairs has opened the door for a variety of in vitro applications involving
the visualization of RNA transcripts [14,15,17,18,23,44]. The RNA nanoring, in particular, offers an
attractive scaffolding platform for further functionalization and the development of high-throughput,
automated medicine [6,45]. In order to evaluate the robustness of the split-aptamer/nanoring system
we looked at its sensitivity with respect to fully- and partially-assembled nanorings directly resulting
from the transcription of the individual DNA templates. Initial experiments evaluated the split-aptamer’s
performance from equimolar mixtures of its composite RNA strands. In these cases RNA assembly was
carefully controlled via a snap-cooling protocol to ensure proper folding of individual components (see
Material and Methods). In the case of co-transcriptional assembly, equimolar concentrations of DNA
templates were added to a transcription mixture along with T7 RNA polymerase. The resulting transcripts
were left to self-assemble in the mixture during the course of the experiment.
We evaluated the self-assembly of the split-aptamer modified RNAs by fluorescence spectroscopy
and by gel electrophoresis (Figure 4). Native PAGE gels (40 mM HEPES, pH 8.2 buffer and 2 mM
Mg(OAc)2) were used to compare the resulting RNA assemblies of the transcription mixture with an
RNA ladder prepared via snap-cooled assembly of the corresponding nanoring. Native PAGE reveals
that the fully-assembled nanorings constitute the primary assembly product (Figure 4A). The fluorescent
signal associated with dimers, partially-assembled, and fully-assembled nanorings supports this same
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outcome. While the signaling ratio between fully-assembled and partially-assembled rings was on the
whole lower, the fully-assembled rings achieved between 2- and nearly 7-fold increase in fluorescence
over the partially-assembled rings. Fully-assembled nanorings have been shown to be more chemically
and thermodynamically stable than partially-assembled ones [37]. Given that the partially-assembled
nanorings would have much shorter half-lives and be less prone to form, we postulate that sensitivity of
the fully-assembled nanoring over the partially-assembled ones could be increased in certain environments.
More impressively (considering fluorescence is triggered by the folding and assembly of six independent
strands versus a single transcript) the fluorescent signal of three of the ring systems produced signal
levels that remained at over 50% of the single-transcript Spinach aptamer. This is particularly remarkable
given the fact that maximum fluorescence is achieved only by the production and assembly of six
individual strands compared to the transcription and intramolecular folding of the single control strand.
Because the fluorescent output of the split-aptamer remains quite strong compared to the full-length
Spinach control, it shows promise as a reporter for nanoparticle formation from isothermal assembly of
transcription products. Collectively, we believe that these results demonstrate the system’s potential for
use in high-throughput assembly and other applications.
Figure 4. Co-transcriptional assembly of nanorings monitored by native PAGE and fluorescent
spectroscopy. (A) Native PAGE gel (1× HEPES and 2 mM Mg2+) was used to reveal the composition of
nanoring assemblies formed in transcription mix as compared to an RNA ladder that was snapped
cooled (top). Fluorescent values associated with the nanoring products were normalized to the Spinach
control also formed via transcription (bottom). (B) Average fluorescent data for top split-Spinach
variants assembled during transcription with ratio of fluorescent signal of fully-assembled ring (green
bar) to partially-assembled ring (blue bar) and fully-assembled ring to dimer (grey bar). Data is based
on a minimum of three trials. The error bars represent the standard deviation associated with each
collection of measurements.
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4. Conclusions
The design and characterization of an aptamer/fluorophore integrated RNA nanoparticle system
demonstrates the ability to identify perihperal tertiary interactions between assembled RNA strands
of the six-membered RNA nanoring. While many of the particular design constraints discussed above
pertain to the specific system at hand, our work reveals a few general principles relating to the design
of future split-aptamer systems. During the course of our design we observed that stem stability and
performance of any particular sequence (characterized by the various linker designs) require careful
testing. This suggests that full-scale automation of the design process remains elusive and that the
design of new sytems will undoubtedly contain their own particular parameters which will also require
their own experimental optimization. Simply put, the overall performance of variants is and remains
context dependent and very difficult to predict. In this regard, even though in vitro studies provide a
baseline for assessing the behavior of the a self-assembling nanoparticle/split-aptamer/fluorophore
system, evaluation in increasingly complex environments remain necessary for validation and further
refinenment. Modeling and design provide an essential starting point but due to myriad of parameters,
experimental refinement remains absolutely necessity. Our work also shows that the destablization
of stems surrounding the aptamer core generally provide increased sensitivity between fully- and
partially assembled nanoparticles. The same is likely to be true for future developments with different
nanoparticles—where the goal or purpose of nanoparticle assembly functions, at least in part, to restore
and/or compensate the intentionally diminished stabilities of the altered stems.
The split-aptamer/nanoparticle system demonstrates the ability, not only to monitor the assembly
of multiple strands, but the ability to monitor the assembly of RNA strands not directly linked to the
aptamer units. To our knowledge this is the first system developed that demonstrates the ability to
detect the formation of tertiary interactions on contiguous strands of RNA. We demonstrate further
that fluorescent signaling associated with fully-assembled nanorings can be maximized over the
partially assembled split-aptamer system associated with two or five strand mixtures. Given its
ability to assemble isothermally from DNA templates, we propose that the co-transcriptional assembly
of the split-aptamer/nanoring system provides a robust platform for the further development of
a variety of automated and/or high-throughput applications. The nanoring’s four other struts are
readily functionalizable and because the nanoring’s helical struts can be increased a full helical turn to
accommodate a larger interior space, it is possible that more complex aptamer systems may be able to
be incorporated (such as the addition of secondary modular aptamer domain). Finally, fluorescent
reporting of fully-formed nanorings provides instant feedback for the previously proposed automated
assembly of therapeutic RNA nanoparticles [45].
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/3/378/s1,
Figure S1: 2D diagram of aptamer integrated nanoring, Table S1: List of sequences tested, Figure S2: Predicted
secondary structures. Figure S3: Fluorescent profile of partially-assembled nanorings.
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Abstract: Besides being a passive carrier of genetic information, DNA can also serve as an architecture
template for the synthesis of novel fluorescent nanomaterials that are arranged in a highly organized
network of functional entities such as fluorescent silver nanoclusters (AgNCs). Only a few atoms in
size, the properties of AgNCs can be tuned using a variety of templating DNA sequences, overhangs,
and neighboring duplex regions. In this study, we explore the properties of AgNCs manufactured on
a short DNA sequence—an individual element designed for a construction of a larger DNA-based
functional assembly. The effects of close proximity of the double-stranded DNA, the directionality of
templating single-stranded sequence, and conformational heterogeneity of the template are presented.
We observe differences between designs containing the same AgNC templating sequence—twelve
consecutive cytosines, (dC)12. AgNCs synthesized on a single “basic” templating element, (dC)12,
emit in “red”. The addition of double-stranded DNA core, required for the larger assemblies, changes
optical properties of the silver nanoclusters by adding a new population of clusters emitting in
“green”. A new population of “blue” emitting clusters forms only when ssDNA templating sequence
is placed on the 5′ end of the double-stranded core. We also compare properties of silver nanoclusters,
which were incorporated into a dimeric structure—a first step towards a larger assembly.
Keywords: silver nanoclusters; fluorescence; i-motif DNA; cytosine rich sequences
1. Introduction
The field of nucleic acid (NA) nanotechnology has brought various designs of materials and
devices created with facilitation of nucleic acids both DNA and RNA [1–4]. The progress already made
in the field makes nucleic acid molecules very promising candidates for fabrication of complex shapes
and functional structures at the nanoscale. The NA nanotechnology toolbox utilizes not only traditional
DNA and RNA bases but also their chemical analogs and backbone modifications, for example peptide
nucleic acid (PNA) [5]. Additional flexibility is added by the architectural elements of NA that employ
tertiary interactions, such as kissing loops [6,7], loop receptor interactions [8], paranemic motifs [9],
G-quadruplexes [10], and i-motifs [11], just to name a few. All these combined properties of NA
provide a remarkable control over the versatile molecular structures that they can be programmed
to assemble. NA nanotechnology opens large prospects for practical applications of novel materials
design, diagnostics, and nanomedicine.
Besides being used as architectural elements for construction of complex nanostructures, NA can
be utilized as scaffolds for hosting various functionalities including moieties with unique optical,
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electronic, and magnetic properties [12]. One example is the use of DNA template to arrange gold
nanoparticles in a plasmonic linear array [12]. Silver nanoclusters (AgNCs) represent a family of such
novel functionalities. AgNCs cannot exist on their own—they have to be stabilized with capping
agents that (1) limit their size, (2) stabilize nanoclusters, and (3) modify their electronic properties.
DNA oligonucleotides have been widely utilized for making AgNCs (reviewed in [13]). DNA protects
the metallic core of the clusters and also determines the size and geometry of the AgNCs, which in
turn dictates the optical properties and stability of the nanoclusters. The resultant silver nanoclusters
are only a few atoms in size. Unique optical properties of AgNCs originate from their size. In this
“few atoms” size regime, the continuous density of states breaks up into discrete energy levels
in the nanoclusters. With discrete states, the nanoclusters resemble molecular-like behavior with
strong fluorescence observed in the visible-near IR range of the spectrum [14]. Additionally, AgNCs
are more resistant to photobleaching than widely used organic dyes, quantum dots, or fluorescent
proteins, which makes these structures suitable for a plethora of practical applications, including
optoelectronics and nanophotonics [15]. It is especially exciting because AgNCs can be naturally
integrated with NA assemblies [16] and NA assemblies can be tracked with AgNCs formation [17].
Importantly, NA template sequence can be varied to produce fluorescent silver clusters of distinct
optical properties [14].
While promising, AgNCs exhibit complex optical behavior including various fluorescence peaks,
effects of templating and non-templating NA sequences [18–21]. Interactions between silver and
NA bases might produce long-lived dark electronic states that can be used to enhance fluorescence
detection [22]. The complexity of AgNC optical properties is also manifested by the possibility of direct
and indirect excitation: Directly in the visible spectral range or indirectly via UV-excitation of DNA
bases [23]. The structure and nature of optically active electronic states are poorly understood [24,25].
Therefore, a detailed characterization of these effects is needed to establish how AgNC function in
larger assemblies. Recent efforts indicate that large scale photonic applications might benefit from
arranging AgNC in DNA-templated arrays [26] and spatial control of nanocluster positioning [27].
In this article, we report a detailed characterization of C12-based templates designed for creation
of larger NA assemblies. The design requires the presence of a double-stranded DNA region in close
proximity to templating single-stranded sequences. Such proximity of dsDNA has a significant effect
on optical properties of silver nanoclusters. We also observe the effect of directionality as optical
properties of AgNCs depend strongly on whether C12-templating sequence is positioned on the 3′
or 5′ end of the double-stranded core. Multiple contiguous cytosines in the C12 templating sequence
trigger the formation of non-canonical structures in the presence of silver atoms, and this modulates the
fluorescence of AgNC to a large extent. Atomic Force Microscopy imaging provides an unambiguous
proof of conformational heterogeneity of DNA templates. We correlate such conformational differences
with optical heterogeneity of AgNCs. A detailed comparison of emissive properties of AgNCs between
UV excitation and visible excitation also points to the complex heterogeneous nature of generated
AgNCs. The designed constructs presented here can be further programmed into NA nanostructures
and networks bearing multiple functionalities. We demonstrate a simple assembly of two nanoclusters
into a linear construct, which is the first step towards larger patterned NA-based functional assemblies.
Practical applications of such networks are discussed.
2. Materials and Methods
2.1. Materials
All DNA oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
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OEC12: CCCCCCCCCCCCTGAGATGCTAACATGGCTCTAGTCGACGA; ssSD9-DimerC–
TCAACATCAGTCTGATAAGCTATTTCGTCGACTAGAGCCATGTTAGCATCTC.




Sodium borohydride was purchased from TCI (TCI America, Inc., Portland, OR, USA), all other
reagents were purchased from Sigma-Aldrich (Sigma-Aldrich, Inc., St. Louis, MO, USA).
2.2. Synthesis of Ag-DNA Nanoclusters
In a typical preparation, DNA and AgNO3 aqueous solutions were mixed at 55 ◦C and incubated
for 25 min at room temperature in the ammonium acetate buffer. Next, NaBH4 aqueous solution
was added and samples were placed on ice and stirred vigorously. The final concentrations of the
components were CDNA = 10 μM, CAgNO3 = 100 μM, CNaBH4 = 100 μM, and CNH4Ac = 50 mM.
The solution then was incubated in the dark for 24 h at 4 ◦C.
For manufacturing the assembly, the duplet sequence was utilized. To avoid interference of the
neighboring C12–C12 sequences, nanoclusters were first created on ssSD9-C12 or ssR21-C12 strands as
described above and subsequently annealed onto the larger complimentary ssDNA. For annealing,
the mix was subjected to 1 h thermal treatment in water bath at 40 ◦C, followed by cooling in an
ice-water bath. For fluorescence and atomic force microscopy (AFM) measurements, DNA-AgNC
samples were used without further purification.
2.3. Atomic Force Microscopy Imaging
AFM imaging of DNA-templated AgNCs was performed on MultiMode AFM Nanoscope
IV system (Bruker Instruments, Santa Barbara, CA, USA) in tapping mode. Briefly, 5 μL of the
DNA-templated AgNC solution were deposited on amino-propyl-silatrane (APS) modified mica [28]
for a total of 2 min [29]. Excess sample was washed with DI water and gently dried under a flow of high
purity argon gas and under vacuum overnight. AFM images in air were then recorded with a 1.5 Hz
scanning rate using TESPA-300 probes (Bruker AFM Probes, Santa Barbara, CA, USA) The probes have
~320 kHz resonance frequency and a spring constant of about 40 N/m. Images were processed using
the “FemtoScan Online” software package (Advanced Technologies Center, Moscow, Russia). Heights
of the structures were measured using the “cross section” tool within the “FemtoScan Online” program.
Height was measured as the highest point in the cross-section profile with the background subtracted.
2.4. Fluorescence Measurements
The excitation and emission spectra were acquired on a Cary Eclipse Fluorescence
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). In all the measurements,
the concentration of DNA was kept the same at 10 μM. Experiments were carried out at a room
temperature of ~22 ◦C. Fluorescence measurements were carried out in Sub-Micro Fluorometer Cell,
model 16.40F-Q-10 (StarnaCells, Inc., Atascadero, CA, USA). Only freshly prepared solutions were used
for spectroscopic measurements. The excitation–emission matrix spectra (EEMS) were recorded with
2 nm resolution. Fluorescence spectra were recorded with the emission wavelength range from 270 nm
to 800 nm, and the initial excitation wavelength was set to 220 nm and final excitation wavelength was
set to 700 nm with an increment of 2 nm. The slits were open to 5 μm and the PMT voltage was set to
700 V. EEMS data were then used for the 2D contour plot using MagicPlot Pro software (Magicplot
Systems, LLC, Saint Petersburg, Russia).
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3. Results
3.1. Design of AgNC DNA Template
A number of DNA sequences that template and stabilize AgNCs have been studied (reviewed
in [13]). Recently, it was proposed that identification of specific genome sequences can be made
based on the properties of AgNCs that these sequences template [21]. The most common ones used
in AgNC synthesis are cytosine-rich sequences due to the very high affinity of cytosines to silver
cations [20,30]. Our primary goal was to characterize the properties of DNA-templated AgNC and
explore the possibility of incorporating AgNCs into larger NA networks with functional properties
via a bottom-up assembly. We have designed sequences consisting of two parts: one that templates
AgNCs formation and another that is used for the further construction of the assembly. The designed
sequences have a double-stranded core, schematically illustrated in Figure 1A, with a random 30 bp
sequence, which does not form any secondary stable folds or hairpins [31]. AgNC templating sequence
has a stretch of twelve consecutive cytosines—(dC)12, Figure 1A. This DNA construct can be used
simultaneously as a template for AgNC formation and as a building block for making larger assemblies.
Two sequences were initially studied: SD9 core modified with (dC)12 at only one end and SD9
core modified with (dC)12 at both ends. These sequences were named SD9-OEC12 and SD9-BEC12,
respectively. Comparison with (dC)12 sequence alone–named C12 later in the text–was performed to
elucidate the effect of the neighboring duplex region on the properties of AgNCs created with the
single-stranded DNA template.
Figure 1. (A) Schematic representation of the template design, (B) a photograph of fluorescent glowing
of solutions containing fluorescent silver nanoclusters (AgNC) templated on C12 (red), SD9-OEC12
(yellow), and SD9-BEC12 (green), (left to right) under the UV excitation on a trans-illuminator.
Fluorescence spectra of AgNCs recorded with 254 nm excitation wavelength for the following templates
(C) C12, (D) SD9-OEC12, and (E) SD9-BEC12. Gaps in the spectra are due to the removal of the second
order scattering. Green and red solid lines are plotted as “guide for the eye” in the positions of major
“green” and “red” emission peaks.
3.2. The Formation of Silver Nanoclusters and Their Optical Properties under UV Excitation
The formation of DNA-templated AgNCs is manifested by the changes in solution that are
observed after 24 h incubation after the addition of Ag+ and sodium borohydride. Fluorescent
glowing of the solutions is evident with UV excitation under a trans-illuminator. Figure 1B shows
such glowing effect of AgNC-DNA solutions for three samples corresponding to sequences C12,
SD9-OEC12, and SD9-BEC12. Since the templating sequence is the same for all three samples—C12
31
Nanomaterials 2019, 9, 613
stretch, we expected similar colors. It appears, however, that all three samples have distinct fluorescence
colors: Red for C12, yellow for SD9-OEC12, and green for SD9-BEC12 (Figure 1B). The entire fluorescence
spectrum with excitation at 254 nm is shown in Figure 1 for all three sequences C12, SD9-OEC12,
and SD9-BEC12 (Figure 1C–E, respectively).
The spectra have many similar fluorescent peaks. For example, the broad peak in the 300–400 nm
part of the spectrum, which is assigned to the fluorescence of DNA bases [32]. The colors of AgNC
observed in the trans-illuminator suggested that fluorescence peaks in the visible should be detected.
SD9-OEC12 and SD9-BEC12 samples have a broad fluorescence in the visible region with two major
peaks “red” at λR = 640 nm and “green”, λG = 525 nm for SD9-OEC12, and λG = 510 nm for SD9-BEC12,
confirming that DNA template sequence has a direct effect on the fluorescent properties of silver
nanoclusters. Closer inspection of the fluorescence spectra also revealed two shoulders to the major
peaks at λ = 715 nm (red shoulder) and λ = 445 nm (green shoulder). Similar peaks are observed for
C12–templated AgNC but the red fluorescence at 640 nm dominates the spectrum (Figure 1C). Table 1
shows the relative intensity of “green” to “red” peaks measured as areas of Gaussian fits for the two
peaks in the spectrum plotted as fluorescence intensity vs. energy (Supplementary Figure S1). There
is a clear trend of dominant red fluorescence in the following order: C12 > SD9-OEC12 > SD9-BEC12.
The apparent color observed under UV excitation in the trans-illuminator thus represents a mix of two
primary fluorescent peaks with different proportions—rather than a single color.
Table 1. Relative ratios of fluorescence intensities for “green” and “red” emitters obtained from spectra
recorded using 254 nm excitation. The numbers were obtained as areas under the Gaussian fits to
intensity of fluorescence plotted vs. energy (shown in Supplementary Figure S1).
FMAX, nm C12 SD9-OEC12 SD9-BEC12
510-525 (green) 13 42 69
640 (red) 87 58 31
Despite the similarities of the templating sequences, C12, for all three designs, we observe large
differences in the optical properties of the synthesized AgNCs. These differences go beyond the
expected double intensity for SD9-BEC12 compared to SD9-OEC12. The intensity of “red” emission is
similar, while “green” emission is dramatically enhanced for SD9-BEC12-templated AgNCs compared
to SD9-OEC12. The SD9-OEC12 and C12 also exhibit noticeable differences. The “green” AgNCs
have low fluorescence yield when C12 template is used. The “green” emission, however, seems to
be largely present in SD9-OEC12 and even more intense in SD9-BEC12. It is tempting to speculate
that the formation of “green” emitters is triggered by the double-stranded core SD9. Alternatively,
a potential self-assembly of individual strands (Supplementary Figure S2) of SD9-OEC12 and SD9-BEC12,
as predicted by NUPACK [33], may result in reorganization of the C12 strands in 3D space, thus changing
the AgNC formation.
We have further characterized the properties of AgNCs templated with SD9-BEC12,
SD9-OEC12, and C12 by employing fluorescence excitation-emission matrix (EEM) spectroscopy.
The excitation/emission relationship of the optical response of the AgNCs can be a little complicated
and a better way to represent such responses is through measuring the entire 3D excitation/emission
matrix presented as contour maps. EEM has the advantage of showing the relationship between
excitation, emission, and their intensities in the wide range of wavelengths, allowing for complete and
quantitative characterization of sample’s fluorescence profile [25].
Figure 2 shows EEM maps for all three DNA sequences in the range 220–370 nm for the excitation
while the entire emission spectrum in the UV and visible spanning 270–800 nm wavelengths was
recorded. Some similarities in the behavior of emissions are obvious. For example, emissions of
nucleobases spanning ~300 to ~350 nm was excited with UV: 220 to ~230 nm [32]. However, there are
major differences observed in the emission of AgNCs in the visible spectral range excited via UV.
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Similar to the spectra shown in Figure 1, the red emission dominates C12, while green emission is
dominant in the case of SD9-BEC12 template.
Figure 2. Excitation/emission maps of silver nanoclusters with excitation in UV: (A) AgNC templated
on C12, (B) AgNC templated on SD9-OEC12, (C) AgNC templated on SD9-BEC12.
Close inspection of the emission peaks reveals that C12 has the maximum fluorescence at 645 nm,
SD9-OEC12 at 640 nm, and SD9-BEC12 at 635 nm. Interestingly, this trend in the shift to lower
wavelength also follows the increase in intensity of green fluorescence in the following order: C12,
SD9-OEC12, and SD9-BEC12. These observations suggest that the “red” emitters synthesized using the
three templates are either different species or the same species experiencing distinct surroundings.
While the “green” emission is practically absent in C12, it becomes detectable for SD9-OEC12
and is very intense for SD9-BEC12. The maximum of green emission for SD9-OEC12 is observed at
525 nm while for SD9-BEC12 it is observed at 510 nm, a noticeable 15 nm shift. Again, SD9- BEC12
template causes the fluorescence maximum to shift to lower wavelengths. Another major difference
is an extra excitation band at 335 nm that only appears for the SD9-BEC12-templated AgNC and
only for the green emission. This fluorescence peak has a maximum at 490 nm (“blue”). This serves
as additional evidence of different surroundings of the emitting AgNC. We hypothesize that such
differences are related to conformational heterogeneity of the DNA template induced by the presence
of double-stranded SD9 core. Our EEM spectroscopic measurements reveal that the color of emission
changes dramatically from template to template suggesting that AgNC of the same kind, “red” or
“green”, experience different surroundings for the three templates used here.
It appears that the emission of AgNCs in the visible part of the spectrum is universally excited
via DNA bases, which agrees well with published data [23]. It has been shown before that visible
emission of AgNCs can be excited by both direct excitation into the visible band and by UV light into
the absorption peak of DNA nucleobases [30,34]. A detailed study of UV excitation of DNA-templated
silver nanoclusters suggests optical interactions between the DNA template and AgNC [23]. Excitation
of AgNC fluorescence in the area of nucleobase absorption is a valuable feature of a DNA template.
As such, optical properties of nucleobases can be beneficial for the excitation of AgNCs. The proximity
of AgNC to DNA nucleobases, which not only nucleate and stabilize AgNC but also transfer the
energy of the excitation, prompted more detailed studies of the phenomenon [23]. It has been proposed
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that DNA serves as an antenna in funneling the energy of UV light to fluorescence of AgNC [35],
but the mechanism of energy transfer from the UV-excited nucleobases remains unclear. Nevertheless,
the presence of coordinated DNA bases is necessary for the excitation of AgNC fluorescence by the
UV light. Treating DNA-templated AgNC with DNAse reduces fluorescence intensity with time
of treatment (Supplementary Figure S3). These results indicate an intimate relationship between
optical properties of AgNC and templating DNA bases. In addition, during treatment “green” color
disappears while “red” color still persists, although faintly, suggesting tighter connection of “green”
emitters with DNA bases.
3.3. Optical Properties of AgNC under Visible Light Excitation
Next, we measured excitation/emission maps for all three sequences while exciting in the range of
visible wavelengths between 370 nm and 700 nm. While EEM with UV excitation reveal properties of
the AgNCs that are in close proximity to nucleobases where efficient energy transfer from DNA bases
is possible, the visible excitation probes optical properties of the nanoclusters in general, regardless of
their association with the bases. Figure 3 shows the maps for C12, SD9-OEC12, and SD9-BEC12 (A, B,
and C respectively).
Figure 3. Excitation/emission maps of silver nanoclusters with excitation in the visible: (A) AgNC
templated on C12, (B) AgNC templated on SD9-OEC12, (C) AgNC templated on SD9-BEC12.
It is obvious that there is one peak, which is similar for all three templates—the red emission
above 600 nm. Interestingly, this peak appears as a duplet with maxima at 640 nm and 650 nm for all
three samples. Another similarity is the emission at ~715 nm. It is well pronounced in C12 template
but faintly present in both SD9-OEC12 and SD9-BEC12.
Consistent with the UV excitation, EEM maps for the visible excitation do not show any green
fluorescence for the C12 template, while it is present for SD9-OEC12 and SD9-BEC12. We infer that
such differences might be associated with the influence of the core SD9, which either stabilizes green
emissive species or alters the conformation of C12–stretch in such a way that also allows for the
formation of the clusters emitting in green.
Unlike other studies, we find that green and red emissions are not equivalent for the excitation
in UV and the visible spectral region. Despite its bright appearance when excited in UV, green
emission seems to be relatively silent when excitation is performed in the visible range of wavelengths.
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The maximum of emission is also shifted to lower wavelengths when comparing visible vs. UV
excitation. The maximum of emission shifts by 10 nm for SD9-OEC12, with λ = 535 nm for visible
excitation and λ = 525 nm for the excitation in UV. The maximum of emission for SD9-BEC12 shifts by
more than 20 nm, with λ = 530 nm (for visible excitation) and λ = 510 nm (for UV excitation).
Additionally, red emission has very similar intensity for all three templates, while green clearly
dominates the emission for SD9-BEC12-templated AgNCs when excited via UV. We hypothesize that
SD9-OEC12 and SD9-BEC12 templates are capable of producing both types of AgNCs, green emitting
and red emitting species with population largely shifted towards red species. The coordination
with DNA bases in the case of green emitting clusters allows for more efficient energy transfer,
larger quantum yield, and, therefore, greater fluorescence intensity of the green emitters when excited
via DNA bases in UV.
One interesting feature of the red emission behavior for the AgNCs is that the emission maximum
progressively shifts to the red as the excitation wavelength is increased starting from 515 nm all the
way to ~700 nm (see Figure 3 and Figure S5). The magnitude of Stokes shift (λEM − λEX), however,
remains similar at ~70 nm throughout the visible part of the map. This bathochromic shifting in the
emission band with the increase of the excitation wavelength resembles the phenomenon observed
previously for polar organic fluorophores in “rigid” solutions [36–38]. The phenomenon of fluorescence
dependence on the excitation wavelength is known as “red-edge excitation shift” (REES) [39]. This kind
of dependence seems to be inconsistent with the Kasha’s rule, which states that the fluorescence
spectrum should originate from the lowest vibrational level of the first excited singlet state irrespective
of the excitation wavelength. Our AgNCs do not seem to obey this rule, exhibiting an obvious shift
of emission to the red when excitation wavelength is increased, which is consistent with the REES
effect. One possible explanation of such an effect in AgNCs is the “rigid” nature of clusters and their
surroundings. The randomization of the local environment is not fast enough to allow for efficient
relaxation of the excited state of the cluster. They are forced to emit not from the lowest level of the
first excited singlet state but from the higher levels.
It is quite peculiar that no bathochromic shift is observed with the emission bands when excited
via DNA bases. Quite smooth spectra with the same maxima are observed regardless of the change
in excitation wavelength throughout the UV region. This observation suggests that Kasha’s rule is
obeyed for the excitation of nanoclusters via UV, providing additional ground for speculation that
the two populations of clusters are different in their photophysical properties, which stem from their
different surroundings. The differences in optical properties between nanoclusters excited in UV and
visible spectral range suggests a large degree of AgNC heterogeneity.
3.4. AFM Topography of DNA-Templated AgNC
We have further investigated the morphology of the DNA-templated AgNC complexes using
Atomic Force Microscopy. Figure 4 shows AFM topography images of samples for all three AgNC
templating sequences: C12, SD9-OEC12, and SD9-BEC12. The AFM images of SD9-OEC12 show that
templated silver nanoclusters adopt mostly small elongated shapes (Figure 4B, I) when deposited
on mica substrate. The spherical structures were expected based on previously published data for
long C-rich strands [40]. We assign these elongated shapes to a single SD9-OEC12. In addition to
small elongated shapes, the SD9-OEC12 forms longer strands (Figure 4B, II), some of which have an
angled junction. The total length of the entire SD9-OEC12 template is expected to be ~14 nm, if one
assumes 0.34 nm base–base distance as in dsDNA. The measured contour length for elongated shapes
in the AFM topography image exceeds the expected 14 nm. The strands with the angled junctions
morphologies most likely represent adducts of two SD9-OEC12 templates joined together. Inset II
in Figure 4B shows the length of the arms for angled shape is ~11 nm, which corresponds well to
the expected length of 30 bp of the SD9 core. Inset III in Figure 4B shows another representative
shape where two molecules form an adduct with a straight junction. This suggests that SD9-OEC12
sequences form a variety of shapes in solution as well as adducts between two or more molecules.
35
Nanomaterials 2019, 9, 613
Some shapes are tri-point or Y shapes with three strands joined together. Figure 4B inset IV shows one
such representative shape, each strand measures ~14 nm indicating that the tri-point is a result of three
connected SD9-OEC12 monomers.
 
Figure 4. Atomic force microscopy (AFM) topography images of AgNC template with (A) C12,
(B) SD9-OEC12, (C) SD9-BEC12. Insets show representative structures of the template sequences.
Scale bar in all insets is 10 nm.
The structures of SD9-BEC12-templated AgNCs are markedly different. There are still some
elongated shapes observed in the AFM topography image shown in Figure 4C, but there are more
longer strands in the image. The length of the strands for the SD9-BEC12 sample is rather heterogeneous
with contour lengths up to 80 nm (Figure 4C, inset V). With extended C12 stretches, a single SD9-BEC12
molecule should measure ~18 nm assuming 0.34 nm base–base distance. The 80 nm long shape should
be comprised of ~5 monomeric SD9-BEC12 molecules. Angled and straight dimeric/multimeric strands
can also be found in topography images (insets II–IV in Figure 4B).
Longer assemblies are observed in the images of the C12 sample as well. Figure 4A shows an
AFM image of C12-templated AgNCs. Elongated curved structures absolutely dominate the image.
The length of the observed shapes exceeds the length of 12 base long oligonucleotide suggesting that
the adducts of multiple C12 are formed. We further examined the cross-sections of the elongated shapes
in the images. Typical AFM images in tapping mode produce the height of double-stranded DNA
at around 0.5–0.8 nm [41–43]. While height values for most of the strands measured in our images
do fall within this range, some areas show height values that exceed the height of the regular DNA
duplex. A cross section in Figure 4B (inset II) for SD9-OEC12 indicates h = 0.7 nm in the arms of the
dimeric adduct and h = 1.1 nm at the junction. Even visually, these two regions appear very different.
The height of the point where two molecules are joined together suggests that the morphology of the
DNA structure different from duplex is formed at the junction.
The observed differences in elongated shapes for C12, SD9-OEC12, and SD9-BEC12 are obviously
due to the differences in the sequence that allow such distinct shapes to appear. We propose that
the elongated strands observed are due to single-stranded (ss) C12 stretch forming a non-canonically
bonded double-stranded DNA form via Ag+ linkage. Such a possibility has been demonstrated
recently [44]. Alternatively, a tetra-stranded structure termed i-motif [45] could also form with the help
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of silver cations [46]. While connected via Ag+ linkage, double-stranded form is expected to appear as
regular dsDNA in the AFM images. The i-motif, on the other hand, is composed of four strands and
should appear higher on the image, as we observe at the junction (Figure 4B, inset II).
Both alternative structures differ from ss-DNA and yet serve as AgNC templates in a distinct
way. While AFM provides unambiguous evidence for the formation of different shapes, we also
observe remarkable differences in fluorescence between nanoclusters templated by C12, SD9-OEC12,
and SD9-BEC12. We hypothesize that the differences in optical properties of silver nanoclusters are
likely associated with the extent of non-canonical structure formations such as Ag+-C12 duplex or
i-motif. Visually, C12 templates appear more curved, providing ground for speculation that curved
geometry of template is responsible for the red emission of AgNCs in C12 while green emitters are
predominately formed in linearly shaped templates (SD9-BEC12). The results of this section are an
additional manifestation of how sensitive the optical properties are towards surroundings, namely the
sequence of templating DNA and its secondary structure.
3.5. The First Step Towards Assembly
Dimeric assembly with a dual cluster templating sequence can represent a first step towards a
larger DNA-based network. Figure 5 schematically illustrates such a dimeric design. We explored
two different variants of the dimeric assembly: (1) “Forward” design, where C12 templating stretches
are separated by 30 bp double-stranded core sequences—SD9 (Figure 5A), and (2) “reverse” design,
with C12-templating sequences brought together by this assembly (Figure 5B). Fluorescence properties
of AgNCs templated by the “forward” assembly resemble well the properties of AgNCs formed with
SD9-BEC12 sequence including the unusual 335/490 nm “blue” peak (Figure 5C,D). The intensities of
all the peaks, both in UV-excited emission and visibly-excited emission for the “forward” assembly
are exactly the same as for SD9-BEC12, confirming the similarity of the structure and conformation of
DNA and AgNCs.
Figure 5. (A) Schematic representation of template design for the “forward” assembly, (B) schematic
representation of template design for the “reverse” assembly. Templating C12 sequences are shown in
red. Excitation/emission maps of silver nanoclusters: (C) AgNC templated on “forward” assembly with
excitation in the visible spectral range, (D) AgNC templated on “forward” assembly with excitation
in the UV, (E) AgNC templated on “reverse” assembly with excitation in the visible spectral range,
(F) AgNC templated on “reverse” assembly with excitation in the UV.
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It is quite interesting that the optical properties of the resultant assemblies do not resemble
SD9-OEC12 but appear similar to SD9-BEC12 including the prevalence of green fluorescence and the
“blue”—335/490 nm peak. Visible excitation of emission produces a similar map as for SD9-BEC12 and
SD9-OEC12 with the characteristic double peak: 570/650 nm and 590/660 nm. In addition, a small peak
at 435/530 nm is observed, similar to both SD9-OEC12 and SD9-BEC12 templates.
Dramatic changes of the AgNC optical properties are observed when “reverse” design was
utilized, Figure 5E,F. The enhancement of the green emission is quite obvious. There are only slight
remnants of the red fluorescence while green emission dominates the 2D map when excited in the UV
(Figure 5F). The 335/490 nm “blue” peak is now dominant in the excitation/emission map, providing
additional clues to the origin of this peak, which are described in the Discussion section. The 2D
excitation/emission map with visible excitation for the “reverse” design appears to be different from
the one for “forward” design. “Green” peak is intensified and shifted to longer wavelengths in the
“reverse” assembly. In addition, “red” fluorescence at ~700 nm is enhanced in the “reverse” design
compare to “forward” assembly. Similar to individual templates, the maxima of emission in the
assemblies do not coincide when AgNCs are excited via UV and visible, as clearly observed in the
maps. “Red” emission is intensified with visible excitation and “green” is shifted to lower wavelengths
when excited via UV.
4. Discussion
NA-based tools of nanotechnology open large prospects in designing and controlling the size
and shape of nanostructures. DNA can serve as a template for the controlled synthesis of novel
nanomaterials that are arranged in a highly organized network of functional entities, exemplified in
this work by AgNCs. Beneficial novel properties may result from placing AgNCs into nanostructures
with organized patterns. Examples of such beneficial properties are the use of AgNCs as logic optical
gates [47], optoelectronics [15], bioimaging, or detection of specific nucleic acid sequences where
the signal is amplified due to optical coherence of the signal from AgNCs organized in patterned
nanostructures. Additionally, controlled AgNC formation can be used as the means of label-free
visualization of NA supra-assemblies and nanomaterials.
One of the questions that we address with this study is, what would be the properties of AgNCs
when they are assembled into larger networks using DNA as an architectural element? The effects
needed to be probed are the close proximity of the DNA on the optical properties of templated AgNCs
such as double-stranded core, loose ends of nucleic acids, and other structural elements used in the
field of DNA nanotechnology [48]. Our choice of template sequence was single-stranded cytosine
stretch—C12, which has been previously shown to produce silver nanoclusters with high yield of
fluorescence in the visible range of wavelengths [30]. Additional double-stranded region was placed
next to C12 mimicking the nanostructure design when larger assembly is created. Double-stranded
DNA show no template activity unless modified to contain a mismatched site, an abasic site, a gap,
a bulge, or a loop [13]. Silver nanoclusters generated by the double-stranded templates exhibit
negligible fluorescence signal. We verified the inability of SD9 core to generate and stabilize any type
of clusters by running a control experiment where SD9 core duplex was mixed with AgNC forming
components: Ag+ and NaBH4. No detectable fluorescence was observed without the C12-templating
sequence (Supplementary Figure S4).
While C-rich sequences have high affinity to silver, which makes them very good templating
sequences for AgNC synthesis, they also have the ability to form alternative non-canonical DNA
structures. For example, a duplex stabilized by silver in a C-Ag-C pairing rather than canonical
Watson-Crick [49]. Such structures are quite stable, Ag+ bridges the N3 atoms of the C bases
resulting in the C-Ag-C pairing link [50]. Another example of non-canonical form is the i-motif where
semiprotonated C-rich oligonucleotides are arranged in a tetra-stranded structure [51]. Typically,
the formation of i-motif structures is favored at mild acidic conditions due to protonation of N3 in the
cytosine. The entire structure is stabilized via hydrogen bonds between C+–C in the semi-protonated
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base pairs. However, silver cation can join C strands in a C-Ag+-C bridge even at neutral pH values [46].
The affinity to silver is so specific that an Ag+ detection has been proposed based on i-motif formation
due to the presence of Ag [52].
At neutral pH, the formation of alternative structures leading to elongated shapes observed in
AFM experiments depends critically on the silver content in the solution. Our data suggest that the
elongated strands are linked together via a non-canonical structure with the help of Ag+. We considered
both versions of the possible structures: The silver-stabilized duplex between two C12 stretches and the
i-motif. The duplex between C12 strands stabilized by silver is not expected to appear much different
from regular DNA duplex in the AFM topography images. An example is round shaped adducts
observed in AFM topography images for the C12 sequence. While it is clearly an adduct of many
molecules of C12, the height of the structure appears similar to dsDNA at ~0.7 nm. Contour length
analysis of the shape shown in Figure 4A, inset V (LC = 30 nm) suggests that up to 20 molecules of
C12 need to join together to form such a shape. On the other hand, the i-motif is structurally different
from single-stranded or double-stranded DNA. The four-stranded nature of the i-motif increases the
lateral size of the structure, which can be easily identified using AFM. Indeed, AFM allowed us to
recognize the features that are larger than DNA duplex. Examples of structures formed with i-motif
are dimeric and trimeric adducts with junctions that exceed sizes of ds-DNA (Figure 4B, insets I
and II). Figure 4 presents our vision as to how such i-motif junctions can form. It has been shown
that both inter-molecular packing and intra-molecular folding of strands into i-motif is possible [53].
Several studies have already started exploring the use of i-motif as a structural element in DNA
nanotechnology [11].
The i-motif formation results in a more compact shape than duplex. It has a shorter distance
between the bases, 0.31 nm as compared to 0.34 nm in a regular double strand [40,54]. Therefore,
i-motif creates a denser population of silver cations holding the i-motif together. The alignment of
silver cations and the shape of the resultant nanoclusters templated by the i-motif are expected to be
different from those of both single-stranded C12 and double-stranded C12-Ag-C12. Because of such
difference, the i-motif structure should also affect optical properties of templated AgNCs. It has been
stated previously that i-motif structures primarily produce red emissive AgNCs [55]. Further studies
using single nanocluster fluorescence measurements and their correlation with AFM imaging will
unambiguously assign the color and photophysics of AgNCs to the template type, specifically i-motif,
and we are currently considering these single nanocluster studies.
The measured excitation/emission matrices for C12, SD9-OEC12, and SD9-BEC12 sequences
indicate that there are mostly two distinct color clusters—“green” and “red”. Previously, the distinct
fluorescence peaks have been associated with clusters of different sizes [30]. DNA templates are capable
of stabilizing various (Ag)N clusters where N is the number of silver atoms forming a nanocluster. It is
commonly accepted that the DNA templated (Ag)N nanoclusters are rod like in shape and include both
neutral Ag0 atoms and charged Ag+ [56]. Recent study revealed that a “magic number” of neutral silver
atoms is required for distinct “green” and “red” fluorescence to occur. Namely, it has been inferred
that four neutral atoms produce green fluorescence and six neutral Ag atoms produce red fluorescence
regardless of the number of Ag+ [57]. In general, larger AgNCs emit at longer wavelengths [58].
Therefore, it seems appropriate in our case to assign green fluorescence to AgNCs of smaller cluster
size with four Ag0 and red fluorescence at 640 nm to larger clusters with six Ag0.
The environment of the clusters composed of nucleobases, although very important, is poorly
understood. The tuning of fluorescent properties of AgNCs is often done only empirically. Recent
studies have tried to look into a deeper understanding of the role different nucleobases play in
optical/photophysical properties of AgNCs [23,59]. When placing AgNC into larger assemblies of
nucleic acid structures, several factors may play a role in altering the AgNC fluorescence: (1) Templating
sequence, (2) adjacent double-stranded sequence, and (3) the overhang sequence. As all three are
contributing factors to fluorescence, changing them provides additional degrees of freedom for tuning
the fluorescence properties of AgNCs. A vivid example of the effect of non-templating sequence on
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optical properties of AgNCs is the presence of overhang strands. G-rich overhangs produce drastic
changes in excitation, emission, and quantum yield of fluorescence [18]. Our results demonstrate that
simply changing the direction of dimeric assembly from “forward” to “reverse” drastically increases
“green” fluorescence when excited via DNA bases with UV. “Red” emitting species are still formed
in the “reverse” assembly, as indicated by the excitation in the visible, but the UV excitation channel
via DNA bases is completely turned off for the “red” emitting nanoclusters. It has been established
that bases are electronically coupled to silver nanoclusters. One manifestation of such coupling is the
AgNC emission when excited at nucleobases’ UV absorption. The heteroatoms of bases, particularly
N7, N3, and N2 change the electronic environment of the cluster. This, in turn, stabilizes particular
emissive levels, enhances the fluorescence quantum yield, and increases fluorescence lifetime by several
nanoseconds [59]. Our observations point to the complexity of the electronic structure of the nanoclusters
and the abundance of possibilities of the de-excitation processes (Supplementary Figure S5).
We hypothesize that the “green” emitting nanoclusters are tightly associated with DNA bases
leading to their selective UV excitation. This is contrary to the “red” emitting clusters where association
is not as tight, resulting in preferential excitation in the visible. More evidence of tight DNA association
with “green” emitting clusters is the apparent lack of red-edge emission shift (REES) for these AgNCs
excited in the visible. In general, REES is observed when the process of internal conversion is very slow
compared to fluorescence lifetime. REES has been observed for polar fluorophores in viscous media [38].
Relaxation due to solvent molecule reorientation is not fast enough within the fluorescence lifetime,
leading to the observation of the emission maximum shifting to the red. No REES is observed for the
AgNCs, both “green” and “red” emission, when excited via UV. This indicates that nanoclusters tightly
associated with DNA bases experience an environment that provides effective randomization. The “red”
emission excited in the visible has a clear REES effect. On the other hand, the maximum of the 550 nm
peak in the fluorescence of AgNCs excited in the visible for the “reverse” design appears to be shifting
only slightly to the red but not as fast as the emission in the ~600–700 nm region. This situation appears
somewhat intermediate between the “rigid” and “flexible” environments, providing some degree of
randomization of the surroundings. We hypothesize that this effective randomization originates from
tighter association of “green” nanoclusters with DNA bases. While the observed differences between
“green” and “red” emitting species indicate a distinct AgNC environment, additional time-resolved
detailed spectroscopic measurements will help to more fully describe this phenomenon. One of the
most intriguing results of our study is the appearance of the “blue” emitting species, 335/490 nm.
These species are excited via UV but emit in the visible spectral range. The magnitude of Stokes shift
for these species, Δλ ≈ 155 nm, is almost double that for nanoclusters excited in the visible range
with Δλ ≈ 70 nm, but not nearly as high as the Stokes shift observed for UV excited emission, Δλ up
to 300 nm for “green” or Δλ up to 420 nm for “red”, indicating uniqueness of these hybrid species.
The formation of the “blue” emitters is favored whenever C12 templating sequence is placed at the 5′
end of the double-stranded core. This is the case with SD9-BEC12 as well as both dimer assemblies.
We have verified the link between 5′ template and blue nanocluster formation by placing C12 at 5′ in
the SD9-5′-OEC12. There is a clear peak in the blue indicating the formation of the “blue” emitters
(Supplementary Figure S6). We, therefore, conclude that C12 sequence placed at 5′ somehow stimulates
the formation of the “blue” emitters, perhaps by adopting favorable conformation.
Overall, our results suggest a high degree of heterogeneity of synthesized AgNCs. Since the
resulting AgNCs are so heterogeneous, it might be very difficult to purify a single population of AgNCs,
which will exhibit homogeneous optical properties as the environment variation affects individual
clusters. Therefore, ensemble-based measurements may not be an appropriate choice of method
for studying properties of AgNCs. It is reasonable to suggest that single nanocluster spectroscopic
studies should provide a clearer understanding of the AgNC optical properties free of complications
originating from the heterogeneous nature of nanoclusters in ensemble.
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5. Conclusions
In summary, our studies offer a detailed characterization of AgNC synthesized using C12-based
template sequences designed for construction of larger DNA-based assemblies. We have shown the
possibility of combining silver nanoclusters into larger assemblies of nucleic acids using a simple
design containing a single-stranded template and a double-stranded core. A full excitation/emission
data matrix has proven to be an effective tool in exploring the complex optical behavior of silver
nanoclusters templated on nucleic acid sequences. Our findings indicate that close proximity of
double-stranded region changes preferential formation of “red emitters” with λEM = 640 nm observed
on C12 sequences to the formation of “green emitters” with λEM = 510 nm when double-stranded
region is present. Further detailed exploration of NA templates, specifically their conformation and the
possibility of non-canonical structure formation, will facilitate our understanding and control of AgNC
properties. Our results also show that the fluorescence of AgNCs can be modulated by controlling the
position of the AgNCs within the dimeric assembly. Placing nanoclusters closer together dramatically
enhances the fluorescence of AgNCs, but also changes the electronic structure of the nanoclusters,
primarily affecting the excitation/emission of the “green” and the “blue” emitters. Our observations
point to the complexity of the electronic structure of the nanoclusters and the abundance of possibilities
of the de-excitation processes. This in turn allows for fine-tuning of fluorescent properties of AgNCs.
Effective randomization of the local environment for the “green” emitting species, as manifested by the
reduction in REES, is primarily observed for the clusters placed in proximity. We envision a construction
of large assemblies using nucleic acids as architectural templates with unique tunable fluorescent
properties of AgNCs that could be used in novel materials, devices, and diagnostic applications.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/4/613/s1,
Figure S1: Fluorescence spectra of AgNCs recorded with 254 nm excitation wavelength and plotted as fluorescence
intensity vs. energy (eV), Figure S2: Predicted secondary structures using NUPACK, Figure S3: Fluorescence
intensity change of C12-templated AgNCs treated with RQ1 DNase, Figure S4: Full excitation/emission map for
double-stranded SD9-core template, Figure S5: Full excitation/emission energy map of AgNCs templated on
SD9-OEC12 sequence with schematic Jablonski diagrams showing de-excitation pathways for the “red” and the
“green” emitters, Figure S6: UV excitation/emission map for SD9-5′-OEC12 templated AgNCs.
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Abstract: Nucleic acid-based technologies are an emerging research focus area for pharmacological and
biological studies because they are biocompatible and can be designed to produce a variety of scaffolds
at the nanometer scale. The use of nucleic acids (ribonucleic acid (RNA) and/or deoxyribonucleic
acid (DNA)) as building materials in programming the assemblies and their further functionalization
has recently established a new exciting field of RNA and DNA nanotechnology, which have both
already produced a variety of different functional nanostructures and nanodevices. It is evident
that the resultant architectures require detailed structural and functional characterization and that
a variety of technical approaches must be employed to promote the development of the emerging
fields. Small-angle X-ray and neutron scattering (SAS) are structural characterization techniques
that are well placed to determine the conformation of nucleic acid nanoparticles (NANPs) under
varying solution conditions, thus allowing for the optimization of their design. SAS experiments
provide information on the overall shapes and particle dimensions of macromolecules and are
ideal for following conformational changes of the molecular ensemble as it behaves in solution.
In addition, the inherent differences in the neutron scattering of nucleic acids, lipids, and proteins,
as well as the different neutron scattering properties of the isotopes of hydrogen, combined with
the ability to uniformly label biological macromolecules with deuterium, allow one to characterize
the conformations and relative dispositions of the individual components within an assembly of
biomolecules. This article will review the application of SAS methods and provide a summary of their
successful utilization in the emerging field of NANP technology to date, as well as share our vision
on its use in complementing a broad suite of structural characterization tools with some simulated
results that have never been shared before.
Keywords: small-angle X-ray scattering; small-angle neutron scattering; contrast variation; nucleic
acid nanoparticle; structural characterization
1. Introduction
Nucleic acid-based nanoparticles (NANPs) [1–13] and other nucleic acid-based nanodevices [14–17]
are an emerging research focus area in pharmacological and biological studies. NANPs can be designed
and manipulated to produce a variety of different functionalized nanostructured scaffolds; the novel
resultant structures require detailed characterization prior to further biomedical transition and in vivo
studies [7,18–22]. Conventional characterization techniques include the routinely used analysis of
NANPs by native-PAGE (non-denaturing PolyAcrylamide Gel Electrophoresis) [23], dynamic light
Nanomaterials 2019, 9, 681; doi:10.3390/nano9050681 www.mdpi.com/journal/nanomaterials45
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scattering (DLS) [4], atomic force microscopy (AFM) [24], and more sophisticated methods employing
cryogenic-electron microscopy (cryo-EM) [25], nuclear magnetic resonance (NMR) [26], and X-ray
crystallography [27] (see Table 1 for a comparison of the advantages and limitations of these structural
characterization techniques). However, none of the aforementioned techniques allows for direct
visualization of large (>100 kDa) three-dimensional NANPs in solution, and they often require working
with high concentrations of NANPs.
Table 1. Comparison of nanoparticle structural characterization techniques.
Technique Parameters Analyzed/Advantages Limitations
Solid State/Static Techniques
Crystallography [28]
High resolution molecular structure
Broad Mass range
Model building is well-developed
Static crystalline state structure; may
not reflect dynamic or flexible
structures
Sample must form a crystal
Scanning Electron Microscopy
(SEM) [28,29]
Particle size, size distributions, shape
Sample preparation is relatively
simple
Structure in native state
Allows analysis of hydrated materials
without fixation, drying, freezing, or
coating
Limited to larger molecules (up to
~200 nm)
Highly dependent on electron
microscopy (EM) techniques and
access to costly equipment
Cannot be used on certain biological
materials due to degradation caused
by the electron beam
Low resolution
Transmission
Electron Microscopy (TEM) [28]
Particle size, size distributions, shape
Produces high resolution images that
can provide information about
structure and elemental composition
High resolution TEM has Å resolution
Harsh chemical treatment of the
sample
Statistics are highly dependent on
technique
2D images
Samples need to be dehydrated,
collected on metal mesh, and stained
Small viewing section of sample
Atomic Force Microscopy (AFM)
[30,31]
Provides a three-dimensional surface
profile
Minimal sample preparation
Shown to give true atomic resolution
in ultra-high vacuum (UHV) and,
more recently, in liquid environments
Can only image a maximum height on
the order of 10–20 micrometers and a
maximum scanning area of about
150 × 150 micrometersImages can
also be affected by hysteresis of the
piezoelectric material
Possibility of image artifacts







Hydrodynamic particle size, size
distributions, surface charge
Sample volumes are small (μL)
Particle size across a broad range (~0.1
nm to ~10 μm)
Allows measurements under
physiological conditions
Can only measure solid particles,
polymers, and proteins dispersed in a
solvent or emulsions
Light absorption by the dispersant or
sample can interfere with detection
Concentration dependent
Samples need to be homogenous
Little shape information; size of
particles can be under or
over-estimated
Dust/traces of agglomerates can
interfere with results
Cannot distinguish between similarly
sized populations without coupling to
a separation
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Table 1. Cont.




3D structure in solution
Dynamics can be studied









Structure in native state
Particle size and shape, size
distribution, particle interactions and
interatomic distances: some
parameters determined with sub Å
precision
Small sample size (10–25 μL solution;
0.01–10 mg/mL)
Highflux synchrotron sources allow
for time-resolved, kinetic studies
Low-resolution shape information
interpreted from interatomic distance
distributions
Highest level of structural information
requires pure, monodisperse samples
Small-Angle Neutron Scattering
(SANS) [28,33]
Amenable to contrast variation
Sensitive to fluctuations in the nuclei
density of the sample
Experiments require access to user
facilities with appropriate neutron
source and instrumentation
Flux of neutron source is
intrinsically low
Small-angle scattering (SAS) is a structural characterization technique that is well placed to
determine the conformation of NANPs under varying solution conditions, which will allow for
optimization of their design and pipe-line production. SAS experiments yield information on the
overall shapes and electron (or nuclear) density distribution within macromolecules in solution (for
additional primers on this technique, see [33–37]). In addition, the inherent differences in the neutron
scattering of nucleic acids, lipids, and proteins allow for the characterization of the conformations and
relative dispositions of the individual components of an assembly of biomolecules using methods
of contrast variation or solvent matching. Also, due to the different neutron scattering properties of
the isotopes of hydrogen the neutron scattering contrast can be enhanced by labeling one component
within a macromolecular assembly with deuterium. An example application would include using
contrast variation methods to examine the overall shape of NANPs that have been functionalized
with short interfering RNAs (siRNAs), ribozymes, aptamers, proteins, or other small molecules (for a
review of functionalized nanoparticles see [38,39]. Conformational changes within the NANP itself as a
result of direct or indirect fusion with these therapeutically relevant molecules could then be observed
independently. Small-angle neutron scattering (SANS) combined with contrast variation or contrast
matching methods would allow for detection of the conformation of each of the individual components
within the resultant NANP assembly, as well as the distance between their centers of mass. A structural
basis for understanding the resultant functionalized NANPs will be essential to guarantee precise
control over the composition and stoichiometry of therapeutic modules for simultaneous delivery into
diseased cells and eventually for their successful transitions to in vivo preclinical studies [7,11,18–20,40].
Certainly, the direct visualization of various NANPs and NA multi-stranded assemblies can be, and
has been, achieved with AFM [41] and cryo-EM [7], as mentioned previously. However, the resolution
of these techniques is currently limited by the size (with smaller NPs < 20 nm being preferred), shape,
and composition of the nanoparticles. Also, neither of these techniques addresses the complicated,
dynamic environment of the particle in solution. Therefore, to gain additional information about the
structure of NANPs and to understand more completely the structure-to-function relationship, thus
possibly enhancing its functionality, several techniques must be combined. This article will review
the application of small-angle X-ray and neutron scattering methods and provide a summary of their
successful utilization in the emerging field of NANP technology to date. Importantly, we share our
vision for how it may be used in the near future to add to and complement a broad suite of structural
47
Nanomaterials 2019, 9, 681
characterization tools with some guidance and the feasibility of the proposed applications by including
some simulated results that have never been shared before.
2. Discussion
A model for the structure of nucleic acids was initially proposed by Watson and Crick in 1953.
Interpretation of the X-ray diffraction patterns from meticulously prepared 2D deoxyribonucleic acid
(DNA) crystals recorded by Rosalind Franklin provided the key to understanding this structure. Since
then, X-ray diffraction has played a vital role in further discoveries of numerous types of nucleic
acid structures. An excellent review of the applications of various synchrotron-based spectroscopic
techniques, including small-angle X-ray scattering (SAXS), has been recently published by Yi Lu and
his research group [42]. High-resolution techniques such as X-ray crystallography have the capability
to provide atomistic structural views. However, SAS techniques can be applied to molecules in
solution and can give insights into systems in which inherent flexibility, which may cause problems for
crystallization, is in fact essential for its proper function. SAS was first described for biomolecules
(proteins) in the late 1940s [43] and has been widely used for several decades to solve problems
requiring an understanding of the nanoscale phenomena. SAS techniques in fact depend on the same
physics as the corresponding larger angle scattering methods (X-ray or neutron diffraction), but reveal
larger, more global structures due to the inverse relationship between length scale and scattering angle;
refer to Glatter and Kratky [44] for an excellent textbook describing the physics of SAS.
In lieu of a crystal, X-ray scattering from nucleic acid samples in solution can provide essential
structural information on the time-averaged ensemble structure. Information about the size, shape,
compactness, and molecular weight of the scattering molecules are readily obtained from the
scattering data. Beginning in the late 1980s, as the methods of analysis and image reconstruction
technologies became more accessible and sophisticated (see the ATSAS software package [45]), so too
did the functional insights and applications. Thanks to advances in computational capabilities and
instrumentation, particularly with the increased flux available now at synchrotron sources, SAS has
developed into a powerful structural tool that complements and enhances other structural information
to provide a more complete understanding of the structure-function relationship. For example,
Wang and co-workers used SAS to describe an unusual topological structure that the HIV-1 (human
immunodeficiency virus) uses to recognize its own messenger ribonucleic acid (mRNA) [46]. SANS
and contrast variation techniques are ideally suited to examining the conformational changes within
the protein and its nucleic acid binding partner upon complexation with one another. Recently,
Sonntag et al. [47] demonstrated the power of contrast variation and SANS in resolving ambiguities
and improving the interpretation of complementary SAXS and NMR data on a ternary protein-RNA
complex involved in alternate splicing.
Of importance in extending these SAS technologies to study NANPs specifically, SAS provides not
only information on the sizes and shapes of particles but also information on the internal structures of
disordered and partially disordered systems. Rambo and Tainer [48,49] have improved and tested the
SAS computational tools and technologies specifically for applications to the inherently flexible nucleic
acid and related structures. Their SAXS results have discovered and demonstrated that conformational
variation is a general functional feature of macromolecules. Importantly, SAS can tolerate a variety of
measurement conditions, thus allowing rapid comparison of the effects of environmental changes on
the detected structural properties. Moreover, extraction of meaningful 3D details from 1D scattering
data via molecular modeling techniques has become increasingly sophisticated [50,51], allowing for
the development of experimentally constrained structural models that can be further interpreted or
constrained by other types of structural knowledge on the system being studied (for recent reviews
see [35,52]). Indeed, a major concern in interpreting resultant SAS-based models is that there may
be several structures that produce similar scattering patterns. One must always keep in mind that
these models represent the time-averaged ensemble, which could include a mixture of dynamic
48
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conformations and/or intermolecular interactions. For this reason, complementary data from other
structural techniques is essential to proper interpretation.
Small-Angle Scattering Methodology: Light scattering, in general, is useful for studying the state of
association or conformation of biological macromolecules in solution [53]. Both static (elastic) and
dynamic (quasi-elastic) light scattering techniques are generally easy to perform and can be done on
solutions with relatively low concentrations of analyte. The static light scattering (SLS) experiment
monitors the total light scattering intensity averaged over time and can provide information on the
“apparent” molecular weight (Mapp) and the radius of gyration (Rg) of the macromolecule in solution.
Dynamic light scattering (DLS) experiments monitor fluctuations in the intensity of light scattered by
small volume elements in solution, which are directly related to the Brownian motion of the solutes,
thereby providing information on the hydrodynamic radius (RH), which also can be related to an
apparent molecular weight. In either case, light scattering techniques can be used as an initial probe
of the NANP conformations to monitor aggregation or conformational changes in varying solution
environments. Determining particle size and shape, however, requires a light source with much smaller
wavelengths, such as X-rays or neutrons.
X-ray and neutron SAS represents a major tool for obtaining global information on the size
and shape of folding intermediates of RNA molecules in solution, since it provides quantitative
characterization of mixtures by measuring the radius of gyration and maximum linear dimension of
the molecules to ~1–10 nm resolution. Typical experimental set-up and analysis is shown in Figure 1.
A sample containing randomly oriented molecules in solution is placed in an X-ray or neutron beam
with wavelengths between 1–6 Å. The coherent scattering, I(Q), from a homogeneous solution of
monodisperse particles can be expressed mathematically as:
I(Q) = 〈 |
∫
[ρ (r) − ρs]•exp(−iQ•r) dr | 2 〉 (1)
The integration is taken over the volume of the particle and 〈 〉 denotes the average over all particle
orientations. Q is the momentum transfer or scattering vector and can be expressed as 4π(sinθ)/λ, where
θ is half the scattering angle and λ is the wavelength of the scattered radiation. ρ (r) and ρs are the
scattering length densities for the particle and solvent, respectively. Structural information is derived
from a measurement of the intensity of the scattered X-ray (I(Q)) as a function of scattering angle (Q).
Analysis of these data is accomplished initially with a Guinier approximation by fitting the data in
the low Q region (where Q·Rg < 1.3). This approximation can be done for globular or for rod-like
particles and yields a direct estimation of the molecule’s Rg or cross-sectional radius (Rc), respectively.
For well-folded samples, a Kratky plot can be used to estimate the hydrated volume, or Porod volume.
Comparative changes in a Kratky plot can reveal flexibility, unfolding, or a conformational change.
More detailed structural information may be obtained from analysis of the pair-distance
distribution function, P(r). An inverse Fourier transformation of the scattering data yields the
probable distribution of atom-pair distances (r) weighted by the product of their scattering powers,
and is typically represented as a 1-dimensional P(r) versus r profile. For well-behaved samples, the P(r)
will approach zero at the maximum linear dimension, dmax, of the scattering particle. The zeroth
and second moments of the P(r) give forward scatter, I0, and radius of gyration, Rg, respectively.
The forward scatter, I0, is directly proportional to the molecular weight squared of the scattering
molecule and thus is very sensitive to changes in the size of the scattering particle due to, for example,
complex formation, specific oligomerization, or aggregation. P(r) is sensitive to the symmetry of the
scattering particle and to the relationships between domains or repeating structures. This effect is
demonstrated in Figure 1, which shows the P(r) functions for various one- and two- domain structures
of uniform scattering density. It is worth noting how the asymmetry of the P(r) function increases with
the asymmetry of the shape of the object. Determining the 3-dimensional shape that gives rise to a
measured SAS (intensity versus Q) profile is recognized as an ‘underdetermined’ problem (as a result
of rotational averaging of the scattered intensity arising from the random orientation of molecules
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in solution). Nonetheless, molecular modeling of these data can be highly informative, particularly
if the models are interpreted by utilizing other known structural constraints [54]. One interesting
approach to assessing the ambiguity in SAS profiles has been reported [55]. An accepted practice is to
generate multiple solutions using Monte Carlo-based minimization methods and simple constraints,
such as connectivity and compactness, and then to evaluate the variability and range of potential
solutions. The software for completing this type of analysis is available in the popular ATSAS analysis
package [45].
Figure 1. Typical small-angle X-ray and neutron scattering (SAS) experimental set-up and data analysis.
I(q) is the intensity of the scattered light as a function of momentum scattering vector, q, as defined
above. I(0) is the intensity of the scatter at zero angle and is directly proportional to the square of
the molecular weight of the biomolecule (MWt)2. Rg is the biomolecule’s Radius of Gyration, and
is defined as the average distance of each scattering center, atom, from the center-of-mass. P(r) is
the pair distance distribution function, calculated as an inverse Fourier Transform of the scattering
data and representative of the probability of finding a vector of length r between the atoms within
the biomolecule.
Neutron (SANS) Methodology: Examination of the individual component structures within the
context of larger macromolecular assemblies (NA:protein or NA:lipid:protein structures, for instance)
can be achieved by collecting neutron scattering data on the complexes while varying the solvent
contrast (for a recent review see [56]). Scattering length densities (SLDs) are calculated by summing
the scattering amplitudes of each atom within a volume and dividing by that volume. From Equation
(1) it can be readily seen that the intensity of the scattering from a particle in solution depends
upon the difference in scattering density between the particle and the solvent, i.e., its “contrast”.
The SLD of a particle is a function of its elemental composition and the associated atomic scattering
lengths (specifically the coherent scattering lengths, bcoh), which are a measure of the strength of the
interaction of an X-ray or neutron with an atom. The fact that hydrogen and its isotope deuterium
have dramatically different scattering lengths (bcoh = −3.74 × 10−15 m and 6.67 × 10−15 m, respectively)
empowers a neutron scattering contrast variation technique for structural biology. The fraction of D2O
substitution for H2O in aqueous buffers provides a continuous spectrum of values for the solvent’s SLD.
The true utility of being able to change the SLD of the solvent relative to that of the scattering particle
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becomes evident when working with structures composed of materials which have different SLDs,
such as proteins, lipids, and NAs. These various biomolecules have an inherently dissimilar elemental
composition and thus different average scattering lengths, so each will be ‘visible’ (or ‘invisible’) at
unique solvent contrasts. Furthermore, the production of deuterium-enriched biological materials
makes possible the reconstitution of multi-component structures with selectively deuterated subunits.
Example SLDs of various biological macromolecules, including examples involving deuterium-labeled
material, are shown in Figure 2 as a function of the H2O/D2O mixture in the background solution.
Figure 2. Scattering length densities of various biological macromolecules plotted as a function of
percent D2O in the solvent: a hydrogenated protein (blue), a deuterated protein with 65% of the
non-exchangeable protons replaced by deuterium (red), messenger ribonucleic acid (mRNA) (green),
and lipid (purple). The black line corresponds to the scattering length density of the background
solution. The “match” point of these macromolecules (circled) is found at the percent D2O where the
scattering light density (SLD) of the solvent equals that of the molecule.
Of particular interest in this plot are the intersections where the scattering length density of
the solvent (black line) matches that of the various biomolecules. At these points (referred to as
contrast match points), the contrast between the molecule and background (solvent), and therefore
the measured intensity of that molecule, is zero. The measured scattering intensity I(Q) from a
multi-subunit assembly containing a subunit(s) with a solvent contrast-matched SLD would only
reflect the remaining subunit(s), which have a nonzero contrast. The result is structural information
on individual subunit components within the macromolecular complex. This particular kind of
experiment is known as a contrast-matching experiment. An extension of the contrast-matching
experiment is a contrast variation experiment. In a contrast variation experiment, the total scattering
of the complex is measured at several solvent contrasts (fractions of D2O) and then mathematically
extrapolated to yield the scattering profile of the individual components.
SANS Applications: A classic set of examples for the application of SANS with contrast variation
involves the study of various ribosomes. The earliest studies probed the internal structure of the 30S
ribosome [57–59]. Contrast-variation methods were used to determine the relative distances between
subunits in this multi-subunit complex. Ultimately, this research led to a structural model for the
disposition of these subunits in space [60]. These early studies were followed by subsequent studies
of the larger 50S and 70S ribosomes. A map of the distribution of protein and RNA within the 50S
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ribosome from Escherichia coli was generated using SANS with contrast variation data and shape
restoration by spherical harmonics [61–63].
More recently, SANS has demonstrated the structural influence that ionic strength and temperature
have on the corona structures found in DNA-capped gold nanoparticles [64] (Figure 3). These data will
assist in customizing tailor-made corona structures for designer materials and devices. X-ray data has
provided information on the inorganic cores of these nanoparticles but the complementary neutron
data has expanded the structural scope, revealing the 15-mer DNA capped corona structures and the
formation of ionic strength- and temperature-dependent aggregate species.
 
Figure 3. The pair distribution function P(r) is shown for two DNA-capped nanoparticles, T15 (a) and
T7−8 (b) conjugates computed at various temperatures (30 ◦C, 46 ◦C, 70 ◦C, and 22 ◦C) in 0.5 M salt
buffer. Insets are the scheme of temperature effect on poly(dT) sequenced deoxyribosenucleic acid
(DNA) and palindromic sequenced DNA. Reprinted (adapted) with permission from (Yang, W.; et al.
Probing Soft Corona Structures of DNA-Capped Nanoparticles by Small Angle Neutron Scattering.
J. Phys. Chem. C 2015, 119, 18773–18778). Copyright (2015) American Chemical Society.
SAXS Applications: The structures of small fragments of functional RNAs have been successfully
solved using SAXS and confirmed by other techniques [65,66]. This approach allows for an investigation
of the influence of the size, composition, and shape of functionalized NANPs on their ability to be
delivered to diseased cells and to further their functional efficiency. Structural models built from the
solid-state, i.e., X-ray crystal diffraction or cryo-EM, can be used to generate an expected scattering curve,
which can then be directly compared with the measured solution scattering data to detect differences
in the solution state of the particle. One ultimate goal might be to utilize SAXS under varying solvent
52
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conditions (e.g., ionic strength, pH, or binding partners, etc.) in order to gain a better understanding of
structure-to-function relationships in various synthetic and natural RNAs. These results would assist
in refining computational-experimental protocols for functional RNA nanoparticle pipeline production.
Additionally, time-resolved methods using bright synchrotron sources could provide kinetic insights
into their assembly. These methods have been successfully used to provide kinetic data on ribozyme
folding [67], transfer ribonucleic acid (tRNA) assembly [68], and riboswitches [69,70], so precedents
exist for using them to examine the assembly dynamics of NANPs.
Conformational changes, flexibility, and self-assembly [71,72] processes of DNA nanostructures are
being investigated using SAS techniques with increased frequency. The structural features determined
by these solution-based techniques offer structural insights that are distinct from those provided by
techniques that require the nanostructure to be fixed onto a substrate. For example, an X-shaped
DNA-based molecular switch has been examined through SAXS, solution fluorescence resonance energy
transfer (FRET), single-molecule FRET, and transmission electron microscopy (TEM) to determine the
population of the two distinct conformational states (Figure 4). The switch’s conformation, which
closes to form a linear rod-like structure in high ionic strength environments, was shown through
SAXS and solution FRET to have a statistically significantly lower population of molecules in the
linear conformation than was determined by single molecule FRET or TEM. It is suggested that the
fixation to surface, dyeing, and/or the manual assignment of conformations of TEM images may bias
these experimental methods towards a closed conformation, while the solution-based techniques
gave more accurate assessments of the particle conformations [72]. The increased availability of SAS
instruments located off high flux, synchrotron sources allowed these measurements to be made with
reasonable signal to noise profiles on samples at concentrations of only 25–100 nM. They have been
able to detect conformational changes triggered by changes in the solution environment. These studies
were followed up with time-resolved SAXS [74] to monitor this large-scale conformational transition
and it was found that it switches from its open to closed conformation upon addition of MgCl2 within
milliseconds, which is close to the theoretical diffusive speed limit. The construction of functional
NANPs will likely require dynamic structures that can undergo controllable conformational changes
and SAXS is well placed as a tool for resultant structural kinetic studies. DNA devices based on shape
complementary stacking interactions have been demonstrated to undergo reversible conformational
changes triggered by changes in ionic environments or temperature. In another, unrelated experiment,
molecular dynamics and SANS were used in combination to predict and test the gelling properties of
tetravalent DNA nanostars as a function of temperature [71]. The time-resolved growth of the DNA
nanostar gel was monitored by following changes in a signature peak intensity, and, thus, these studies
allowed for kinetic and thermodynamic measurements of the nanostar structural formation.
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Figure 4. (a) and (b) depict the mode-based refinement of a DNA switch structure against small-angle
X-ray scattering (SAXS) data. (a) Experimental SAXS data for the DNA switch in the closed, linear
conformation and (b) the open, X-shaped conformation are shown as red and blue circles, respectively,
against the scattering profile predicted by preliminary models in CanDo (dashed black lines) and
CRYSOL software (gray lines) [73]. The preliminary structures of the (c) open and (d) closed switch
conformations are shown as red and blue cylinders with the refined structures shown as gray
and light-blue orbs, respectively. Reprinted (adapted) with permission from Bruetzel, L.K.; et al.
Conformational Changes and Flexibility of DNA Devices Observed by Small-Angle X-ray Scattering.
Nano Lett. 2016, 16, 4871–4879. Copyright (2016) American Chemical Society.
SAS Vision Application for Nucleic Acid Architectures: One of the examples where SAS can be
readily employed may be seen in the recent achievements of RNA nanotechnology, where two
orthogonal NANP designing strategies (exemplified by RNA nanocubes [4,8,12,13,23,25,75] and RNA
nanorings [7,13,24,41,75–77]) were introduced, with potential for broad use in nanotechnology and
biomedical applications. In one strategy (nanocubes) the RNA strands are specifically designed to
only form intermolecular bondings with their cognate partners while avoiding the formations of
any intramolecular secondary structures. Another strategy (nanorings), takes advantage of RNA
long-range tertiary interacting motifs that require the formation of specific secondary structures of
individual monomers, and the intermolecular interactions are activated in the presence of magnesium
ions. Both NANPS were tested against several different cancer- and HIV-infected cell lines and showed
a significant therapeutic effect. Furthermore, the desired activity of these functional NANPs was
demonstrated remarkably in vivo [7]. Importantly, the immunorecognition of NANPs by human
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peripheral blood mononuclear cells strongly depends on the type of NANPs and the extent of their
functionalization with siRNAs [13,78,79]. In vitro characterization with cryo-EM microscopy has
revealed that the structure of the nanoring functionalized with six siRNAs has a pinwheel-like crown
shape (Figure 5a). That topology, if accurately reflecting the in vivo state, may affect the efficiency of
the intracellular release of siRNAs through ‘dicing’, due to steric issues, and influence their interactions
with the pathogen recognition receptors of the immune system. The issues of imprecisely predicted
and verified topology may become even more evident in the case of 3D polyhedral self-assembled
functional nanostructures such as nanocubes [4]. Figure 5b provides the calculated SAXS profiles
for several of these predicted structures, demonstrating that SAXS data is sufficient to differentiate
between the various architectures. It is possible that further optimization of the existing designs is
needed (such as an extension of dicable siRNA-containing arms, modification of the 5′-end of the
scaffold, changes in base composition, or introduction of additional RNA structural motifs, etc.) to
ensure the enhancement of siRNA release and processivity.
Figure 5. (a) Cryogenic-electron microscopy (cryo-EM) reconstruction of RNA nanoring functionalized
with six short interfering RNAs (siRNAs) and (b) its calculated SAXS profile (red circles) compared to
the calculated SAXS profile for other predicted NA nanoparticle structures. Profiles were calculated
from models based on cryo-EM pdb files using the program CRYSOL [73].
Moreover, 3D structures of other individual, relatively bulky groups, such as aptamers or
antibodies introduced for targeting, are not known, and their function may be attenuated due to steric
clashes within NANPs. Therefore, alternative approaches that can provide complementary data about
3D orientations and shapes of the NANPs and their individual components in solution are needed.
Utilizing natural contrast between the scattering components in these systems, neutron scattering will
allow for determination of the structural parameters of the NANPs bound to any functional groups.
Another vision for the use of SAS in structural characterization of NANPs is to extend the SAS profile
collected to include a larger angle scattering region (WAXS). These data may be useful for investigating
the Ag-Ag distances within DNA-based assemblies of fluorescent silver nanoclusters [80].
Additionally, delivery of NANP-based therapeutics in vivo is one of the most challenging tasks
due to RNA’s negative charge, chemical instability, and stimulation of immune system responses.
Investigating different potential carriers, such as lipids or cell-penetrating peptides, for in vivo delivery
of RNA therapeutics is therefore one area of RNA nanotechnology that would benefit from SAS-based
approaches. Experiments with NANPs employing various carriers such as magnetic nanoparticles [81],
lipids [82], mesoporous silica-based nanoparticles [79], polysilsesquioxane [83], and bolaamphiphiles or
‘bolas’ [84,85] have already been successfully initiated. The use of SANS can significantly improve our
current understanding of the interactions between the NANPs and carriers, which can further improve
NANP delivery in vivo. For example, bolas consist of positively charged acetylcholine head groups on
each side of a hydrophobic chain. In aqueous solution, these bolas form micelles and are efficiently
associated with siRNAs for their further delivery in vivo. It was also recently demonstrated that bolas
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can form vesicles, rather than micelles, and can be used for delivery of encapsulated analgesic peptides
and small molecules within a mouse brain [86,87]. These vesicles may become strong candidates
for the delivery of functional RNA nanoparticles in vivo, especially across the blood-brain barrier
to glioblastomas. Preliminary, unpublished results indicate formation of stable siRNA/bola vesicle
complexes and cryo-EM images show changes in the shape of the particle upon siRNA addition.
Constraints for the formation of functional RNA nanoparticles/bola vesicle complexes must be directed
by the architecture of the components including shape, size, and total charge. Therefore, comparison of
different shapes for functional RNA nanoparticles and different RNA-to-bola ratios will be necessary
to maximize the RNA-bola interaction capacity. The self-assembly of similar, stable monomolecular
nucleic acid lipid particles has been studied by SAXS and complemented by SANS and TEM [88]. These
SAXS data confirmed the overall size and spherical shape of the particles, whereas the inherent contrast
between nucleic acid and lipid moieties’ neutron scattering allowed for a more detailed structural
description of the core shell-like structure of these particles.
3. Conclusions
Small-angle X-ray and neutron scattering are structural characterization techniques that are
well placed to determine the conformation of nucleic acid nanoparticles under varying solution
conditions, thus allowing for optimization of their design. SAS results should complement and extend
the structural information obtained through direct imaging techniques and other high-resolution
structures. SAS experiments provide information on the overall shapes and particle dimensions of
macromolecules and are ideal for following conformational changes and dynamics of the molecular
ensemble as it behaves in solution. In addition, the inherent differences in the neutron scattering
of nucleic acids, lipids, and proteins, as well as the different neutron scattering properties of the
isotopes of hydrogen, combined with the ability to uniformly label biological macromolecules with
deuterium, allow for the characterization of the conformations and relative dispositions of the individual
components within an assembly of biomolecules.
Funding: This work was supported by National Institute of General Medical Sciences of the National Institutes of
Health grant R15GM128100 (JKK co-PI)).
Acknowledgments: We would like to thank Maya Hunter for her critical review and helpful editing suggestions
during the assembly of this article.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Guo, P.X. The Emerging Field of RNA Nanotechnology. Nat. Nanotechnol. 2010, 5, 833–842. [CrossRef]
[PubMed]
2. Shukla, G.C.; Haque, F.; Tor, Y.; Wilhelmsson, L.M.; Toulmé, J.J.; Isambert, H.; Guo, P.; Rossi, J.J.;
Tenenbaum, S.A.; Shapiro, B.A. A Boost for the Emerging Field of RNA Nanotechnology. ACS Nano
2011, 5, 3405–3418. [CrossRef]
3. Li, H.; Lee, T.; Dziubla, T.; Pi, F.; Guo, S.; Xu, J.; Li, C.; Haque, F.; Liang, X.J.; Guo, P. RNA as a Stable Polymer
to Build Controllable and Defined Nanostructures for Material and Biomedical Applications. Nano Today
2015, 10, 631–655. [CrossRef] [PubMed]
4. Kirill, A.A.; Kasprzak, W.; Bindewald, E.; Praneet, S.; Puppala Alex, R.; Diehl Kenneth, T.; Hall Tae Jin
Kim Michael, T.; Zimmermann Robert, L.; Jernigan, L.J.; Shapiro, B.A. Computational and Experimental
Characterization of RNA Cubic Nanoscaffolds. Methods 2014, 67, 256–265.
5. Kirill, A.A.; Kasprzak, W.K.; Bindewald, E.; Kireeva, M.; Viard, M.; Kashlev, M.; Shapiro, B.A. In Silico Design
and Enzymatic Synthesis of Functional RNA Nanoparticles. Account. Chem. Res. 2014, 47, 1731–1741.
6. Afonin, K.A.; Viard, M.; Kagiampakis, I.; Case, C.L.; Dobrovolskaia, M.A.; Hofmann, J.; Vrzak, A.; Kireeva, M.;
Kasprzak, W.K.; KewalRamani, V.N.; et al. Triggering of RNA Interference with RNA-RNA, RNA-DNA,
and DNA-RNA Nanoparticles. ACS Nano 2015, 9, 251–259. [CrossRef]
56
Nanomaterials 2019, 9, 681
7. Afonin, K.A.; Viard, M.; Koyfman, A.Y.; Martins, A.N.; Kasprzak, W.K.; Panigaj, M.; Desai, R.; Santhanam, A.;
Grabow, W.W.; Jaeger, L.; et al. Multifunctional RNA Nanoparticles. Nano Lett. 2014, 14, 5662–5671.
[CrossRef] [PubMed]
8. Dao, B.N.; Viard, M.; Martins, A.N.; Kasprzak, W.K.; Shapiro, B.A.; Afonin, K.A. Triggering Rnai with
Multifunctional RNA Nanoparticles and Their Delivery. DNA RNA Nanotechnol. 2015, 1, 27–38. [CrossRef]
9. Ohno, H.; Kobayashi, T.; Kabata, R.; Endo, K.; Iwasa, T.; Yoshimura, S.H.; Takeyasu, K.; Inoue, T.; Saito, H.
Synthetic RNA-Protein Complex Shaped Like an Equilateral Triangle. Nat. Nanotechnol. 2011, 6, 116–120.
[CrossRef]
10. Shibata, T.; Fujita, Y.; Ohno, H.; Suzuki, Y.; Hayashi, K.; Komatsu, K.R.; Kawasaki, S.; Hidaka, K.; Yonehara, S.;
Sugiyama, H.; et al. Protein-Driven RNA Nanostructured Devices That Function in Vitro and Control
Mammalian Cell Fate. Nat. Commun. 2017, 8, 540. [CrossRef]
11. Lee, H.; Lytton-Jean, A.K.; Chen, Y.; Love, K.T.; Park, A.I.; Karagiannis, E.D.; Sehgal, A.; Querbes, W.;
Zurenko, C.S.; Jayaraman, M.; et al. Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted in
Vivo Sirna Delivery. Nat. Nanotechnol. 2012, 7, 389–393. [CrossRef]
12. Halman, J.R.; Satterwhite, E.; Roark, B.; Chandler, M.; Viard, M.; Ivanina, A.; Bindewald, E.; Kasprzak, W.K.;
Panigaj, M.; Bui, M.N.; et al. Functionally-Interdependent Shape-Switching Nanoparticles with Controllable
Properties. Nucleic Acids Res. 2017, 45, 2210–2220. [CrossRef]
13. Hong, E.P.; JHalman, R.; Shah, A.B.; Khisamutdinov, E.F.; Dobrovolskaia, M.A.; Afonin, K.A. Structure and
Composition Define Immunorecognition of Nucleic Acid Nanoparticles. Nano Lett. 2018, 18, 4309–4321.
[CrossRef]
14. Douglas, S.M.; Bachelet, I.; Church, G.M. A Logic-Gated Nanorobot for Targeted Transport of Molecular
Payloads. Science 2012, 335, 831–834. [CrossRef]
15. Bindewald, E.; Afonin, K.A.; Viard, M.; Zakrevsky, P.; Kim, T.; Shapiro, B.A. Multistrand Structure Prediction
of Nucleic Acid Assemblies and Design of RNA Switches. Nano Lett. 2016, 16, 1726–1735. [CrossRef]
16. Roark, B.K.; Tan, L.A.; Ivanina, A.; Chandler, M.; Castaneda, J.; Kim, H.S.; Jawahar, S.; Viard, M.; Talic, S.;
Wustholz, K.L.; et al. Fluorescence Blinking as an Output Signal for Biosensing. ACS Sens. 2016, 1, 1295–1300.
[CrossRef] [PubMed]
17. Andersen, E.S.; Dong, M.; Nielsen, M.M.; Jahn, K.; Subramani, R.; Mamdouh, W.; Golas, M.M.; Sander, B.;
Stark, H.; Oliveira, C.L.; et al. Self-Assembly of a Nanoscale DNA Box with a Controllable Lid. Nature 2009,
459, 73–76. [CrossRef]
18. Binzel, D.W.; Shu, Y.; Li, H.; Sun, M.; Zhang, Q.; Shu, D.; Guo, B.; Guo, P. Specific Delivery of Mirna for High
Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol. Ther. 2016, 24, 1267–1277. [CrossRef]
19. Shu, D.; Li, H.; Shu, Y.; Xiong, G.; Carson, W.E.; Haque, F.; Xu, R.; Guo, P. Systemic Delivery of Anti-Mirna for
Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano 2015, 9, 9731–9740.
[CrossRef]
20. Feng, L.; Li, S.K.; Liu, H.; Liu, C.Y.; LaSance, K.; Haque, F.; Shu, D.; Guo, P. Ocular Delivery of Prna
Nanoparticles: Distribution and Clearance after Subconjunctival Injection. Pharm. Res. 2014, 31, 1046–1058.
[CrossRef]
21. Shu, Y.; Shu, D.; Haque, F.; Guo, P. Fabrication of Prna Nanoparticles to Deliver Therapeutic Rnas and
Bioactive Compounds into Tumor Cells. Nat. Protoc. 2013, 8, 1635–1659. [CrossRef]
22. Afonin, K.A.; Viard, M.; Martins, A.N.; Lockett, S.J.; Maciag, A.E.; Freed, E.O.; Heldman, E.; Jaeger, L.;
Blumenthal, R.; Shapiro, B.A. Activation of Different Split Functionalities on Re-Association of RNA-DNA
Hybrids. Nat. Nanotechnol. 2013, 8, 296–304. [CrossRef] [PubMed]
23. Kirill, A.A.; Grabow, W.W.; Walker, F.M.; Bindewald, E.; Dobrovolskaia, M.A.; Shapiro, B.A.; Jaeger, L.
Design and Self-Assembly of Sirna-Functionalized RNA Nanoparticles for Use in Automated Nanomedicine.
Nat. Protoc. 2011, 6, 2022–2034.
24. Sajja, S.; Chandler, M.; Fedorov, D.; Kasprzak, W.K.; Lushnikov, A.; Viard, M.; Shah, A.; Dang, D.; Dahl, J.;
Worku, B.; et al. Dynamic Behavior of RNA Nanoparticles Analyzed by Afm on a Mica/Air Interface.
Langmuir 2018, 34, 15099–15108. [CrossRef]
25. Afonin, K.A.; Bindewald, E.; Yaghoubian, A.J.; Voss, N.; Jacovetty, E.; Shapiro, B.A.; Jaeger, L. In Vitro
Assembly of Cubic RNA-Based Scaffolds Designed in Silico. Nat. Nanotechnol. 2010, 5, 676–682. [CrossRef]
[PubMed]
57
Nanomaterials 2019, 9, 681
26. Davis, J.H.; Tonelli, M.; Scott, L.G.; Jaeger, L.; Williamson, J.R.; Butcher, S.E. RNA Helical Packing in Solution:
Nmr Structure of a 30 Kda Gaaa Tetraloop-Receptor Complex. J. Mol. Biol. 2005, 351, 371–382. [CrossRef]
27. Dibrov, S.M.; McLean, J.; Parsons, J.; Hermann, T. Self-Assembling RNA Square. Proc. Natl. Acad. Sci. USA
2011, 108, 6405–6408. [CrossRef]
28. Manaia, E.B.; Abuçafy, M.P.; Chiari-Andréo, B.G.; Silva, B.L.; Junior JA, O.; Chiavacci, L.A. Physicochemical
Characterization of Drug Nanocarriers. Int. J. Nanomed. 2017, 12, 4991–5011. [CrossRef] [PubMed]
29. Xavier, P.L.; Chandrasekaran, A.R. DNA-Based Construction at the Nanoscale: Emerging Trends and
Applications. Nanotechnology 2018, 29, 062001. [CrossRef]
30. Ukraintsev, V.; Banke, B. Review of Reference Metrology for Nanotechnology: Significance, Challenges,
and Solutions. J. Micro Nanolithogr. MEMS MOEMS 2012, 11, 011010. [CrossRef]
31. Bald, I.; Keller, A. Molecular Processes Studied at a Single-Molecule Level Using DNA Origami Nanostructures
and Atomic Force Microscopy. Molecular 2014, 19, 13803–13823. [CrossRef]
32. Song, Y.; Chen, S. Janus Nanoparticles: Preparation, Characterization, and Applications. Chem. Asian J. 2014,
9, 418–430. [CrossRef]
33. Svergun, D.I.; Koch, M.H. Small-Angle Scattering Studies of Biological Macromolecules in Solution. Rep. Prog.
Phys. 2013, 66, 1735–1782. [CrossRef]
34. Jacques, D.A.; Trewhella, J. Small-Angle Scattering for Structural Biology-Expanding the Frontier While
Avoiding the Pitfalls. Protein Sci. 2010, 19, 642–657. [CrossRef]
35. Vestergaard, B.; Sayers, Z. Investigating Increasingly Complex Macromolecular Systems with Small-Angle
X-Ray Scattering. IUCrJ 2014, 1, 523–529. [CrossRef]
36. Heller, W.T. Small-Angle Neutron Scattering and Contrast Variation: A Powerful Combination for Studying
Biological Structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 2010, 66, 1213–1217. [CrossRef]
37. Heller, W.T.; Littrell, K.C. Small-Angle Neutron Scattering for Molecular Biology: Basics and Instrumentation.
Micro Nano Technol. Bioanal. Methods Protoc. 2009, 544, 293–305.
38. Hong, E.; Halman, J.R.; Shah, A.; Cedrone, E.; Truong, N.; Afonin, K.A.; Dobrovolskaia, M.A. Toll-Like
Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (Nanps) in Human Primary Blood Cells.
Molecules 2019, 24, 1094. [CrossRef]
39. Chandler, M.; Afonin, K.A. Smart-Responsive Nucleic Acid Nanoparticles (Nanps) with the Potential to
Modulate Immune Behavior. Nanomaterials 2019, 9, 611. [CrossRef]
40. Rychahou, P.; Haque, F.; Shu, Y.; Zaytseva, Y.; Weiss, H.L.; Lee, E.Y.; Mustain, W.; Valentino, J.; Guo, P.;
Evers, B.M. Delivery of RNA Nanoparticles into Colorectal Cancer Metastases Following Systemic
Administration. ACS Nano 2015, 9, 1108–1116. [CrossRef] [PubMed]
41. Grabow, W.W.; Zakrevsky, P.; Afonin, K.A.; Chworos, A.; Shapiro, B.A.; Jaeger, L. Self-Assembling RNA
Nanorings Based on RNAi/Ii Inverse Kissing Complexes. Nano Lett. 2011, 11, 878–887. [CrossRef]
42. Wu, P.W.; Yu, Y.; McGhee, C.E.; Tan, L.H.; Lu, Y. Applications of Synchrotron-Based Spectroscopic Techniques
in Studying Nucleic Acids and Nucleic Acid-Functionalized Nanomaterials. Adv. Mater. 2014, 26, 7849–7872.
[CrossRef] [PubMed]
43. Dervichian, D.G.; Fournet, G.; Guinier, A. X-Ray Scattering Study of the Modifications Which Certain Proteins
Undergo. Biochim. Biophys. Acta 1952, 8, 145–149. [CrossRef]
44. Glatter, O.; Kratky, O. Small Angle X-Ray Scattering; Academic Press: London, UK; New York, NY, USA, 1982.
45. Franke, D.; Petoukhov, M.V.; Konarev, P.V.; Panjkovich, A.; Tuukkanen, A.; Mertens, H.D.T.; Kikhney, A.G.;
Hajizadeh, N.R.; Franklin, J.M.; Jeffries, C.M.; et al. Atsas 2.8: A Comprehensive Data Analysis Suite for
Small-Angle Scattering from Macromolecular Solutions. J. Appl. Crystallogr. 2017, 50, 1212–1225. [CrossRef]
46. Fang, X.; Wang, J.; O’Carroll, I.P.; Mitchell, M.; Zuo, X.; Wang, Y.; Yu, P.; Liu, Y.; Rausch, J.W.; Dyba, M.A.; et al.
An Unusual Topological Structure of the Hiv-1 Rev Response Element. Cell 2013, 155, 594–605. [CrossRef]
47. Hennig, J.; Wang, I.; Sonntag, M.; Gabel, F.; Sattler, M. Combining Nmr and Small Angle X-Ray and Neutron
Scattering in the Structural Analysis of a Ternary Protein-RNA Complex. J. Biomol. NMR 2013, 56, 17–30.
[CrossRef] [PubMed]
48. Rambo, R.P.; Tainer, J.A. Bridging the Solution Divide: Comprehensive Structural Analyses of Dynamic
RNA, DNA, and Protein Assemblies by Small-Angle X-Ray Scattering. Curr. Opin. Struct. Biol. 2010, 20,
128–137. [CrossRef]
49. Rambo, R.P.; Tainer, J.A. Improving Small-Angle X-Ray Scattering Data for Structural Analyses of the RNA
World. RNA 2010, 16, 638–646. [CrossRef] [PubMed]
58
Nanomaterials 2019, 9, 681
50. Etoukhov, M.V.; Konarev, P.V.; Kikhney, A.G.; Svergun, D.I. Atsas 2.1—Towards Automated and
Web-Supported Small-Angle Scattering Data Analysis. J. Appl. Crystallogr. 2007, 40, S223–S228. [CrossRef]
51. Svergun, D.I. Restoring low resolution structure of biological macromolecules from solution scattering using
simulated annealing. Biophys. J. 1999, 76, 2879–2886. [CrossRef]
52. Yang, S. Methods for Saxs-Based Structure Determination of Biomolecular Complexes. Adv. Mater. 2014, 26,
7902–7910. [CrossRef] [PubMed]
53. Maguire, C.M.; Rosslein, M.; Wick, P.; Prina-Mello, A. Characterisation of Particles in Solution—A Perspective
on Light Scattering and Comparative Technologies. Sci. Technol. Adv. Mater. 2018, 19, 732–745. [CrossRef]
54. Trewhella, J. Small-Angle Scattering and 3d Structure Interpretation. Curr. Opin. Struct. Biol. 2016, 40, 1–7.
[CrossRef] [PubMed]
55. Petoukhov, M.V.; Svergun, D.I. Ambiguity Assessment of Small-Angle Scattering Curves from Monodisperse
Systems. Acta Crystallogr. Sect. D 2015, 71, 1051–1058. [CrossRef]
56. Mahieu, E.; Gabel, F. Biological Small-Angle Neutron Scattering: Recent Results and Development.
Acta Crystallogr. D Struct. Biol. 2018, 74, 715–726. [CrossRef] [PubMed]
57. Ramakrishnan, V.; Capel, M.; Kjeldgaard, M.; Engelman, D.M.; Moore, P.B. Positions of Protein-S14,
Protein-S18 and Protein-S20 in the 30-S Ribosomal-Subunit of Escherichia-Coli. J. Mol. Biol. 1984, 174,
265–284. [CrossRef]
58. Ramakrishnan, V.R.; Yabuki, S.; Sillers, I.Y.; Schindler, D.G.; Engelman, D.M.; Moore, P.B. Positions of Proteins
S6, S11 and S15 in the 30-S Ribosomal-Subunit of Escherichia-Coli. J. Mol. Biol. 1981, 153, 739–760. [CrossRef]
59. Ramakrishnan, V.; Engelman, D.M.; Moore, P.B. 3-Dimensional Localization of 12 Proteins of the 30s Ribosome
of Escherichia-Coli. Fed. Proc. 1980, 39, 2122.
60. Capel, M.S.; Engelman, D.M.; Freeborn, B.R.; Kjeldgaard, M.; Langer, J.A.; Ramakrishnan, V.; Schindler, D.G.;
Schneider, D.K.; Schoenborn, B.P.; Sillers, I.Y.; et al. A Complete Mapping of the Proteins in the Small
Ribosomal-Subunit of Escherichia-Coli. Science 1987, 238, 1403–1406. [CrossRef]
61. Svergun, D.I.; Koch, M.H.J.; Pedersen, J.S.; Serdyuk, I.N. Structural Model of the 50-S Subunit of
Escherichia-Coli Ribosomes from Solution Scattering.2. Neutron-Scattering Study. J. Mol. Biol. 1994,
240, 78–86. [CrossRef]
62. Svergun, D.I.; Pedersen, J.S. Propagating Errors in Small-Angle Scattering Data Treatment. J. Appl. Crystallogr.
1994, 27, 241–248. [CrossRef]
63. Svergun, D.I.; Pedersen, J.S.; Serdyuk, I.N.; Koch, M.H.J. Solution Scattering from 50s Ribosomal-Subunit
Resolves Inconsistency between Electron-Microscopic Models. Proc. Natl. Acad. Sci. USA 1994, 91,
11826–11830. [CrossRef]
64. Yang, W.; Lu, J.; Gilbert, E.P.; Knott, R.; He, L.; Cheng, W. Probing Soft Corona Structures of DNA-Capped
Nanoparticles by Small Angle Neutron Scattering. J. Phys. Chem. C 2015, 119, 18773–18778. [CrossRef]
65. Zuo, X.B.; Wang, J.B.; Yu, P.; Eyler, D.; Xu, H.; Starich, M.R.; Tiede, D.M.; Simon, A.E.; Kasprzak, W.;
Schwieters, C.D.; et al. Solution Structure of the Cap-Independent Translational Enhancer and
Ribosome-Binding Element in the 3′Utr of Turnip Crinkle Virus. Proc. Natl. Acad. Sci. USA 2010,
107, 1385–1390. [CrossRef]
66. Wang, J.B.; Zuo, X.B.; Yu, P.; Xu, H.; Starich, M.R.; Tiede, D.M.; Shapiro, B.A.; Schwieters, C.D.; Wang, Y.X.
A Method for Helical RNA Global Structure Determination in Solution Using Small-Angle X-Ray Scattering
and Nmr Measurements. J. Mol. Biol. 2009, 393, 717–734. [CrossRef]
67. Sosnick, T.; Pan, T.; Fang, X.W.; Shelton, V.; Thiyagarajan, P.; Littrel, K. Metal Ions and the Thermodynamics
and Kinetics of Tertiary RNA Folding. Indian J. Chem. Sect. A Inorg. Bio Inorg. Phys. Theor. Anal. Chem. 2002,
41, 54–64.
68. Fang, X.W.; Littrell, K.; Yang, X.; Henderson, S.J.; Siefert, S.; Thiyagarajan, P.; Pan, T.; Sosnick, T.R.
Mg2+-Dependent Compaction and Folding of Yeast Trna(Phe) and the Catalytic Domain of the B-Subtilis
Rnase P RNA Determined by Small-Angle X-Ray Scattering. Biochemistry 2000, 39, 11107–11113. [CrossRef]
69. Serganov, A.; Nudler, E. A Decade of Riboswitches. Cell 2013, 152, 17–24. [CrossRef]
70. Stoddard, C.D.; Montange, R.K.; Hennelly, S.P.; Rambo, R.P.; Sanbonmatsu, K.Y.; Batey, R.T. Free State
Conformational Sampling of the Sam-I Riboswitch Aptamer Domain. Structure 2010, 18, 787–797. [CrossRef]
71. Fernandez-Castanon, J.; Bomboi, F.; Rovigatti, L.; Zanatta, M.; Paciaroni, A.; Comez, L.; Porcar, L.; Jafta, C.J.;
Fadda, G.C.; Bellini, T.; et al. Small-Angle Neutron Scattering and Molecular Dynamics Structural Study of
Gelling DNA Nanostars. J. Chem. Phys. 2016, 145, 084910. [CrossRef] [PubMed]
59
Nanomaterials 2019, 9, 681
72. Bruetzel, L.K.; Gerling, T.; Sedlak, S.M.; Walker, P.U.; Zheng, W.; Dietz, H.; Lipfert, J. Conformational Changes
and Flexibility of DNA Devices Observed by Small-Angle X-Ray Scattering. Nano Lett. 2016, 16, 4871–4879.
[CrossRef]
73. Svergun, D.; Barberato, C.; Koch, M.H.J. Crysol—A Program to Evaluate X-Ray Solution Scattering of
Biological Macromolecules from Atomic Coordinates. J. Appl. Crystallogr. 1995, 28, 768–773. [CrossRef]
74. Bruetzel, L.K.; Walker, P.U.; Gerling, T.; Dietz, H.; Lipfert, J. Time-Resolved Small-Angle X-Ray Scattering
Reveals Millisecond Transitions of a DNA Origami Switch. Nano Lett. 2018, 18, 2672–2676. [CrossRef]
75. Afonin, K.A.; Kireeva, M.; Grabow, W.W.; Kashlev, M.; Jaeger, L.; Shapiro, B.A. Co-Transcriptional Assembly
of Chemically Modified RNA Nanoparticles Functionalized with Sirnas. Nano Lett. 2012, 12, 5192–5195.
[CrossRef]
76. Afonin, K.A.; Viard, M.; Tedbury, P.; Bindewald, E.; Parlea, L.; Howington, M.; Valdman, M.; Johns-Boehme, A.;
Brainerd, C.; Freed, E.O.; et al. The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple
Functionalities. Nano Lett. 2016, 16, 1746–1753. [CrossRef]
77. Yingling, Y.G.; Shapiro, B.A. Computational Design of an RNA Hexagonal Nanoring and an RNA Nanotube.
Nano Lett. 2007, 7, 2328–2334. [CrossRef] [PubMed]
78. Ke, W.; Hong, E.; Saito, R.F.; Rangel, M.C.; Wang, J.; Viard, M.; Richardson, M.; Khisamutdinov, E.F.;
Panigaj, M.; Dokholyan, N.V.; et al. RNA-DNA Fibers and Polygons with Controlled Immunorecognition
Activate Rnai, Fret and Transcriptional Regulation of Nf-Kappab in Human Cells. Nucleic Acids Res. 2018, 47,
1350–1361. [CrossRef] [PubMed]
79. Rackley, L.; Stewart, J.M.; Salotti, J.; Krokhotin, A.; Shah, A.; Halman, J.; Juneja, R.; Smollett, J.; Roark, B.;
Viard, M.; et al. RNA Fibers as Optimized Nanoscaffolds for Sirna Coordination and Reduced Immunological
Recognition. Adv. Funct. Mater. 2018, 28, 1805959. [CrossRef]
80. Yourston, L.E.; Lushnikov, A.Y.; Shevchenko, O.A.; Afonin, K.A.; Krasnoslobodtsev, A.V. First Step
Towards Larger DNA-Based Assemblies of Fluorescent Silver Nanoclusters: Template Design and Detailed
Characterization of Optical Properties. Nanomaterials 2019, 9, 613. [CrossRef]
81. Cruz-Acuna, M.; Halman, J.R.; Afonin, K.A.; Dobson, J.; Rinaldi, C. Magnetic Nanoparticles Loaded with
Functional RNA Nanoparticles. Nanoscale 2018, 10, 17761–17770. [CrossRef]
82. Gupta, K.; Mattingly, S.J.; Knipp, R.J.; Afonin, K.A.; Viard, M.; Bergman, J.T.; Stepler, M.; Nantz, M.H.;
Puri, A.; Shapiro, B.A. Oxime Ether Lipids Containing Hydroxylated Head Groups Are More Superior Sirna
Delivery Agents Than Their Nonhydroxylated Counterparts. Nanomedicine 2015, 10, 2805–2818. [CrossRef]
83. Juneja, R.; Lyles, Z.; Vadarevu, H.; Afonin, K.A.; Vivero-Escoto, J.L. Multimodal Polysilsesquioxane
Nanoparticles for Combinatorial Therapy and Gene Delivery in Triple-Negative Breast Cancer. ACS Appl.
Mater. Interfaces 2019, 11, 12308–12320. [CrossRef] [PubMed]
84. Kim, T.; Afonin, K.A.; Viard, M.; Koyfman, A.Y.; Sparks, S.; Heldman, E.; Grinberg, S.; Linder, C.;
Blumenthal, R.P.; Shapiro, B.A. In Silico, in Vitro, and in Vivo Studies Indicate the Potential Use of
Bolaamphiphiles for Therapeutic Sirnas Delivery. Mol. Ther. Nucleic Acids 2013, 2, e80. [CrossRef] [PubMed]
85. Gupta, K.; Afonin, K.A.; Viard, M.; Herrero, V.; Kasprzak, W.; Kagiampakis, I.; Kim, T.; Koyfman, A.Y.;
Puri, A.; Stepler, M.; et al. Bolaamphiphiles as Carriers for Sirna Delivery: From Chemical Syntheses to
Practical Applications. J. Control. Release 2015, 213, 142–151. [CrossRef] [PubMed]
86. Dakwar, G.R.; Hammad, I.A.; Popov, M.; Linder, C.; Grinberg, S.; Heldman, E.; Stepensky, D. Delivery
of Proteins to the Brain by Bolaamphiphilic Nano-Sized Vesicles. J. Control. Release 2012, 160, 315–321.
[CrossRef] [PubMed]
87. Popov, M.; Grinberg, S.; Linder, C.; Waner, T.; Levi-Hevroni, B.; Deckelbaum, R.J.; Heldman, E. Site-Directed
Decapsulation of Bolaamphiphilic Vesicles with Enzymatic Cleavable Surface Groups. J. Control. Release
2012, 160, 306–314. [CrossRef]
88. Rudorf, S.; Radler, J.O. Self-Assembly of Stable Monomolecular Nucleic Acid Lipid Particles with a Size of
30 Nm. J. Am. Chem. Soc. 2012, 134, 11652–11658. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Structural and Functional Stability of DNA
Nanopores in Biological Media
Jonathan R. Burns 1,* and Stefan Howorka 1,2,*
1 Department of Chemistry, Institute of Structural Molecular Biology, University College London,
London WC1H 0AJ, UK
2 Institute of Biophysics, Johannes Kepler University, A-4020 Linz, Austria
* Correspondence: jonathan.burns@ucl.ac.uk (J.R.B.); s.howorka@ucl.ac.uk (S.H.)
Received: 12 March 2019; Accepted: 23 March 2019; Published: 29 March 2019
Abstract: DNA nanopores offer a unique nano-scale foothold at the membrane interface that can help
advance the life sciences as biophysical research tools or gate-keepers for drug delivery. Biological
applications require sufficient physiological stability and membrane activity for viable biological
action. In this report, we determine essential parameters for efficient nanopore folding and membrane
binding in biocompatible cell media. The parameters are identified for an archetypal DNA nanopore
composed of six interwoven strands carrying cholesterol lipid anchors. Using gel electrophoresis and
fluorescence spectroscopy, the nanostructures are found to assemble efficiently in cell media, such as
LB and DMEM, and remain structurally stable at physiological temperatures. Furthermore, the pores’
oligomerization state is monitored using fluorescence spectroscopy and confocal microscopy.
The pores remain predominately water-soluble over 24 h in all buffer systems, and were able to bind
to lipid vesicles after 24 h to confirm membrane activity. However, the addition of fetal bovine serum
to DMEM causes a significant reduction in nanopore activity. Serum proteins complex rapidly to the
pore, most likely via ionic interactions, to reduce the effective nanopore concentration in solution.
Our findings outline crucial conditions for maintaining lipidated DNA nanodevices, structurally and
functionally intact in cell media, and pave the way for biological studies in the future.
Keywords: DNA nanotechnology; nanopores; biological media; serum; stability; aggregation
1. Introduction
DNA nanotechnology excels at the bottom-up fabrication of engineered nanostructures. DNA
duplexes can be manipulated into user-defined shapes by exploiting the base-pairing rules for
duplex formation [1–3]. Discrete nanostructures can be assembled in two and three dimensions with
sub-nanometer control using dedicated design software [4,5]. Chemical diversity and functionality can
be incorporated into structures site-specifically using, for example, solid phase DNA synthesis [6,7],
or non-specifically via intercalation [8,9], or electrostatic interactions [10,11]. This rapidly evolving field
has transformed materials science with wide-ranging applications, including the generation of DNA
origami devices for optical sensing [12], controlled single molecule synthesis using a lab-on-a-chip
DNA board [13], computation devices [14,15], and finite sub-nm movement of DNA-based robots
using DNA ligands [16].
DNA nanotechnology applied to the life sciences is gaining traction. DNA nanostructures
can help control processes within cells, or at the membrane interface to advance biological
understanding [17–20]. This progress includes the generation of novel diagnostic tools [21–23], the
enhancement of existing drugs [24], and devices with novel therapeutic action [25]. Recently,
intracellular DNA-based delivery vehicles have been used to transport biomolecules. Engineered DNA
cages that encapsulate small molecule drugs [25], mRNA [26], peptides, and proteins [27,28] have
been developed to deliver biomolecular cargo. DNA nanostructures can be internalized in specific
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mammalian cells, although the nature of the design appears to play an important role [29,30]. Coating
the nanostructures in certain chemical groups can improve cellular uptake [10,31,32].
To fulfill desirable biomolecular functions, the DNA nanostructures have to be stable. DNA
origami-based nanostructures have been studied previously in vitro and in vivo [33]. Generally,
the origami constructs withstand diverse biology conditions under short time durations. Yan and
colleagues have recently shown intact and functional DNA origami in the renal system of a mouse
model [34]. However, other reports have identified significant degradation and unfolding of DNA
origami structures in biological media [35,36]. This instability has been attributed to the low level of
Mg2+ ions—essential to stabilize DNA origami nanostructures—and digestion from enzymes including
DNAses. The susceptibility to degradation appears to be design-specific, with tubular designs proving
more resilient [37]. Other strategies can be employed to help stabilize the nanostructures, including
chemical ligation of DNA nicks [38], the introduction of non-native base pairs, such as LNA, PNA,
and XNA [39]. Alternatively, cationic peptides [10], polymers [32], or intercalators [9] can be used to
improve structural stability.
DNA-based nanopores are the most recent class of membrane channels which can potentially
offer a unique degree of control at the membrane interface [40–44]. Naturally occurring nanopores are
usually composed of proteins or peptides to help regulate ion transport across cell membranes [45].
However, it can be challenging to de novo design amino acid-based nanopores due to unexpected
protein misfolding [46]. In contrast, utilizing DNA as a construction material can help overcome this
issue. To date, DNA nanotechnology has produced nanopores with highly customizable properties,
including channel diameter, length, functionalized groups within the lumen, and ligand-controlled
pore opening [40–44]. For future biological applications, including pore-mediated drug delivery,
nanopore stability and solubility within biological media must be maintained.
To investigate DNA nanopore stability, this study employs the DNA nanopore NP-3C
(Figure 1a) [42]. The pore is assembled from six single strands (Tables S1 and S2, Figures S1 and
S2), which form six interwoven DNA duplexes to generate a six helical barrel. Three cholesterol
lipid anchors are site-specifically incorporated to the exterior of the bundle to facilitate membrane
binding and nanopore behavior. The assembled pore punctures the membrane to generate a toroidal
pore to enable ion transport across the lipid bilayer (Figure 1b) [44,47,48]. However, the hydrophobic
lipid anchors can also mediate other undesired behavior, including intermolecular oligomerization
(Figure 1c) [49,50]. To help distinguish the lipid anchor effect, a cholesterol-free version, NP-0C,
was assembled to serve as a negative control (Tables S1 and S2, Figure S1).
 
Figure 1. Identifying the formation, structural and solution-phase stability of amphiphilic DNA
nanopores in biological media. (a) Depiction of six helical bundle nanopore (blue cylinders)
containing cholesterol lipid anchors (orange) and the parameters monitored within; (b) the desired
monomer membrane binding action in vivo; (c) and the undesired hydrophobic lipid anchor-mediated
oligomerization which can prevent membrane binding and reduce the active nanopore concentration.
Cell media is composed of complex ions and nutrients which help to maintain cell homeostasis and
phenotype. For biological applications, the amphiphilic DNA nanostructures must remain structurally
stable within the used medium. Therefore, this report assayed biologically compatible media to
identify the pore’s structural stability and membrane activity, including phosphate-buffered saline
(PBS), bacterial growth medium lysogeny broth (LB), mammalian cell media Dulbecco’s modified Eagle
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medium (DMEM), and DMEM supplemented with 10% v/v fetal bovine serum (FBS) (Table 1) [51,52].
Serum is required for specific cell types to maintain cell function, and is composed of a wide array
of entities including proteins, hormones, and electrolytes. The total protein concentration in FBS is
~0.3–0.5 mg/mL [53]. Albumin, globulin, and fibrinogen make up the majority of proteins found in
serum, at approximately 55, 38, and 7%, respectively. In addition, over a thousand other regulatory
proteins exist at much smaller levels. Metal ions must also be considered. Positively charged metal ions
coordinate with DNA ionically to stabilize duplexes. Therefore, a range of metal cations was assayed
to identify the counterion stabilization on the nanostructures [33]. We tested monovalent sodium and
potassium ions typically used for single channel current recordings used to study nanopores [54],
and divalent magnesium ions, conventionally used for the stabilization of DNA origami constructs.
The nanopore formation was determined using gel electrophoresis. To identify the thermal stability
at physiological temperatures in biological media, the melting temperatures of the constructs were
identified using fluorescence spectroscopy [55]. Further, our study identified the aggregation extent
of the nanostructures using fluorescence spectroscopy and confocal microscopy over time. Finally,
to confirm membrane activity of the nanopore, binding to model membranes was determined using
fluorescence microscopy. With the knowledge gained using our approach, new pore formulations and
folding protocols can be established which should help provide insights for future applications across
the life sciences.
Table 1. Buffer solutions and biological media including their ionic strength.
Abbreviation Na K Mg PBS LB D FBS








D + 10% fetal
bovine serum
Ionic strength 0.32 M 0.32 M 0.11 M 0.17 M 0.17 M 0.17 M 0.19 M
2. Materials and Methods
All reagents were purchased from Sigma Aldrich (UK) unless stated otherwise. The DNA
nanopore was published previously (information on the sequences, including 2D maps and dimensions
is provided in the Supporting Information) [42]. The DNA nanopores were assembled by mixing an
equimolar mixture of the component DNA strands (0.5 μM, unless stated otherwise) (Integrated DNA
Technologies, Coralville, IA, USA) containing the stated buffer or media. The nanopores were folded
by heating the solution from 95 ◦C for 2 min, and cooling to 20 ◦C at a rate of 5 ◦C per min. The folded
DNA nanopore constructs were stored at room temperature, and vortexed for 2 s before use. Where
stated, n-octyl-oligo-oxyethylene (OPOE) (Enzo Life Sciences, Exeter, UK) was added to the folding
mixture prior to nanopore assembly (1.5% v/v).
Buffer and reagents. Na: NaCl 300 mmol/L, tris 15 mmol/L, pH 8.0. K: KCl 300 mmol/L,
tris 15 mmol/L, pH 8.0. Mg: MgCl2 14 mmol/L, tris 40 mmol/L, acetic acid 20 mmol/L,
ethylenediaminetetraacetic 1 mmol/L, pH 8.3. PBS: NaCl 137 mmol/L, KCl 2.7 mmol/L, Na2HPO4
8 mmol/L, KH2PO4 2 mmol/L, pH 7.4. LB: tryptone 10 mg/mL; yeast extract 5 mg/mL; NaCl 10
mg/mL values taken from [56]. D components include CaCl2 2.4 mmol/L, MgSO4 0.8 mmol/L, KCl 5.4
mmol/L, NaHCO3 44.0 mmol/L, NaCl 109.5 mmol/L, NaH2PO4 0.9 mmol/L. Neat fetal bovine serum
components include bilirubin 2.4 mg/L; Cholesterol 340 mg/L; creatinine 27.3 mg/L; urea 260 mg/L;
Na+ 142 mmol/L; Cl− 155.5 mmol/L; K+ 8 mmol/L; Ca2+ 3 mmol/L; Mg2+ 1.1 mmol/L; PO43−
2.3 mmol/L; Fe 1.6 mg/L; glucose 550 mg/L; protein 36 g/L; albumin 17 g/L; α-globulin 17 g/L;
β-globulin 2 g/L; γ-globulin 1 g/L, values taken from [57].
DNA nanopore folding was characterized using 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (Bio-Rad, Watford, UK) with standardized buffers typically applied to
proteins. The gel was thermally equilibrated at 8 ◦C prior to loading. The gel was run at 140 V for
70 min. The bands were visualized by first removing SDS with deionized water, then stained using
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ethidium bromide solution. A 100 base-pair DNA marker (New England Biolabs, Hitchin, UK) was
used as a reference.
The Förster resonance energy transfer (FRET) characteristics of the fluorescein (FAM) and Cy3
labeled nanopore constructs were identified using a Varian Eclipse fluorescence spectrophotometer
(Agilent, Stockport, UK). 20 μL of the various DNA nanostructures (folded in PBS at 1 μM) (see Tables
S1 and S2 for strand information) was added to PBS (180 μL) in a quartz cuvette with a path length
of 1 cm. The samples were analyzed by excitation at 495 nm, and the emission monitored between
505–700 nm. A 5 nm slit width and 600 PMT voltage was applied, along with a scanning rate of 600 nm
per min; the scan was performed 3 times and averaged.
The melting transitions of the DNA nanostructures were identified using a MyIQ real-time PCR
(Bio-Rad, Watford, UK). The nanostructures were assembled containing FAM and Cy3 FRET pairs
(folded at 1 μM in PBS). The DNA constructs were diluted into the stated buffer systems to give a
final DNA concentration of 0.1 μM (total volume of 25 μL) in a 96-well thin wall fluorescence plate
(Bio-Rad, Watford, UK). Optical quality sealing tape (Bio-Rad, Watford, UK) was placed on top to
prevent evaporation. The sample was heated from 30–85 ◦C at a rate of 0.5 ◦C per min. The melting
temperature was determined from taking the derivative of the donor fluorescence profile. Errors were
identified from 3 independent experiments.
Fluorescence spectroscopic analysis was performed on Cy3-modified DNA nanostructures using
a Varian Eclipse fluorescence spectrophotometer (Agilent, Stockport, UK) with a fluorescence cuvette.
The samples were analyzed by excitation at 540 nm, and by monitoring the emission from 550–600 nm,
using a 10 nm slit width, 800 PMT voltage, scanning at 600 nm per min and taking the average of 3
repeat scans. The DNA nanostructures (2 μL, folded at 0.5 μM) in the stated buffers were scanned
once the folding temperature reached 40 ◦C by diluting in the buffer systems (200 μL final volume).
At the designated time points, the samples were centrifuged for 10 min at 16k revolutions per min at
room temperature (Eppendorf, Stevenage, UK), and the supernatant was carefully extracted and the
fluorescence monitored using the same dilution and settings as described.
Confocal laser scanning microscopy (CLSM) images were collected using a 60× oil objective
FV-1000 Olympus microscope. Images were analyzed using ImageJ software. To image the DNA
nanopore constructs, the folded pore containing a Cy3 dye (10 μL, 0.5 μM in PBS) was deposited
on a fluorodish (World Precision Instruments, Sarasota, FL, USA), and left to settle for 20 min
prior to imaging. For the vesicle-binding assays, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) giant unilamellar vesicles (GUVs) were prepared by modifying a published protocol [48,58].
POPC (150 μL, 10 mM) in chloroform was added to a 1 mL glass vial, the solvent was removed under
vacuum, and underwent rotation using a rotary evaporator. The thin film generated was resuspended
in mineral oil (150 μL) by vortexing and sonicating for 10 min. Green fluorescent protein (5 μL,10 μM
in PBS) was mixed with sucrose solution (20 μL, 400 mM), followed by addition of mineral oil (150 μL).
The suspension was vortexed and sonicated for 10 min at room temperature, then carefully added to
the top of a glucose solution (1 mL, 400 mM) in a plastic vial (1 mL). The vesicles were generated by
centrifuging at 16K RPM at 4 ◦C for 10 min. The mineral oil top layer and the majority of the sucrose
layer (~800 μL) were carefully removed. The remaining solution containing the pelleted vesicles was
gently mixed with a pipettor, then transferred to a clean plastic vial. The POPC GUVs (5 μL) were
added to a KCl solution (5 μL, 0.5 M), and then Cy3-labeled NP-3C (2 μL folded at 0.25 μM) in the
stated buffers was mixed, and the solution deposited on the confocal slide and used within 24 h.
For the serum time series assay, NP-3C (10 μL, 0.25 μM folded in PBS) was added to FBS (10 μL) for
the stated time durations. The NP-3C-FBS solution (4 μL) was added to the GUV solution as described
above. All images were collected after 20 min using identical settings.
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3. Results
3.1. Determining Nanopore Formation in Media
The folding efficiency of the DNA nanopores in biological media was analyzed using SDS-PAGE
(Figure 2). First, the formation of the folded barrel was confirmed by assembling NP-0C, as well
as versions missing some of the component strands (Figure 2a). Combining all six strands yielded
the slowest migrating band slightly above the 1517 base pair marker band, as indicated by the top
arrow. Removal of a single strand from the folding mixture resulted in an increase in band mobility.
The 5-component construct migrated towards the 500 base pair marker band, as indicated by the bottom
arrow. The large shift in band migration between a fully and partially assembled barrel is consistent
with the formation of a higher order tertiary nanostructure. However, the strand combinations 1–4
and 1–3 also gave rise to a band migrating aligned to the 500 bp marker band. This result indicates
that the addition of strands 4 and 5 to the pooled mixture did not successfully incorporate within
the assembled bundle. Comparing component strands 1–2 and 1 gave the expected step-wise change
indicating successful assembly.
 
Figure 2. The DNA nanopores fold efficiently and remain structurally stable in a range of salts
and buffer conditions as shown by gel electrophoresis. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) reveals (a) step-wise assembly of NP-0C, left to right, fully assembled
barrel strands (1–6), followed by component strands (1–5), (1–4), (1–3), (1–2), (1), and 100 base pair
marker (M), the arrows indicate the 1517 (top) and 500 base pair (bottom) marker bands; (b) 1 h (top)
and 24 h (bottom) after folding of NP-0C assembled in a variety of conditions; 100 base pair marker (M),
0.3 M sodium chloride (Na), 0.3 M potassium chloride (K), 14 mM magnesium chloride (l Mg), 140 mM
magnesium chloride (h Mg), phosphate buffered solution (PBS), Lysogeny Broth (LB), Dulbecco’s
modified Eagle medium (D), and Dulbecco’s modified Eagle medium supplemented with 10% fetal
bovine serum (FBS).
The assembled NP-0C construct folded efficiently in all biological buffers as assayed by SDS-PAGE
(Figure 2b). This result confirmed stable DNA nanostructure formation in diverse media over short
time durations, even in the presence of low salt conditions. After 24 h the gel was repeated, all bands
showed very similar behavior—except for the media containing FBS—indicating that the pores are
generally stable under these varied conditions. Adding protein-containing FBS led to the formation
of protein-DNA complexes that did not migrate into the gel. The surfactant in the gel buffer, sodium
dodecyl sulfate (SDS), was not able to disrupt the protein binding to the DNA nanostructure.
3.2. Identifying Nanopore Melting Temperatures in Biological Media
The thermal stability of the pores was established using DNA nanostructures labeled with a
fluorophore pair for Förster resonance energy transfer (FRET). FAM (fluorescein) (donor) and Cy3
(acceptor) FRET pairs [59] were incorporated into the nanostructures on strands 2 and 6, respectively
(see the Supporting Information for details for the DNA strands) (Figure 3a). Successful FRET was
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confirmed by scanning the donor emission in the absence and presence of the acceptor in assembled
NP-3C (Figure 3b). Next, the donor emission was monitored upon heating (Figure 3c). The donor
profile gave rise to a sigmoidal curve and its derivative yielded the melting transition. All constructs in
the media types displayed melting transitions significantly above physiological temperatures (Table 2).
Monovalent sodium and potassium gave very similar melting transitions for NP-3C, at 51.3 ◦C and 52.2
◦C, respectively. However, divalent magnesium gave rise to a 1.6 ◦C enhancement, even though the
counterion concentration was significantly lower. Biologically compatible PBS reduced the structural
stability by 4 ◦C, possibly due to the lower concentration of monovalent sodium (137 mM). However,
the overall high thermal stability of all the nanostructures in all the media conditions confirmed their
suitability for biological applications from a structural perspective.
Figure 3. Determining the thermal stability of DNA nanopores in biological media using the Förster
resonance energy transfer (FRET) pair labeled DNA nanopores. (a) Representation of fluorescein
(FAM) (purple) and Cy3 (green) fluorophores incorporated into the DNA nanopore constructs; (b)
fluorescence emission spectra of FAM (donor) and Cy3 (acceptor) labeled DNA nanopores, excitation at
495 nm, the donor emission is decreased in the presence of the acceptor in the assemble pore construct;
(c) fluorescence donor emission thermal melting profiles of NP-3C in the stated buffers. The different
fluorescence intensities reflect how the applied buffer system influence fluorophore emission.
Table 2. Melting temperatures of DNA nanopore constructs in stated salt and media systems. Errors
were identified from three independent experiments.
Construct Na K Mg PBS LB D FBS
NP-0C 49.7 ± 0.3 50.9 ± 1.2 52.7 ± 0.3 46.4 ± 0.9 46.6 ± 0.3 45.8 ± 0.3 45.7 ± 0.3
NP-3C 51.3 ± 0.6 52.2 ± 0.8 53.8 ± 1.5 46.7 ± 0.3 45.0 ± 1.0 46.8 ± 0.3 47.2 ± 0.3
3.3. Identifying Time-Dependent Nanopore Water-Solubility
We tested the water solubility of constructs in the different media conditions. Centrifugation
was used to pellet and separate any large NP-3C clusters from smaller water-soluble fractions.
The fluorescence in the supernatant was quantified using a fluorometer (Figure 4a), and fluorescence
in the pellet using confocal laser scanning microscopy (CLSM) (Figure 4b). The cholesterol-free
construct remained predominantly water-soluble over the course of 48 h in all assayed media.
The cholesterol labeled nanopore, NP-3C, showed some aggregation and pelleting after 24 h. However,
the majority of the oligomerized and monomeric form remained water soluble (>75%) even after 48 h.
The protein-DNA complexes generated by FBS resulted in a noticeable increase in the pelleting fraction;
however, the majority of complexed NP-3C in FBS remained water-soluble. By comparison, NP-0C
showed no aggregation either in the supernatant, or CLSM images after 48 h across all conditions.
This result confirms the cholesterol lipid anchors were responsible for the detectable pelleting observed.
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Figure 4. Identifying aggregation of DNA nanopores over time. Relative fluorescence intensities of
Cy3-labeled (a) NP-0C and (b) NP-3C remaining in solution after centrifugation at 1, 24, and 48 h, in the
stated buffers; (c) CLSM images of Cy3-labeled NP-3C in the stated buffers at 1 and 24 h. Scale bar 50 μm.
3.4. Identifying Nanopore Membrane Binding Activity in Media
We tested the ability of DNA nanopores to bind to vesicles in media. The DNA nanopores
binding towards giant unilamellar vesicles (GUVs) was identified using CLSM (Figure 5). Green
fluorescence protein (GFP) was encapsulated inside the GUVs to aid visualization. Cy3-labeled NP-3C
in PBS, LB, or DMEM was diluted into the GUV solution to minimize the effect different salts and
buffers have on dye fluorescence. Extensive membrane binding to GUVs was observed for these
combinations, as shown by intense membrane halos around the vesicles’ perimeter. In contrast, NP-3C
in serum-containing media blocked the nanopores’ binding event significantly. In agreement with
SDS-PAGE analysis described above, FBS proteins complexed to the pore, via the generation of a higher
molecular weight complex which prevents cholesterol-mediated binding. However, this problem
can be circumvented by minimizing the pores exposure to FBS prior to vesicle addition. Adding the
pores to FBS for 20 min, or directly from PBS, followed by addition to GUVs resulted in significant
membrane binding, comparable to the other media conditions. This is an important finding for future
lipidated DNA nanodevices employed in serum-containing media.
Figure 5. Confocal microscopy shows NP-3C binding to GUVs in biological buffers while FBS
complexes to NP-3C to block membrane tethering. (a) Cy3-labeled NP-3C (magenta) mixed in the stated
buffers for 1 h, and NP-3C added to FBS for different time periods, then added to GUVs containing GFP
(green), image collected after 20mins of pore-vesicle incubation on a glass slide; (b) relative membrane
fluorescence intensities from (a). All images collected under identical conditions. Error bars represent
the averages of three experiments. Scale bar 10 μm.
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3.5. Adding Detergent Prevents Nanopore Aggregation
We employed the non-ionic surfactant n-octyl-oligo-oxyethylene (OPOE) to generate a DNA
nanopore-detergent complex to improve solubility and prevent aggregation. Naturally occurring
membrane proteins are amphiphilic and can aggregate due to poor aqueous solubility. To help
overcome this issue surfactants are routinely utilized to extract, solubilize, and stabilize membrane
proteins [60]. OPOE was previously shown to aid DNA nanopore insertion into membranes during
single channel current recordings [42]. We tested whether the surfactant can reverse pre-aggregation
of nanopores using the centrifugation assay described above. The surfactant was added in high
concentrations above the critical micelle concentration (CMC). OPOE was added after incubating the
pore 48 h in FBS. CLSM revealed NP-3C aggregates after the addition of OPOE (Figure 6a) suggesting
that the surfactant was not able to disrupt the pre-formed NP-3C aggregate. However, when the
detergent was added to the pooled DNA prior to assembly, no aggregates were observed either by
confocal microscopy, or a decrease in the supernatant fluorescence after 48 h (Figure 6a,b). These results
confirm that the mild surfactant was able to solubilize the pores and prevent higher-order assembly
for long durations. These results indicate that future folding protocols should include detergent
within the folding mixture, prior to, or shortly after nanopore folding to help prevent lipidated DNA
nanostructure aggregation.
Figure 6. Adding surfactant prevents nanopore aggregation and precipitation. (a) CLSM images of
Cy3-labeled NP-3C (magenta) in FBS 48 h after folding, with OPOE added at 48 h (left), or prior
to folding (right), all images collected under identical conditions, scale bar 50 μm; (b) fluorescence
analysis of the supernatant fraction after centrifugation of NP-0C (blue) and NP-3C (magenta) folded
in the presence of OPOE. Error bars represent the averages of three independent experiments.
4. Discussion
DNA-based nanopores are a recent and exciting class of synthetic membrane channel.
This construction approach provides a unique level of biophysical control across lipid bilayers. For
DNA nanopores to provide functionality in the life sciences, for example, as biosensors, drug delivery
vehicles, or cytotoxic-inducing agents, biocompatibility needs to be addressed. Essential parameters
before in vitro and in vivo testing include confirming structural stability and solution-phase solubility
in biologically compatible media. We have employed an archetypical DNA nanopore and tested its
folding capabilities in diverse biological media routinely used to culture mammalian or bacterial
cells. The conditions were deliberately chosen to be stringent as folding was performed in the cell
media. It would also have been possible to fold pores in protein-free buffers and then add them to the
protein-containing media. This differential treatment would have, however, made a fair comparison
across all buffers and media more difficult. Our results suggest that pores folded efficiently and
remained structurally stable in all media assayed. Importantly, the pore constructs displayed melting
temperatures above physiological temperatures, even in the absence of divalent magnesium ions. With
the exception of FBS-containing media, the DNA nanopores remained predominately water soluble
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in all conditions tested over 48 h. These results reinforce the suitability of DNA nanotechnology as a
good building material for use in biological studies.
Serum proteins cause aggregation most likely due to complexation towards the DNA’s negatively
charged phosphate backbone. Albumin serum proteins have been shown to complex to antisense
oligonucleotides, which in some instances enhances the half-life of intravenously injected DNA [61,62].
However, hydrophobic groups can further increase the protein complexation extent [63]. In the case of
amphiphilic DNA nanopores used in this study, the resultant complexes caused significant aggregation,
drastically reducing the amount of membrane tethering action. This result is an important finding in
the field of lipidated DNA nanostructures, and if the use of FBS is unavoidable, the DNA nanopores
should be applied for short time periods of less than 1 h, or the cells transferred temporarily into other
media, such as phosphate buffered saline. Alternatively, vesicle delivery agents may be employed to
shield the nanostructures from aggregation. Other strategies include using DNA masking groups, such
as coating the structures in polyethylene glycol, or carboxylic acids, both are known to improve the
circulation time of biomolecules in the bloodstream. Cationic groups such as lysine and arginine-rich
peptides [32], polyamines [64], and metal cations can be used to block the serum proteins from binding.
In addition, charge-neutral peptide nucleic acids nanopore equivalents [39] can be developed to
prevent serum complexation. We expect lipidated DNA nanodevices and DNA nanopores to provide
a useful foothold cell biology, and should find use as drug delivery gate-keepers, to function as drug
molecules, such as immunosuppressants or immunoactivators, or act as novel tools in diagnostics
and sensing.
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Abstract: RNA aptamers that bind non-fluorescent dyes and activate their fluorescence are highly
sensitive, nonperturbing, and convenient probes in the field of synthetic biology. These RNA
molecules, referred to as light-up aptamers, operate as molecular nanoswitches that alter folding and
fluorescence function in response to ligand binding, which is important in biosensing and molecular
computing. Herein, we demonstrate a conceptually new generation of smart RNA nano-devices
based on malachite green (MG)-binding RNA aptamer, which fluorescence output controlled by
addition of short DNA oligonucleotides inputs. Four types of RNA switches possessing AND, OR,
NAND, and NOR Boolean logic functions were created in modular form, allowing MG dye binding
affinity to be changed by altering 3D conformation of the RNA aptamer. It is essential to develop
higher-level logic circuits for the production of multi-task nanodevices for data processing, typically
requiring combinatorial logic gates. Therefore, we further designed and synthetized higher-level
half adder logic circuit by “in parallel” integration of two logic gates XOR and AND within a single
RNA nanoparticle. The design utilizes fluorescence emissions from two different RNA aptamers:
MG-binding RNA aptamer (AND gate) and Broccoli RNA aptamer that binds DFHBI dye (XOR gate).
All computationally designed RNA devices were synthesized and experimentally tested in vitro.
The ability to design smart nanodevices based on RNA binding aptamers offers a new route to
engineer “label-free” ligand-sensing regulatory circuits, nucleic acid detection systems, and gene
control elements.
Keywords: logic gates; nucleic acid computing; RNA aptamers; RNA nanotechnology
1. Introduction
The progression in the field of RNA nanotechnology makes RNA molecules the most promising
candidate to fabricate bio-computers due to their variable folding properties as well as their catalytic
functions [1,2]. Numerous non-canonical nucleotide interactions, found only in RNA [3,4], enable this
biopolymer to self-assemble into various shapes and dimensions as exemplified by naturally occurring
ribosomal RNA [5] and ribozymes [6,7] as well as by artificially constructed RNA polygons [8–12],
prisms, and cubes [13–15]. This diverse structural capability of RNA led to the development of
aptamer technology almost 30 years ago [16,17]. Aptamers are single-stranded RNA or DNA
oligonucleotides, with typical length of no more than 100 nts that were artificially selected from
combinatorial libraries for high binding affinities to specific molecular targets. Since their development,
aptamers have revolutionized the field of biosensing by enabling scientists to rationally generate
different aptamers targeting a diverse range of ligands [18–20]. RNA-based fluorogenic modules
are of particular interest [21–23] since they have applications in monitoring gene expression [24,25]
and new drug screening pipelines using microarrays developed to sense target molecules of variable
size [26]. This florescence module includes a light-up RNA aptamer and fluorogen. The light-up
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RNA aptamers are selected to specifically bind to small organic molecules exhibiting minimal
to no fluorescent emission when free in solution (fluorogen or fluorogenic dyes) and trigger its
florescence. The well-studied examples include malachite green (MG)-binding RNA aptamer [27],
and 3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI)-binding RNA aptamers [28,29] among
others [30,31].
In RNA nanotechnology, the development and implementation of RNA-based nanodevices that
respond to biomolecular inputs by generating output signals in accordance with logic gate behavior has
attracted considerable attention [32–36]. Computing using both RNA and DNA molecules integrates
biochemistry and molecular biology disciplines to achieve a certain goal through designing algorithmic
processes embedded within polynucleotide structures. The concept of using nucleic acids (NAs) for
computation was proven in 1994 when Leonard Adleman demonstrated the ability of synthetic DNA
oligonucleotides to solve a seven-point Hamiltonian path problem [37] and, since then, many studies
have reviewed the possibility of developing a new generation of molecular logic gates and molecular
computers based on nucleic acids [38,39]. In contrast to silicon-based computers, NA computers
implement concentrations of specific molecules, such as metal ions, small organic dyes, single stranded
DNA or RNA oligonucleotides, peptides or proteins, as inputs to derive certain signals, e.g., switching
between RNA conformations, activation or deactivation of ribozyme activity, down- or up-regulation of
certain genes, etc. [40–45]. This relies on the algorithmic processes carefully designed and encompassed
within a nucleic acid complex (referred to as logic gates (LGs)) that are capable of performing simple
AND, OR, NAND, and NOR logic operations, as well as more sophisticated logic circuits.
DNA has been routinely used for the development of biochemical circuits and all basic logic
operations, including INHIBIT, IMPLICATION, and XOR have been mimicked with DNA as a
template [46–50]. There are also various classes of functional RNA molecules, such as ribozymes,
riboswitches, miRNA, siRNA, and orthogonal ribosomes, that enable the fabrication of computational
systems [51–54] and simple RNA fluorogenic biosensors [55,56]. However, it is often essential to
develop higher-level logic circuits for the production of multi-task nanodevices for data processing,
which usually require combinatorial logic gates [57,58]. For example, a half adder can perform an
addition operation on two binary digits by integration of an XOR gate and an AND gate in parallel
to generate a SUM (S) output and a CARRY (C) output, respectively. To the best of our knowledge,
the development of combinatorial RNA logic gates based on light-up RNA aptamer fluorogenic
systems has yet to be realized, and would represent a label-free oligonucleotide bio-sensing platform
with potential applications in biocomputing and biosensing.
Herein, we report the design and assembly of a conceptually new generation of molecular logic
gates that possess simple AND, OR, NAND, and NOR logic operations implementing the light-up
MG-binding RNA aptamer. Single stranded DNA (ssDNA) oligonucleotides were used as inputs to
trigger conformational changes in the RNA aptamer. The corresponding output values of OFF (0) and
ON (1) are obtained by low and high fluorescence emissions, respectively (Figure 1A).
Furthermore, we developed a basic half adder computing platform based on the RNA light-up
aptamer strategy (Figure 1B). The design utilizes fluorescence emissions from two distinct fluorogenic
RNA modules, MG-binding RNA aptamer [27,59] and DFHBI-binding Broccoli RNA aptamer [29],
fused with the previously reported tetragon RNA nanoparticle [8,9].
The function of the half adder is triggered by the same two ssDNA inputs. The ssDNA inputs
alter the conformation of the RNA aptamers in such a manner as to either permit or deny fluorogen
dye binding to the aptamer, resulting in fluorescent (ON) or non-fluorescent (OFF) states within
one nanostructure. This RNA logic gate system demonstrates the great potential of light-up RNA
aptamers as an arithmetic tool for molecular programming and will open a way to further development
concerning well-regulated molecular electronic devices and biosensors.
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Figure 1. Logic gate design strategy based on light-up RNA aptamers. (A) malachite green
(MG)-binding RNA aptamer used to design four simple AND, OR, NAND, and NOR logic gates.
(B) Illustration of RNA half adder system based on MG RNA and Broccoli RNA aptamers conjugated
with RNA tetragonal nanoparticle. Fluorophores MG and DFHBI in their unbound state exhibit low
fluorescence (0), the emission of these chromophores increases upon binding to their corresponding
RNA aptamers (1).
2. Results and Discussion
2.1. Design and Fabrication of a Logic Gate Possessing AND, OR, NAND and NOR Boolean Functions
RNA molecules featuring aptamers that bind a fluorogenic dye and activate its fluorescence have
the potential to be highly sensitive and convenient probes in the field of synthetic biology. The initial
system is comprised of an RNA hairpin molecule containing the MG RNA binding aptamer sequence
and the MG fluorogen dye [60]. The fluorescence of the MG dye is negligible when free in solution
(OFF state) and is increased significantly upon binding to its RNA aptamer (ON state) (Figure 1).
The principle of the LG design is based on the structural manipulation of the RNA aptamer, due to the
fact that binding affinity of the fluorogenic dye to its light-up RNA aptamer depends on the correctly
folded RNA structure. Thus, the fluorescence emission can be precisely turned ON (correctly folded
RNA structure) and OFF (disrupted conformation). The four logic gates AND, OR, NAND, and NOR
were designed using this highly effective and modular approach (Figure 2).
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Figure 2. Logic gate design principles for an AND gate (A), OR gate (B), NAND gate (C), NOR gate
(D). The predicted 2D conformations of the RNA aptamers in the presence and absence of individual
or both inputs are shown to the right. The rules specified by each gate are shown in truth tables to the
left. Normalized fluorescence enhancement of the gates is displayed in the middle. The fluorescence
enhancement data are reported with ± standard error of the mean (SEM) bars; measurements have
been reproduced from least three repetitive trials.
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Individual gates employed light-up RNA aptamers consisting of two extended sequences localized
at both the 5′- and 3′-ends highlighted in Figure 2 in black. This will further be referred to as the
interfering end for the AND and OR gates or the non-interfering ends for the NAND and NOR
gates. The MG RNA aptamer core sequence is highlighted in red. The end sequences are tailored to
bind the ssDNA oligonucleotides which serve as inputs. All the RNA gates were designed in silico
relying on secondary structure prediction algorithms encompassed within NUPAC [61] or mfold
programs [62] to confirm the secondary structures of each RNA sequence prior to synthesis. If the
calculated lowest free-energy secondary structure corresponded to the desired RNA conformation,
and no other secondary structure was closer than 20% in energy to the lowest energy structure,
the sequence was used without alternations. Otherwise, minor changes were made to Watson–Crick
base-paired positions to destabilize competing conformations. The fluorescence was measured at 22 ◦C
in 1× TMS buffer as described in the materials and methods. Each RNA logic gate was designed to
have complementary regions at the 5′- and 3′- ends to ssDNA oligonucleotide inputs with lengths
ranging from 15 to 27 nucleotides (Supplementary Table S1). Each gate processes a different pair
of oligonucleotide inputs—for instance, input A of the AND gate is not the same as input A of the
OR gate—and the terms A and B were merely applied across the table for simplicity. However,
the sequences and therefore 2D structures for AND and OR gates were designed to be identical as both
initial structures, at the no inputs setting, should have 0 output or exist in the OFF state according to
the truth table (Figure 2A,B).
In a similar manner, initial structures for the NAND and NOR gates were chosen to share identical
nucleotides as the ON state is a requirement for both structures at the no inputs condition. For each
logic gate, the fluorescence intensities were normalized throughout the experiments. The threshold
value was determined to be 60% where an intensity greater than this value yields an output = 1,
while an intensity below this value yields an output = 0.
The AND and OR gates with default setting (0-0; no inputs present) was designed using
interfering ends. The purpose of this was to form a complementary base pairing with the RNA
aptamer MG-binding region as illustrated in Figure 2A,B. The interfering sequences at both ends were
chosen to form weak hairpin-like 2D structures (2D structures available in Supplementary Figure S1).
These hairpins are formed by involving core nucleotides that are responsible for forming a binding
pocket for the MG fluorogen (Supplementary Figure S1). Thus, the presence of the hairpins prevents
the light-up aptamer from binding to its MG chromogen and ultimately diminishing the fluorescent
signal. The AND operation is achieved by carefully designing two short ssDNA inputs (A and B)
to bind to the 5′ and the 3′ interfering ends, respectively. The structural rearrangement to the ON
conformation occurs only when there are two inputs present at the same time. The presence of
the inputs releases the core MG nucleotides (nts) thus allowing them to fold into the proper ON
conformation. The selection of these particular ssDNA inputs was achieved by varying their length
using RNA structure prediction programs (Supplementary Figure S2). The goal was to select the
appropriate length of the inputs that would hybridize (or not hybridize at all) with its target hairpin
without perturbing the conformation of the other hairpin when only one input is added. The selection
of the DNA inputs was based on the computed melting temperature (Tm), the temperature at which
50% of double stranded nucleic acid is converted to single-standard form. The desired Tm values
for inputs hybridization were chosen to be slightly greater than 22 ◦C, the temperature at which the
experiment was performed. Such input selection relies on the equilibrium between duplex (formed by
ssDNA and hairpin nts) and hairpin structures where equilibrium shifts slightly in favor of the hairpin
structure (Figure S2, AND GATE). However, inclusion of both inputs favors the formation of two
duplexes triggering structural rearrangement of the overall complex, which leads to the liberation of
the core nts accountable for MG-binding site formation. As shown in Figure 2A, resulting fluorescence
intensity measured for four annealed samples (0-0; 0-1; 1-0, and 1-1) clearly indicates the effectiveness
of the AND gate function.
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The OR construct, which yields output = 0 for scenario 0-0 and output = 1 for scenarios 1-0,
0-1, and 1-1, shares the identical RNA sequence as the AND gate. However, the ssDNA inputs were
designed to have several extra nucleotides to achieve an equilibrium state where inclusion of at least
one input will trigger conformational change in favor of the correctly folded MG-binding RNA aptamer.
The design criterion is based on a strand displacement reaction. Upon binding to its corresponding
hairpin, input A or B will create a stable hybrid RNA/DNA duplex. The DNA inputs were selected
to contain longer sequences with much higher Tm values as compared to the AND gate, so that
disrupted hairpin nts initiate a conformational change of the whole construct favoring formation of
the ON aptamer state (Figure S2, OR GATE). The measured fluorescence emission values in solution
demonstrates OR behavior of the RNA construct (Figure 2B).
In contrast to the AND and OR gates, the NAND and NOR gates were designed so the default
structures possess correctly folded light-up MG RNA aptamers and the extensions at the 5′- and
3′-ends do not interfere with the core structure. To produce the corresponding NAND operation, the
non-interfering ends must be able to bind input A or input B without sacrificing the conformation of
the aptamer. However, when both A and B are presented, the conformation of the aptamer needs to be
sufficiently distorted to register an output = 0. Figure 2C summarizes the fluorescence enhancement
measurement for the NAND gate. Interestingly, while input A alone (1-0) decreases fluorescence as
compared to the 0-0 state, input B alone (0-1) increases it slightly. Inputs A and B in tandem (1-1)
triggered a noticeable decrease in fluorescent intensity (Figure 2C).
The NOR logic gate was constructed utilizing the NAND RNA molecule. Figure 2D shows an
obvious increase in fluorescence intensity between output = 0 and output = 1, owing to the nature of
the RNA NAND logic gate. The designed ssDNA inputs that complimentarily pair with the RNA gate
can significantly disrupt the conformation of the RNA molecule, rendering MG binding impossible.
Hence, the output was “1” when only neither DNA input was added (Figure 2D).
Collectively, the modular approach to the fabrication of RNA Boolean logic gates based on the
light-up RNA aptamer was demonstrated. All designed gates produced the expected OFF or ON
values corresponding to low or high fluorescence intensity at λmax = 650 nm, respectively, in response
to DNA oligonucleotide inputs. A threshold value of fluorescence enhancement of 60% was chosen
to distinguish the OFF (any value bellow 60%) and ON (any value above 60%) states. Various
concentrations of RNA molecular gates, inputs, and MG dye in solution were explored, with those
yielding the greatest difference in fluorescence between output = 0 and output = 1 reported here.
The extent to which these modular RNA logic gates can be used to probe three or more inputs
simultaneously will depend on their reliability in tandem.
2.2. Implementing Logic Gates to Construct a Half-Adder Logic Circuit
The production of multi-functional nanodevices for data analysis or processing is extremely
important and yet challenging due to requirements of multiple coordinated logic gates operations
within a single unit. Based on the aforementioned results, we next integrated two different
fluorogen-binding RNA aptamers: (i) MG RNA aptamer and (ii) the recently developed Broccoli
RNA aptamer that binds DFHBI dye within one RNA complex. As a key building block, the half
adder is used to construct more advanced computational circuits and is in high demand in information
technology [63]. The representative secondary structure of this complex is demonstrated in Figure 3A.
The differences in the emission properties of these two fluorogens (MG emits in the “red” region while
DFHBI emits in the “green” region of the visible spectra range) were implemented to construct a
half-adder logic circuit, which is a primary step in constructing a full adder, a basic arithmetic unit
in computing.
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Figure 3. Implementation principle of the developed half adder. (A) Secondary structure of the RNA
complex based on MG and Broccoli RNA aptamer conformations fused to tetragonal nano-scaffold.
(B) Representative atomic force microscopy image (AFM) of the RNA half adder (bar scale = 100 nm)
and Dynamic Light Scattering (DLS) data showing average size of the complex ± SEM. (C) AFM and
DLS data for control RNA tetragonal nanoparticle, with the diameter of the nanoparticles is reported.
The half adder is composed of an AND gate with a MG-binding light-up RNA aptamer, and a XOR
(eXclusive OR) gate based on the DFHBI-binding Broccoli light-up RNA aptamer [29]. The fluorescent
intensity was measured in solution using fluorescent spectroscopy with excitation wavelengths of
λex/em = 465/510 nm (corresponding to the XOR gate) and λex/em = 615/650 nm (corresponding
to the AND gate). These gates were rationally designed to use two ssDNA inputs to output two
fluorescence signals: SUM (λem = 510 nm) and CARRY (λem = 650 nm) generated by the AND
and XOR gates, respectively (Figure 4). Both the MG RNA aptamer and Broccoli RNA aptamers
were incorporated on alternating vertices to a previously developed RNA tetragon nanoparticle.
The RNA half adder self-assembles from five RNA strands with a yield exceeding 80% (Supplementary
Figures S3 and S4). The conformation of the assembled RNA tetragonal geometry was confirmed by
atomic force microscopy and size was determined by dynamic light scattering (Figure 3B). Atomic Force
Microscopy image (AFM) imagining revealed the extensions at each vertex in the designed RNA half
adder as compared to the control RNA square nanoparticle. The size of the nanoparticle increases
from 15 nm to approximately 35 nm with the addition of the RNA aptamers as shown by Dynamic
Light Scattering (DLS) experiment. Also, the significant size variation between RNA tetragon and
RNA half-adder nanoparticles was confirmed by native polyacrylamide gel electrophoresis (PAGE)
(Figures S5 and S6).
To perform the XOR and AND logic operations using the same two ssDNA inputs, additional
DNA inhibitor strands were introduced to bind complementary to the light-up RNA aptamers and
interfere with their ON states or correctly folded structures. This tetragonal shaped half-adder RNA
complex is designed according to the competitive hybridization and displacement principle of the
DNA strands. The assembly experiments shown in Figure S5 confirm complexation of both inhibitors
with the tetragonal nanoparticle. Importantly, the RNA tetragon containing 2 MG and 2 Broccoli
RNA aptamers assembles with their corresponding DNA inhibitors at 1:2 ratio, i.e., one tetragon and
2 AND_DNA inhibitors and 2 XOR_DNA inhibitors.
The Broccoli RNA aptamer was designed to act as an XOR gate. To maintain the proper XOR
gate function, an inhibitor DNA strand was designed (XOR_DNA inhibitor). The inhibitor bound
to the aptamer, disrupting the binding of DFHBI and thus diminishing fluorescence in the presence
of neither input. This XOR_DNA inhibitor contains two loop regions on either side of the aptamer.
These internal loops contain eight unpaired nts and are designed to complement the ssDNA inputs.
The addition of either ssDNA input destabilizes the RNA aptamer-inhibitor complex, separating the
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strands enough to reform the functional RNA aptamer shape allowing (1-0) or (0-1) truth values in
fluorescence with an output of “1” (Figure 4A).
Figure 4. Design principles of the RNA AND and XOR gates using inhibitor DNA strand. (A) Predicted
secondary structures of the nucleic acid displacement reactions within XOR and AND gates. (B) Truth
table of a half adder. (C) The normalized fluorescence enhancement of the system at 510 nm and
650 nm as a function of the various inputs (Inputs A and B); the error bars indicate ± SEM from three
independent measurements.
However, in the presence of both inputs, fluorescence is once again inhibited as the hybridization
of inputs A and B is favored over hybridization with XOR_DNA inhibitor. To achieve this, inputs A and
B were designed to bind more competitively to one another than to the XOR_DNA inhibitor through
17 “sticky” nts at the 5′ end of input A and 3′ end of input B (Table S1). Therefore, the XOR_DNA
inhibitor paired with the RNA aptamer yielded a low fluorescent output signal. Figure 4C shows the
normalized fluorescence intensity of the designed XOR system at 510 nm output readout in response to
the ssDNA inputs. The presence of each input is defined as “1” (the absence is considered “0”) and the
output signal is defined as ON or OFF when the normalized fluorescence emission is higher or lower
than 40%, respectively. The system exhibits ON in the presence of the individual inputs; otherwise,
it remains OFF. The XOR logic operation performs the SUM digit function in the half adder as shown
in the Truth Table (Figure 4B).
The AND logic operation of the half adder was designed utilizing the fluorescent properties
of the MG-binding RNA aptamer system as the output signal. Similar to the XOR gate approach,
a DNA inhibitor (AND_DNA) was used to disrupt the RNA aptamer conformation. The AND gate
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has an output of OFF or (0) in the absence of inputs (0-0) or in the presence of only one of the inputs
(1-0 or 0-1). As the inputs are the same as those used for the Broccoli XOR gate, it is critical for
the AND_DNA inhibitor to be complementary to the previously designed inputs. For this purpose,
the AND_DNA inhibitor was designed to contain “sticky” nts at the 5′- and 3′-ends. These “sticky”
nts are complementary to the ssDNA inputs. The addition of either input causes only a partial
displacement of the AND_DNA inhibitor from the light-up RNA aptamer resulting in the low
output value as demonstrated in Figure 4C. However, in the presence of both inputs, fluorescence
increases significantly (ON state). This was accomplished by disassociating the AND_DNA inhibitor.
The ssDNA inputs bind more competitively to the inhibitor to form a three-stranded DNA/DNA/RNA
complex enabling the successful separation from the RNA light-up aptamer. Figure 4A (lower panel)
summarizes the 2D structures computed for the AND logic system in the presence and absence of
the ssDNA inputs. The normalized fluorescence intensities of the system at 650 nm as a function of
the inputs are plotted in Figure 4C indicating that the system exhibits “1” only when both inputs
coexist, indicative of an AND logic gate. The AND logic gate is responsible for the CARRY digit
function in the half adder, as shown in the truth table in Figure 4B. To conclude, the AND and the
XOR gates were implemented in parallel utilizing light-up RNA aptamers as a label-free fluorogenic
platform. Both gates were triggered by the same set of inputs, satisfying the requirements for a half
adder [64]. The further development of the full adder system based on the RNA high-up aptamers is
currently under investigation. By definition, the full adder should perform an addition operation on
three binary digits and similarly to the half adder, it generates a carry out to the next addition column.
This development requires three inputs, which can be the same two ssDNA inputs and an additional
carry-in DNA input to receive the carry signal from a previous stage.
3. Materials and Methods
3.1. Nucleic Acid Sequence Design, Synthesis, and Assembly
Polynucleotide sequence design was carried out using the multi-strand secondary structure
prediction programs NUPACK and mfold [61,62]. To meet the requirements of the developed logic
gates, the DNA and RNA sequences used in the experiments were first designed and then analyzed
by the above 2D structure folding predicting software. According to the predicted 2D structures,
experiments were performed to determine whether the designed ssDNA oligonucleotides were
operational in the corresponding logic gate processing reactions. If the satisfying fluorescence readouts
were not achieved, the DNA sequences were redesigned and the procedures were repeated until the
desired DNA sequences obtained.
All DNA oligonucleotides were purchased from IDT DNA (Coralville, IA, USA) as desalted
products and used without purification. RNA strands corresponding to individual logic gates
and to the tetragonal half-adder complex were prepared by in vitro transcription using T7 RNA
polymerase [8]. For this, synthetic DNA strands coding for the anti-sense sequence of the RNA
strands were amplified by polymerase chain reaction (PCR) using primers containing the T7 RNA
polymerase promoter. PCR products were purified using the QiaQuick PCR purification kit
(Qiagen Sciences, Germantown, MD, USA). The transcribed RNA molecules were purified by
denaturing 20% polyacrylamide gel electrophoresis containing 8M UREA.
The self-assembly of individual MG-based light-up RNA logic gate complexes AND, OR, NAND,
and NOR was achieved by mixing equimolar oligonucleotide strands (1 μM) in TMS (50 mM TRIS
pH = 8.0, 100 mM NaCl and 10 mM MgCl2) buffer and heating the mixture to +80 ◦C and gradually
cooling it down to +4 ◦C over a period of 1 h on a PCR thermocycler. Once the RNA aptamer
self-assembly was achieved, a small amount (2 μM final concentrations) of the malachite green oxalate
salt (Sigma Aldrich Co., St. Louis, MO, USA) was added to each RNA or RNA/DNA assembly.
The mixture was left to incubate for an additional 30 min at 22 ◦C to reach proper binding equilibrium.
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DNA inputs oligonucleotides were added to the assembled AND, OR, and NOR gates at the final
concentrations of 2 μM (each) making the final stoichiometry of the complexes as follows:
1 GATE: 1 INPUT A: 1 INPUT B.
For the NAND system the optimal results achieved at stoichiometry:
1 NAND: 2 INPUT A: 2 INPUT B.
The self-assembly of the half-adder RNA construct was achieved by mixing corresponding
RNA and DNA polynucleotides at 1:1 stoichiometric ratio. For example, the RNA half adder
in the absence of inputs contained 1 μM of each RNA strands, 2 μM of AND_DNA inhibitor,
and 2 μM XOR_DNA inhibitor. Malachite green and 3,5-difluoro-4-hydroxybenzylidene imidazolinone
(DFHBI) (Sigma Aldrich Co., St. Louis, MO, USA) dyes were added to the corresponding complexes
(0-0, 0-1, 1-0, 1-1) to make 5 μM final concentration. The resulting mixture was allowed to incubate for
an additional 30 min at 22 ◦C. After reaching equilibrium, DNA inputs (5 μM each) were added in
accordance to the truth table for the half-added RNA systems and fluorescence were recorded after
additional 30 min incubation, which was necessary to achieve input driven strand displacement effect
(Figure S8)
3.2. Fluorescence Measurements
Fluorescence was measured on a Fluoromax-3 (Hibora Jobin-Yvon, Horiba Scientific, Edison,
NJ, USA) spectrofluorimeter using a Sub-Micro quartz fluorometer cell (Starna cells Inc., Atascadero,
CA, USA). Fluorescence intensities were recorded separately for each dye. For the DFHBI-binding
Broccoli RNA aptamer, the excitation wavelength centered at 465 nm and emission was collected in
the range of 475–700 nm. For the MG-binding RNA aptamer, the excitation was centered at 615 nm
and emission was recorded from the range of 630–750 nm.
The fluorescent enhancement was quantified by the ratio of the maximum emission of the
fluorogenic dyes bound to its aptamers divided by the emission of the free dyes in solution.
The fluorescence enhancement data were normalized after the experiments; a threshold value was
chosen to be 60% for the MG based RNA logic gates, an intensity greater than this value yields an
output = 1, while an intensity below this value yields an output = 0.
3.3. Dynamic Light Scattering
Hydrodynamic diameters of assembled half-adder RNA constructs and the control tetragon RNA
nanoparticles were measured by a Zetasizer nano-ZS (Malvern Instrument Ltd., Malvern Panalytical
Ltd., Malvern, UK) at 22 ◦C following previously described protocols [9].
3.4. Atomic Force Microscopy Imaging
The RNA tetragon and RNA half-adder complexes were imaged with MultiMode AFM
NanoScope IV system (Veeco Instruments Inc., Plainview, NY, USA), following previous methods [65].
4. Conclusions
Molecular logic gates hold great potential for a wide range of biotechnological applications,
including gene expression regulation, biosensors, therapeutic molecule design, metabolic
reprogramming, studies of drug-nucleic acid interactions, and tools for elucidating cellular
functions. The emergence of RNA nanotechnology offers great opportunities for applications of
RNA-based logic gates. In this study, we have used a computational approach to design various
oligonucleotide-responsive RNA logic gates (AND, OR, NAND and NOR) based on the MG-binding
RNA aptamer. The structures of four logic gates were designed based on the general 2D architecture
depicted in Figure 2 and all functioned as robust RNA switches that exhibit fluorescence emission
once activated. The design process used here accounts for the thermodynamic stability of various
base-paired structures in the absence or presence of input oligonucleotides. This functional design
was possible due to the fact that nucleic acid secondary structure folding largely follows the simple
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rules of Watson-Crick base pairing, and the thermodynamic parameters for base-pair interactions are
available. In addition, a half adder was successfully demonstrated by combining the hybridization and
replacement of ssDNA strands. Specifically, introducing two light-up RNA aptamers MG and Broccoli
into a half-adder system to modulate the output signal makes it flexible and enables the potential
design of various other types of logic gates according to the requirements of the data processing.
Although the developed individual logic gates and half adder are implemented in an experimental
stage and exclusively in vitro, the demonstrated system presents great potential for the development
of other RNA-light up based logic circuits as a universal arithmetic tool. To summarize, this work
provides a novel light-up RNA aptamer-based platform for the design and assembly of higher-order
circuits for arithmetic operations and opens the possibility to develop a new approach for constructing
multicomponent devices on a single biomolecular nano-platform.
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Abstract: Several varieties of small nucleic acid constructs are able to modulate gene expression
via one of a number of different pathways and mechanisms. These constructs can be synthesized,
assembled and delivered to cells where they are able to impart regulatory functions, presenting
a potential avenue for the development of nucleic acid-based therapeutics. However, distinguishing
aberrant cells in need of therapeutic treatment and limiting the activity of deliverable nucleic
acid constructs to these specific cells remains a challenge. Here, we designed and characterized
a collection of nucleic acids systems able to generate and/or release sequence-specific oligonucleotide
constructs in a conditional manner based on the presence or absence of specific RNA trigger molecules.
The conditional function of these systems utilizes the implementation of AND and NOT Boolean
logic elements, which could ultimately be used to restrict the release of functionally relevant nucleic
acid constructs to specific cellular environments defined by the high or low expression of particular
RNA biomarkers. Each system is generalizable and designed with future therapeutic development
in mind. Every construct assembles through nuclease-resistant RNA/DNA hybrid duplex formation,
removing the need for additional 2′-modifications, while none contain any sequence restrictions on
what can define the diagnostic trigger sequence or the functional oligonucleotide output.
Keywords: RNA; RNA logic; conditional activation; functional RNA; nucleic acid therapeutic
1. Introduction
Deliverable nucleic acid-based systems present powerful methods to modulate specific gene expression
and have the potential to be developed for therapeutic purposes, however, restricting their activity to
a subset of intended cells remains challenging [1–3]. Numerous methods that utilize relatively small
synthetic nucleic acids to regulate endogenous gene expression have originated in recent years, providing
several approaches for which targeted therapeutics can be developed. The use of single-stranded antisense
oligonucleotides (AON) were among the first of these regulatory techniques, whereby an oligonucleotide
complementary to an mRNA of interest could be used to regulate expression of that gene [4]. AONs were
originally designed to inhibit gene expression through steric inhibition of the translation machinery but have
evolved into several parallel regulatory approaches. These include targeted degradation of mRNA through
RNaseH activity [5], as well as alteration of mRNA splicing patterns by limiting the accessibility of
specific splice sites [6]. RNA interference (RNAi) methods then followed, again evolving from the general
notion of double stranded RNA being able to silence a complementary target mRNA [7], to the design
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of synthetic short interfering RNA (siRNA) [8], Dicer substrate siRNA (DsiRNA) [9], and other related
constructs [10,11]. More recently, analogous approaches have been developed that increase rather than
downregulate expression of a target gene. Delivery of double-stranded siRNA-like duplexes termed
short activating RNA (saRNA) has been observed to activate gene expression when targeted to promotor
regions [12], while single-stranded antagomiRs (also referred to as antimiRs) can be designed to sequester
mature endogenous microRNAs and inhibit their native regulatory function [13]. Despite the development
of diverse regulatory approaches, the prospect of these functional nucleic acids altering gene expression in
non-afflicted healthy cells can be a cause for concern and presents a roadblock towards clinical development.
Strategies to date for cell-specific functions of nucleic acid constructs can largely be divided into
two categories: targeted delivery and conditional activation. Targeted delivery most often involves
the conjugation of a functionally active nucleic acid to a small molecule, protein, aptamer or other
targeting agent that interacts with a receptor specifically expressed on the target cells of interest [14–17].
This approach can be effective but requires the development or identification of a ligand for the particular
target cells of interest, the conjugation of such a ligand to the functional nucleic acid, and necessitates that
the ligand/receptor interaction induces internalization of the nucleic acid payload.
Conditional activation represents an opposite approach to targeted delivery, in which the functional
nucleic acid could be systemically delivered in an inactive state and only performs its active function
in a subset of specified cells. This can be achieved through the implementation of nucleic acid logic
elements that promote generation of a functional oligonucleotide construct through recognition of
a specific cellular environment. The occurrence of disease can often be the result of, as well as result in,
the mis-regulation of gene expression, and these differentially expressed genes can be used as biomarkers
to distinguish corrupted cells from healthy tissue [18–20]. Numerous systems have been devised that
incorporate nucleic acid logic elements to perform a specified function or generate predetermined
molecular outputs conditional on the presence of an input oligonucleotide sequence. These include
systems such as molecular beacons [21,22] and allosteric ribozymes [23,24], as well as nucleic acid
strand exchange events and strand displacement cascades [25–32]. Several incarnations of nucleic
acid logic systems have been previously devised which are able to release an oligonucleotide product
in a conditional manner. For such approaches to be amenable to practical therapeutic application
and systemic delivery, they should ideally be robust in their design to accommodate great diversity in
terms of input and output oligonucleotide sequences, protect their RNA components from ribonuclease
degradation, and be cheap and efficient to synthesize and produce. Existing strand exchange systems
often fulfill one or two of these requirements, but rarely meet these criteria in their entirety.
Here, we present the design of several new systems for the conditional release of single-stranded
(ss) and double-stranded (ds) nucleic acid constructs that are specifically tailored to meet these
criteria of ideal characteristics, which many existing systems fail to adequately satisfy. These designs
are influenced by several existing nucleic acid technologies such as cognate RNA/DNA hybrids,
molecular beacons, and trigger-responsive multi-stranded switch constructs [21,31–34], with the aim to
take the most favorable characteristics from existing systems and create derivative systems with
improved features [35]. Within each construct, the diagnostic region is structurally separated
from the oligonucleotide payload, resulting in systems where input and output sequences are completely
decoupled and impart no sequence constraints on one another. Additionally, any RNA strands are
initially bound within RNA/DNA hybrid duplexes to provide resistance from ribonuclease degradation
without the need of additional 2′-modifications [31], as these modifications can increase the costs
and reduce efficiency of commercial oligonucleotide synthesis. Furthermore, we expand the degree of
conditional control commonly observed in systems designed for conditional generation of sequence
specific dsRNA by demonstrating that conditional dsRNA release can not only be induced but also
repressed upon interaction with an RNA trigger, culminating in a cognate pair of RNA/DNA hybrid
constructs for which dsRNA release is under the control of multiple input triggers. As a complete
collection, these novel conditional systems provide an assortment of diversity in terms of addressing
different scenarios for treatment (ss vs. ds oligo release) and diagnosis (biomarker mediated induction
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or repression). Ultimately, this assemblage of conditional nucleic acid systems can be modified
to harbor components with biologically relevant function and developed to act as conditionally
regulated therapeutics.
2. Materials and Methods
2.1. Computational Considerations and RNA/DNA Hybrid Construct Design
The computational folding of individual strands and assembly of DNA/RNA constructs was
assessed using Hyperfold [32], a nucleic acid structure prediction algorithm capable of predicting
multi-strand assemblies from combinations of RNA and DNA strands. All folding predictions were
performed at strand concentrations of 1 μM at 37 ◦C. The visualization and depiction of resulting
secondary structure predictions was performed using Ribosketch [36]. A detailed design description
of RNA/DNA hybrid pairs can be found in supporting information.
2.2. Oligonucleotide Synthesis and Purification
The DNA and RNA oligonucleotides used to assemble the conditional RNA/DNA constructs,
including those that were fluorescently labeled, were purchased from Integrated DNA Technologies
(IDT, Coralville, IA, USA) and reconstituted in nuclease-free water (Quality Biological, Gaithersburg,
MD, USA) for use. All AlexaFluor546, AlexaFluor488 and 6-carboxyfluorescein (6-FAM) fluorescently
labeled oligonucleotides were purchased from IDT. For commercially purchased oligonucleotides,
10 nmol quantities were purified as needed by denaturing polyacrylamide gel electrophoresis (PAGE).
Specifically, 10 nmol quantities were mixed with 100 μL urea loading buffer (6 M Urea, 20 mM
ethylenediaminetetraacetic acid (EDTA), 10% glycerol, 0.05% bromophenol blue) and heated to 90 ◦C
for 2 min prior to loading on an 8% or 10% 19:1 acrylamide/bis-acrylamide denaturing gel (1× TBE buffer
(89 mM Tris, 89 mM boric acid, 2 mM EDTA), 6 M Urea) for purification. Following electrophoresis,
bands were cut from the gel and eluted in an elution buffer (10 mM Tris pH 7.5, 200 mM NaCl,
0.5 mM EDTA) overnight at 4 ◦C while shaken at 850 rpm. Eluted oligonucleotides were ethanol
precipitated and reconstituted in nuclease-free water.
RNA trigger oligonucleotides either purchased from IDT or prepared from in vitro runoff
transcription using T7 RNA polymerase. DNA templates for transcription were amplified by PCR using
primers purchased form IDT. PCR was performed using MyTaq 2×mix (Bioline, Memphis, TN, USA)
and purified using DNA Clean & Concentrator (Zymo Research, Irvine, CA, USA). Transcription was
performed in 10 mM Tris pH 7.0 containing 6 mM MgCl2, 0.5 mM MnCl2, 2.5 mM each NTP, 0.01 u/μL
inorganic pyrophosphatase, 2 mM dithiothreitol, and 2 mM spermidine. Approximately 50 pmol of
DNA template was added to the transcription mix along with an in-house produced T7 RNA polymerase
and incubated at 37 ◦C for 4 h. Transcription was terminated by addition of DNase I (New England
Biolabs, Ipswich, MA, USA) for 30 min. The transcription mix was combined with 1/2 volume of urea
loading buffer and heated at 90 ◦C for 2 min before purification by denaturing PAGE and precipitation
as described above.
2.3. RNA/DNA Construct Assembly
Conditional RNA/DNA constructs were assembled using equimolar concentrations of their
component strands. Strands were combined in water, heated to 90 ◦C for 1.5 min, and then immediately
placed on a 37 ◦C heat block for 5 min. After this, samples were briefly spun in a tabletop centrifuge
to collect condensed solvent and assembly buffer was added to a final 1× concentration of 2 mM
Mg(OAc)2, 50 mM KCl, 1× TB (89 mM Tirs, 89 mM boric acid, pH 8.2). The assembly was then
incubated an additional 25 min at 37 ◦C. Control dsRNA duplexes and RNA trigger molecules were
assembled/folded using the same protocol.
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2.4. Non-Denaturing PAGE Analysis of Conditional Oligonucleotide Release
Assembled constructs were examined for their ability to regulate conditional oligonucleotide
release in the presence and absence of specific RNA trigger molecules. All constructs and triggers
were initially prepared separately in 1× assembly buffer. From these bulk individual assemblies,
various construct/trigger combinations were combined and incubated at 37 ◦C for either 30, 90
or 180 min. Individual controls were prepared from the same bulk assemblies and subjected to identical
incubation conditions. Generally, the conditional constructs were present at a final concentration
of 500 nM. In the case of the beacon switch and adjacent targeting hybrids, RNA triggers were present
in a 1× concentration relative to the conditional constructs. For inducible and repressible hybrid
systems, the RNA triggers were generally present at 2×–3× concentrations, as indicated in the text.
Following this incubation, samples were transferred to ice, combined with 1/5 volume of loading
buffer (1× assembly buffer, 50% glycerol) and were loaded on non-denaturing PAGE gels (8–12% 19:1
acrylamide/bis-acrylamide, 2 mM Mg(OAc)2, 1× TB). Electrophoresis was generally performed at 6 W
for 2–3 h at 10 ◦C. Acrylamide concentrations and duration of electrophoresis were optimized on
a case-by-case basis to achieve the necessary separation of species. In some instances, gels were subjected
to total nucleic acid staining with ethidium bromide. In other instances, an individual molecule within
a construct was fluorescently labeled (~10% of total molecules used in an assembly). In both cases,
gels were imaged using a Typhoon Trio variable mode imager (GE Healthcare, Chicago, IL, USA)
using appropriate excitation and emission filters. The amount of fluorescently labeled dsRNA output
released from conditional systems was quantitated using ImageQuant 5.1 (Molecular Dynamics
(now GE Healthcare), Chicago, IL, USA). Unless otherwise noted, the fraction of dsRNA released
for a given sample is reported as the ratio of fluorescence observed in the released dsRNA band
to the total amount of fluorescence observed for the entire lane. Statistical significance between
populations was determined by a two-tailed Student’s t-test performed using values from three distinct
replicate experiments.
2.5. Analysis of RNA/DNA Strand Exchange by Förster Resonance Energy Transfer (FRET)
RNA/DNA strand exchange between cognate partners of inducible and repressible hybrid systems
were examined by FRET. Cognate hybrids were assembled separately, and pre-warmed to 37 ◦C.
Hybrids were combined and added to the cuvette, at which point the RNA trigger molecule was spiked
in, if appropriate. The cuvette was immediately placed in a FluoroMax-3 fluorimeter (Jobin Yvon Horiba,
Kyoto, Japan) at 37 ◦C and measurement was started. For FRET experiments where a fluorescence
spectrum was measured at a given time point, the sense hybrid was assembled with an RNA sense
strand containing a 3′ 6-FAM donor fluorophore, while the antisense hybrid was assembled with
an RNA antisense strand possessing a 5′ AlexaFluor546 acceptor fluorophore. Hybrids were prepared
to a final concentration of 250 mM and the trigger molecule was in three-fold molar excess, when present.
Excitation was performed at 475 nm and emission measured between 480–620 nm at 1 nm increments
using 0.5 s integration times and 2 nm slit widths.
For FRET experiments where time courses were recorded, the 6-FAM donor fluorophore on
the RNA sense strand was replaced with AlexaFluor488. Hybrid and trigger concentration mirrored
the conditions of analogous non-denaturing PAGE experiments, with hybrids at a final concentration
of 500 nM, and trigger concentrations in 2–3 fold molar excess, as indicated. Measurements were
recorded every 60 s using excitation at 475 nm and emission was measured at 515 nm and 565 nm,
using a signal integration time of 0.5 s and slit widths of 2 nm. Observed rate constants (kobs) were
obtained by fitting the decrease in measured AlexaFluor488 donor fluorescence as a function of time to
the equation y = y0 + Ae−k*t for single exponential decay.
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3. Results
3.1. Crafting a Collection of Diverse, Logic-Based Nucleic Acid Systems Geared Towards
Therapeutic Development
Multiple nucleic acid systems were designed to specifically adhere to the ideal structural
and functional criteria for an RNA-based conditional therapeutic that were outlined above.
Each individual assembly is composed of only RNA and DNA oligonucleotides, with no additional
2′-modified nucleotides. Every initial-state assembly was designed to contain RNA/DNA hybrid
duplexes to minimize potential ribonuclease cleavage of the RNA payloads, and the diagnostic
components of each system are composed entirely of DNA to prevent its processing by ribonucleases,
which would likely compromise its conditional function.
The conditional systems that follow display a continuous increase in design complexity, starting with
a simple bimolecular switch that is able to detect a single input biomarker and release an ssRNA oligo
when the RNA biomarker is present. From there, several pairs of cognate RNA/DNA hybrid constructs
are characterized that perform conditional dsRNA release though differing diagnostic mechanisms.
The first utilizes a diagnostic method whereby the two cognate constructs recognize neighboring sequence
regions of a single input trigger to induce dsRNA release. The subsequent RNA/DNA hybrid pairs
were all designed such that the diagnostic component responsible for the RNA biomarker that governed
conditional function was completely contained within one of the two hybrids, while the cognate partner
hybrid recognized a biomarker-dependent structural change of the first hybrid. Using this strategy, it is
first demonstrated that dsRNA release can be induced by a single input, but then also that dsRNA release
can be repressed following slight alterations to the design of the diagnostic component. Ultimately, a single
cognate pair of RNA/DNA hybrid constructs are coupled that are able to detect multiple RNA triggers,
with the release of dsRNA being dependent on the presence of one biomarker and the absence of a second.
As a whole, the suite of conditional systems provides diversity in terms of the oligonucleotide output that
can be generated, and the ability to either induce or repress oligonucleotide release based on the presence
or absence of a specific RNA of interest.
3.2. A Beacon-Derived Conditional Switch Releases a Single-Stranded Oligonucleotide in the Presence
of an RNA Trigger
Traditional molecular beacons act as a unimolecular diagnostic tool, giving a fluorescent
output signal that changes as a result of the presence of a specific oligonucleotide trigger [21]
(Figure 1A). Rather than use fluorescence as an output signal, we have re-engineered the beacon
system as a bimolecular switch construct that is able to release a single-stranded oligonucleotide
upon recognition of a specific trigger sequence. Whereas traditional molecular beacons contain
complementary regions at the 5′ and 3′ ends resulting in a hairpin structure (Figure 1A), the beacon
switch is designed such that the output oligonucleotide is complementary across its length to
the 5′ and 3′ ends of the diagnostic strand, generating a structure that resembles the shape of
a horseshoe (Figure 1B). As with traditional molecular beacons, the diagnostic strand contains
a large loop that is complementary to the trigger and serves as an internal toehold. Hybridization
between the internal toehold and the trigger RNA acts as a thermodynamic driver that is intended to
disrupt the pairing between the output strand and the diagnostic strand, resulting in the release of
the single-stranded output.
Since the internal toehold of the diagnostic strand does not need to overlap with the 5′ and 3′
regions that are bound to the output oligonucleotide, essentially any set of trigger and target sequences
can be implemented. The single-stranded output of the beacon switch could be composed of RNA or
DNA depending on the desired function of the output strand. This conditional system could find
application in instances where an irregular or diseased cellular state can be identified by a high copy
number of a specific endogenous RNA, and the use of an AON, antagomir or other short single-stranded
RNA would have a significant impact on rectifying the irregular state or inducing cell death.
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Figure 1. A conditional nucleic acid system based on the design of molecular beacons.
(A) “Traditional” molecular beacons are fluorescence-based unimolecular diagnostic systems that adopt
an initial hairpin structure. Hybridization of a trigger sequence complementary to the hairpin loop
opens the hairpin and alters the fluorescence of the beacon by separating a fluorophore/quencher
pair. (B) The “beacon-derived” switch is a biomolecular system composed of a diagnostic strand
and an output strand. The output strand is hybridized to the 5′ and 3′ ends of the diagnostic strand
creating a large bulge in the diagnostic strand. This bulge acts as an internal toehold. Hybridization of
a trigger to this toehold region forms a persistent helix that outcompetes the internal pairing between
the diagnostic and output strands, causing release of the output strand. (C) The conditional function of
the beacon-derived switch was analyzed by 10% acrylamide non-denaturing PAGE and total staining
with ethidium bromide. The beacon switch was assembled from the diagnostic and output strands.
Addition of the trigger RNA to the pre-assembled beacon switch releases an output strand (red box)
and shows generation of the expected waste byproduct. The fraction of output strand released was
estimated by comparing the density of the output band to the output strand control lane of the same
initial concentration. However, it should be noted that this approach is only semi-quantitative as it
cannot be assumed that nucleic acid staining is completely uniform across the entirety of the gel.
All samples were incubated for 30 min at 37 ◦C.
For proof-of-principle illustration, a beacon switch was designed to respond to a fragment of
the Kirsten rat sarcoma proto-oncogene (KRAS) mRNA as a trigger and release an RNA antagomir
output strand in a conditional fashion. Analysis of beacon switch assembly and conditional output
release was performed by non-denaturing polyacrylamide gel electrophoresis (PAGE) (Figure 1C).
Assembly between the diagnostic strand and output strand to form the beacon switch is extremely
efficient based on non-denaturing PAGE and total nucleic acid staining, with only trace amounts
of single-stranded output strand observed after assembly. Co-incubation of the assembled beacon
switch with the KRAS trigger at 37 ◦C results in the release of the output strand and the appearance
of a band corresponding to the expected waste product. A higher migrating band also appears in
this lane, which is presumed to be a trinary molecular complex of the assembled beacon switch bound
to the trigger. The amount of output strand observed to be released is likely a lower limit of the amount
of single-stranded oligo that is actually newly accessible following interaction with the trigger RNA.
This is because only one end of the single-stranded output needs to be released by the diagnostic strand
to allow complete hybridization with the trigger oligonucleotide (Figure S1). However, even a partially
released single-stranded output oligo should be accessible to hybridize to a target RNA and still be
able to perform its intended regulatory function.
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3.3. Strand Exchange between RNA/DNA Hybrid Duplexes Can Be Facilitated by Toeholds That Target
Adjacent Sequence Regions of an RNA Trigger
Cognate RNA/DNA hybrid pairs were previously designed that harbor split functional RNAs,
devised to release a recombined functional dsRNA through recognition of complementary single
stranded toeholds (Figure 2A) [31,37,38]. The separated single strands composing the functional duplex
can be referred to as the sense strand and the antisense strand, and each of these RNA strands were
annealed to a complementary DNA oligo. These assembled RNA/DNA hybrids are denoted as the sense
hybrid (sH) and the antisense hybrid (aH), respectively. The “traditional” approach to cognate hybrid
design utilized complementary single stranded toeholds emanating from sH and aH, with hybridization
of these toeholds to one another initiating RNA/DNA strand exchange. Here, we have redesigned
the toeholds to be complementary to adjacent regions of an RNA trigger sequence, rather than
complementary to one another. As the toeholds can no longer drive strand exchange by hybridization
to one another, release of the dsRNA product is conditional on the presence of the RNA trigger molecule.
In this “adjacent targeting” incarnation of the RNA/DNA hybrid system, a fragment of the connective
tissue growth factor (CTGF) mRNA was used as the RNA trigger sequence, acting as a template for
DNA toehold binding which in turn initiates strand exchange (Figure 2B). Since the antisense hybrid
binds upstream on the RNA trigger, it was termed aHUP. Similarly, the sense hybrid is referred to
as sHDOWN. Binding of the cognate hybrid pair to the trigger RNA positions the two RNA/DNA hybrid
regions adjacent to one another in space. The close proximity of the trigger-bound cognate hybrids will
induce strand exchange through progressive hybridization of the trigger-bound DNA strands to one
another, forming a three-way junction with the RNA trigger, and leading to formation and release of
a dsRNA product. Like the beacon-derived switch, this activatable RNA/DNA hybrid system could find
use in instances where a cell population of interest can be distinguished by the high relative expression
level of an endogenous RNA. However, this RNA/DNA hybrid system (and those that follow) could be
of use in cases where conditional generation of a double-stranded RNA is desirable, which could take
the form of an RNA interference substrate, saRNA, aptamer, or another functionally relevant dsRNA.
In this instance, the dsRNA product was designed as a 25/27-mer DsiRNA.
Formation of the dsRNA product was visualized by non-denaturing PAGE. The initial
aHUP/sHDOWN cognate pair did not induce strand exchange and dsRNA release when co-incubated with
the CTGF trigger for 180 min (Figure 2C, “0 bp”). In the presence of the RNA trigger, a large fraction of
the hybrid constructs appear to be stuck in an intermediate complex displaying slow electrophoretic
mobility. Presumably, this observed band corresponds to a state in which both RNA/DNA hybrids
are bound to the trigger through their respective toeholds, but strand exchange in not stimulated.
Despite no observed dsRNA release from this system, the strand exchange reaction is predicted to be
thermodynamically favored (Figure S2). In an attempt to provide a greater driving force for strand
exchange, additional sets of cognate hybrids pairs were designed in which additional complementary
DNA nucleotides were inserted between the toehold region and the RNA/DNA hybrid region of each
hybrid construct. These complementary nts were inserted to essentially serve as a nucleation site for
strand exchange between the cognate partners once bound to the RNA trigger. In total, four additional
hybrid pairs were designed which contained between 1 and 4 additional bps to seed the strand
exchange (Figure 2C).
Increasing the number of complementary DNA bps inserted immediately prior to
the RNA/DNA hybrid regions resulted in increased DsiRNA release (Figure 2C,D). Insertion of
at least 2 DNA bps was needed to observe significant increases in DsiRNA release in the presence of
the trigger RNA, as compared to background in the absence of the trigger after three hours (Table S1).
Insertion of 3 bps appears to be enough to achieve close to the maximal degree of product duplex
release, as increasing to 4 inserted bps results in negligible further increases in DsiRNA release after
180 min. However, the gel electrophoresis experiments suggest that insertion of additional bps does
seem to speed up the rate at which this plateau of apparent maximal possible product release is
reached, as the +4 bp pair releases significantly more dsRNA after 30 min than the +3 bp system,
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and likewise the+3 bp system shows greater release than the+2 bp hybrid pair (Figure 2D and Table S2).
Despite the +3 bp and +4 bp hybrid pairs eventually reaching a similar level of dsRNA release after
three hours, their differences in the fraction of dsRNA released at early time points suggests that
the initiation of strand exchange within the adjacent targeting system may be impeded by slow kinetics.
Interestingly, despite these systems containing complementary DNA nts that could potentially serve
as toeholds to promote strand exchange in the absence of the trigger RNA, increasing the number of
inserted seed base pairs up to four did not result in significant differences in the degree of non-triggered
dsRNA release when co-incubated over the longest duration examined (Table 1 and Table S1).
Table 1. Summary of observed dsRNA release from connective tissue growth factor (CTGF)
trigger-inducible hybrid pairs. The average fraction of dsRNA release is reported in the presence
and absence of CTGF trigger, at each of three time intervals examined. An efficiency score metric is
determined for each hybrid pair at a given time point, with a larger score indicating better efficiency of
conditional dsRNA release. The efficacy score takes into account both the fraction of dsRNA released
and the signal-to-noise ratio. It is calculated as (fraction of triggered release) * (fraction triggered
release/fraction non-triggered release). The hybrid pairing that yields greatest efficiency score at each





















sHDOWN.0bp aHUP.0bp 0.07 ± 0.004 0.04 ± 0.01 0.03 0.10 ± 0.03 0.06 ± 0.01 0.04 0.07 ± 0.05 0.06 ± 0.03 0.05
sHDOWN+1bp aHUP+1bp 0.09 ± 0.02 0.08 ± 0.02 0.07 0.08 ± 0.02 0.11 ± 0.06 0.15 0.08 ± 0.08 0.12 ± 0.04 0.20
sHDOWN+2bp aHUP+2bp 0.05 ± 0.03 0.18 ± 0.10 0.62 0.05 ± 0.01 0.31 ± 0.16 1.79 0.06 ± 0.05 0.40 ± 0.03 2.69
sHDOWN+3bp aHUP+3bp 0.08 ± 0.01 0.39 ± 0.13 2.01 0.06 ± 0.02 0.49 ± 0.08 4.00 0.06 ± 0.02 0.63 ± 0.01 6.29
sHDOWN+4bp aHUP+4bp 0.07 ± 0.04 0.60 ± 0.05 5.28 0.06 ± 0.01 0.60 ± 0.06 5.63 0.04 ± 0.02 0.67 ± 0.04 10.77
sHˆCTGF12/8 aHˆCTGF-cgnt.12 0.05 ± 0.02 0.66 ± 0.06 9.5 0.06 ± 0.02 0.78 ± 0.06 9.7 0.07 ± 0.03 0.85 ± 0.04 10.0
sHˆCTGF.12/12 aHˆCTGF-cgnt.12 0.05 ± 0.02 0.66 ± 0.05 8.1 0.09 ± 0.01 0.81 ± 0.05 7.6 0.11 ± 0.05 0.85 ± 0.04 6.8
sHˆCTGF.16/8 aHˆCTGF-cgnt.12 0.04 ± 0.01 0.69 ± 0.09 13.3 0.05 ± 0.01 0.78 ± 0.06 12.0 0.07 ± 0.02 0.83 ± 0.04 10.5
sHˆCTGF.20/8 aHˆCTGF-cgnt.12 0.02 ± 0.01 0.66 ± 0.06 17.8 0.04 ± 0.01 0.83 ± 0.06 17.5 0.05 ± 0.02 0.79 ± 0.05 13.6
sHˆCTGF12/8 aHˆCTGF-cgnt.16 0.04 ± 0.01 0.24 ± 0.08 1.5 0.05 ± 0.02 0.39 ± 0.04 3.0 0.09 ± 0.01 0.46 ± 0.07 2.4
sHˆCTGF.12/12 aHˆCTGF-cgnt.16 0.06 ± 0.01 0.37 ± 0.09 2.5 0.09 ± 0.04 0.48 ± 0.02 2.6 0.11 ± 0.04 0.55 ± 0.03 2.8
sHˆCTGF.16/8 aHˆCTGF-cgnt.16 0.05 ± 0.01 0.61 ± 0.13 7.5 0.05 ± 0.01 0.63 ± 0.02 7.2 0.07 ± 0.02 0.67 ± 0.03 6.5
sHˆCTGF.20/8 aHˆCTGF-cgnt.16 0.03 ± 0.01 0.50 ± 0.06 9.4 0.04 ± 0.004 0.59 ± 0.05 9.7 0.05 ± 0.01 0.64 ± 0.02 9.2
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Figure 2. An RNA/DNA cognate pair system was designed to undergo conditional strand exchange
by hybridizing to neighboring sites on an RNA trigger. (A) “Traditional” RNA/DNA hybrid pairs
act as an 2-input AND gate. Hybridization between the single stranded toeholds of a sense hybrid
(sH) and antisense hybrid (aH) initiates a thermodynamically driven strand exchange that generates
a dsRNA duplex and DNA waste byproduct. (B) The “adjacent targeting” RNA/DNA hybrid system
functions as a 3-input AND gate, requiring a hybrid pair as well as a specific RNA trigger sequence.
The hybrid pair’s respective toeholds bind to regions of the trigger that are immediately upstream
and downstream from one another. Anchoring the cognate hybrids in close proximity leads to initiation
of the thermodynamically favorable strand exchange reaction and dsRNA release. (C) Five different
cognate pairs of adjacent targeting hybrids were analyzed by 12% acrylamide non-denaturing PAGE
for their ability to release a DsiRNA product. Each sense hybrid and the DsiRNA control assembly
contained a 3′ 6-carboxyfluorescein (6-FAM) labeled sense RNA strand for visualization. The pairs
of constructs differ in the number of DNA nucleotides inserted between the single-strand toehold
and the RNA/DNA hybrid duplex. These inserted nucleotides were complementary between cognate
hybrids, resulting in either 0,+1,+2,+3 or+4 DNA bp that can seed the strand exchange (colored orange).
The presence or absence of each component is indicated above each lane. The samples in the gel
depicted were all incubated for 180 min at 37 ◦C. (D) Analysis of the fraction of dsRNA released by
hybrid pairs in the presence and absence of the RNA trigger following 30, 90 or 180 min incubations
at 37 ◦C. Error bars indicate standard deviation of three replicate experiments. Indication of statistical
significance between samples is reported in the supporting information.
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3.4. A Responsive Structural Element Can Act to Conditionally Induce Strand Exchange between
RNA/DNA Hybrids
In an alternative approach for the implementation of conditional function within
an RNA/DNA hybrid system, hybrid pairs were designed in which the accessibility of the toehold(s)
needed to facilitate strand exchange was altered based on the presence or absence of a specific
RNA trigger sequence. Although the adjacent targeting hybrid system described above performs its
designed conditional function to release dsRNA, the fraction of dsRNA release for the best performing
hybrid pair topped out at 0.67 after three hours. This second approach was pursued in an attempt to
improve the efficiency of strand exchange and increase conditional dsRNA release. The “traditional”
RNA/DNA hybrid methodology requiring the hybridization of complementary toeholds to one
another for strand exchange serves as the basis of the conditional activation. We designate these
single stranded toeholds as “exchange toeholds”, since they are required to initiate strand exchange.
To create a hybrid system responsive to conditional activation, a structured hairpin element was
incorporated in the DNA strand immediately adjacent to the RNA/DNA hybrid duplex region of
the sense hybrid (Figure 3A). This DNA hairpin ultimately controls the reassembly fate of the split
functional RNA. In its initial folded state, the DNA hairpin is designed to sequester the entire length of
the exchange toehold sequence within its helical stem, preventing the toehold from readily interacting
with the complementary exchange toehold of the cognate antisense hybrid. The resulting hybrid pair
initially exists in an “off” state that is unable to initiate strand exchange.
A new single stranded toehold, termed the “diagnostic toehold”, is then implemented as a means
to control the conditional activation of the hybrid by altering the accessibility of the exchange
toehold imbedded within the DNA hairpin upon recognition of a specific RNA trigger sequence
(Figure 3A). This single-stranded diagnostic toehold within the sense hybrid is positioned at the 5′ end
of the DNA strand adjacent to the DNA hairpin (at the side opposite, the RNA/DNA hybrid region).
By designing the sequence of the diagnostic toehold and the adjacent 5′ side of the DNA hairpin to
be fully complementary to a region of an RNA trigger, hybridization of the trigger to the diagnostic
toehold unzips the adjacent DNA hairpin and exposes the exchange toehold. Once the exchange
toehold has been liberated, the complementary exchange toeholds of the hybrid pair can facilitate
a strand exchange event and release a dsRNA output (Figure 3A). It is intended that this method of
exchange toehold recognition, whereby the hybridization of complementary toeholds to one another
forms a single duplex that can be directly extended by stacking additional DNA bps formed during
RNA/DNA hybrid strand exchange, will exert a greater kinetic and/or thermodynamic drive than
the three-way junction dependent method employed within the adjacent targeting system.
To illustrate the function of this “trigger-inducible” hybrid system, conditional hybrid constructs
were designed to release a 25/27-mer DsiRNA when triggered by a fragment of the CTGF mRNA.
The DNA strand of the sense hybrid was designed to contain a central hairpin with a 12 bp stem
and 8 nt loop. This sense hybrid is referred to as sHˆCTGF.12/8, as the hybrid is designed to stimulate
dsRNA release in the presence of CTGF (“ˆCTGF”) and contains a DNA hairpin composed of a 12 bp
stem and 8 nt loop (“12/8”). The exchange toehold within sHˆCTGF.12/8 is 12 nt in length and is initially
completely sequestered within the DNA hairpin stem. The cognate partner hybrid is composed of
an RNA/DNA hybrid duplex containing the DsiRNA antisense strand, with a 12 nt extension of
the DNA strand at its 3′ end to encode the complementary exchange toehold. This hybrid is referred to
as aHˆCTGF-cgnt.12 to reflect that it contains a 12 nt exchange toehold (“12”) and is the cognate partner
(“cgnt”) to the CTGF-triggered sH hybrid (“ˆCTGF”).
Non-denaturing PAGE and total nucleic acid staining was used to examine interactions occurring
between the cognate hybrids, as well as between the hybrids and the trigger RNA (Figure 3B).
While not quantitative, initial analysis using a nucleic acid stain allowed for surveillance of all
molecular species and products. As expected, no changes to the hybrids’ electrophoretic mobility
is observed when incubated together at 37 ◦C in the absence of the trigger RNA, indicating that no
interaction occurs between the hybrids and no dsRNA is released. Introduction of the RNA trigger
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activates sHˆCTGF.12/8 and induces the release of a dsRNA product when aHˆCTGF-cognt12 is also present.
Higher migrating species are also observed when both hybrids are co-incubated with the trigger
RNA. One of the high migrating bands corresponds to the expected waste product as indicated by
similar migration of a control assembled from the RNA trigger and two DNA strands. An even slower
migrating band is also observed and is likely to be a 5-molecule intermediate complex. Förster resonance
energy transfer (FRET) experiments were performed to further verify the generation of the expected
double stranded RNA product in the presence of the trigger molecule (Figure 3C). The cognate hybrids
used for these FRET studies had a 3′ donor fluorophore on the RNA sense strand, and a 5′ acceptor
fluorophore on the RNA antisense strand. In the absence of the RNA trigger, the FRET-labeled hybrid
pair show no significant change in their emission spectrum after one hour at 37 ◦C. However, one hour
after the introduction of the CTGF trigger a large decrease in donor emission (~515 nm) and increase in
acceptor fluorescence (~565 nm) is observed, indicating formation of the DsiRNA duplex product.
Figure 3. Incorporation of a structured responsive element can generate a trigger-inducible RNA/DNA hybrid
system. (A) The inducible hybrid system functions as a three-input AND gate. The sense hybrid sHˆCTGF.12/8
contains a responsive DNA hairpin composed of a 12 bp stem and an 8 nt loop, and is flanked by an extended
5′ single strand that acts as a diagnostic toehold. Trigger hybridization to the diagnostic toehold progresses
through the hairpin stem and unzips the hairpin (sequence regions colored blue). This liberates a previously
sequestered toehold within sHˆCTGF.12/8 which can then hybridize with the complementary toehold of
the cognate antisense hybrid, aHˆCTGF-cgnt.12. Hybridization of these exchange toeholds (sequence regions
colored orange) initiates strand exchange and releases a dsRNA product. (B) The function of this conditional
system was assessed by 8% acrylamide non-denaturing PAGE and total staining with ethidium bromide.
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DsiRNA release is observed when the sense and antisense hybrids are co-incubated in the presence of
trigger (red box). Formation of the expected waste product is observed by comparison to a control assembly
of the s’ and a’ DNA strands with the trigger molecule. All samples were incubated for 30 min at 37 ◦C.
(C) Förster resonance energy transfer (FRET) analysis was performed as another method to verify conditional
dsRNA formation. sHˆCTGF.12/8 was assembled using a 3′ 6-carboxyfluorescein (6-FAM) (ex/em 495/520 nm)
labeled sense RNA strand. aHˆCTGF-cgnt.12 was assembled using a 5′-AlexaFluor546 (ex/em 555/570 nm)
labeled antisense RNA strand. The hybrids were mixed and incubated at 37 ◦C for one hour in the presence
or absence of the RNA trigger. Fluorescence emission spectra were recorded at t = 0 and t = 60 min using
excitation at 475 nm.
3.5. Alteration of Structural Elements Was Explored as a Means to Optimize dsRNA Release from Cognate
RNA/DNA Hybrids
Within the inducible hybrid system, the accessibility of one exchange toehold is impeded by
being sequestered within a responsive DNA hairpin. This toehold becomes liberated upon opening of
the hairpin in the presence of an RNA trigger and allows for a strand exchange to proceed. As such,
altering the stability of this responsive hairpin structure, as well as the length and accessibility of
the liberated exchange toehold once the hairpin is open, could potentially modulate the degree of strand
exchange between a cognate hybrid pair. The initially characterized sHˆCTGF.12/8 hybrid contained
a 12 bp DNA hairpin stem capped by an 8 nt loop. Three additional CTGF-triggered sH hybrids were
designed to investigate how changing the structure of the responsive DNA hairpin affects strand
exchange and dsRNA release (Figure 4A). The first of these variants maintains a 12 bp DNA hairpin
stem but expands the hairpin loop from 8 to 12 nts. This hybrid is denoted sHˆCTGF.12/12. The two
additional sH variants maintain the original 8 nt hairpin loop, but contain hairpin stems of 16 and 20 bps
in length. These hybrids are named sHˆCTGF.16/8 and sHˆCTGF.20/8, respectively.
Each of the four sHˆCTGF constructs were assembled with a fluorescently labeled RNA sense
strand to quantitatively examine their ability to liberate a dsRNA duplex following strand
exchange with aHˆCTGF-cgnt.12 in the presence and absence of the CTGF trigger RNA (Figure 4B).
Interestingly, analysis using fluorescently labeled constructs revealed that the various sHˆCTGF
/aHˆCTGF-cgnt.12 hybrid pairs release a small fraction of dsRNA when incubated together in the absence
of the trigger RNA. This was not originally observed in the initial qualitative experiments that
utilized staining with ethidium bromide. The degree of non-triggered release among pairs of hybrid
constructs was relatively minor after 30 min (~2–5% of signal) and was observed to marginally
increase over time for each variant sHˆCTGF construct paired with aHˆCTGF-cgnt.12 (Figure 4C). sHˆCTGF.20/8,
which is predicted to contain the most stable hairpin stem (Figure S3), exhibited the smallest degree of
non-triggered DsiRNA release compared to other hybrids pairs after 30 min. Likewise, sHˆCTGF.12/12
was predicted to have the weakest hairpin structure and displayed the greatest extent of non-triggered
DsiRNA release after 30 min. This trend persists at longer time points; however, differences in
non-triggered DsiRNA release among variant hybrids pairs were not all statistically significant,
especially at longer time points (Table S3).
Structural changes to the responsive DNA hairpin of the sHˆCTGF hybrids resulted in negligible
differences in trigger-induced dsRNA release between the four sHˆCTGF/aHˆCTGF-cgnt.12 pairs assayed
(Figure 4C). However, these constructs did show a 12–18% improvement in conditional dsRNA release
over the best performing adjacent targeting hybrid pair after three-hour incubations with the CTGF
trigger (Table 1). The lack of differences in triggered DsiRNA release among the variant sHˆCTGF
constructs was somewhat surprising based on the predicted change in free energy (ΔΔG) between
the unbound and CTGF trigger-bound states for each hybrid’s responsive DNA element (Figure S3).
However, it may be that the favorable change in free energy for each construct upon trigger binding is
so great (ΔΔG < −25 kcal mol−1 for each) that the comparatively small differences in ΔΔG between
the various sHˆCTGF hybrids becomes inconsequential. Alternatively, differences in the ΔΔG of trigger
binding could be offset by differences in steric accessibility of the newly liberated exchange toehold
once the DNA hairpin has opened. Increasing the loop size or length of the hairpin stem increases
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the distance between the exchange toehold and the region bound by the RNA trigger once hybridized
(Figure S3). This could in turn alter the accessibility of the liberated exchange toehold to the incoming
cognate hybrid. The sHˆCTGF.12/8/aHˆCTGF-cgnt.12 hybrid pair has the shortest nucleotide distance between
the region bound by the trigger and its exchange toehold, and time course FRET experiments indicate
the observed rate constant of dsRNA release is slower for this hybrid pairing than for any of the other
three sHˆCTGF hybrids paired with aHˆCTGF-cgnt.12 (Figure S4).
Extending the length of the exchange toehold was also explored as a means to boost triggered
dsRNA release within the CTGF-inducible hybrid system. A variant aHˆCTGF-cgnt hybrid was designed
containing a 16 nt toehold and was termed aHˆCTGF-cgnt.16. The toehold of aHˆCTGF-cgnt.16 was designed
to encode the same 12 nt sequence as the aHˆCTGF-cgnt.12 toehold, with four additional nucleotides
appended to the toehold’s distal end. These four additional nucleotides are complementary to
corresponding regions within sHˆCTGF.16/8 and sHˆCTGF.20/8 and result in complete pairing of the 16 nt
exchange toeholds between these cognate hybrids. However, these four added nucleotides at the distal
end of the aHˆCTGF-cgnt.16 toehold do not have complementary sequences in sHˆCTGF.12/8 and sHˆCTGF.12/12
(Figure 4A), leaving the distal end of the aHˆCTGF-cgnt.16 toehold unpaired.
Increasing the toehold length of the cognate antisense hybrid from 12 to 16 nucleotides was
observed to have a negative impact on DsiRNA release when paired with any of the sHˆCTGF
variants (Figure 4D,E). The use of aHˆCTGF-cgnt.16 in place of aHˆCTGF-cgnt.12 had a negligible effect on
the degree of non-triggered release but presented a large significant impediment to CTGF-triggered
release in nearly all instances (Table S4). The extent of diminished triggered-release was most
pronounced when aHˆCTGF-cgnt.16 was paired with sHˆCTGF.12/8 and sHˆCTGF.12/12, suggesting that having
non-complementary nucleotides at the distal end of the aHˆCTGF-cgnt.16 toehold interferes in some manner
with the ability of the hybrids to promote the strand exchange reaction. As a way to compare the overall
performance of the each conditionally-active hybrid pair, an “efficiency score” was determined for
each time point examined. This efficiency score metric was calculated as the product of the fraction of
triggered dsRNA release and the signal-to-noise ratio (triggered/non-triggered release). Larger scores
indicated greater efficiency of conditional dsRNA release. Out of the eight pairs of CTGF-inducible
hybrids and the five sets of adjacent-targeting hybrids, the sHˆCTGF.20/8/aHˆCTGF-cgnt.12 pairing displays
the highest efficiency score for each time interval that was examined (Table 1).
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Figure 4. Effects of DNA structural alteration on the degree of trigger-inducible dsRNA release.
(A) Four different sense hybrids that are responsive to the connective tissue growth factor (CTGF)
trigger were designed, each having different features within the structured DNA hairpin. The hairpins
differed in the size of their loop or the length of their stem. Two different cognate antisense hybrids
were designed and differ in the length of their single-stranded toehold. Sequence regions are indicated
by lowercase letters and different colors to convey sequence identity or sequence complementarity.
(B,D) DsiRNA release in the presence and absence of trigger was assessed by 10% acrylamide
non-denaturing PAGE for each sense hybrid paired with a cognate antisense hybrid exhibiting
either (B) a 12 nt toehold (aHˆCTGF-cgnt.12) or (D) a 16 nt toehold (aHˆCTGF-cgnt.16). Each sense hybrid
and the DsiRNA control contained a 3′ 6-carboxyfluorescein (6-FAM) labeled sense RNA strand for
visualization and quantification. Gels in both (B) and (D) depict samples that were incubated for 30 min
at 37 ◦C. (C,E) Analysis of the fraction of dsRNA released by the four sense hybrids paired with (C)
aHˆCTGF-cgnt.12 or (E) aHˆCTGF-cgnt.16, in the presence and absence of the RNA trigger following 30, 90,
or 180 min incubations at 37 ◦C. Error bars indicate standard deviation of three replicate experiments.
Indication of statistical significance between samples is reported in the supporting information.
3.6. Redesigned Responsive Structural Elements Can Be Used to Inhibit Strand Exchange and Repress
dsRNA Release
The concept and method of toehold sequestration used to impart conditional function within
the trigger-inducible RNA/DNA hybrid system can be modified and redesigned to instead allow for
the repression of strand exchange in the presence of a specific RNA trigger and thereby expands
the degree of control over dsRNA release. In this embodiment, both exchange toeholds are initially free
to undergo strand exchange, but one becomes sequestered into a DNA hairpin when interaction with
an RNA trigger facilitates a structural rearrangement of that hybrid’s responsive structural element
(Figure 5A). Such a system would be of interest in situations where a cellular state of interest cannot be
identified by the high expression of a particular RNA, but rather by a significant under expression of
a specific RNA relative to the normal population.
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Whereas the previously described inducible hybrid pairs contain a responsive hairpin element
within the DNA strand of sH that is triggered by CTGF, the repressible hybrid pair contains a responsive
DNA element within aH that is responsive to the KRAS mRNA-derived trigger. This new hybrid
is termed “aH∨KRAS” to indicate that dsRNA release from the hybrid is negatively impacted by
the KRAS trigger. In the absence of the cognate RNA trigger, the most stable DNA fold of aH∨KRAS
is that which results in a single stranded exchange toehold and a 14 bp DNA hairpin (Figure S5).
When the trigger is present, however, it can bind to the 3′ diagnostic toehold present in aH∨KRAS
and proceed to unzip the 14 bp hairpin, as the trigger is complementary to the entire 3′ side of
the hairpin stem. As the initial 14 bp hairpin can no longer form, a structural rearrangement can
occur where the exchange toehold pairs to the 12 nts that compose the apical loop of the original
hairpin. This new hairpin structure makes the exchange toehold inaccessible to the cognate hybrid
and represses the ability for the hybrid pair to release a dsRNA duplex (Figure 5A).
The ability to repress hybrid strand exchange was examined for aH∨KRAS with its cognate hybrid,
“sH∨KRAS-cgnt”, that contains a complementary 12 nt DNA exchange toehold extending from its
RNA/DNA hybrid region. Analysis by non-denaturing PAGE at several time points illustrates
that the cognate hybrids successfully undergo strand exchange and release dsRNA in the absence
of the KRAS trigger (Figure 5B,C). However, when the KRAS trigger and sH∨KRAS-cgnt hybrid are
premixed and added simultaneously to aH∨KRAS, DsiRNA release is repressed more than 3-fold
compared to in the absence of KRAS. A second context was also examined, where aH∨KRAS was
permitted to interact with the KRAS trigger for five minutes prior to the addition of the cognate
sH∨KRAS-cgnt hybrid. This scenario allowed the responsive DNA hairpin to rearrange and adopt its
alternative “off”-state structure before the cognate exchange toehold was present in the reaction mix.
In this context, DsiRNA release is reduced 12-fold after 30 min at 37 ◦C compared to in the absence of
trigger, and maintains more than 7-fold repression after 3 h (Figure 5C). FRET experiments further
illustrate that strand exchange occurs quickly and efficiently in the absence of the KRAS trigger, but is
severely impeded upon introduction of KRAS (Figure S6).
To illustrate that repression of dsRNA release is dependent on the presence of a trigger RNA with
a specific nucleotide sequence, additional non-cognate trigger molecules were co-incubated with
the repressive hybrid pair. Neither of the non-cognate trigger molecules tested resulted in a reduction
in dsRNA release (Figure S7). This same degree of trigger specificity is observed for the CTGF-inducible
hybrid system, as the sHˆCTGF.20/8/aHˆCTGF-cgnt.12 hybrid pair are only observed to initiate dsRNA release
in the presence of the CTGF trigger, and not when co-incubated with non-cognate trigger molecules
(Figure S7). An orthogonal trigger-repressible system was also designed that is responsive to CTGF
rather than KRAS, as a means to demonstrate versatility in accommodating various trigger sequence
inputs, as well as an ability to position the response element at different locations within this generalized
conditional system. In this system, the CTGF responsive DNA element was added to the sense hybrid
rather than the antisense hybrid. Nonetheless, this cognate hybrid pair (sH∨CTGF/aH∨CTGF-cgnt) displays
a repressed ability to generate dsRNA in the presence of the CTGF trigger, as intended (Figure S8).
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Figure 5. A redesign of the structured DNA responsive element allows for trigger-based conditional
repression of dsRNA release. (A) A trigger-repressive hybrid system can be designed by combining
a 2-input AND gate with a NOT gate. The antisense hybrid, aH∨KRAS, is designed to repress strand
exchange in the presence of a trigger sequence derived from the Kirsten rat sarcoma proto-oncogene
(KRAS) mRNA. If the trigger is absent, the exchange toehold of aH∨KRAS (sequence region colored
orange) is freely accessible and can promote dsRNA release. If the trigger is present, its hybridization to
the diagnostic toehold of aH∨KRAS (sequence region colored red) results in a structural rearrangement
that blocks access to the exchange toehold and prevents interaction with the cognate sense hybrid,
sH∨KRAS-cgnt. (B) The conditional function of this repressible system was assessed by 10% acrylamide
non-denaturing PAGE. DsiRNA release from the aH∨KRAS /sH∨KRAS-cgnt pair was examined in three
contexts: in the absence of the KRAS trigger (middle lane), when sH∨KRAS-cgnt and the KRAS trigger are
premixed and added simultaneously to aH∨KRAS (2nd lane from right), or when aH∨KRAS and the KRAS
trigger are preincubated for 5 min prior to sH∨KRAS-cgnt addition (right lane). The KRAS trigger was
added in 3-fold excess in both cases. The depicted gel shows samples incubated for 180 min at 37 ◦C
once all components are present. (C) Analysis of the fraction of dsRNA released from the KRAS
repressible system following 30, 90, or 180 min incubations at 37 ◦C. Error bars indicate standard
deviation of three replicate experiments. Indication of statistical significance between samples is
reported in the supporting information.
3.7. Cognate Hybrids Pairs with Multiple Responsive Elements Allow for Multi-Trigger Regulation
Because the strand exchange reaction between cognate hybrid partners is dependent on
the accessibility of a specific toehold sequence (exchange toehold) present on each of the two hybrids,
it is possible to generate a system in which the accessibility of each toehold is under the control of
a different RNA trigger sequence. In the case of the trigger-repressible hybrids, such as aH∨KRAS,
the trigger RNA imparts no sequence constraints on the exchange toehold and allows the exchange
toehold to be any sequence that permits proper folding. With this in mind, the exchange toehold of
construct aH∨KRAS was designed to be complementary to the exchange toehold of the sHˆCTGF hybrids
characterized previously.
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Hybrid construct sHˆCTGF.20/8 was partnered with aH∨KRAS to generate a pair of conditional
RNA/DNA hybrids whose function is dependent on the presence or absence of two RNA triggers,
CTGF and KRAS (Figure 6A). The strand exchange reaction between these two hybrids is initially
inhibited, as sHˆCTGF.20/8 initially exists in an “off” state and requires interaction with the CTGF trigger
to promote strand exchange. aH∨KRAS is initially in an active state; however, the exchange toehold of
aH∨KRAS becomes inaccessible upon interaction with the KRAS trigger. For efficient strand exchange
to occur between this hybrid pair, the presence of the CTGF trigger is required, as well as the absence
of the KRAS trigger.
The degree to which dsRNA could be conditionally released from this cognate hybrid pair was
assessed by non-denaturing PAGE (Figure 6B) and FRET (Figure S9). In the absence of any trigger
molecules, the sHˆCTGF.20/8/aH∨KRAS hybrid pair releases very small amounts of dsRNA when co-incubated.
The addition of the KRAS trigger to the hybrid pair reduces the degree of dsRNA release close to zero.
However, if the CTGF trigger is added rather than the KRAS trigger, substantial release of dsRNA product
occurs, as expected. Sequential addition of the KRAS trigger followed by the CTGF trigger to the hybrid
pair results in very little dsRNA generation, suggesting that aH∨KRAS inactivation by the KRAS trigger
occurs relatively quickly. Additional characterization was performed to examine how differences in
the relative concentration of the two triggers affect dsRNA release. Various ratios of CTGF and KRAS trigger
molecules were premixed and added to the co-incubating sHˆCTGF.20/8/aH∨KRAS hybrid pair. As might
be expected, increasing the relative amount of CTGF trigger (activating) to KRAS trigger (deactivating)
increases the extent of dsRNA release (Figure S10). When equal amounts of the KRAS and CTGF triggers
are added to the hybrid pair, the degree of dsRNA release is about 60% of the maximum amount of
dsRNA released when an excess of CTGF trigger is added to the hybrids in the absence of the KRAS
trigger. However, when the ratio of CTGF/KRAS triggers is varied away from 1:1, induction/repression of
dsRNA release disproportionately favors the trigger that is present in a greater amount, beyond what
would be predicted based on the trigger stoichiometry (i.e.,: when a 3:2 ratio of KRAS/CTGF is present,
the fraction of dsRNA is less than 40% of the maximal dsRNA released in the absence of any KRAS).
Figure 6. Multi-trigger systems can be composed in which each RNA/DNA hybrid contains a responsive
DNA structural element. (A) A system comprising a 3-input AND gate and a NOT gate can be constructed
by pairing sHˆCTGF.20/8 (activated by the connective tissue growth factor (CTGF) derived trigger)
with aH∨KRAS (repressed by the Kirsten rat sarcoma proto-oncogene (KRAS) mRNA derived trigger).
Co-incubation of the two hybrids results in no interaction. Both hybrids and the CTGF trigger are
required for dsRNA release, while the presence of the KRAS trigger will inhibit strand exchange.
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(B) The multi-trigger system was assessed by 10% acrylamide non-denaturing PAGE. The fraction of
DsiRNA released is indicated in the gel depicted, in the presence of indicated trigger combinations
following 30 min incubation at 37 ◦C. The sH and aH hybrid were present at equimolar concentration,
while the triggers were added at a 2-fold or 3-fold excess, as indicated. In samples when both triggers are
present, they were added to premixed hybrids sequentially (KRAS followed by CTGF). The antisense
hybrid and DsiRNA control in were assembled using a 5′-AlexaFluor546 labeled antisense RNA strand
for the purpose of visualization and quantification.
3.8. Three-Strand RNA/DNA Hybrid Constructs Allow “Activated” Hybrids to Dissociate from Their
Cognate Trigger
With both of the inducible and repressible conditional systems described above, the entirety of
the hybrid construct containing the diagnostic toehold remains bound to the RNA trigger molecule
following recognition and hybridization of the diagnostic toehold. However, one can imagine that there
may be instances where the function of the conditional hybrid systems may benefit from allowing their
RNA/DNA hybrid domains to freely diffuse away from their cognate trigger following hybridization
through their diagnostic toehold/domain. A three-strand design approach was used to create
an inducible hybrid that separates from the RNA trigger after hybridization. The design is based on
that of the sHˆCTGF.20/8 hybrid. The 8 nt hairpin loop is removed, splitting the 20 bp hairpin into a duplex
that assembles from two distinct DNA strands. One DNA strand retained the 5′ diagnostic toehold,
while the other maintained the RNA/DNA hybrid region (Figure S11). This new three-strand hybrid
was termed “sHˆCTGF.20split” and works in conjunction with aHˆCTGF-cgnt.12. Analysis by non-denaturing
PAGE illustrates that the three-piece hybrid sHˆCTGF.20split appears to function very similarly to that of
sHˆCTGF.20/8, although the three-piece hybrid seems to have a slight increase in its degree of non-triggered
dsRNA release (Figure S11).
A similar approach was used to investigate a three-strand repressible hybrid construct based on
the aH∨KRAS hybrid. A nick was positioned within the 5′ strand of the DNA hairpin, aiming to maintain
stable formation of the initial 14 bp hairpin and allow strand exchange in the absence of the KRAS
trigger. Four different variants were designed to identify a nick position that retained the greatest
conditional function. The function of the four variants partnered with sH∨KRAS-cgnt was examined
by non-denaturing PAGE (Figure S12). Each of the three-strand repressible systems tested show
a diminished ability to promote desirable dsRNA release in the absence of the KRAS trigger compared
to the original design. This may stem from the possibility that a larger fraction of the three-strand
hybrids initially adopt their “off” state when assembled. However, some three-strand systems did
retain their repressible function. “aH∨KRAS.nick14”, where the nick was placed immediately below
the hairpin loop and preserves the entire 14 bp stem, displayed the greatest degree of conditional
function. Progressively moving the nick down the stem resulted in continued loss of the responsive
function to the KRAS trigger.
4. Discussion
Due to their ability to easily store and recognize information at the level of their primary sequence,
nucleic acids serve as an excellent material for the construction of logic elements and performance
of molecular computing [39,40]. Nucleic acid strand displacement and conformational change
driven by single-stranded toehold interactions have found use in a wide variety of applications [41],
with many great successes achieved by utilizing these techniques to perform complex diagnostics both
in the test-tube [42–44] and in-cell [25,30,45]. However, the development of conditional therapeutics
using similar logic-based diagnostic elements has lagged behind. In part, this is likely due to an increase
in design constraints associated with development of therapeutics, as both the input and output
oligonucleotides need to adhere to predetermined sequences. In the case of logic-driven diagnostic
systems, the reporter output often induces translation of fluorescent proteins or the release of fluorescent
nucleic acid probes, each of which are governed by structural changes within strands whose primary
sequences are largely malleable to fulfill structural requirements. In most cases, these diagnostic
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systems function by the opening of a structure, or releasing a single-stranded oligonucleotide, both of
which tend to be easier functions to design than the generation and release of a double-stranded duplex
required in the case of RNAi-based applications. These increases in design complexity are evident in
the conditional systems presented above. Conditional release of a single-stranded oligonucleotide
that is triggered by a single input can be regulated by using a small, simple bimolecular system,
whereas the release of duplex RNA similarly governed by a single input required much more complexity.
For a conditional RNA-based therapeutic system to be considered for practical application, it likely
needs to fulfill three essential criteria: first, the RNA components must be protected from potential
ribonuclease degradation; second, the sequences of the trigger input and the oligonucleotide output
must be functionally and structurally independent from one another, such that either can be altered
without necessitating a change in the other; and, third, the systems must be cheap and easy to produce,
meaning that the use of modified nucleotides should be kept to a minimum. Previous incarnations of
conditional RNA therapeutic systems have struggled to simultaneously fulfill these criteria. An early
scheme for conditional Dicer substrate generation by Masu et al. utilized a hairpin design similar to
that of a molecular beacon, where trigger binding to the loop unpairs an adjacent stem and allows
formation of the functional sense-antisense hybrid [27]. This construct was successful at separating
the trigger and target sequence elements, and demonstrated conditional gene silencing in HeLa cells.
However, the system required co-delivery of a completely single-stranded cognate antisense strand
leaving it vulnerable to ribonuclease degradation, while the hairpin construct required significant
2′-O-methyl (2′-OMe) modification to prevent Dicer from processing the initial hairpin stem.
A similar approach was designed by Xie et al. whereby an antisense strand was pre-annealed to
a chemically modified “protector” strand and this complex was co-delivered with a single-stranded
sense RNA. The protector strand contained significant overhangs on each end and was completely
complementary to a trigger RNA, allowing hybridization to the trigger to drive antisense release
and siRNA formation [28]. This approach though fails to decouple trigger and output sequences,
while suffering from the same ribonuclease susceptibility and extensive modification issues of the hairpin
based approach. Hochrein et al. have constructed some of the most promising systems conceptually for
the generation of a Dicer substrate siRNA. Their system utilizing stable small conditional RNAs both
effectively separates trigger and output sequence requirements and provides nuclease protection of
functional RNA regions through hybridization to 2′-OMe RNA [29], but again the significant use of
chemically modified nucleotides can hinder efficient and cost effective synthesis. This use of extensive
2′-modification to not only protect regions of functional RNA, but also to prevent off-site Dicer cleavage
is a reoccurring theme among these previous generations of conditional systems. Work by Kumar et al.
explored a completely different approach by genetically expressing a pri-miRNA-like conditional
construct from a plasmid [26]. While the system was able to perform conditional silencing in cell
culture, this system required the delivery of modified oligonucleotide triggers to induce activation
and processing by Drosha. Additionally, the need to prepare and express constructs from a plasmid
brings additional complications.
The original incarnation of split-function RNA/DNA hybrid pairs from Afonin et al. lacks
a true diagnostic component that would be able to sense an RNA biomarker but was able to
successfully separate the output oligonucleotide sequences from the toehold regions that controlled
the conditional strand–exchange reaction. Importantly, they were able to demonstrate that formation
of an RNA/DNA hybrid duplex both protected the RNA from degradation and prevented the initial
duplexes from being processed by Dicer [31]. As described above, these “traditional” RNA/DNA hybrid
duplexes served as a jumping off point for the development of a new generation of conditional
RNA-based therapeutics, by inserting or appending new diagnostic components able to respond
to the presence of RNA biomarkers. These new systems fulfill our outlined criteria for conditional
therapeutics by combining the nuclease resistance of the RNA/DNA hybrid technology with
independent diagnostic components. In addition, the earlier generations of conditional systems
described above each functioned as Boolean AND gates, releasing a double stranded RNAi substrate
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based on the presence of a single RNA trigger. We demonstrate in this current work that these
next-generation RNA/DNA hybrid systems can be based on AND gates, NOT gates and combinatorial
systems able to sense multiple biomarker triggers. Furthermore, although the proof of principle
demonstrations we have presented here release a single dsRNA duplex from each RNA/DNA hybrid
system, it should be possible to release multiple different dsRNA products in a conditional fashion
from a single pair of conditional RNA/DNA hybrids, as this has been demonstrated previously with
the “traditional” hybrid approach [37]. As an assembled collection, this suite of nucleic acid logic
systems represents a robust toolkit for the conditional generation of nucleic acid species that encode
a specific sequence and function while serving as a foundation for future therapeutic development.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/4/615/s1:
a detailed description of conditional RNA/DNA hybrid construct design, all RNA and DNA sequences used in
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experiments of variant sHˆCTGF hybrids paired with aHˆCTGF.cgnt12, Figure S5: Free energy calculations pertaining
to the responsive DNA hairpin element of aH∨KRAS, Figure S6: Time course FRET experiments of aH∨KRAS paired
with sH∨KRAS.cgnt, Figure S7: PAGE analysis of conditional dsRNA in presence of non-cognate trigger molecules,
Figure S8: PAGE analysis of a CTGF-repressible conditional hybrid pair, Figure S9: Time course FRET experiments
of a multi-input conditional hybrid pair, Figure S10: Effect of trigger titration on dsRNA release from a multi-input
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between various adjacent-targeting hybrid pairs at a single time point, Table S3: Statistical significance of
dsRNA release among various trigger-inducible sHˆCTGF hybrids pairs at a single time point, Table S4: Statistical
significance of dsRNA released for a given sHˆCTGF when paired with aHˆCTGF-cgnt.12 versus aHˆCTGF-cgnt.16, Table S5:
Statistical significance of dsRNA release from a single CTGF trigger-inducible hybrid pair at various timepoints,
Table S6: Statistical significance of dsRNA released for the KRAS-repressible hybrid pair.
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Abstract: Nucleic acids are programmable and biocompatible polymers that have beneficial uses in
nanotechnology with broad applications in biosensing and therapeutics. In some cases, however,
the development of the latter has been impeded by the unknown immunostimulatory properties of
nucleic acid-based materials, as well as a lack of functional dynamicity due to stagnant structural
design. Recent research advancements have explored these obstacles in tandem via the assembly of
three-dimensional, planar, and fibrous cognate nucleic acid-based nanoparticles, called NANPs, for
the conditional activation of embedded and otherwise quiescent functions. Furthermore, a library of
the most representative NANPs was extensively analyzed in human peripheral blood mononuclear
cells (PBMCs), and the links between the programmable architectural and physicochemical parameters
of NANPs and their immunomodulatory properties have been established. This overview will cover
the recent development of design principles that allow for fine-tuning of both the physicochemical
and immunostimulatory properties of dynamic NANPs and discuss the potential impacts of these
novel strategies.
Keywords: nucleic acid nanoparticles; NANPs; immunostimulation; dynamic; conditionally activated;
RNA interference; RNA nanotechnology
1. Introduction
Nanotechnology has been integrated into many aspects of modern life [1] by providing a means of
additional control over the unique physicochemical properties of functional moieties—including size,
surface charge, and hydrophobicity, as well as their precise incorporation—and making them useful for
biomedical applications. The ability to fine-tune these properties subsequently allows for the improved
efficacy of therapeutic treatments and has implications for the future of personalized medicine [2–5].
Nucleic acids, including both DNA and RNA, represent a branch of biopolymers which additionally
offer a biocompatible and programmable therapeutic approach. Beyond their traditionally known
roles as passive carriers of genetic information, DNA and RNA have emerged as building materials
for versatile biological drugs, called therapeutic nucleic acids (TNAs), which can take advantage of
cellular pathways for the sensing, targeting, and silencing of a broad spectrum of various diseases,
including asthma, cystic fibrosis, viral infections, and cancers [6,7]. TNAs are a diverse class of
biomacromolecules that include antisense oligonucleotides, triplex-forming oligodeoxyribonucleotides,
immunostimulatory oligos, catalytic oligos, inhibitory DNAs, interfering RNAs, and aptamers, which
differ by composition, secondary structure, and mechanism of action [8]. Each TNA class may include
multiple subtypes. For example, RNA interference (RNAi) inducers include siRNAs, miRNAs, and
shRNAs, to name just a few. The great potential of RNAi technologies became apparent from the recent
inspiring example of the very first siRNA therapeutic agent, patisiran (trade name ONPATTRO®),
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which was developed against polyneuropathy in patients with hereditary transthyretin-mediated
amyloidosis and approved by the U.S. Food and Drug Administration (FDA) in 2018 [9], in addition to
the many studies showing the versatility and modularity of TNAs [10–12]. Usually, TNAs affect the
flow of genetic information, mimic antibodies, or stimulate the immune system, causing either the
suppression of disease-specific genes or the stimulation of gene expression in response to an antigen.
Besides specific siRNAs, several other promising therapeutically potent classes of nucleic acids, such as
antisense oligonucleotides, aptamers, DNA decoys, and ribozymes, are also under consideration [13].
Currently, three additional successful examples of TNAs are approved for therapeutic uses: fomivirsen
(brand name Vitravene™), an antisense oligonucleotide designed against cytomegalovirus retinitis
which was also the very first nucleic acid-based therapy approved by the FDA [14]; mipomersen (trade
name KYNAMRO®), an antisense oligonucleotide approved for the treatment of homozygous familial
hypercholesterolemia [15]; and pegaptanib (brand name MACUGEN®), an aptamer approved for the
therapy of age-related macular degeneration [16].
If several different TNAs are simultaneously chosen for the same treatment and they must target the
same cells, the optimal route for their controlled co-administration would be through the introduction
of nucleic acid-based nanoparticles, or NANPs [17–27]. This strategy has resulted in multiple new
methods for the design and assembly of nano-TNAs, in which nucleic acids also serve as building
blocks to assemble programmable scaffolds with well-defined properties. To achieve this, biomedical
sciences benefit not only from the natural roles of nucleic acids, but also from their known ability to form
both canonical Watson–Crick (e.g., G–C and A–U (or T for DNA)) and non-canonical base pairings [28].
Non-canonical base pairs are mostly characteristic of RNAs and include 12 basic geometric families [28],
thus leading to a diverse set of oligonucleotide structures, called motifs, that can fold into complexes
with a precise 3D shape. The existing RNA motifs [25,29–35] can be rationally combined to promote
the assembly of various NANPs that can be further decorated with therapeutic domains and employed
as drug delivery platforms [36]. Such a novel use of RNA as a starting material in bottom-up assembly
has helped to establish the burgeoning field of RNA nanotechnology, which also utilizes the biological
functions of nucleic acids to address specific biomedical challenges [21,33,36]. Programmable NANPs
guarantee precise control over versatile functionalization with different moieties, such as aptamers,
fluorescent dyes, and proteins, and their simultaneous delivery with numerous siRNAs targeting
different biological pathways [20–23,25,31,37]. NANPs’ ability to successfully combat diseases at their
source has already been confirmed by multiple animal studies [25,38–43]. Additionally, the design
principles being developed in RNA nanotechnology address fundamental problems relevant to the
biophysics of RNA co-transcriptional folding [24,44–47], structure–activity relationships [48], and their
physicochemical interactions with other classes of biomolecules (e.g., lipids [41,49,50], proteins [51,52])
or inorganic materials [53,54].
Though TNAs in general and NANP-based nano-TNAs in particular are strong candidates
in nanotherapeutics, their transition into a clinical setting has been hindered by a lack of general
knowledge about their immunostimulatory properties [55], while their statically designed structures
have posed limits to the conditional activation or deactivation of preprogrammed biological functions.
To overcome these obstacles, recent efforts, as described in this review, have been focused on a new
platform of design principles for assembling dynamic nucleic acid assemblies with a controlled and
fine-tunable immune response (Figure 1).
110
Nanomaterials 2019, 9, 611
Figure 1. Schematic of the development of nucleic acid-based nanoparticle (NANP) technologies and
their current applications. Structural motifs inspired by structure–activity studies of natural RNAs,
computer-assisted design, or determined by SELEX (systematic evolution of ligands by exponential
enrichment) are used for the rational design of NANPs. NANPs can then be programmed for multiple
applications for materials organization, sensors, and dynamic structures, or can be functionalized with
therapeutic nucleic acids (TNAs) or used to elicit a controlled immune response.
2. Dynamic Shape-Switching and Functional Activation with NANPs
To take full advantage of the programmability of nucleic acids, therapeutic NANPs could be
conditionally activated inside human cells for the release of preprogrammed functionalities which
would offer higher targeting specificity, thereby potentially reducing off-target effects. The “dynamicity”
preprogrammed in NANPs’ behavior defines their ability to be activated in response to various stimuli.
By interacting with, for example, a target strand or environmental variable of choice as a diagnostic step,
switching NANPs can be designed to release therapeutics only when these interactions occur [56,57].
In the absence of the predetermined intracellular trigger mRNA, characteristic only for the diseased cells,
these switching NANPs are not in active therapeutic conformations (Figure 2). The single-stranded
bait sequences made of RNA (or chemically modified nucleotides) that deactivate switching NANPs
are computationally designed to provide a thermodynamically more favorable binding to the trigger
mRNA than to NANP strands [56,57]. The interactions between the switching NANPs and trigger
mRNA removes the bait strand and consequently exposes shRNA-like hairpins that become the next
most thermodynamically stable fold of the remaining NANP. The human enzyme Dicer can now
recognize and cleave these refolded structures and load the RISC with the “guide” strand which, in
turn, will activate RNAi. RNAi activation results in the suppression of targeted anti-apoptotic genes,
thus inducing the programmed death of the diseased cell.
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Figure 2. Dynamic NANPs exemplified by two-stranded RNA switch. The presence of trigger mRNA
promotes strand rearrangements in an otherwise inactive switch, thus allowing for the release of
therapeutic siRNA.
Besides activation from environmental stimuli, RNA/DNA assemblies can also be designed to
interact with their cognate counterparts for their activation [40]. Hybrid structures composed of both
RNA and DNA (or chemical analogs [58]) can be used to synchronize the activation of functionalities
embedded into the hybrid structures [40,59]. Thus, for RNAi activation, two halves of a Dicer substrate
(DS) RNA [60] can be split between two hybrid duplexes which undergo strand displacement when
both are present to form a complete duplex for processing and subsequent gene silencing. The process
of reassociation is thermodynamically driven and can be initiated via complementary ssDNA [40,61,62]
or ssRNA [26] toehold interactions. The use of hybrids also offers some preclinical benefits, such as
controlled rates of reassociation, significantly reduced degradation in human blood serum, and the
possibility to chemically introduce additional functionalities into the DNA strands without affecting
the function of the released RNAs. Besides RNAi inducers, split aptamers have also been tested which,
when presented as separate halves, are non-functional. However, when the halves of the split aptamer
are brought together during the reassociation, the completed aptamer regains its function [40,63,64].
The development of split fluorescent aptamers, such as malachite green [65], Spinach [63], and
Broccoli [66], has produced tools which are especially useful when applied as a validating output for
dynamic RNA nanotechnology [63,64,66–68], in the visualization of NANP assemblies [45,69], and for
logic gating [70].
Another design scheme, which evolved from the approach using RNA/DNA hybrids, utilizes
NANPs which are designed to completely reassociate with one another and thus activate embedded
functionalities. An example of such conditional activation has been shown via interdependent NANPs
in the shape of three-dimensional cubes which interact with their cognate “anti-cubes” under isothermal
conditions to trigger a change in the shape and successive activation of attached functionalities [71].
Cubes are composed of six strands of RNA and/or DNA, while the anti-cube strands are designed
as the reverse complements of the cube sequences (Figure 3A). Only two NANPs—the cube and
anti-cube—are required for activation. Upon interaction, the two cubes that each have a total of nine
unpaired bases per corner undergo a thermodynamically driven switch into six double-stranded
duplexes. Moieties which are split across the cube and anti-cube complement strands are then brought
together for activation of functionality.
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Figure 3. Conceptual representation of interdependent shape-switching NANPs programmed to
activate multiple functionalities upon their isothermal reassociation. (A) Hexameric NANP cubes
and complementary anti-cubes reassociate to drive the formation of six double-stranded duplexes.
Functionalities which can potentially be added to the NANPs are split between the two functionally
interdependent cubes to become active upon reassociation, resulting in the completion of siRNAs for
gene silencing, Förster resonance energy transfer (FRET) pairs for visualization, aptamers, or T7 RNA
polymerase promoter sequences for the co-transcriptional assembly of RNA NANPs. The cubes can
be composed of varying ratios of DNA and/or RNA, with melting temperature, blood stability, and
immune activation increasing with RNA composition. (B) Hybrid DNA/RNA fibers (top) and polygons
(bottom) reassociate to form DNA duplexes containing NF-κB decoys, as well as Dicer substrate (DS)
RNA duplexes for gene silencing. The NF-κB decoy binds to and prevents NF-κB from entering
the nucleus, thereby stopping it from producing pro-inflammatory cytokines. As a result, immune
activation decreases as the hybrid structures reassociate.
2.1. Activation of RNA Interference, FRET, RNA Aptamers, and Transcription Initiation
Conditional activation of the functionalities upon reassociation of the cube and anti-cube has been
demonstrated with a variety of methods which also establish the wide range of applications for this
technology [71]. A set of cognate cubes were decorated with split DS RNAs against multiple different
genes (BCL2, PLK1, and green fluroscent proteins—GFP). DS RNAs were labeled with fluorophores
chosen to undergo a Förster resonance energy transfer (FRET) for real-time intracellular analysis. Upon
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reassociation, the formation of DS RNA duplexes could be further processed in a cellular environment,
through dicing, for the release of functional siRNAs. Cognate functionally interdependent NANPs
carrying DS RNAs against GFP [60] showed a significant knockdown in the fluorescence of human
breast cancer cells expressing enhanced GFP [71]. Also, the downregulation of BCL2 and PLK1
genes [27], which have been shown to induce apoptosis, was confirmed by a significant decrease in the
viability of human cervical and prostate cancer cells.
The reassociation of the cube and anti-cube and the consecutive formation of RNA fibers was
also demonstrated with the activation of a split aptamer. The RNA aptamer Broccoli [72], which binds
the chemically synthesized fluorophore DFHBI-1T to mimic the natural function of GFP, was split
into two separate strands termed Broc and Coli [66,68]. With both parts of the aptamer attached to
cognate RNA cube strands, the Broc cube and Coli anti-cube reassociated in the presence of DFHBI-1T,
allowing for the interaction to be traced via fluorescence in real time [71].
The reassociation of the DNA cubes and anti-cubes carrying split T7 RNA polymerase promoters
was shown to form templates for the co-transcriptional assembly of complete RNA cubes in vitro.
Anti-cubes carrying a complete T7 promoter can be used for the RNA cube’s co-transcriptional assembly,
thus providing a template for the future intracellular production of RNA nanoparticles that can be
activated upon interaction of functionally interdependent NANPs [71].
Lastly, hybrid RNA/DNA fibers and polygons can interact with their cognate structures for
reassociation, resulting in the release of DS RNAs as well as double-stranded DNAs carrying NF-κB
decoys (Figure 3B) [73]. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is
expressed in most animal cells and generally remains in an inactive state in the cytoplasm until
it can be activated for translocation to the nucleus, where it is then involved in the production of
pro-inflammatory cytokines. With the release of NF-κB decoys [74,75], which can bind and retain
NF-κB in the cytoplasm, the hybrid fibers and polygons dynamically modulate the immune response
in addition to RNAi activation. Further, this strategy takes advantage of all strands included in the
assembly to utilize them in functional roles, leaving no static byproducts [73].
2.2. Fine-Tunable Properties
Besides the activation of multiple functionalities, an important feature of the rational design of
the cube/anti-cube NANP system is the ability to fine-tune the physicochemical and immunological
properties of NANPs simply by adjusting the ratios of DNA and RNA strands in their composition [71].
With an increasing number of RNA strands, both the thermodynamic stability and the reassociation
time of cubes increased. The immune response to these NANPs was also assessed via the measurement
of the activation and secretion of interferon (IFN)α and a panel of pro-inflammatory cytokines and
chemokines (IL-1β, TNFα, IL-8, and MIP-1α). NANPs composed of all RNA strands were the most
potent stimulators of an immune response, indicating that they may serve an application as a vaccine
adjuvant. By adjusting the nucleic acid composition, the immune response to nanoparticles can be
fine-tuned in such a way that assemblies could be utilized for drug delivery or immunotherapy.
3. Immunostimulatory Properties of NANPs
It is becoming apparent that interactions between NANPs and the immune system must be
defined to permit the successful translation of this technology to the clinic. Foreign nucleic acids
can produce a robust and severe response in immune cells. Pro-inflammatory cytokines and type I
interferons are characteristic of nucleic acid sensing in immune cells, and in animals, it can produce
anywhere from minor inflammation to severe cytokine storms. Therefore, to address fundamental
questions regarding the immune recognition of these novel materials in a timely fashion, the relation
of features such as the size, shape, composition, and physicochemical properties of various polygonal
NANPs [76] to the activation of immune responses in human microglia-like cells (hμglia or hHμ) was
examined [48] using a series of assembled RNA, DNA, and RNA/DNA hybrid NANPs. A set of several
polygons designed based on the versatile tetra-U helix linking motif [76] was assembled by using
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a ubiquitous set of strands (both RNA and DNA) so that their immunostimulatory effects—when
composed of all RNA, RNA with a DNA center, all DNA, and DNA with a RNA center—could be
characterized (Figure 4A). The engineered NANPs were designed to assume various shapes and sizes
as well as variations in their content (RNA vs. DNA) and physicochemical stabilities while having
minimal differences in their sequences. The measured biomarkers of a pro-inflammatory response
were cytokines and type I interferons. Using modern machine learning techniques, the quantitative
structure–activity relationship (QSAR) models were developed to successfully predict and engineer
NANPs able to stimulate an intended immune response, or lack thereof [48].
Figure 4. The very first application of quantitative structure–activity relationship (QSAR) modeling
for NANP immunostimulation uses measured physical and chemical properties as inputs to predict
a given NANP’s ability to generate a pro-inflammatory response. (A) A library of 16 NANPs which
incorporate the same sequences was used to determine the physicochemical properties contributing to
immune response. From the study, size (diameter) was determined to contribute the least to immune
response, followed by KD, GC content, molecular weight, Tm and, finally, stability with the highest
contribution into the random forest model. (B) A schematic showing the QSAR modeling approach
which uses the 16 NANP library.
This very first application of QSAR modeling for NANPS studied measured physical and chemical
properties as inputs to predict a given NANP’s ability to generate a pro-inflammatory response
(Figure 4B). Importantly, this QSAR model [48] can be used to more intelligently design nucleic
acid-based pharmaceuticals to reduce detrimental immune responses, stimulate desired protective
immune responses, and increase their intended activity. This work is instrumental in bridging the
rapidly narrowing gap between basic research on NANPs and advanced pharmaceuticals containing
these novel materials.
Following these findings, the very first systematic investigation of NANP recognition by immune
cells using primary human peripheral blood mononuclear cells (PBMCs) from a cohort of more than
100 healthy human donors was recently designed and executed [77]. Despite expectations [78], the
researchers did not find a strong, uniform immune response for all NANPs. Instead, the tests found
varying and specific responses from different immune cells, depending on each NANP’s shape and
formulation. It was discovered that all NANPs used without a delivery carrier were immunoquiescent,
and that type I and III IFNs are key cytokines triggered by NANPs after their internalization by
phagocytic cells. It was shown that overall immunostimulation relies on the NANPs’ shape, type of
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connectivity, and composition. Importantly, plasmacytoid dendritic cells were identified as the primary
interferon producers among all PBMCs treated with NANPs, and it was demonstrated that scavenger
receptor-mediated uptake and endosomal toll-like receptor (TLR) signaling are essential for NANPs’
recognition. In particular, TLR 7 (Figure 5) was identified as a key player in immunostimulation
triggered by NANPs that was observed both in model HEK-Blue TLR 7 cells [77] and in human
PBMCs [79], as well as being later confirmed by extensive mechanistic studies [79]. All immunological
studies strongly suggest that the further understanding of how particular NANPs can trigger the
immune response is required to open up possibilities in a new field where NANPs can be used as
vaccine adjuvants.
Figure 5. Abridged illustration detailing the pathways involved in the endosomal and cytosolic sensing
of smaller therapeutically relevant nucleic acids. NANPs have been observed to enter through the
endosomal pathway (when complexed with Lipofectamine 2000) and trigger the toll-like receptors
(TLRs). The pathway shown in red (for TLR 7) demonstrates the identified route for RNA cube
recognition. For the purpose of this review, the figure shows all individual TLRs (related to NA sensing)
in separate endosomes in order to better highlight the particular pathway of NANPs’ recognition.
Importantly, the following work has also demonstrated that the functionalization of NANPs with
RNAi inducers completely changes their known immunorecognition [80]. However, the possibility
to control the magnitude and specificity of the immunostimulatory response by varying the design
parameters and functional moieties in each NANP has also been revealed (Figure 6). Additionally,
through using RNA fibrous structures which have been shown to have minimal recognition by
the immune system, the delivery of multiple modalities, such as siRNAs and fluorophores, can be
coordinated with minimal immunorecognition. Relying on HIV-like (~180◦) kissing loop interactions,
dumbbell-shaped hairpins are the modular building blocks for these assemblies and allow for simple
customizability [80].
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Figure 6. Initial overall immunostimulatory trends observed with variations in NANP designs.
(A) Three-dimensional RNA cubes are potent immunostimulants, followed by two-dimensional RNA
rings and one-dimensional RNA fibers. (B) Between structures of the same dimensionality, RNA
NANPs are more immunostimulatory than DNA NANPs. (C) A NANP scaffold becomes more
immunostimulatory if it is functionalized, for example, with TNAs. (D) For RNA fibers which are
less immunostimulatory in terms of dimensionality, functionalization at every monomer results in
a greater immune response than if the fibers are functionalized at every other monomer. Different
colors emphasize the architecture of NANPs consisting of multiple strands (A,C,D) or changes in their
composition (B) such as DNA vs. RNA.
4. Conclusions
In conclusion, the responsive behaviors of NANPs can be determined by the specific design
principles for individual NANPs, their assembly type, compositions, physicochemical properties,
and the presence of any additional functionalities in their structure. The use of NANPs for the
controlled design of dynamic stimuli-responsive systems presents multiple advantages: (i) NANPs
can be programmed to gather multiple different functionalities for their simultaneous delivery
to cells [17,25,37,42,61]; (ii) RNA NANPs and their chemical analogs can be co-transcriptionally
assembled [23,24,45,46]; (iii) the relatively inexpensive production of NANPs with a high batch-to-batch
consistency [22] enables their economic industrial scale production; (iv) the thermal and chemical
stabilities of NANPs can be fine-tuned by introducing chemically modified nucleotides or DNA strands
into their composition [45,71,77]; (v) carrier-free NANPs avoid nonspecific cell penetration due to
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their negative charge [77] and, thus, can be used for extracellular tasks; and (vi) the immunological
properties of NANPs are controllable and can potentially be predicted [48,77]. The ability to fine-tune
immunostimulation and the conditional activation of functionalities are important facets in the rational
design strategies of programmable biopolymers. Stimulation of the controlled production of IFNs
and pro-inflammatory cytokines by human immune cells is instrumental for immunotherapies and
vaccine use when activation of the immune response is necessary [77]. The excessive and uncontrolled
induction of cytokines, however, may promote tissue necrosis and become harmful [81]. The innovative
development of NANP-based tools that can be used for communication with the human immune
system can be employed in achieving the desirable activation of the immune system for vaccines and
cancer immunotherapies, while immunoquiescent NANPs can be used as nano-TNAs and for dynamic
NANP construction.
Predicting and controlling the immune responses triggered by NANPs, especially when the
magnitudes of those responses may vary between donors, remains a substantial challenge for the
furtherment of nano-TNAs. In addition, due to their negative charges which inhibit free passage across
the cell membrane, a carrier or targeting moieties are needed for delivery. While there is a plethora of
nanoparticles formulated for nucleic acid delivery, the effects of the carrier on the immunostimulatory
properties of NANPs remain unclear. Furthermore, the healthy host immune tolerance to nucleic acids
and the generation of antibodies against DNA and RNA after exposure to NANPs is an important
safety topic which, so far, has not been addressed. Thus, assessing the immunogenicity of NANPs is a
future logical direction in this field.
The activation of RNA interference, FRET, RNA aptamers, transcription, and other responses
upon the reassociation of cognate NANPs at isothermal conditions exhibits the potential for dynamic
constructs to operate only in the presence of a target. Additionally, the degree to which the properties
of TNAs contribute to the elicitation of an immune response will allow for their intentional activation or
evasion, depending on whether immunotherapy or drug delivery is desired. By optimizing conditional
activation and immunostimulation, NANPs can be better designed for future clinical applications.
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Abstract: Spinal cord tumors (SCT) are uncommon neoplasms characterized by irregular growth of
tissue inside the spinal cord that can result in non-mechanical back pain. Current treatments for SCT
include surgery, radiation therapy, and chemotherapy, but these conventional therapies have many
limitations. Suicide gene therapy using plasmid encoding herpes simplex virus-thymidine kinase
(pHSV-TK) and ganciclovir (GCV) has been an alternative approach to overcome the limitations of
current therapies. However, there is a need to develop a carrier that can deliver both pHSV-TK and
GCV for improving therapeutic efficacy. Our group developed a cationic, amphiphilic copolymer,
poly (lactide-co-glycolide) -graft-polyethylenimine (PgP), and demonstrated its efficacy as a drug
and gene carrier in both cell culture studies and animal models. In this study, we evaluated PgP as
a gene carrier and demonstrate that PgP can efficiently deliver reporter genes, pGFP in rat glioma
(C6) cells in vitro, and pβ-gal in a rat T5 SCT model in vivo. We also show that PgP/pHSV-TK with
GCV treatment showed significantly higher anticancer activity in C6 cells compared to PgP/pHSV-TK
without GCV treatment. Finally, we demonstrate that PgP/pHSV-TK with GCV treatment increases
the suicide effect and apoptosis of tumor cells and reduces tumor size in a rat T5 SCT model.
Keywords: suicide gene therapy; non-viral gene delivery; ganciclovir; spinal cord tumor
1. Introduction
Intramedullary spinal cord tumors (IMSCT) constitute 8 to 10% of primary spinal cord tumors [1]
and are uncommon neoplasms characterized by irregular growth of tissue found inside the spinal
cord. These tumors cause significant neurologic morbidity and mortality [2], such as pressure on
sensitive tissues and reduced function, resulting in pain, sensory changes, and motor deficits. Current
treatments for spinal cord tumor include surgical therapy, radiotherapy, and chemotherapy [3–5].
However, these conventional therapies have limitations such as tumor cell survival that leads to high
recurrence rate, as well as infiltration of tumors into the spinal cord [6,7]. Radiation therapy is limited
by dose-related toxicity to the normal spinal cord and surrounding tissues, and systemic toxicity [8].
Chemotherapy has also been used to treat SCT [9], but it has dose-limiting toxicity and side effects
such as sensory neuropathies and gastrointestinal disturbances after systemic administration [10,11].
Gene therapy has been investigated as an alternative approach to overcome the limitations
of current therapies for SCTs [12,13]. Among gene therapies, suicide gene therapy has received
considerable attention in the field of cancer gene therapy. Suicide gene therapy is based on the
gene-directed enzyme prodrug strategy, which requires suicide genes and prodrugs. In gene-directed
enzyme prodrug therapy, a viral or non-viral vector is used to transfect tumor cells with a gene
encoding a specific exogenous enzyme. A prodrug is then administered that can be only activated
by the specific enzyme expressed in the tumor cells. The Herpes simplex virus thymidine kinase
(HSV-TK) gene is the most frequently used suicide gene with the anticancer prodrug, ganciclovir
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(GCV) [13–16]. Won et al. reported that reducible poly (oligo-D-arginine) (rPOA) could deliver
plasmid encoding herpes simplex virus-thymidine kinase (pHSV-TK)and demonstrated that locally
injected rPOA/pHSV-TK with systemically administered GCV significantly reduced tumor volume
and improved locomotor function compared to the GCV only group and naked pHSV-TK with
GCV-treated group [12,13]. One of the drawbacks of this pHSV-TK and GCV combination therapy
is the GCV concentration in tumor cells. GCV has a very low oral bioavailability (~5%) and short
plasma half-life (~2–6 h), so GCV has to be injected daily (5 mg/kg) to maintain the therapeutic plasma
concentration. To improve GCV concentration in plasma, several delivery systems have been studied,
including liposomes [17,18] and silicone pellets [19]. Kajiwara et al. reported that they achieved longer
circulation of liposome encapsulated GCV (PEG-GCV-lipo) in blood and the area under the curve
(AUC) of liposome encapsulated GCV (PEG-GCV-lipo) was 36-fold and 32-fold higher compared to
GCV solution after intravenous and intraperitoneal injection in mice, respectively [18]. They reported
that PEG-GCV-lipo was three times more effective than GCV solution in inhibiting tumor growth in a
mouse KB xenografts model. Therefore, there is a need to develop a carrier that can efficiently deliver
both pHSV-TK and GCV to improve the efficacy of this suicide gene therapy.
Our group developed a cationic, amphiphilic copolymer, poly (lactide-co-glycolide)-graft-
polyethylenimine (PgP), as a drug and nucleic acid delivery carrier [20–22]. We reported its ability to
efficiently deliver plasmid DNA (pDNA) and small interfering RNA (siRNA) in various cell lines and
primary neurons in vitro, as well as in the normal rat spinal cord [20]. We showed that PgP loaded with
a fluorescent, hydrophobic dye (DiR; 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindotricarbocyanine Iodide)
is retained within the injured spinal cord for up to five days after intraspinal injection. Injection of PgP
complexed with siRNA targeting Ras homolog gene family, member A (RhoA) in the injured rat spinal
cord resulted in RhoA knockdown, reduced astrogliosis and necrotic cavity formation, and increased
axonal sparing/regeneration [21]. Finally, we reported that a hydrophobic drug, rolipram, can be
encapsulated in the hydrophobic core of PgP, increasing its aqueous solubility seven times compared
to that in water alone [22].
Our long-term goal is to develop PgP as a platform technology for delivery of therapeutic drugs
and nucleic acids to spinal cord tumors. In this study, we investigated PgP as a suicide gene carrier.
We show that PgP can efficiently deliver pDNA encoding green fluorescence protein (pGFP) in rat
glioblastoma (C6) cells in vitro and deliver pDNA encoding β-galactosidase protein (pβ-gal) in a rat
spinal cord tumor model in vivo. We demonstrate that PgP/pHSV-TK with GCV achieves a suicide
effect in C6 cells in vitro. Finally, we show the suicide effect of PgP/pHSV-TK with GCV treatment in a
rat T5 spinal cord tumor model.
2. Material and Methods
2.1. Plasmid Amplification and Purification
Plasmids encoding the Monster Green Fluorescent Protein (phMGFP Vector, pGFP, Promega,
Madison, WI, USA), beta-galactosidase (pSV40-βGal, βGal, Promega), and herpes simplex
virus-thymidine kinase (pHSV-TK, Invivogen, San Diego, CA, USA) were transformed into
Escherichia coli DH5α (Life Technologies, Grand Island, NY, USA) and amplified in Lysogeny broth (LB)
medium with ampicillin at 37 ◦C overnight with shaking at 250 rpm. The amplified plasmids were
purified by the Endorsee Maxi plasmid purification kit (Qiagen, Valencia, CA, USA). The quantity
of plasmid was determined by the absorbance at 260 nm and the quality of plasmid was determined
by the ratio of 260/280 nm using BioTek Take 3 microplate reader (BioTek, Synergy HT, Winooski,
VT, USA).
2.2. Particle Size and Surface Charge of PgP/pDNA Polyplex
PgP was synthesized using PLGA (lactide:glycolide 75:25, 25 kDa, 120 μmole, Durect Corporation,
Pelham, AL, USA) and branched polyethylenimine (bPEI, MW: 25 kDa, 100 μmol, Sigma, Milwaukee,
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WI, USA) as previously published by our laboratory [22]. PgP/pGFP polyplexes were prepared by
mixing PgP and pGFP at various N/P (number of nitrogen atoms in PgP/number of phosphorus
atoms in DNA) ratio and incubated for 30 min at 37 ◦C. Polyplex size distribution was measured
using dynamic laser light scattering and zeta potential was measured electrophoretically by Zeta
PALS (Brookhaven Instruments Corp., Holtsville, NY, USA). The mean diameter and zeta potential of
polyplexes were measured in triplicate.
2.3. Transfection Efficiency and Cytotoxicity of PgP/pDNA Complex in 10% Serum Condition
To evaluate PgP as a non-viral gene carrier, we first measured the transfection efficiency and
cytotoxicity of polyplexes formed with PgP and reporter gene, pGFP, in rat glioma (C6) cells in vitro.
C6 cells were maintained in DMEM/F12 supplemented with 10% FBS and 1% penicillin/streptomycin
at 37 ◦C in 5% CO2. For transfection, the cells were seeded at a density 1 × 105 cells/well in a 12-well
plate and cultured overnight. The polyplexes of PgP/pGFP (2 μg pGFP) were prepared at various N/P
ratios ranging from 15/1 to 60/1 and incubated for 30 min at 37 ◦C. Polyplexes (2 μg pDNA/well) were
added to the cells in the media containing 10% FBS and incubated at 37 ◦C. At 24 h post-transfection,
the media containing polyplexes were removed and the cells were washed and replenished with fresh
media and then cultured for an additional 24 h. GFP-expressing cells were counted by easyCyte flow
cytometer (Millipore, Darmstadt, Germany) and transfection efficiency is expressed as % transfected
cells according to the following equation:
% transfection efficiency = (number of GFP-positive cells/number of total cells) × 100
Transfected cells were imaged using an inverted fluorescent microscope (Zeiss Axiovert 200,
Göttingen, Deutschland). The bPEI/pGFP (N/P ratio 5/1) complex was used as a positive control.
Cytotoxicity was analyzed in parallel experiments using the MTT assay. At 48 h post-transfection,
the medium was removed and cells were washed with PBS, and incubated with 1 mL of fresh
medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 2 mg/mL in
PBS, Sigma, Milwaukee, WI, USA). After incubation for 4 h at 37 ◦C, the MTT solution was removed
and 1.5 mL of dimethylsulfoxide (DMSO) was added to dissolve the formazan crystals formed by the
live cells. Absorbance (A) was measured at 570 nm. The cell viability (%) was calculated compared to
non-transfected control according to the following equation:
Cell viability (%) = (A570(sample)/A570(control)) × 100%
2.4. Characterization of PgP/pDNA Polyplexes
2.4.1. Stability of PgP/pDNA Polyplex
To evaluate the stable complex formation of the PgP/pDNA polyplex, PgP/pGFP complexes were
prepared at various N/P ratios in deionized water and incubated for 30 min at 37 ◦C. The complexes
were loaded on a 1% (w/v) agarose gel and electrophoresed for 60 min at 80 V. The gel was stained with
ethidium bromide for 30 min and then imaged on an ultraviolet (UV) illuminator (GELDOC-IT2 imager,
UVP, Waltham, MA, USA) to visualize the retention of complexes and migration of naked pDNA.
2.4.2. Heparin Competition Assay
The stability of the PgP/pGFP polyplexes was evaluated using a heparin competition assay. Briefly,
PgP/pGFP at an N/P ratio of 60/1 was prepared as described above. Ten microliter aliquots of complex
solutions were placed into tubes. Then heparin, a negatively charged polysaccharide, was added at
0–40 heparin/pDNA, w/w ratio and the polyplex/heparin solutions were incubated at 37 ◦C for 30 min.
The samples were immediately analyzed by 1% agarose gel electrophoresis as described above.
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2.4.3. Stability of PgP/pDNA in Serum
To measure the stability of the PgP/pGFP polyplexes in serum, PgP/pGFP polyplexes were
prepared at a N/P ratio of 60/1 and then incubated in the media containing 10% FBS at 37 ◦C. Naked
pDNA incubated in the media containing10% FBS was used for comparison. At 30 min, and 1, 3,
6, 24, and 72 h post-incubation, the samples were evaluated by 1% agarose gel electrophoresis as
described above.
2.5. Long-Term Storage Stability of PgP/pDNA Polyplexes
To evaluate stability during long-term storage, PgP/pGFP polyplexes at an N/P ratio of 60/1 were
selected based on the results from in vitro transfection and cytotoxicity. PgP/pGFP polyplexes at an
N/P ratio of 60/1 (2 μg pGFP) were prepared and incubated at 4 ◦C for 6 months. The stability of
stored PgP/pGFP polyplexes was evaluated at predetermined time points (6 h, 1 day, 3 days, 1 week,
and 1, 3, 4, 5, and 6 months) using 1% agarose gel electrophoresis and transfection efficiency in C6
cells as described above. Freshly prepared PgP/pGFP polyplexes were used as a control. GFP-positive
transfected cells were imaged using an inverted fluorescent microscope (Zeiss Axiovert 200, Göttingen,
Germany).
2.6. Suicide Effects of PgP/pHSV-TK Polyplex and GCV Treatment In Vitro
To evaluate the suicide effect of PgP/pHSV-TK polyplex with GCV prodrug, C6 cells were seeded
in 12-well plates at 1 × 105 cells/well and cultured for 24 h. PgP/pHSV-TK polyplexes (2 μg, pHSV-TK)
were prepared at an N/P ratio of 60/1, added to the cells cultured in DMEM/F12 containing 10% FBS,
and incubated at 37 ◦C. At 24 h post-transfection, the media were relaced with fresh media containing 2
different GCV concentrations (50 and 100 μg/mL). At 1 and 4 days post-GCV treatment, the anti-cancer
efficacy of PgP/pHSV-TK with GCV was analyzed via the MTT assay as described above. PgP/pHSV-TK
at the N/P ratio of 60/1 only, GCV (100 μg/mL) only, and bPEI/pHSV-TK at an N/P ratio of 5/1 with
GCV (100 μg/mL) were used for comparison. We used PgP/pGFP at an N/P ratio of 60/1 as a control to
eliminate the cytotoxicity of the polyplex itself.
2.7. Generation of Spinal Cord Tumor Model
All surgical procedures and postoperative care were conducted according to National Institute
of Health (NIH) guidelines for the care and use of laboratory animals (NIH publication No. 86–23,
revised 1996) and under the supervision of the Clemson University Institutional Animal Care and
Use Committee. Sprague Dawley rats (250–300 g, male) were anesthetized using isoflurane gas and
laminectomy was performed at the T5 spinous process using an orthopedic bone cutter. C6 glioma
cells (1.0 × 106 cells in 3 μL PBS) were injected into the T5 position using a Hamilton syringe (26 G)
(Hamilton, Bonaduz, Switzerland) [12,13,23]. As a control, PBS was injected into the T5 spinal cord.
After C6 cell injection, the paraspinal muscles and the skin were closed with 3–0 silk suture. After
surgery, animals were warmed with a heating blanket for recovery. To verify the tumor formation,
animals were euthanized 12 days post-tumor cell injection by CO2 overdose, and spinal cord tissue
from the region surrounding the injection site was explanted. Samples were embedded in Tissue-Tek®
O.C.T compound (Sakura Finetek Inc., Torrance, CA, USA) on liquid nitrogen, sectioned, and stained
with hematoxylin and eosin (H&E).
2.8. Transfection Efficiency of PgP/pβ-Gal in a Rat Spinal Cord Tumor Model In Vivo
To evaluate PgP as a gene carrier in vivo, we used pβ-gal instead of pGFP for transfection to
avoid potential interference from tissue autofluorescence. Animals were injected with C6 glioma
cells (1.0 × 106 cells in 3 μL PBS) at T5 as described above. At 5 days post-injection, the rats were
randomly assigned to one of three experimental groups: (1) PgP/ pβ-gal polyplexes (n = 4 rats/group),
(2) bPEI/pβ-gal complex, and (3) naked pβ-gal. PgP/ pβ-gal polyplexes (20 μL, 10 μg pβ-gal) at an N/P
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ratio of 60/1 were injected into the spinal cord tumor using a Hamilton syringe (26 G). bPEI/pβ-gal
complex (20 μL, 10 μg pβ-gal) at an N/P of ratio 5/1 and naked pβ-gal (20 μL, 10 μg pβ-gal) were injected
for comparison. After injection, the paraspinal muscles and the skin were closed with 3-0 silk suture.
Seven days after treatment, rats were sacrificed by cardiac perfusion with 4% para-formaldehyde (PFA)
in saline. The retrieved spinal cords were embedded in Tissue-Tek® O.C.T. compound and sectioned
into 10-μm thickness using a cryostat (Lecia CM 1950, Leica, Wetzlar, Germany) for histological
analyses. The sections were fixed with 4% PFA, washed two times in PBS (pH 7.4) for 5 min, stained
using X-gal staining solution (Invitrogen, NY, USA) overnight, washed in distilled water, and then
counter stained with eosin.
2.9. Suicide Effect of PgP/pHSV-TK Polyplexes with GCV in a Rat Spinal Cord Tumor In Vivo
To evaluate the suicide effect of PgP /pHSV-TK polyplexes with GCV in vivo, rats were randomly
assigned to one of three experimental groups (n = 4/group): (1) PgP/pHSV-TK polyplexes with GCV,
(2) PgP/pHSV-TK polyplexes without GCV, and (3) saline injection (Untreated) at 5 days after C6 cell
injection, as described above. PgP/pHSV-TK polyplexes (10 μg pHSV-TK, 20 μL) at an N/P ratio of 60/1
were prepared and injected in the tumor lesion by Hamilton syringe (26 G ) and GCV (40 mg/kg) was
administered by intraperitoneal (i.p.) injection every day for 10 days [13]. PgP/pHSV-TK polyplexes
(10 μg pHSV-TK, 20 μL) at an N/P ratio of 60/1 without GCV treatment were used for comparison and
saline-injected animals were used as the untreated control. At 10 days post-GCV treatment, the rats
were sacrificed by cardiac perfusion with 4% PFA in saline. The spinal cords were explanted, embedded,
and sectioned as described above. To measure the tumor size, 16 sections (4 sections/rat, 4 rats/group)
were stained with H&E, imaged. Quantitative measurements of tumor area were analyzed by Image J.
The percent tumor area was calculated according to the following equation:
% Tumor area = (Tumor area/Total area of spinal cord) × 100
To evaluate the suicide effect by PgP/pHSV-TK polyplex (N/P ratio of 60/1) with GCV, the terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed to identify
apoptotic cells. Briefly, the sections were stained by using the ApopTag Plus Fluorescein In situ
Apoptosis Detection kit (Chemicon International, Temecula, CA, USA) and nuclei were counterstained
by 4′,6-diamidino-2-phenylindole (DAPI) and digitally imaged using an inverted epifluorescence
microscope (Zeiss Axiovert 200, Göttingen, Germany). The untreated spinal cord tumor group and the
PgP/pHSV-TK polyplex (N/P ratio of 60/1) without GCV group were used for comparison. We also
evaluated the suicide effect of the PgP/pHSV-TK polyplex (N/P ratio of 60/1) with GCV on expression
of Bcl-2-associatied X protein (Bax), a pro-apoptotic protein. Briefly, sections were stained using
antibody against Bax (1:200, sc-23959, Santa Cruz Biotechnology, Dallas, TX, USA), followed by
Cy3-conjugated anti-rabbit IgG (1:200, ab97035, Abcam, Cambridge, MA, USA). The stained sections
were counterstained with DAPI and imaged using an inverted epifluorescence microscope.
2.10. Statistical Analysis
Quantitative data are presented as the mean ± standard deviation. Statistical analysis was
performed by one-way ANOVA with the least significant difference (LSD) method used for post-hoc
comparisons between subgroups. A p-value less than 0.05 was considered significant.
3. Results
3.1. Characterization of PgP/pDNA Polyplexes
The particle size and zeta potential of PgP/pDNA polyplexes at various N/P ratios were evaluated.
The mean size of the PgP/pDNA polyplexes at all N/P ratios was about 143.4 nm with narrow
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polydispersity. The negatively charged pDNA was completely neutralized by positively charged PgP
and the surface charge of PgP/pDNA polyplexes at N/P ratio of 15/1 or above was positive (Table 1).
Table 1. Mean particle size (PS), zeta potential (ZP), and polydispersity index (PDI) of PgP/pDNA
polyplexes at various N/P ratios.
N/P ratio 15 30 45 60
Particle Size (nm) 141.2 ± 3.8 148.5 ± 3.8 138.0 ± 3.2 145.7 ± 1.5
PDI 0.17 ± 0.01 0.16 ± 0.01 0.20 ± 0.01 0.17 ± 0.01
Zeta potential (mV) 34.4 ± 0.2 41.3 ± 2.5 41.5 ± 0.7 41.5 ± 0.3
3.2. Transfection Efficiency and Cytotoxicity of PgP/pDNA Polyplexes in 10% Serum Condition In Vitro
Transfection efficiency of PgP/pGFP polyplexes was evaluated in C6 cells in media containing
10% serum. GFP expression increased with increasing polyplex N/P ratio and the highest transfection
efficiency (69%) was observed at an N/P ratio of 60/1. In contrast, the transfection efficiency of
bPEI/pDNA polyplexes at an N/P ratio of 5/1 was approximately 1% (Figure 1A). Cell viability was
modestly lower for bPEI/pGFP and PgP/pGFP at all N/P ratios, but the difference was only statistically
significant at N/P ratios of 50/1 and 60/1 (Figure 1B). Figure 1C shows representative images of
GFP-positive cells after transfection with PgP/pGFP polyplexes at various N/P ratios. Based on the
high transfection efficiency with low cytotoxicity, we performed all subsequent experiments using
PgP/pDNA at an N/P ratio of 60/1.
Figure 1. Transfection efficiency and cytotoxicity of PgP/pGFP polyplexes: (A) percent transfection
efficiency and (B) percent cell viability after transfection of PgP/pGFP polyplexes in C6 cells in media
containing 10% serum. Data represent the mean ± SD. (C) Representative images of GFP-positive cells
after transfection with (i) bPEI/pGFP at N/P ratio of 5/1 and (ii–v) PgP/pGFP polyplexes at N/P ratios of
15/1, 30/1, 45/1 and 60/1. Scale bars indicate 100 μm.
3.3. Stability of PgP/pDNA Polyplex
The ability of PgP to condense pGFP was evaluated by gel retardation assay. Complete retardation
of electrophoretic mobility was achieved at N/P ratios of 15/1 or above (Figure 2A). The stability of
PgP/pGFP polyplexes was also evaluated by heparin competition assay. PgP/pDNA polyplexes at
an N/P ratio of 60/1 that selected for highest transfection efficiency were prepared and incubated in
128
Nanomaterials 2019, 9, 573
solutions with varying heparin concentrations. PgP/pDNA polyplexes were stable in the presence of
up to 6 w/w heparin/pDNA ratio and completely dissociated at ratios of 10 or higher (Figure 2B). The
integrity of PgP/pDNA polyplexes at the N/P ratio of 60/1 in the presence of serum was evaluated after
incubation in media containing 10% FBS. Naked pDNA incubated in the presence of serum was used
for comparison. Naked pDNA was degraded by nucleases in the serum and undetectable after 3 h
incubation (Figure 2Ci), whereas PgP/pDNA polyplexes were stable up to 24 h incubation (Figure 2Cii).
Figure 2. Analysis of polyplex stability. (A) Gel retardation assay of PgP/pDNA polyplexes at varying
N/P ratios. Molecular weight marker (M, lane 1), naked pDNA (N, lane 2), PgP/pDNA polyplexes
prepared at N/P ratios of 15/1, 25/1, 30/1, 40/1, 45/1. 50/1, and 60/1 (lanes 3–8) and bPEI/pDNA polyplex at
N/P ratio of 5/1 (lane 9). (B) Heparin competition assay. PgP/pDNA polyplexes (2 μg pDNA) at N/P ratio
of 60/1 were incubated with solutions containing heparin at varying concentration (0–40 heparin/pDNA,
w/w ratio) at 37 ◦C for 30 min. M: Molecular marker. (C) Naked pDNA and PgP/pDNA polyplexes at
N/P ratio 60/1 at various time points during incubation in 10% serum-containing media. (i) Naked
pDNA and (ii) PgP/pDNA polyplex at N/P ratio 60/1, N is naked, untreated pDNA control.
3.4. Long-Term Storage Stability of PgP/pGFP Polyplexes
To evaluate long-term stability, PgP/pGFP polyplexes at N/P ratio 60/1 were stored at 4 ◦C for six
months. Gel electrophoresis analysis showed that PgP/pGFP polyplexes were stable up to six months
at 4 ◦C (Figure 3A). Transfection efficiency of PgP/pGFP polyplexes stored at 4 ◦C for up to four months
was not significantly different compared to freshly prepared PgP/pGFP polyplexes, but significantly
decreased after six months’ storage (Figure 3B). Figure 3C shows representative images of GFP-positive
cells after transfection with PgP/pGFP polyplexes stored at 4 ◦C.
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Figure 3. Long-term stability of PgP/pGFP polyplexes (2 μg pGFP, N/P ratio 60/1) at 4 ◦C. (A) Gel
retardation assay by 1% agarose gel electrophoresis of PgP/pGFP polyplexes. M: Molecular weight
marker (lane1), DNA: naked pDNA (lane 2), PgP only (lane 3), lanes 4–13: Polyplexes at pre-determined
time points (0, 6 h, 1, 3, 7 days, 1, 3, 4, 5 and 6 months, respectively) during storage at 4 ◦C. (B) Transfection
efficacy of polyplexes stored at 4 ◦C in C6 cells in media containing 10% serum at pre-determined
time points. Data represent the mean ± SD. * p < 0.05 compared with freshly prepared polyplexes. (C)
Representative images of GFP-positive cells at 2 days post-transfection with PgP/pGFP polyplexes
stored 4 ◦C. Scale bars indicate 100 μm.
3.5. Suicide Effect of PgP/pHSV-TK Polyplex with GSV Treatment In Vitro
The suicide effect of PgP/pHSV-TK (N/P ratio of 60/1, 2 μg pHSV-TK) polyplexes with two
different GCV doses (50 and 100 μg/mL) was evaluated at 1 and 4 days after GCV treatment in C6 cells.
PgP/pGFP polyplexes (N/P ratio of 60/1, 2 μg pGFP) were used as a control instead of untreated cells
to eliminate the cytotoxicity caused by the polyplex itself. PgP/pHSV-TK only or GCV (100 μg/mL)
only, and PEI/pHSV-TK (N/P ratio of 5/1, 2 μg pHSV-TK) were used for comparison. PgP/pHSV-TK
only or GCV only (100 μg/mL) did not show significantly different anti-cancer efficacy compared
to PgP/pGFP polyplexes at both 1 and 4 days after treatment (Figure 4). The anti-cancer efficacy of
PgP/pHSV-TK polyplexes with both GCV doses of 50 and 100 μg/mL was significantly higher than that
of PgP/pGFP polyplexes at both 1 and 4 days post-treatment. We also observed that the anti-cancer
efficacy of PgP/pHSV-TK polyplexes was significantly higher than that of bPEI/pGFP polyplexes (both
with 100 μg/mL GCV) at 1 and 4 days post-treatment.
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Figure 4. The suicide effect of PgP/pHSV-TK polyplexes and GCV. C6 cells were transfected with
PgP/pHSV-TK (2 μg pHSV-TK) and then treated with GCV (50 and 100 μg/mL). At 1 and 4 days
post-GCV treatment, anti-cancer efficacy was analyzed by MTT assay. PgP/pGFP (N/P of 60/1), PgP/pTK
(N/P ratio of 60/1), GCV only (100 μg/mL), bPEI/pTK (N/P ratio of 5/1) with GCV (100 μg/mL) were used
for comparison. Data represent the mean ± SD. *: p < 0.05 compared to PgP/pGFP at 1 day post-GCV
treatment and +: p < 0.05 compared to PgP/pGFP at 4 days post-GCV treatment.
3.6. Transfection Efficiency of PgP/pβ-Gal in a Rat Spinal Cord Tumor Model In Vivo
To verify spinal cord tumor formation, rats were sacrificed at 12 days post-injection of C6 cells,
tissues sectioned, and stained with H&E. The tumor masses were observed by high-density cell growth
in between T5 and T6 in C6 cell-injected animals (Figure 5B,D), compared to normal spinal cord
(Figure 5A,C). To evaluate the efficacy of PgP as a gene carrier in vivo, PgP/pβ-gal polyplexes (N/P
60/1, 10 μg) were intratumorally injected 5 days after C6 cell injection. Seven days later, the transfection
efficiency of PgP/pβ-gal polyplexes in the spinal cord tumor was evaluated by x-gal staining. Figure 6
shows representative images of β-Gal-positive cells stained in blue within the spinal cord tumor area.
We observed that the x-gal positively stained area in animals receiving PgP/pβ-gal polyplexes was
substantially larger compared to animals receiving bPEI/pβ-gal polyplexes or naked pβ-gal (Figure 6).
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Figure 5. Generation of a rat T5 spinal cord tumor model at 12 days post-injection of C6 cells. (A,B)
Representative images of isolated spinal cord and (C,D) H&E stained spinal cord section. (A,C) Normal
spinal cord and (B,D) spinal cord with C6 cell-derived tumor. Scale bars indicate 500 μm.
Figure 6. Representative images of β-Galactosidase-positive cells at 7 days post-injection of PgP/pβ-Gal
polyplexes (N/P of 60/1) in rat T5 spinal cord tumor in vivo. (left) Naked pβ-Gal, (middle) bPEI/pβ-Gal
polyplexes at N/P of 5/1, and (right) PgP/pβ-Gal polyplexes at N/P of 60/1. Original magnification:
(Top) 40× and (Bottom) 100×. Scale bars indicate 100 μm.
3.7. Suicide Effect of PgP/pHSV-TK Polyplexes with GCV in a Rat Spinal Cord Tumor In Vivo
To evaluate the suicide effect of PgP/pHSV-TK with GCV treatment, PgP/pHSV-TK polyplexes at
an N/P ratio 60/1 (10 μg pHSV-TK) were injected into spinal cord tumors at 5 days post-injection of C6
cells and then received i.p. injection of 40 mg GCV/kg for 10 days. Figure 7A shows representative
images of H&E stained spinal cord tumor sections from various animal groups. The percent tumor
area in animals treated with PgP/pHSV-TK polyplexes and GCV injection was significantly lower than
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that of groups receiving PgP/pHSV-TK polyplexes alone and the untreated SCT group (Figure 7B).
We also evaluated the effect of PgP/pHSV-TK with GCV treatment on apoptosis using the TUNEL assay
and immunohistochemistry (IHC) for expression of the pro-apoptotic protein, Bax. The number of
TUNEL-positive cells in spinal cord tumors was substantially higher in animals receiving PgP/pHSV-TK
polyplexes with GCV injection than both the PgP/pHSV-TK polyplexes only group and the untreated
spinal cord tumor group (Figure 8A). We also observed that Bax expression was highly upregulated in
animals injected with PgP/pHSV-TK polyplexes plus GCV compared to both PgP/pHSV-TK polyplexes
only and untreated spinal cord tumor groups (Figure 8B).
Figure 7. Histological analysis of the suicide effect on tumor size at 10 days post-intratumoral injection
of PgP/pHSV-TK (10 μg pHSV-TK, N/P ratio of 60/1) polyplexes with GCV (40 mg/kg, intraperitoneal
injection). (A) Representative images of H&E stained longitudinal spinal cord sections. Scale bars
indicate 500 μm. (B) The percent tumor area of spinal cord tumors. The % tumor area was measured
and averaged from 16 different sections of spinal cords from each group (4 sections/rat, 4 rats/ group).
* p < 0.05 compared with untreated SCT group.
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Figure 8. Representative images of (A) TUNEL+ cells (green), (B) Bax+ cells (red), in spinal cord tumor
at 10 days post-intratumoral injection of PgP/pHSV-TK (10 μg pHSV-TK, N/P ratio of 60/1) polyplexes
with GCV (40 mg/kg, intraperitoneal injection). Cell nuclei were counter stained with DAPI (blue).
Scale bars indicate 100 μm.
4. Discussion
Intramedullary spinal cord tumor (IMSCT) is an uncommon neoplasm that causes significant
neurologic morbidity and mortality [2]. Surgical therapy, radiotherapy, and chemotherapy are currently
the most common treatments [3–5]. In addition to these current treatments, gene therapy has been
explored as a possible alternative approach to overcome some of the limitations associated with current
therapies for SCTs [12,13].
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A cationic, amphiphilic copolymer, PgP, has been developed by our group and has been shown
to perform as an efficient drug and non-viral gene carrier in vitro as well as in in vivo animal
models [21,22,24]. As a block copolymer that forms polymeric micelles in aqueous solution with a
hydrophobic core and hydrophilic, cationic shell, PgP has the potential to serve as a combinatorial
carrier for the simultaneous delivery of hydrophobic drugs and anionic therapeutic nucleic acids. Our
long-term goal is to use PgP as a carrier for GCV and pHSV-TK co-delivery. In this study, we evaluated
PgP as a gene carrier in glioma (C6) cells in vitro using reporter genes such as pGFP and a rat spinal cord
tumor model in vivo using reporter gen, pβ-Gal, and therapeutic gene, pHSV-TK. We first evaluated
the particle size and surface charge of PgP/pGFP polyplexes at various N/P ratios and found that PgP
can form stable complexes with pDNA 138–148.5 nm in size and positive surface charge at all N/P
ratios (Table 1). This size range and surface charge are suitable for intracellular uptake by endocytosis
and avoidance of rapid clearance by the reticuloendothelial system (RES) in systemic delivery [25,26].
Barriers for systemic gene therapy in vivo are polyplex stability and degradation by nucleases in
the blood stream. To model the stability of PgP/pGFP in the blood stream, we conducted a heparin
competition study using negatively charged polysaccharide, heparin. PgP/pGFP at an N/P ratio of
60/1 showed high stability and heparin was only able to dissociate pGFP from PgP at 10 w/w ratio
of heparin/pGFP and higher (Figure 1B). We also observed that PgP can efficiently protect pDNA
from nucleases in serum for up to 24 h, whereas pDNA without PgP was completely degraded by
serum nucleases within 3 h. These results show that PgP may be a promising non-viral gene carrier for
systemic gene therapy in vivo. In the long-term storage stability study, we observed that the transfection
efficiency of PgP/pGFP polyplexes in C6 (rat glioma) cells was maintained up to four months at 4 ◦C
and this result is consistent with the long term stability of PgP/pGFP and PgP/siRhoA observed in B35
(neuroblastoma) cells in our laboratory [21,24]. This demonstrates that PgP can form a stable complex
with both pDNA and siRNA and preserve the bioactivity of nucleic acids during long-term storage,
an important challenge for the clinical translation of non-viral vectors.
To evaluate PgP as a pHSV-TK gene carrier, we administered two doses of GCV (50 and 100 μg/mL)
after PgP/pHSV-TK transfection in C6 cells in vitro. The PgP/pHSV-TK transfected group with both
GCV doses showed significantly higher anti-cancer efficacy compared to control groups including GCV
only, PgP/pGFP only, and PgP/pHSV-TK without GCV treatment at both one and four days. The lack
of a significant effect of GCV dose on the anti-cancer efficacy of PgP/pHSV-TK is consistent with results
obtained for rPOA/HSV-TK transfection and GCV treatment by Won et al. [13]. We observed that
the PgP/pHSV-TK transfection with GCV (100 μg/mL) treatment group showed significantly higher
cell cytotoxicity compared to bPEI/pHSV-TK transfection with GCV (100 μg/mL) treatment group
one day post-GCV treatment. In vivo β-Gal expression was substantially higher in animals receiving
PgP/pβ-Gal polyplexes compared with bPEI/pβ-Gal polyplexes in the rat spinal cord tumor model.
bPEI is known as an effective transfection reagent, being widely studied both in vitro and in vivo
due to its high transfection efficacy and the ability of the proton sponge effect to facilitate endosomal
escape [27,28]. However, poor transfection efficiency in the presence of serum and cytotoxicity are
limitations to clinical application [29].
Finally, we evaluated the suicide effect of PgP/pHSV-TK with GCV in the rat spinal cord tumor
model and observed that the percent tumor area in animals treated with PgP/pHSV-TK and GCV was
significantly smaller than that of those receiving PgP/pHSV-TK polyplexes without GCV (Figure 7).
This result was further confirmed by the presence of more TUNEL+ cells as well as increased expression
of the pro-apoptotic protein, Bax, in the PgP/pHSV-TK polyplexes with GCV treatment group compared
with the PgP/pHSV-TK without GCV group. These data demonstrate that PgP can serve as an effective
pHSV-TK carrier to activate the prodrug GCV for the treatment of spinal cord tumors.
5. Conclusions
In this study, we demonstrated that the cationic amphiphilic copolymer PgP can be a gene
carrier due to the stability of polyplexes in the presence of negatively charged serum proteins and the
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ability to protect pDNA from nucleases in the serum, PgP/pDNA polyplexes maintain bioactivity for
transfection after storage at 4 ◦C for up to 4 months—an important feature for commercial and clinical
application. We demonstrated that PgP can efficiently deliver pHSV-TK in C6 cells and PgP/pHSV-TK
in combination with GCV showed significantly higher suicide effect on C6 cells compared to various
control groups in vitro. Finally, we demonstrated that PgP/pHSV-TK with GCV treatment increases the
suicide effect and apoptosis of tumor cells and reduces tumor size in a rat T5 spinal cord tumor model
compared with PgP/pHSV-TK without GCV treatment. In the future, we will evaluate the potential of
PgP as a GCV and pHSV-TK co-delivery carrier to improve the bioavailability and half-life of GCV as
well as increase the survival rate after treatment of PgP/pHSV-TK with PgP-GCV in rat T5 spinal cord
tumor model.
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Abstract: Glioblastoma multiforme is the most common and aggressive primary brain tumor. Even
with aggressive treatment including surgical resection, radiation, and chemotherapy, patient outcomes
remain poor, with five-year survival rates at only 10%. Barriers to treatment include inefficient drug
delivery across the blood brain barrier and development of drug resistance. Because gliomas occur
due to sequential acquisition of genetic alterations, gene therapy represents a promising alternative
to overcome limitations of conventional therapy. Gene or nucleic acid carriers must be used to deliver
these therapies successfully into tumor tissue and have been extensively studied. Viral vectors have
been evaluated in clinical trials for glioblastoma gene therapy but have not achieved FDA approval
due to issues with viral delivery, inefficient tumor penetration, and limited efficacy. Non-viral vectors
have been explored for delivery of glioma gene therapy and have shown promise as gene vectors for
glioma treatment in preclinical studies and a few non-polymeric vectors have entered clinical trials.
In this review, delivery systems including viral, non-polymeric, and polymeric vectors that have
been used in glioblastoma multiforme (GBM) gene therapy are discussed. Additionally, advances
in glioblastoma gene therapy using viral and non-polymeric vectors in clinical trials and emerging
polymeric vectors for glioma gene therapy are discussed.
Keywords: glioblastoma multiforme; gene therapy; viral vector; non-viral vector; gene delivery;
siRNA
1. Introduction
Glioblastoma multiforme (GBM) is a type of glioma that arises from astrocytes, defined by the
World Health Organization (WHO) as a grade IV glioma [1,2]. GBM is not only the most common
malignant primary brain tumor, but also the most aggressive of malignant tumors, with recurrence in
nearly all patients [3]. GBM affects about three people out of every 100,000 per year, accounting for
approximately 15% of primary brain tumors, and 80% of malignant primary brain tumors. GBM is
about two times more common in whites than in blacks, and 1.5 times more common in men than in
women, with an average age at onset of 64 [4].
High-grade gliomas are typically located in undesirable locations in the cerebral hemisphere and
are classified as diffuse gliomas due to their high rate of infiltration into surrounding brain tissue.
These factors allow for persistent tumor growth and lessen the chance of remission, with progression
to grade III or IV gliomas likely even in most low-grade diffuse gliomas [2,5]. The current standard of
care for treating GBM includes surgical resection of the tumor, radiation therapy, and chemotherapy
via temozolomide (TMZ) [6]. Carmustine (BCNU, Gliadel™) wafers have been used as local adjuvant
therapy in combination with systemic TMZ since its approval; however, its use has been limited due
to observed toxicities and ambiguity of overall survival benefit [7,8]. Additionally, bevacizumab, a
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monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), is used for the treatment
of recurrent glioblastomas [9]. However, even with aggressive treatment, survival rates remain between
12 and 15 months, and the 3-year survival rate is less than 16% [1,10]. GBM remains an essentially
incurable disease, resulting in a patient death rate of greater than 95% within five years of diagnosis [11].
Consequently, there is a clear need for advancement in treatment strategies to improve outcomes for
patients with GBM. Gene therapy may provide a viable alternative to conventional treatments towards
combating cancer progression in GBM.
This review discusses gene expression in GBM, the limitations to conventional therapy, and
current approaches to circumvent these barriers using gene therapy. Advances in gene delivery
systems will be reviewed, highlighting viral and non-viral vectors used for GBM gene therapy. Trials
bringing these therapies closer to clinical approval to date will be discussed, as well as preclinical
studies, particularly using polymeric nanoparticles, which have shown promise as future vectors for
delivery of gene therapy in GBM patients.
2. Gene Expression in GBM
Glioma occurs due to sequential acquisition of genetic alterations, causing a transformation
from benign to malignant tissue [12]. Glioblastoma can occur in four clinical subtypes including
classical, proneural, mesenchymal and neural GBM [13]. Classical, or primary GBM arises de novo, and
occurs in about 95% of cases, only requiring about 3–6 months to develop [1]. Proneural or secondary
GBM arises as a recurrence from a previous anaplastic or low-grade astrocytoma, usually requiring
10–15 years to develop [14]. Classical GBM can be identified by chromosome 7 amplification paired
with chromosome 10 loss, as well as by increased expression of the epidermal growth factor receptor
(EGFR) and mutations in phosphatase and tensin homologue (PTEN) [1,13]. In a study conducted by
Verhaak et al., point or vIII EGFR mutations were found in over half of GBM cases analyzed [13]. EGFR
overexpression, observed in 97% of patients with classical GBM, causes a reduction in apoptosis and
increased proliferation through the Ras-Shc-Grb2 pathway, causing uncontrolled cell growth [14]. PTEN
is a tumor suppressor, and when mutated, the loss of function causes activation of the P13K/Akt/mTOR
pathway, leading to proliferation, growth, and migration [15]. Disrupted regulation of this pathway has
been shown to contribute to tumorigenesis and resistance in various cancers [16]. Deletion of CDKN2A,
coding for tumor suppressor p16INK4A, was also significantly associated with the classical subtype.
Proneural GBM often presents with increased expression of platelet-derived growth factor receptor
alpha (PDGFRA), as well as mutated tumor suppressor p53, isocitrate dehydrogenase 1 (IDH-1), and
retinoblastoma genes [11,13,14]. PDGFRA is mitosis-promoting, and overexpression of this mitogen
promotes tumor cell proliferation [14]. IDH-1 point mutations were found to occur in about 30% of
proneural cases [14]. Mutation of IDH alters DNA and histone methylation and is often found in the
early development of diffuse gliomas [17,18]. The p53 gene normally functions as a switch to turn on
G1 cell cycle arrest or apoptosis, regulating cell growth [14]. Overexpression of p53 has been shown
to negatively regulate MGMT transcription, suggesting that repair of wild-type p53 may increase
therapeutic efficacy in GBM therapy [19]. Interestingly, p53 mutations have been found in 54% of
proneural GBM but are almost never observed in classical GBM [13]. More recently, interferon-β (IFN-β)
has been found to sensitize T98G GBM cells to TMZ, which was also thought to be a function of induced
p53 overexpression [20].
Mesenchymal GBM presents most prominently with deletion or mutations of the tumor
suppressor gene, neurofibromin 1 (NF-1). Similar to the proneural subtype, p53 and mutations
occur in about 32% of mesenchymal cases [13]. Genes in the tumor necrosis factor superfamily are
also overexpressed, correlating with the high degree of necrosis observed [13]. Mesenchymal GBM
also shows characteristics of epithelial-to-mesenchymal transition (EMT) with high expression of
mesenchymal and astrocytic markers, such as CD44 and MERTK [13]. EMT in GBM may be induced
by hypoxia [21] or upstream regulators of EMT, including TGF-β [21] and S100A4 [22].
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A fourth subtype of GBM, the neural subgroup, has been classified due to its similarity in gene
expression to normal neurons or nerve cells. Neural GBM presents with mutations similar to the other
subgroups with no outstanding genetic amplification or mutation rates that would differentiate the
neural subgroup from the other subgroups [13]. In advanced strategies for treating GBM patients,
evaluating the expression of key genes may allow for selection of more personalized and effective
therapies. Gene targets in GBM are summarized in Table 1.
Table 1. Gene expression in glioblastoma multiforme (GBM). Common gene targets that are mutated
or upregulated in glioblastoma.
Gene Target Effect GBM Clinical Subtype References
EGFR (epidermal growth
factor receptor)
Reduction in apoptosis and increased
uncontrolled cell proliferation Classical [13,14]
PTEN (phosphate and
tensin homologue)
Activation of the P13K/Akt/mTOR




growth factor receptor—alpha) Increased tumor cell proliferation Proneural [11,13,14]
IDH-1 (isocitrate dehydrogenase 1) Alters DNA and histone methylation Proneural [17,18]
Tumor suppressor p53 Uncontrolled cell growth Proneural, mesenchymal [13,14,20]
NF-1 (neurofibromin 1) Uncontrolled cell growth Mesenchymal [13]
3. Barriers to Drug and Gene Delivery
Various drugs including TMZ, BCNU, and cisplatin have been used in patients with GBM,
but several barriers limit effective treatment, including inefficient delivery across the blood-brain
barrier (BBB) and chemotherapeutic resistance. The BBB is a cellular barrier that regulates ionic
concentrations to allow for synaptic signaling in the brain, while also preventing entry of cells and
large molecules via tight junctions between endothelial cells (Figure 1) [5,23]. It exists to regulate the
transport of essential nutrients to the brain and to protect the brain from neurotoxins. It is estimated
that less than 2% of small molecule drugs and no large molecule drugs or genes are able to cross
the BBB [24,25]. It has been found that drugs greater than 400 Da are not often able to cross the
BBB. However, this is not a finite cutoff, as peptides greater than 600 Da are known to cross the
BBB with relative ease [26], and a 7800 Da molecule, cytokine-induced neutrophil chemoattractant-1
(CNC1), is able to cross the BBB through transmembrane diffusion [27]. Crossing the BBB is highly
dependent on many other factors, such as charge, molecular weight, and hydrophobicity, creating a
non-linear relationship between size and ability to traverse the BBB [28,29]. Molecules can cross the
BBB through various active transport mechanisms, including carrier mediated influx or efflux, and
through passive transport mechanisms, including transmembrane diffusion, and paracellular transport
(Figure 1) [28,30]. Most molecules that are able to traverse the BBB do so through transmembrane
diffusion or active transport. Low molecular weight lipid-soluble molecules are favorable for passive
diffusion, whereas water-soluble molecules tend to traverse using active transport processes, including
adsorptive- or receptor-mediated transport [26]. The BBB has been a consistent challenge in creating
effective delivery systems for therapeutics. Many nanoparticle (NP) delivery systems are designed to
rely on diffusion and passive targeting of tumor tissue via the enhanced permeability and retention
(EPR) effect [30,31]. Fenestrated capillaries or a dysfunctional endothelium exist in areas of rapidly
grown and poorly developed vessels due to increased vascular endothelial growth factor (VEGF)
expression and angiogenesis [32,33]. The leaky nature of the vasculature creates an interrupted
blood-brain tumor barrier, which may allow for increased therapeutic concentrations in the glioma
tissue. However, the EPR effect may be inefficient in therapeutic delivery to brain tumors due to the
density of the tumor matrix and the increased interstitial fluid pressure inhibiting both diffusion and
convective transport [34]. Furthermore, glioma cells tend to easily travel outside the tumor to other
normal regions of the brain. This metastasis not only makes the glioma more difficult to treat, but also
141
Nanomaterials 2019, 9, 105
reduces the quantity of therapeutic reaching tumor cells in the intact regions of the brain with perfectly
functioning BBB [5].
 
Figure 1. The blood brain barrier (BBB). The BBB regulates entry of nutrients to the brain and
prevents entry of cells and large molecules via tight junctions. There are several mechanisms for
transporting molecules across the BBB, including paracellular transport, diffusion, protein transporters,
receptor-mediated transport, and adsorptive transcytosis.
Drug resistance is another major barrier in the treatment of GBM due to overexpression of
drug resistance genes. Additional protection of the BBB exists in the form of various efflux transport
systems which remove unwanted substances that are able to traverse the BBB. A largely studied
efflux pump, P-glycoprotein or multidrug resistance protein 1 (MDR1), encoded by the ATP-binding
cassette sub-family B member 1 (ABCB1) gene, has been a persistent challenge in therapeutic
delivery due to its efficacy in removing small molecules from the brain [26]. A wide variety of
ATP-dependent substrates are recognized by ABCB1, allowing for resistance to occur when therapeutics
are recognized and pumped out of the cell through the efflux pump, reducing cytotoxicity and drug
efficacy [35,36]. An MDR1a knockout study demonstrated that P-glycoprotein is a major impediment
for drug passage through the BBB, after finding significantly increased drug concentrations in the brains
of P-glycoprotein knockout mice [37]. Drug resistance in GBM patients has also been attributed in part
to overexpression of the (O)6-methylguanine-DNA- methyltransferase (MGMT) gene. The MGMT
gene codes for a protein that removes alkyl adducts at the O(6) position of guanine as a natural repair
mechanism to prevent apoptosis due to DNA methylation [38]. Although it is a natural process for
DNA repair, when MGMT is upregulated in tumor cells, this mechanism allows for drug resistance
when treating GBM with temozolomide (TMZ). TMZ alkylates DNA at the O(6) position of guanine
in order to cause DNA damage and programmed cell death [39]. In this case, the damage done
by TMZ is possibly reversed due to epigenetic or drug-induced upregulation of MGMT in GBM
cells (Figure 2). MGMT methylation status was the first predictive biomarker identified in glioma
patients [40]; additionally, Hegi et al. found that epigenetic silencing of MGMT was correlated with
longer patient survival when treated with alkylating agents and radiotherapy [39]. In attempts to
overcome current barriers to effective treatment, delivery systems for gene and drug therapies have
been researched and tested in vivo and/or in the clinic.
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Figure 2. Mechanisms of TMZ and MGMT in DNA damage and repair. TMZ, a DNA alkylating agent,
methylates DNA at the O6 position of guanine, resulting in DNA damage and apoptosis of tumor cells.
MGMT, a DNA repair protein, removes alkyl adducts from the O6 position of guanine, inhibiting the
potentially therapeutic effect of TMZ.
4. Vectors for Glioblastoma Gene Therapy
Gene therapy for cancer treatment conventionally includes the introduction of growth regulating
or tumor suppressing genes. More recently, RNA interference (RNAi) has been introduced to inhibit the
activity of oncogenes causing tumorigenesis or proliferation. Suicide gene therapy is another approach
that is commonly used in viral gene therapy to convert non-toxic prodrugs into lethal active compounds.
Other approaches include oncolytic and immunomodulatory gene therapy [41]. Gene or nucleic acid
carriers must be used to deliver these therapies successfully into tumor tissue and have been extensively
studied. Delivery vectors such as viral vectors, non-polymeric NPs, and polymeric NPs that have been
used in GBM gene therapy are discussed in detail in the following sections (Figure 3).
Figure 3. Vectors for glioblastoma gene therapy. Various viral, non-polymeric, and polymeric vectors
are used to deliver nucleic acids for GBM gene therapy.
4.1. Viral Vectors
Viral vectors were the first delivery vehicles used for gene therapy in glioma clinical trials and
have been studied for glioma gene therapy over the past 25 years. Viral vectors commonly used for
GBM gene therapy in clinical trials include neurotropic retroviruses [42] and adenoviruses [43] that are
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able to infect neurons and glial cells, such as herpes simplex virus-1 (HSV-1) [44]. Adeno-associated
viruses have recently shown promise for gene therapy in treating gliomas in preclinical trials, but have
not yet been evaluated in clinical trials [45–47]. Current and completed clinical trials using various
vectors for gene therapy in glioblastoma treatment have been outlined in Table 2.
Retroviral vectors were the first delivery systems evaluated in clinical trials for glioma gene
therapy. The initial trial evaluated the combination of modified murine cells containing retroviral
herpes simplex virus-thymidine kinase (HSV-tk) with ganciclovir (Cytovene) and began in 1992
(NCT00001328). HSV-tk functions as a suicide gene and converts the prodrug, ganciclovir, into its active
form, ganciclovir-triphosphate, which inhibits DNA replication and cell division in HSV-tk-transfected
cells [48]. The results of the study demonstrated intratumorally implanted retroviral vector-producing
cells mediated HSV-tk transfection and antitumor activity only in the smaller treated tumors [49],
reflecting the limited transfection efficiency of the retroviral vector. Another retroviral vector, Toca
511 delivers suicide gene, cytosine deaminase (CD), and in combination with oral prodrug, Toca
FC, the CD enzyme mediates conversion of 5-fluorocytosine into the active antineoplastic drug,
5-fluorouracil [50,51]. Phase I clinical trials demonstrated that Toca 511 and Toca FC were well tolerated
and mediated tumor regression in the infusion site in patients with recurrent high-grade glioma [52].
Toca 511 and Toca FC currently make up a regimen in phase 2/3 clinical trials for the treatment of GBM
and anaplastic astrocytoma.
Adenoviral vectors have also been widely evaluated in clinical trials. A phase 1 trial of an
adenoviral vector carrying the wild-type p53 gene (Ad-p53) demonstrated that Ad-p53 successfully
transfected astrocytic tumor cells with minimal toxicity when intratumorally injected pre- and
post-resection of the glioma tumor; however, transfected cells were only detected on average within
5 mm of the injection site [53], demonstrating the limited ability of the therapeutic to penetrate the tumor
tissue. Another study compared combination therapy using ganciclovir and intratumoral injection
of HSV-tk delivered either by retrovirus-packaging cells or adenoviruses in patients with malignant
glioma. The results revealed stable tumor in 3/7 patients treated with the adenovirus compared to tumor
progression in all patients treated with the retrovirus three months post-treatment [54]. Additionally,
survival time nearly doubled in patients treated with adenovirus compared to retrovirus, with averages
of 15 months and 7.4 months, respectively [54]. Sandmair et al. concluded that ineffectiveness of
retroviruses may be due to low transfection and brain tumor penetration [54]. Several clinical studies
have also evaluated the delivery of an adenoviral vector containing HSV-tk (AdV-tk) combined with
valacyclovir, an antiherpetic prodrug. Using gene-mediated cytotoxic immunotherapy, thymidine
kinase mediates conversion of the prodrug into toxic nucleotide analogs, inducing tumor cell death and
activation of antitumor immune cells [55]. A Phase 1B study of AdV-tk with concurrent valacyclovir
and radiation therapy followed by TMZ was conducted in patients with recently diagnosed malignant
glioma [55]. AdV-tk injected into the tumor bed post-resection followed by radiation and chemotherapy
resulted in two and three-year survival rates of 33% and 25% [55], respectively, a small increase over
the current standard of care. Of note, CD3+ T-cells were found in tumors analyzed post-treatment [55],
indicative of immune activation. A phase 2 trial showed that median survival time significantly
increased from 13.5 months for patients that received the standard of care treatment to 17.1 months
for patients treated with AdV-tk combined with valacyclovir and standard of care [56]. Additionally, a
Phase I trial of AdV-tk with combination valacyclovir and radiation therapy was recently conducted in
pediatric malignant glioma and recurrent ependymoma [57]. Half of the patients survived at least 16
months post-treatment with no dose-limited toxicities, though grade 3 lymphopenia was common [57].
Although viral vectors have been studied extensively, they have only resulted in marginal
increases in overall survival and have yet to achieve clinical translation through FDA approval to treat
patients with GBM after decades of study. Efficient tumor penetration of viral vectors has proven to be
a challenge limiting overall efficacy in treating gliomas. However, there has been some clinical success
with viral vectors in other cancers. Talimogene laherparepvec is an oncolytic virotherapy consisting of
genetically modified HSV-1 containing the human granulocyte-macrophage colony-stimulating factor
(GM-CSF) gene and has been FDA approved for the treatment of melanoma [58].
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4.2. Non-Viral Vectors
In addition to viral vectors, non-viral vectors, including both non-polymeric and polymeric delivery
systems (Figure 3), have been explored for delivery of glioma gene therapy and have shown promise as
gene vectors for glioma treatment in preclinical and clinical studies. Though these vectors have yet to
achieve FDA approval for treatment of GBM, the 2018 approval of the first RNAi therapeutic, Patisiran,
a lipid nanoparticle containing siRNAs for the treatment of transthyretin-mediated amyloidosis [59],
a neurodegenerative disease, provides a promising outlook for non-viral vector-based nucleic acid
therapies. A few non-polymeric vectors have been evaluated clinically for GBM gene therapy, including
liposomes, gold nanoparticles, and RNA nanoparticles. SGT-53, a transferrin receptor-targeted liposomal
vector encapsulating wild-type p53 plasmid DNA is able to cross the BBB and target GBM cells,
resulting in a reduction of MGMT and apoptosis in GBM xenografts in mice [60]. Combination
therapy with systemically administered SGT-53 and TMZ enhanced antitumor efficacy compared
to TMZ alone [60,61], demonstrating the ability of SGT-53 to improve chemosensitivity. SGT-53 is
currently in phase II clinical trials for combination therapy with TMZ in treating recurrent glioblastoma
(see Table 2). Additionally, NU-0129, a spherical nucleic acid gold nanoparticle containing siRNAs
targeting Bcl-2-like protein 12 (Bcl2L12), which is involved in tumor progression and resistance to
apoptosis [62], is in early phase 1 clinical trials for patients with recurrent glioblastoma or gliosarcoma.
NU-0129 has previously demonstrated its ability to cross the BBB in xenograft models of GBM in
mice after systemic administration, resulting in increased apoptosis of tumor cells and reduced tumor
progression [62]. In addition to clinical studies, novel polymeric vectors are being explored in research,
such as RNA nanoparticles. RNA nanoparticles completely composed of RNA have been used in
preclinical studies for glioma gene therapy. Croce et al. reported using RNA nanoparticles to deliver
anti-miR-21 locked nucleic acid sequences to inhibit oncogenic miR-21 in xenograft GBM models in
mice, resulting in tumor regression and increased survival compared to untreated mice [63]. Though
still in their preclinical stages of development, RNA nanoparticles have shown promise for gene delivery
in cancer treatment [64].
4.3. Polymeric Delivery Systems
Polymeric delivery of gene therapy is an emerging approach for cancer treatment to improve
therapeutic outcomes. Current research has been focused on micro- and nanoparticles for the systemic
or local delivery of genes and/or drugs. These NPs are advantageous for gene therapy because
they are highly tailorable, allowing for conjugation of nucleic acids, homing peptides, or targeting
ligands. Though they have not yet reached clinical trials specifically for glioblastoma treatment, several
polymeric delivery systems have been studied for use in gene therapy for glioma treatment, and
are discussed in detail as follows, including their advantages and limitations. The advantages and
disadvantages of various vectors that have been studied for glioblastoma gene therapy are summarized
in Table 3.
4.3.1. Dendrimers
Dendrimers are highly branched 3D polymers that have been explored for a variety of applications
in drug and gene delivery. Cationic dendrimers, such as poly(amidoamine) (PAMAM), are particularly
useful for gene therapy in glioma treatment due to their ability to form complexes with negatively
charged nucleic acids, penetrate cellular and endosomal membranes, and cross the BBB. Dendrimers
have been used to deliver several types of nucleic acids, including antisense oligonucleotides [65],
microRNAs [66], siRNAs [67], and genes [68–71] into glioma cells. Functionalized dendrimers have
demonstrated a capacity for enhanced transfection and targeted delivery in glioma cells and tissues.
Specifically, peptide functionalized dendrimers have been used to increase gene transfection in
patient-derived primary glioma cells. Bae et al. showed that PAMAM dendrimers grafted with
histidine and arginine residues enhanced transfection efficiency in glioma cells compared to PAMAM
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alone [68]. This result is likely due to the increased proton buffering capacity provided by the peptides,
resulting in enhanced endosomal escape and gene transfection. Additionally, several groups have used
PAMAM for targeted delivery of gene therapy by functionalizing the polymer with polyethylene glycol
(PEG) to attach a targeting moiety. PAMAM-PEG conjugated with transferrin [69], chlorotoxin [70], or
Angiopep-2 [71] have allowed increased distribution of therapeutics in glioma tissue after systemic
delivery in mice or rats in comparison to treatment with PAMAM-PEG alone, demonstrating the
clinical potential of ligand-conjugated dendrimers for intravenous delivery of gene therapy for glioma
treatment. However, one of the critical limitations of PAMAM dendrimers for clinical translation is
cytotoxicity due to their high positive surface charge. Studies have shown that PAMAM dendrimers
exhibit neurotoxicity by inducing autophagy in glioma cells, resulting in cell death [72]. Strategies
to mitigate this effect include reducing the surface charge through acetylation or functionalization
using PEG.




Adenovirus • Deliver large DNA
• Transient gene expression
• Elicit immune response
Retrovirus
• Transfer to dividing cells
• Sustained expression of vector
• Elicit immune response
• Unable to transfect non-dividing cells
• Low transfection rate in vivo
• Risk of insertion
Adeno-associated virus • Transfer to dividing and non-dividing cells
• Difficult to produce vectors
• Limited transgene capacity




• Ability to co-deliver gene therapy
and chemotherapy
• Ability to functionalize for targeting
• Short shelf- and half-life
• Transient gene expression
• Low transfection efficiency
• Increased cytotoxicity for
cationic lipids
Gold nanoparticles
• Multimodal use for tumor imaging
and therapy




• Self-assemble with nucleic acids
• Ability to functionalize for targeting
• Non-immunogenic
• Increased cytotoxicity for
cationic dendrimers
• Limited release of therapeutics
Polymeric micelles
• Self-assemble with nucleic acids
• Ability to functionalize for targeting
• Increased cytotoxicity for PEI and
other cationic polymers
• Low loading efficiency
Poly(β-amino ester)
• Biodegradable
• Lower cytotoxicity than other
cationic polymers
• High transfection efficiency
• Limited control over release
of therapeutics
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4.3.2. Dendrigraft
Similar to dendrimers, dendrigrafts are also dendritic structures that can be used to deliver
therapeutics. Dendrigraft poly-L-lysine (DGL) was recently discovered as a newer class of dendritic
polymers and has shown potential for delivery of nucleic acids. One major advantage of DGL over
dendrimers is that DGL is composed entirely of naturally occurring lysine residues and is therefore
completely biodegradable. Dendrigrafts are rich in external amino groups, which enables self-assembly
with nucleic acids. DGL is also non-immunogenic and has been demonstrated to cross the BBB [73].
To mediate glioma targeting, transferrin- [74] or laminin-targeted [75] peptides have been conjugated
to DGL for gene therapy with pORF-hTRAIL or survivin, respectively. The results of both studies
revealed that DGL conjugated with targeting peptides exhibits enhanced tumor targeting and long-term
survival in xenograft mouse models of U87 human glioblastoma in comparison to non-targeted
DGL [74,75]. Transferrin-targeted DGL has also been used successfully for RNAi therapy. Kuang et
al. demonstrated that transferrin-targeted DGL mediates increased gene silencing in mouse glioma
tissue in comparison to non-targeted DGL [76]. In another study, a cell-penetrating peptide conjugated
to DGL for delivery of pcDNA3.1-ING4, a plasmid encoding tumor suppressor gene inhibitor of
growth 4 (ING4), demonstrated enhanced apoptosis of U87 tumor cells and resulted in increased
survival of mice in comparison to treatment with DGL/pDNA [77]. DGL has also been used for
combination delivery of a drug and gene. Li et al. demonstrated that choline-targeted DGL delivers
pORF-hTRAIL and doxorubicin to glioma tissue in mice [78]. Similar to dendrimers, the cytotoxicity
of DGL is a major disadvantage due to its excessive cationic charge. Studies have shown that the
cytotoxicity of DGL/nucleic acid complexes increases in a dose-dependent manner and also results in
hemotoxicity [79,80]. To overcome this limitation, toxicity of DGL can be reduced by including anionic
polymers [80] or through PEGylation [81]. Though studies with dendrigrafts are relatively new and
still evolving, data thus far has shown their potential clinical applicability for nucleic acid delivery in
the treatment of gliomas.
4.3.3. Polymeric Micelles
Polymeric micelles are amphiphilic copolymers that have a core/shell structure. They have been
widely used for cancer drug delivery [82], but have recently been explored for delivery of nucleic acids
and shown promise for treatment of gliomas. Cationic polymers, such as polyethyleneimine (PEI),
are commonly combined with hydrophobic polymers for combination delivery of negatively charged
nucleic acids and hydrophobic cancer drugs. Cheng et al. demonstrated that a folate (FA)-targeted
micelle consisting of PEI and polycaprolactone (PCL) mediated co-delivery of BCL-2 siRNA and
doxorubicin in C6 glioma tumors in rats, resulting in increased apoptosis and inhibition of tumor
growth following intratumoral injection [83]. In another study, to reduce the cytotoxic effect of PEI
as well as enable active targeting, FA- was conjugated to hyperbranched PEI (FA-PEG-PEI) using
PEG as spacer for combination gene therapy with CD/5-FC and TRAIL [84]. The results showed
increased anticancer activity in C6 glioma tissue in rats after intratumoral delivery compared to
treatment with a single therapeutic [84]. An RGD-conjugated PEI-PEG micelle used to co-deliver
pORF-hTRAIL and paclitaxel in mice with orthotopic glioblastoma significantly enhanced survival
in comparison to mice treated with gene therapy alone [85]. Additionally, intravenous delivery of
PEI-PEG conjugated to a tumor homing peptide targeting neuropilin-1, retro-inverso C-end rule
(CendR) peptide D(RPPREGR), enhanced gene transfection efficiency in mice with U87 glioma over
non-targeted PEG-PEI [86]. Although PEGylation of PEI reduces cytotoxic effects, it can also reduce
transfection efficiency by hindering proton buffering capacity. To overcome this limitation, PEI can be
reversibly shielded using degradable disulfide (SS) linkages. Lei et al. conjugated RGD peptide to PEI
through PEG using a reversible disulfide linkage (RGD-PEG-SS-PEI) for treatment of mice with U87
glioblastoma [87]. Results showed that the reversibly shielded PEI increased gene expression in the
mouse brain in comparison to irreversibly shielded RGD-PEG-PEI [87], demonstrating the potential of
reversible shielding for reducing cytotoxicity of PEI while maintaining efficient transfection.
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4.3.4. Poly(β-amino ester)
Poly(β-amino esters) (PBAEs) are another class of cationic polymer that were designed to meet
specific criteria for gene delivery, including DNA condensation, biodegradability, and minimal
cytotoxicity [88], PBAEs may contain different types of amines and can be synthesized to create
large libraries of polymers using combinatorial chemistry, allowing high-throughput screening of
hundreds of polymers and identification of optimal vectors for gene delivery [89]. Research has shown
that optimal PBAE vectors can transfect up to 90% of primary GBM cells and mediate up to 85% gene
silencing with minimal cytotoxicity [90]. Further, PBAEs have been used as vectors for local injection
of therapeutics. PBAE nanoparticles have been proven to penetrate glioma tissue for gene delivery
using various strategies. For example, intratumoral injection was used to deliver DNA-containing
PBAE nanoparticles in rat models of 9L gliosarcoma [91]. Convection-enhanced delivery (CED) is
another local delivery strategy that allows administration of a therapeutic into glioma tumor tissue
through catheters placed directly in the tissue with infusion occurring over the course of several hours.
CED has been used for PBAE-mediated DNA delivery combined with intraperitoneal administration
of ganciclovir in mouse xenograft models of primary brain tumor-initiating cells [92]. To enhance
brain penetration, modification of PBAE nanoparticles with PEG has been explored. Mastorakos et
al. demonstrated that PEGylated PBAEs could penetrate brain tissue with 20-fold greater volume
distribution following CED in comparison to non-PEGylated particles [93]. One of the disadvantages
of PBAEs involves their mechanism for cargo release. PBAEs release their cargo through hydrolysis of
ester bonds, which can occur over many hours to a couple days [94], resulting in lack of controlled
release of therapeutics. To overcome this limitation, bioreducible PBAEs have been synthesized
containing disulfide bonds with the ability to trigger release of siRNAs into the cytoplasm [95]. Thus
far, PBAEs have shown promise in overcoming limited tissue distribution, a common barrier in clinical
applications of local gene therapy. Further research demonstrating enhanced tissue-penetration using
PEGylated PBAEs in a glioma model will allow further assessment of the clinical potential of PEGylated
PBAEs for local gene therapy of gliomas.
5. Conclusions
Glioblastoma multiforme is a common and currently incurable brain cancer that desperately
needs new treatment modalities to improve patient outcomes. The current standard of care including
surgical resection, adjuvant chemotherapy, and radiation does not result in remission for the majority
of patients. Barriers limiting efficacy include inefficient delivery across the BBB and therapeutic
resistance. Gene therapy represents an approach to specifically target and regulate oncogenes and
tumor suppressor gene in gliomas. Further, gene therapy can be used to overcome barriers such as
chemotherapy resistance by downregulating resistance genes or using approaches such as suicide gene
therapy. Viral vectors, including retroviruses and adenoviruses, have been evaluated in clinical trials
of GBM for the past few decades for delivery of therapeutic genes or nucleic acids in combination with
other therapeutics. However, viral vectors have not reached clinical approval due to immunogenicity,
limited tumor penetration and marginal improvement in patient outcomes. Non-viral delivery is
an evolving alternative approach that may be used to overcome the barriers of gene delivery. Many
non-viral vectors, including polymeric and non-polymeric vectors, are non-immunogenic and can
be functionalized with targeting moieties to increase receptor-mediated uptake of vectors into tumor
tissue. Multifunctional and multimodal non-polymeric vectors, such as liposomes and gold NPs,
respectively, have the ability to co-deliver multiple therapies or be used for tumor imaging as well as
therapy. Cationic polymeric vectors have the ability to self-assemble with nucleic acids, enhancing
their ease of use for gene therapy over other vectors. Moreover, polymeric vectors such as PBAE,
have demonstrated potential for improving tissue penetration, one of the largest barriers to increasing
efficacy of gene therapy vectors in glioblastoma. To date, only a few non-viral vectors have been
evaluated in clinical trials for GBM; however, further evaluation of non-viral vectors in clinical trials in
the future may provide advanced treatment strategies for gene therapy in glioblastoma.
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Abstract: Genetically encodable sensors have been widely used in the detection of intracellular
molecules ranging from metal ions and metabolites to nucleic acids and proteins. These biosensors
are capable of monitoring in real-time the cellular levels, locations, and cell-to-cell variations of the
target compounds in living systems. Traditionally, the majority of these sensors have been developed
based on fluorescent proteins. As an exciting alternative, genetically encoded RNA-based molecular
sensors (GERMS) have emerged over the past few years for the intracellular imaging and detection of
various biological targets. In view of their ability for the general detection of a wide range of target
analytes, and the modular and simple design principle, GERMS are becoming a popular choice for
intracellular analysis. In this review, we summarize different design principles of GERMS based
on various RNA recognition modules, transducer modules, and reporting systems. Some recent
advances in the application of GERMS for intracellular imaging are also discussed. With further
improvement in biostability, sensitivity, and robustness, GERMS can potentially be widely used in
cell biology and biotechnology.
Keywords: RNA aptamers; biosensors; live-cell imaging; fluorogenic RNA; riboswitch; ribozyme
1. Introduction
The detection and quantification of cellular proteins, nucleic acids, and metabolites is critical in
understanding cellular signaling pathways and many other physiological processes. These cellular
molecules are tightly regulated in living systems. Both their cellular levels and distributions play
essential roles for their biological functions. As a result, the development of sensors to characterize the
spatial and temporal distributions of cellular targets and to accurately quantify their cellular levels has
been a major focus in current biochemical studies [1–3].
Although the expression levels of many biomolecules can be measured using traditional methods
such as gel electrophoresis, mass spectrometry, liquid chromatography, and NMR spectroscopy [4],
most of these techniques require complex pre- and post-treatments on cells and can only deal with
cell lysates. These in vitro assays provide limited information on the cellular distributions, live-cell
dynamics, or cell-to-cell variations of the target analytes.
Fluorescence imaging, on the other hand, overcomes most of these challenges [5–7]. Synthetic
fluorescent compounds, such as fluorescein, rhodamine, BODIPY, and cyanine, have been widely used
as reporters in developing small-molecule sensors for cellular imaging [8–16]. However, the limited
biocompatibilities, cellular interferences, and cellular distributions of these non-natural compounds
remain major issues that limit their actual biological applications [17–19].
Sensors based on naturally occurring proteins or RNA molecules could potentially address
these issues in cellular analysis. For example, fluorescent protein (FP)-based sensors were developed
soon after the isolation of green fluorescent protein (GFP) from the luminous organ of the jellyfish
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Aequorea victoria [20,21]. FP-based Förster resonance energy transfer (FRET) sensors have advanced
the field of bioimaging by quantitatively detecting various classes of targets in living systems [22–26].
However, many critical cellular targets cannot be feasibly detected using these protein-based sensors.
This fact is largely due to the limited choice of protein domains that can selectively bind to the target
molecules, which should also induce conformational changes that lead to significant FRET changes.
Furthermore, the detection range and the signal-to-noise ratio of many FP-based sensors are not ideal
for the cellular imaging and detection of target biomolecules [27,28].
Recently, an alternative class of RNA-based fluorescent biosensors has been developed for
intracellular applications [29–32]. In general, these Genetically Encoded RNA-based Molecular Sensors
(GERMS) consist of three components: a recognition module, a reporting system, and a transducer
module. The recognition module, such as an RNA aptamer (RNA aptamers will be described in
more depth in Section 4.1), is an RNA sequence that can specifically recognize target molecules and
bind to them with a high affinity [33,34]. The reporting system is normally a fluorescent protein or
a fluorogenic RNA aptamer that can bind and induce the fluorescence of its cognate small-molecule
dye [35,36]. The transducer module is used to connect the recognition module and the reporting system.
These transducers act as switches that can convert target binding events into detectable signals [37].
These novel RNA-based sensors can be genetically encoded and transcribed by cells on their own
for long-term studies. GERMS can be easily and rationally modified for the detection of a wide range
of target molecules with good selectivity and sensitivity. These genetically encodable sensors have
shown promising potential in detecting intracellular RNAs, proteins, metabolites, signaling molecules,
and metal ions [29,30,32,38–41]. GERMS have started to be used to monitor cellular signaling pathways
as well as other biological processes [41,42]. There are several great reviews and articles about the
design and application of RNA-based nanodevices [43–49]. In this review, we will focus on a specific
emerging group of RNA devices that can be genetically encoded for the intracellular detection of
biological analytes. We will first illustrate how to design and engineer the three components of GERMS:
the recognition module, transducer module, and reporting system. Recent examples will be further
provided to demonstrate the intracellular applications of these novel RNA-based sensors.
2. Transducer Modules in GERMS
Because GERMS are used to sense essential biomolecules in live cells, a fundamental question
arises: How do GERMS recognize the target molecules and then provide a corresponding signal?
The transducer module couples the recognition module with the reporting system in order to realize
the entire sensing process. These RNA-based transducers provide an additional layer of modulation to
permit an efficient signal transmission. In this section, we will discuss existing transducer modules in
the design of GERMS.
2.1. RNA Duplex Formation or Helix Slipping
In the general design of GERMS, target binding to the recognition module triggers a conformational
change in the transducer module, adjusting the activity of the reporting system. One of the most
straightforward conformational changes in RNA devices is the folding and unfolding of a duplex
structure (Figure 1A). A duplex formation based on the Watson-Crick or wobble base pairs can be
rationally designed as the bridge between the recognition module and the reporting system. Indeed, as
demonstrated in the crystal structures of several naturally occurring riboswitches, the most common
target binding-induced RNA structural changes are the formation of new duplex regions or the
disruption of existing duplexes [50]. In addition, the folding and activation of many reporting systems
in GERMS, such as the fluorogenic RNAs, ribosomal binding sites, and transcriptional activators,
can also be tuned merely by the formation of a duplex. As a result, duplex formation is one of the
most popular and powerful transducer modules in developing allosterically controlled RNA devices,
including GERMS.
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Figure 1. Schematics of different types of transducer module in GERMS. (A) The target binding-induced
proper folding of the recognition module (blue) can trigger the formation of RNA duplexes (red),
which further activate the reporting system (green). (B) The target binding induces helix slipping in the
transducer module (red) to generate the signal. (C) Similar to natural riboswitches, the target binding
induces the strand displacement of the transducer sequence (red) from the recognition module (blue)
to the reporting system (green). (D) The target binding induces the folding (red) and activation of a
hammerhead ribozyme to induce the catalytic cleavage and activation of the reporting system (green).
Helix slipping is another strategy to regulate the formation of the duplex. Helix slipping is a
local nucleotide shift in the transducer region. Here, target binding induces a structural change in the
recognition module, leading normally to shifts in only one or two nucleotides in the transducer helix,
which further activates the reporting system, such as a ribosomal binding site (Figure 1B). The rationale
behind this helix slipping principle is that even in the absence of a target, the transducer module
should preferably still form a structure, instead of a free form, to better inhibit the activity of the
reporting system. As a result, a large signal-to-noise ratio will be realized after the slipping.
2.2. RNA Strand Displacement
The structural rearrangement of the transducer module can also be realized through a strand
displacement reaction. Strand displacement-based RNA signal transductions have been widely used
in natural riboswitches. Riboswitches are regions in mRNAs that contain a specific evolutionarily
conserved target-binding aptamer domain and an expression platform that enables the regulation
of the downstream transcription or translation. The competitive binding of a transducer sequence
to either a switching sequence in the aptamer domain or the expression platform is critical for the
function of riboswitches (Figure 1C). For example, in a naturally abundant thiamine pyrophosphate
(TPP) riboswitch, the addition of TPP allows for the formation of a TPP-binding pocket in the aptamer
domain, which displaces the transducer sequence, further allowing the formation of an expression
platform duplex to inhibit the translation [51].
In general, target binding with riboswitches will alter the relative stability or accessibility of
the RNA duplex involved in the displacement reaction. As a result, new thermodynamically more
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stable duplexes will replace the previously favorable conformations. If the newly formed structure
can induce the activation of a reporting system, such strand displacement reactions can be used to
engineer RNA-based sensors.
Inspired by the mechanism of these naturally evolved riboswitches, synthetic riboswitches
have been engineered into biosensors to detect different biological targets. Here, artificial aptamer
domains and synthetic expression platforms are conjugated based on a strand displacement reaction.
Computational predictions of the RNA folding and energy landscapes are often used in the generation
of these synthetic biosensors. For example, an automated design model has been engineered to generate
synthetic riboswitches from aptamers that can activate the translation initiation by up to 383-fold [52].
Statistical thermodynamics models have been made to measure the sequence-structure-function
relationships to convert synthetic RNA aptamers into translational regulating riboswitches [53].
There are several factors determining the efficiency of such synthetic riboswitches, including their
target-binding affinities, overall induced conformational changes, target and RNA expression levels,
interactions with ribosomes and other protein/RNA complexes, as well as the macromolecular
crowding effect. Due to the existence of these complex factors, the intracellular and in vivo behaviors
of many synthetic riboswitches are still not easily predictable. In situ experimental optimizations are
often necessary. It is expected that the further development of advanced computational tools and
simplified high-throughput in vivo screening approaches will dramatically improve the performance
of these synthetic riboswitch tools.
2.3. Ribozyme-Based Transducers
The transducer modules of GERMS can also stem from catalytic cleavage functions, as shown in
naturally occurring RNA ribozymes. For example, the hammerhead ribozyme is the most widely studied
natural catalytic RNA for this purpose [54–56]. The minimal catalytic domain of a hammerhead ribozyme
comprises three duplexed stem regions. The proper folding of all these three regions is required for the
catalytic self-cleavage of the hammerhead ribozyme. By fusing a target-binding recognition module
and a reporting system into two of the three stem regions, the hammerhead ribozyme can function as
a transducer in developing RNA-based sensors (Figure 1D). Here, a target-bound recognition module
activates the ribozyme so that it self-cleaves and releases the reporting system from the original
connection. As a result, biological analytes can allosterically regulate the reporting system in a highly
modular pattern. The structure and function of hammerhead ribozymes have been well characterized
with rapid kinetics, simple design, and small sizes [57]. Ribozyme-based transducers have been
engineered for the in vitro and intracellular measurement of many metabolites [54,58], as well as for
intracellular gene regulation [55,56].
In addition to hammerhead ribozymes, several other ribozymes have been identified as potential
platforms for engineering the transducer modules. Most of these ribozymes, including twister ribozymes,
twister sister ribozymes, pistol ribozymes, Varkud satellite ribozymes, and hairpin ribozymes [59–62],
are known as “small self-cleaving ribozymes” ranging between 50 and 150 nucleotides in length [63].
Having been evolved directly in the living system, these ribozyme scaffolds will likely still function
properly after incorporation into genetically encoded RNA devices. The diverse choice and advantageous
small sizes of these ribozyme units can be potentially useful for the generation of versatile GERMS, and in
the detection of a wide range of cellular targets.
3. Reporting Systems in GERMS
3.1. Protein-Based Reporters
As mentioned above, fluorescent protein-based sensors have revolutionized cellular imaging.
Fluorescent proteins like GFP have been widely used as genetically encodable tags that can be fused
to virtually any protein molecules. Various fluorescent proteins with optimized physical and optical
properties have been evolved, providing a rich toolbox to study cell biology. Fluorescent protein-based
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reporting systems are straightforward choices in engineering RNA-based genetic devices. Similar to
that shown in synthetic riboswitches, the target recognition module and transducer module can be
inserted into transcripts encoding fluorescent proteins. As a result, variations in the cellular target
levels will lead to changes in the cellular fluorescence.
Luciferase-induced luminescence signals have also been used to report the efficiency of RNA-based
devices. Luciferase is a class of enzymes that can emit light by oxidizing their small-molecule luciferin
substrates. Without the light excitement that induces cellular auto-fluorescence, the luciferase-based
reporting system can provide a better signal-to-noise ratio than that of fluorescent protein reporters.
Furthermore, luciferase signals can be easily quantified [64]. Being widely used for in vitro analysis,
the intracellular functions of these bioluminescent systems can be hindered by their overall dim signals,
limited choice of wavelengths, and due to the limited availability of the luciferin substrates [65].
To realize such an RNA-based regulation of the protein expression, the RNA sensors normally
function at the cotranscriptional level (by alternating RNA splicing or intron synthesis) [66–68],
the post-transcriptional level (by regulating mRNA stability or availability) [69–73], or the translational
level (by controlling the initiation, termination, and specificity of translation) [74–77]. In addition
to the relatively low signal-to-noise ratio, one major challenge is the limited temporal resolution of
such fluorescent protein or luciferase-based reporters. This is mainly due to the time required for the
translation and for nascent fluorescent proteins or enzymes to mature into their activated forms.
3.2. Fluorogenic RNA Complexes
Fluorogenic RNA complexes are composed of a fluorogenic aptamer and a small-molecule
chromophore that exhibit fluorescence when bound together [78]. A fluorogenic RNA aptamer is a
short nucleic acid strand that can specifically bind to and activate the fluorescence of its corresponding
chromophore. For example, Spinach (Figure 2A,C), an RNA mimic of GFP, is one of the most popular
fluorogenic aptamers in developing GERMS [35]. Spinach binds to a DFHBI chromophore and turns
on its fluorescence. DFHBI (Figure 2F) is cell membrane permeable and has a low cellular background
signal. After genetically conjugating Spinach to the target RNA molecules, DFHBI can be added
externally to track the cellular locations and concentrations of the RNA targets.
Spinach can also be engineered as the reporter for the detection of metabolites and proteins.
There is a sequence-independent stem region in Spinach that plays an important structural role in
the activation of the DFHBI fluorescence [29]. By fusing a target-binding aptamer and a transducer
module into this stem region, the binding of the target will fold the aptamer and subsequently stabilize
the stem of Spinach to exhibit fluorescence [29]. It is critical that the target-binding aptamers should
be unstructured until they are bound to the target. These Spinach-based RNA sensors can be used to
detect concentration variations of the targets in real time both in vitro and in living cells [79].
To improve the folding of Spinach, the systematic mutagenesis of the original Spinach RNA has
led to the development of Spinach2 [80]. Spinach2 exhibits a brighter fluorescence and increased
thermal stability than Spinach in living cells [80]. Another notable Spinach derivative is named Baby
Spinach [81]. The shortened sequence of Baby Spinach reduces the overall size of the Spinach tag,
which may allow for the incorporation of multiple fluorogenic RNAs for cellular tracking, and which
may increase the cellular biostability of these fluorogenic RNA complexes [81].
To improve the intracellular folding and brightness of these fluorogenic RNA complexes,
fluorescence-activated cell sorting (FACS) has been used to identify Broccoli (Figure 2B) [79]. Broccoli
is a short sequence, which shows increased folding and fluorescence in cells, even at low magnesium
levels, making it a suitable option for live-cell imaging. A particularly useful version of Broccoli in
engineering biosensors is called Split-Broccoli, where the Broccoli fluorescence is activated only upon
the reassembly of two split pieces of Broccoli RNA [82]. For example, Split-Broccoli can be used to
visualize intracellular RNA-RNA hybridizations with faster kinetics than fluorescent protein-based
reporters [82].
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Another recent advance in these fluorogenic RNA complexes is the Corn/DFHO system [83].
This complex is unique in its high photostability and red-shifted fluorescence emission. For example,
in imaging the activities of RNA Polymerase III in live mammalian cells, a better performance has
been demonstrated in Corn than in Broccoli [83].
Similarly, several other fluorogenic RNA complexes have been developed as potential reporting
systems in engineering GERMS. For example, RNA Mango (Figure 2D) is a class of fluorogenic RNA
aptamers that exhibits a bright fluorescence when bound to TO1-biotin (Figure 2E) or TO3-biotin
dyes [84]. Mutagenesis of the original Mango I aptamer has resulted in the generation of Mango II,
Mango III, and Mango IV aptamers with optimized fluorescence intensities, chromophore-binding
affinities, and a salt dependency [85]. In another example, the binding of a DNB or SRB-2 aptamer can
separate and activate the fluorescence of a sulforhodamine-dinitroaniline (SR-DN) dye-quencher pair,
exhibiting a bright orange/red fluorescence for intracellular imaging [86,87].
Figure 2. 2D/3D structures of fluorogenic aptamers and the chemical structures of their ligands.
(A) Spinach aptamer 2D structure. (B) Broccoli aptamer 2D structure. (C) Spinach aptamer 3D structure [88].
(D) Mango aptamer 3D structure [85]. (E) Mango aptamer’s cognate dye TO1-Biotin. (F) Spinach and
Broccoli aptamers’ cognate dye DFHBI.
Table 1 summarizes the commonly used fluorogenic RNA complexes that can be used as potential
reporters for the sensor development [89]. Right now, these fluorogenic RNA complexes are still far
less versatile than the existing fluorescent protein toolbox. However, with the rapid development of
brighter, more photostable, and multi-color fluorogenic RNA complexes, we expect that more sensitive,
multiplexed, and quantitative imaging can be achieved by these direct RNA-based reporting systems.
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Table 1. Commonly used fluorogenic RNA complexes and their spectral properties.
Aptamer Fluorophore KD (nM) Ex./Em. (nm) ε (M−1cm−1) a Φ b Brightness c
Spinach [35] DFHBI 540 469/501 24,300 0.72 100
Spinach2 [31] DFHBI 530 447/501 22,000 0.72 91
Spinach2 [31] DFHBI-1T 560 482/505 31,000 0.94 167
Spinach2 [31] DFHBI-2T 1300 500/523 29,000 0.12 20
Broccoli [79] DFHBI-1T 360 472/507 29,600 0.94 159
Corn [83] DFHO 70 505/545 29,000 0.25 41
Mango [84] TO1-Biotin 3.2 510/535 77,500 0.14 62
Mango [84] TO3-Biotin 5.1 637/658 9300 N/A d N/A
Mango II [85] TO1-Biotin 0.7 510/535 77,000 0.2 88
Mango III [85] TO1-Biotin 5.6 510/535 77,000 0.56 247
Mango IV [85] TO1-Biotin 11.1 510/535 77,000 0.42 185
DNB [87] SR-DN 800 572/591 50,250 0.98 282
SRB-2 [86] SR-DN 1400 579/596 85,200 0.65 317
a ε—Extinction Coefficient. b Φ—Quantum Yield. c Brightness—Extinction Coefficient × Quantum Yield relative to
Spinach-DFHBI. d N/A—Not Available.
4. Recognition Modules in GERMS
The target-specific recognition module is another critical unit in GERMS. In general, to detect
cellular nucleic acid targets, RNA strands with complementary sequences can be directly used as
highly specific recognition modules. On the other hand, for most non-nucleic acid targets, RNA
aptamers can be engineered as the recognition modules in GERMS.
4.1. Aptamers and Conventional SELEX
Aptamers, first reported in 1990 [90,91], are oligonucleotide strands that have a high binding
affinity and specificity toward their targets. Aptamers can be comparable with antibodies in many ways.
Aptamers can be either selected from a large random library pool using Systematic Evolution of Ligands
by EXponential enrichment (SELEX) or directly adapted from naturally existing riboswitches [90–95].
Depending on the sequence, RNA aptamers can form diverse and intricate three-dimensional
structures, allowing them to tightly and specifically bind with various biological targets.
SELEX has been widely used in aptamer selection. In general, SELEX begins with a chemically
synthesized DNA library. The library contains numerous (normally 1014–1015) oligonucleotides with
a random sequence in the same region, which is flanked by known fixed sequences. After the PCR
and in vitro transcription of the synthetic DNA library into an RNA library, several selection steps are
introduced to remove unwanted unbound oligonucleotides. The RNA sequences that are bound to
the target are then released and reverse transcribed into DNA, before being further amplified by PCR.
Such multiplied DNA molecules are then transcribed, in vitro, back into RNA, and a new selection
round begins. Up to 20 selection rounds are usually performed in conventional SELEX to enrich
aptamers with a high target binding affinity. Negative and counter SELEX are often processed at the
same time to ensure a selective binding toward the target [96].
Using SELEX, RNA aptamers have been identified toward various targets, ranging from metal
ions (e.g., Co2+) [97], small organic molecules (e.g., amino acids [98], ATP [99], antibiotics [100],
vitamins [101], and organic dyes [102]), to proteins (e.g., thrombin [103], transcription factors [104], and
HIV-associated proteins [105]), and even to entire cells or microorganisms (e.g., virus and bacteria [106]).
Through the SELEX procedure, RNA aptamers can be generated toward essentially almost any type
of biomolecule.
4.2. Advanced SELEX Approaches for GERMS
In addition to the conventional SELEX procedure, several other advanced SELEX methods have
been developed that are particularly suitable for engineering GERMS. Among others, three notable
methods are Capture-SELEX, ribozyme-based SELEX, and graphene oxide-based SELEX.
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Capture-SELEX is different from conventional SELEX in that it does not require the immobilization
of the target compounds to beads or surfaces [107]. In a regular Capture-SELEX method (Figure 3A),
short capture DNA strands are first attached to the surface of magnetic beads, and then an
oligonucleotide library is immobilized to the beads by binding to the capture strands through the fixed
sequence region in each oligonucleotide. By adding a solution of the solvated target, aptamers that
can bind to the target and undergo conformational changes to displace the capture strands are then
eluted for further enrichment. This method opens opportunities for RNA aptamer selection against
target molecules that cannot be easily immobilized or chemically modified, such as several small
metabolites and signaling molecules. In addition, similar to riboswitches, the identified aptamers
in the Capture-SELEX have been already optimized to respond to target binding by changing the
RNA conformation, which is important for sensor development. Instead of merely screening for the
recognition module, Capture-SELEX allows the direct identification of both the recognition module
and the transducer module for the development of GERMS.
Figure 3. Schematics of advanced SELEX approaches for GERMS. (A) In a Capture-SELEX, an RNA
library is immobilized on the surface of beads via the attached short capture DNA. RNA aptamers that
can bind with the target and undergo conformational changes will be eluted and further amplified.
(B) In a graphene oxide SELEX, target unbound RNA strands adsorb onto the surface of graphene oxide
and separate from target-binding aptamers. (C) In a ribozyme-based SELEX, target-binding aptamers
induce the catalytic self-cleavage of the ribozyme. Based on the band shift in gel electrophoresis,
aptamer-containing constructs can be isolated from the RNA pool.
Ribozyme-based SELEX is another powerful method for developing RNA-based sensors. As mentioned
above, ribozymes are naturally occurring RNA strands that can catalytically trans- or cis-cleave at a
particular position or sequence [108]. One potential challenge in performing small molecule-targeting
by SELEX is that these small targets normally cannot lead to significant conformational or property
changes between the bound complexes and the free aptamers. Ribozyme-based SELEX, however,
utilizes the self-cleaving properties of ribozymes to realize massive target-induced size changes
in the RNA strands. To design an oligonucleotide library for such a purpose, a random RNA
region is inserted into a structurally critical domain of the ribozymes, such as one of the three stem
regions in a hammerhead ribozyme [109] (Figure 3C). Ribozyme-based SELEX starts with a negative
selection, in the absence of the targets, to remove autonomously self-cleaved RNA strands. Uncleaved
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aptamers are then PAGE gel-purified and incubated with targets in the positive selection. During
this step, the cleaved RNA strands are isolated via gel-purification, further reversibly transcribed,
amplified by PCR, and transcribed back into full-length RNA strands for the next round of selection.
The hammerhead ribozyme is the most widely used ribozyme in this type of SELEX. The identified
aptamers can selectively bind with the target and further induce the folding of a stem region
(i.e., the transducer) of the hammerhead ribozyme. Again, both the recognition module and the
transducer module can be directly identified for the development of GERMS. In addition, with the
diverse choices of different classes of naturally occurring ribozymes, various target molecules can
potentially be recognized with different signal transduction mechanisms.
Graphene oxide (GO) is another platform which has recently become popular in screening for
aptamers. GO-SELEX is based on the non-specific adsorption of the oligonucleotide library by graphene
oxide [110]. The library is normally pre-incubated with the target, after which GO is added. Single-stranded
oligonucleotides can be adsorbed by GO due to π–π stacking, while target-bound complexes
remain free in the solution. After removing sequences not bound to GO through centrifugation,
the target-bound oligonucleotides are then separated and amplified by reverse transcription, PCR
and transcription (Figure 3B). GO-SELEX also does not require a target immobilization. The selected
aptamers have also been optimized in order to obtain the property of target-induced conformational
changes. GO-SELEX is a simple, high-speed, high-throughput aptamer screening method that can be
applied to various target molecules [111].
4.3. Riboswitch-Based Recognition Modules
Riboswitches are naturally occurring recognition modules for many critical cellular metabolites
and signaling molecules [112,113]. Another way of developing GERMS is by directly adopting these
riboswitches as recognition modules. As mentioned previously in this manuscript, a riboswitch consists
of an aptamer domain, a switching sequence, and an expression platform. The aptamer domains
in the riboswitches have been naturally evolved to selectively bind with various cellular targets
including enzyme cofactors, nucleotide precursors, amino acids and atomic ions [114]. For example,
the metH S-adenosylhomocysteine (SAH) riboswitch can selectively recognize SAH in preference to
S-adenosylmethionine (SAM) by 1000-fold [115], while SAM and SAH differ only by a methyl group.
As a result, these SAH riboswitches have been used to develop sensors to measure SAH levels as
well as the methyltransferase activities in vitro, which further facilitates the screening of novel MTase
inhibitors [116].
During the conventional in vitro SELEX process, it is difficult to perform negative or counter
SELEX against all the diverse and structurally related molecules in the cell. In addition, obtaining
aptamers that have a suitable target-binding affinity is in many cases still a challenge. Most in vitro
identified aptamers should be further tested and optimized in the real cellular environment. The major
advantage of riboswitches over SELEX-generated aptamers is that riboswitches have been evolved to
have the type of in vivo selectivity and binding affinity needed to recognize cellular targets.
4.4. Specific Base Pair Formation
RNA-based recognition modules can also be designed based on sequence-specific base pairings.
In addition to the traditional Watson-Crick (A to U and C to G) base pairs, wobble base pairs (e.g., G to
U or I to C), G-quadruplexes, and metallo-base pairs can also be engineered as specific recognition
modules for the development of RNA-based sensors. For example, we have recently developed
a C–Ag+–C metallo-base pair-based fluorogenic RNA sensor for the intracellular imaging of Ag+
ions [117]. In this study, these metallo base pairs can function as both the recognition module and
the transducer module. The signal transduction mechanism is similar to the one discussed above in
Section 2.2.
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5. Recent Examples of GERMS
GERMS have been successfully applied in multiple intracellular studies. For example, the Jaffrey lab
developed a type of allosteric Spinach sensor. Similar to the one shown in Figure 1A, the allosteric
Spinach sensor comprises a target-binding aptamer (recognition module), a transducer duplex
(transducer module), and a Spinach aptamer (reporting system). This type of sensor has been
engineered to detect diverse metabolites and proteins, such as adenosine diphosphate, SAM, guanosine
triphosphate, thrombin, and MCP coat protein [29,30]. In Table 2, we have shown some of the existing
GERMS for intracellular applications. The optimal sensors normally exhibited 10- to 40-fold increases
in fluorescence upon binding their cognate ligands. Notably, a SAM-targeting allosteric Spinach sensor
has been used to reveal cell-to-cell variations in the SAM metabolism, which cannot be observed via
conventional methods [29].
We previously engineered Spinach riboswitches, nature-inspired GERMS for detecting metabolites
in the cytosol of cells with high target selectivity. For example, by engineering the Spinach aptamer
into the expression platform in a natural thiM TPP riboswitch, we developed TPP-targeting GERMS.
Similar to that shown in Figure 1C, the TPP-dependent natural switching mechanism of the riboswitch
enables the proper folding of the Spinach aptamer, which then activates the fluorescence of DFHBI [32].
Compared to aptamers selected by in vitro SELEX, naturally occurring riboswitches have inherent
advantages in their high affinity and selectivity for cellular targets. Currently, many naturally occurring
riboswitches have been discovered, and the Spinach riboswitch strategy enables the direct conversion
of riboswitches into functional GERMS.











ADP [29] SELEX Duplex Formation Spinach 270 20 Bacteria
5-HTP [118] SELEX Duplex Formation Broccoli N/A c >5 Bacteria
L-DOPA [118] SELEX Duplex Formation Broccoli N/A >5 Bacteria
MS2 coat protein [30] SELEX Duplex Formation Spinach ~0.6 41.7 Bacteria
MS2 coat protein [119] SELEX Ribozyme BFP N/A 1.8 Mammalian
Neomycin [120] SELEX Ribozyme β-galactosidase N/A 25 Yeast
Streptavidin [30] SELEX Duplex Formation Spinach <0.2 10.3 Bacteria
Tetracycline/
Theophylline [121] SELEX Ribozyme EGFP N/A N/A Yeast
Tetracycline [122] SELEX Ribozyme Luciferase/EGFP 35.4 4.8 Mammalian
Theophylline [123] SELEX Ribozyme EGFP ~200 10 Bacteria
c-AMP-GMP [38] Riboswitch Duplex Formation Spinach 4.2 ~8 (37 ◦C) Bacteria
c-di-AMP [39] Riboswitch StrandDisplacement Spinach2 3.4 & 29 2.4 & 9.1 Bacteria
c-di-GMP [38] Riboswitch Duplex Formation Spinach 0.23 ~6 (37 ◦C) Bacteria
c-di-GMP [124] Riboswitch Duplex Formation Spinach2 0.005–0.4 ~6 (37 ◦C) Bacteria
c-di-GMP [125] Riboswitch StrandDisplacement TurboRFP N/A 38 Bacteria
Guanine [126] Riboswitch Ribozyme EGFP N/A 9.6 Mammalian
SAM [29] Riboswitch Duplex Formation Spinach 120 25 Bacteria
TPP [32] Riboswitch StrandDisplacement Spinach 9 15.9 Bacteria
TPP [127] Riboswitch StrandDisplacement EGFP N/A ~5 Plant
TPP [128] Riboswitch Ribozyme tRNA N/A 43 Bacteria
N-peptide [129] Ribonucleoproteincomplexes Ribozyme EGFP/SEAP N/A ~12 Mammalian
RNA [130] Base Pairing Ribozyme EGFP N/A ~10 Bacteria
RNA [131] Base Pairing StrandDisplacement Split Broccoli ~0.001 2.2 Bacteria
a Only one example is given when the same design principle has been used to detect the same target molecules.
b ON/OFF indicates the number of fold enhancements in the in vitro fluorescence of GERMS after adding the target
(measured at 25 ◦C unless otherwise stated). c N/A—Not Available.
We recently engineered another class of RNA-based fluorescent sensors, termed RNA integrators,
for the intracellular detection of low-abundance metabolites [132]. In this design, the self-cleaving
property of hammerhead ribozymes is used to activate the Broccoli aptamer upon binding to target
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molecules. Similar to that shown in Figure 1D, in the presence of target molecules, the recognition
module rearranges to form the binding pocket, which leads to the formation of the catalytic pocket in
the hammerhead ribozyme. As a result, target binding induces the activation of the self-cleavage of
the ribozyme and releases the downstream Broccoli aptamer sequence, which then binds DFHBI in
order to emit fluorescence. Here, each target molecule can induce the cleavage of multiple copies of
the RNA integrator, resulting in an amplified signal.
In addition to these nature-inspired designs, GERMS can also be engineered based on recent
advancements in DNA and RNA nanotechnology. For example, our lab has recently developed the
first GERMS based on an RNA logic circuit, termed the Catalytic Hairpin Assembly RNA circuit,
that is Genetically Encoded (CHARGE) [131]. In our CHARGE sensor design, two complementary
RNA hairpins stay separate from each other in the absence of a target (Figure 4A). After adding the
target, one hairpin opens based on a toehold-mediated strand displacement reaction, and then induces
the subsequent hybridization of both hairpins [133]. The target can then be recycled to trigger the
hybridization of multiple copies of hairpins. By coupling with split-Broccoli, we were able to image
cellular RNA targets with a high sensitivity [131].
Figure 4. Schematics of RNA nanotechnology-inspired GERMS. (A) In a CHARGE circuit, target
binding (red) induces the catalytic hybridization of multiple hairpin assemblies (blue), further activating
an amplified signal from reassembled Broccoli RNA (green). (B) In a toehold switch sensor, target
binding releases the ribosome binding site (RBS) and a start codon (AUG), which activates the
expression of the reporting system (green). (C) In an RNA origami construct, target-induced structure
change can regulate the distance and FRET efficiency between two fluorogenic RNA complexes.
In another example showing that dynamic RNA nanotechnology can contribute to the design of
GERMS, the Yin group has developed toehold switches to detect target RNAs with an average ON/OFF
ratio of over 400 [134]. The toehold riboswitch functions by the target-induced post-transcriptional
activation of the gene expression (Figure 4B). Taking advantage of toehold-mediated linear-linear
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interactions [133], target RNA can bind with the sequences around the ribosome binding sites (RBS)
and a start codon (AUG), triggering a branch migration process to expose the RBS and the start codon.
As a result, the presence of the target RNA strand initiates the translation of the downstream fluorescent
protein and emits a corresponding fluorescence signal. The orthogonality and programmability of
toehold switches can even allow for the independent regulation of 12 genes and is used to construct
complex genetic circuits [134].
Synthetic RNA nanotechnology, i.e., the design and construction of artificial RNA nanostructures,
can also provide a useful scaffold to improve the performance of GERMS. For example, the Andersen
group has recently reported a single-stranded RNA origami FRET system [46]. In their nanoconstruct,
two fluorogenic RNA aptamers, Spinach and Mango, were placed in close proximity following a
designed pattern (Figure 4C). In the absence of target molecules, the Spinach and Mango pair produced
a limited FRET signal. Upon target binding, the origami rearranged the structure, bringing the two
aptamers closer to each other and producing a large FRET signal. This construct has been successfully
genetically encoded in E. coli cells, demonstrating its potential for intracellular imaging.
Other than the examples described above, GERMS can also function, in a way, as logic gates.
Alam et al. showed that Split Broccoli aptamers can be converted into an AND gate for monitoring the
assembly of RNA–RNA hybrids [82]. The Khisamutdinov group has recently demonstrated a new
generation of smart RNA nanodevices based on RNA aptamers [129]. In their approach, the Malachite
Green aptamer and the Broccoli aptamer were engineered into four types of oligonucleotide-responsive
RNA logic gates (AND, OR, NAND and NOR), which offer a new route to engineer “label-free”
ligand-sensing regulatory circuits and nucleic acid detection systems.
6. Conclusions and Outlook
Over the past few years, GERMS have emerged for live-cell imaging and the detection of various
RNAs, proteins, metabolites, synthetic compounds, and ions. The high versatility of these RNA
nanostructures has provided GERMS with a wide choice regarding the recognition modules, transducer
modules, and the reporting systems. GERMS can be developed toward various targets with both a high
binding affinity and selectivity. The sensitivity, modularity, and dynamic range of these RNA-based
sensors have been dramatically improved.
One critical challenge in the rational design of GERMS is to understand how the recognition
module changes its conformation after binding to its target. Indeed, it can be difficult to design
transducer modules if the structures of both the apo- and holo- forms of the recognition module remain
unknown. The crystal structures for most existing riboswitches have been solved. However, for many
SELEX-generated aptamers, we still have limited knowledge about their tertiary structures. On the
other hand, computational simulations have been used to assist the design and engineering of GERMS.
Unfortunately, it is still challenging to accurately simulate many complex intramolecular interactions
among different modules within these functional RNA structures, without mentioning the challenge
in predicting how target binding can thermodynamically and kinetically change the conformation
of GERMS.
Currently, it is still taking a long time and many trials to develop a functional RNA-based sensor.
The number of selection rounds will be greatly reduced if there are guidelines for the pairing of
different modules in GERMS. In other words, if we could design the transducer module simply by
looking at the sequence of the recognition module and its binding pocket, this would greatly improve
the design efficiency. Potential milestones in engineering GERMS will likely depend on revolutionary
algorithms in computational simulations and a more comprehensive understanding of the relationships
between RNA sequences and their corresponding tertiary structures.
Another limitation in applying GERMS for mammalian cells or in vivo imaging is RNA
degradation and low-level expression. Short RNA constructs, like those in most GERMS, can be
rapidly degraded in eukaryotic cells. One potential solution for improving the expression level of
GERMS is based on circular RNA constructs. Circular RNAs have been identified in vivo as naturally
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evolved stable RNA molecules. Circular RNAs do not have either a free 5’- or 3’-end, which makes
them invulnerable to most cellular exonucleases. Recent studies have shown that these circular
RNAs can be stable for days-to-weeks and that they accumulate at high levels in diverse eukaryotic
organisms [134–138]. The potential incorporation of the circular RNA strategy in GERMS may open a
new window for the in vivo imaging and detection of targets that have not been successfully studied
with available RNA- or protein-based sensors.
In conclusion, we have summarized in this review the basic design principles and recent
applications of GERMS for bioimaging and the detection of cellular targets. The versatility of these
RNA-based sensors makes GERMS highly useful for studying essentially any molecule in living cells.
GERMS have shown great potential for future live-cell imaging. After improving their biostability,
sensitivity, target selectivity, and kinetics, the next steps will likely be the engineering of GERMS into
working sensors in eukaryotic cells, as well as the generation of universal protocols for developing
GERMS toward any target of interest.
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GERMS Genetically Encoded RNA-based Molecular Sensors
FRET Förster Resonance Energy Transfer
FACS Fluorescence-Activated Cell Sorting
SELEX Systematic Evolution of Ligands by EXponential enrichment
GO Graphene Oxide
PCR Polymerase Chain Reaction
PAGE Polyacrylamide Gel Electrophoresis
CHARGE Catalytic Hairpin Assembly RNA circuit that is Genetically Encoded
BODIPY Boron Dipyrromethene
FP, GFP, EGFP, BFP, RFP
Fluorescent Protein, Green Fluorescent Protein, Enhanced Green Fluorescent




Dinitroaniline-Binding aptamer, Sulforhodamine B,
Sulforhodamine-Dinitroaniline
TO-Biotin Thizole Orange-Biotin
Co2+, Ag+ Cobalt ion, Silver ion
ATP, ADP, AMP, GMP
Adenosine Triphosphate, Adenosine Diphosphate, Adenosine
Monophosphate, Guanosine Monophosphate
HIV Human Immunodeficiency Virus
SAH, SAM S-adenosylhomocysteine, S-adenosylmethionine
MTase Methyltransferase
TPP Thiamine 5’-pyrophosphate
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